<SEC-DOCUMENT>0000906709-21-000008.txt : 20210507
<SEC-HEADER>0000906709-21-000008.hdr.sgml : 20210507
<ACCEPTANCE-DATETIME>20210506200717
ACCESSION NUMBER:		0000906709-21-000008
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210507
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		21899789

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e,d:e41d9301146842468fa4c70d9ab030de--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nktr="http://www.nektar.com/20210331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml8yLTEtMS0xLTA_51d040b0-6e32-4fab-98fb-85d854a43e0c">false</ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml80LTEtMS0xLTA_bfca4caa-063a-4c01-b41e-11c9ccac8210">2021</ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml81LTEtMS0xLTA_e9e9e9a6-c844-4add-a276-b20fe116cff8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml84LTEtMS0xLTA_fec95a8a-8aa1-49b5-b461-a089f4bdec9a">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml85LTEtMS0xLTA_955384fd-eb49-499e-9a29-91327e3dc844">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i98038b0951d74aab974ce098dadaefa2_D20210101-20210331" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQw_d76ba943-ec14-406d-8350-bfab428ccc84">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaec343fe356a4d8d849cff41317060d0_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2e4e93387c65485f981f8737f196c2c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d7a648bf34494885032023666dcc3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1621c8221f654c90b898084da8dedde1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a7998dc7414125be04c9d54bc72e2e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2807087b245b41b19a7c3e71ee219075_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943b5cc32c904e4ea5c4a393252a5f1d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7d876eb9e5443aa74b9b76ae690dff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00bd189bf7d744bd9cc35850e01748a8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i540e6fef44d64cffba3a62b8928bfe6e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7955d98f7e9b4443a246cf12be211aec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b555333a734eb09051cd798b9429f2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c19b8ac3e44e16ad9461cdc3a1ec50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9409701ed42346d398ef2df0711ebbbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df351278d2e475f8037520497f16d08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609c4b091c6f4c3c8fdb643e92816c9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81484fe9ab834f2a96467bf9454ee663_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc5e2729e13461d9320df87f011a0d0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad24cb47b7a42209662cb8b069c2477_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28232c784abe46e9b8bd80d5160c1dcd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774a1d8af37c4a42940da8a89d3cda47_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3434f78d8eda453ea4592a46d4c5cdfc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4af4055073419a9a0ef11ae74dd946_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9070274e17474fff80758eac97feb538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76a2892513a4bfc8774fe6483aaf6e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76d2b5ae1354fc4867eb4b9f92c75ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b2f529f96f4242931a38d1274c3ec5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d08917815cd4606b7605b1bbcaaf74c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i807cf75457a848a09a842cc4c40488d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdca91f683064dc98eaa5aa341fa9983_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9ab8b582354653b3fe82befd406ad2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b300b6a614240b0b082b5312aba0e34_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb29d6015684948aeb9b7feb861a58b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i4185a9a6a21b42b9a45f1c865f2c9d10_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb9564a50a84a4eb505aab0b22a3065_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9cad33a4cec459b8fbd34cf53491766_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbac025559f44dc9a9f56732a029868_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76828c455aa74a82808b4262afd668aa_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98038b0951d74aab974ce098dadaefa2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a7d653175c4b1296680cadb5e5068a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481435efdba94e8490ffd332962979dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3267ba79b04df19ce633889ce7df6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7af717d26bc4360be31f309f87c91ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95376ec14224b34a592fb4d683609b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8561d224210461c901b5f3c17a17ac6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cf135547944cf582acc95627b3f1ac_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd4b3ae29e24484a045a0ea43dd64d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3229216ca2cd4c8f801d00e8cb3409b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83eb3c2ca3a74138bb628878b3e1af2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b987794ba23407893b7dc6257382c77_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2241989dd1a448d7adaf7823411b1840_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0589fec22d0240d48c2ee8a46b1e6051_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-13</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef844280b874a7086af284de909cd28_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifb734f7523814332bc13530cdead90d7_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56b311eba0f474c8c9f8effb8942bdf_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15fe85a66b97435c972422f93be257dd_D20120224-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-24</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b7119025294bdf87c0a688175b3708_D20201230-20201230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-30</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a2169491224aa7bdef145df847c899_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia58a7dcb93434d91861bf0ba9f446985_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cf522fabf34f9f9889d9af3e35f07e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba18dba9b8242f69de0a47836b3bfaa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36426a8b19bd4b7787bbf20a576265cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia868932072e14135b8de20b8fbb05d07_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1e022e0df84f8ab75a646beabe28c7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890cec45aa2c403990c5450c11ff80aa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22f93ce0e6e443c8e9e4d9bde3f79d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e3ac045dec48a8896e485f547a26dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c04572e64e47e09013051eea02caee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f08688820e4c0d944e8590248a9ee2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1355795842ee48cfbb1d6f4c02802112_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2acb647abce34e528ca4a74280583891_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b49c69835b040c4950674cd1f3a94cf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9fb20bbc2d40529eb5a2ad309535ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie451f88b893143fd96763ffbce41fe96_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea24fab4f124cfda87387948817a846_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8141e5c62f534eaf98c103e667821511_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccde389fb0334895aa528d399ab3bf5e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2b40706c664b82b13759271c2bd0a2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e2f8958bdd4de09995408abc27ba55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1803a5ad5a74f649f0ac70f1767a019_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6af6053ea94cd9a9631c23a09ca612_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92fdace84fb408085fe38e47c50a2c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b94fb646ce44bdaf0638dc9f141c2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c61987eb3734024b9a5c864d6cb7045_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecb6e5d960b4fe48ef63d770bac85ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i520e0275aed84e53994d2120ede4c694_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e07bf5444748f28089939d419f2bf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f1b5f37d97c417a87bb5004508a6596_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11baeb47973548c88d4519c8e83b21d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af4d5a03bc141219abdd52011fe5464_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563f7505fa2546d69c640c2577604c52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70ed10561534c5cbf9793749b869293_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44cb50cd1caa4f38a48308a6383f0996_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f50476b334c4003acc68e480643a590_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0e28f4f5464df5bbec94c881c5abc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00c9d902daf42809ecedb590fac715c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ddc60c546d44ef2963908af8e5d76f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8230f0003b5842ae9c7225aa05e51fc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ba56e21f0a4eee853230f5c88beb8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8524ef60ac4f2cb9edab302f616345_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee84611bbab94bc893e75949080dfc54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f24288c76d4f32bd98bf26e7db5c55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67d1e2600b64ef78e842652cb1a0ae9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1ae924c35842629018e614147300a6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff36581ebdf74fdaac3b5805cc4f475d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9249ec543db649c3b5dce617f420aa36_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib876abacb04c4b25be485ce424922ff7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd31d1636dd74a5db8d7c83c962c2942_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc414d1438a4b329c44637d6305aa56_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16676af93154d568c1375d2c0a4d1b8_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb05b3574f34baea4609a9e773edd67_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c479692b49492685f185a1840f7899_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847c7a3b7a4a4032b79d9bcd3421535c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1740f80f6e884279b119d237d3326445_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2664e0c6c2543468ac3615b87452a66_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5369bf90ade043dd854e6754069729a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f602e51e0c49249c41968d3420137b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad1c0adc7fd4601afed8c117d9bebe3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638f2b550bf04881a583181b88610a64_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd3cabc118142ccb19c6e19c224fdcf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cc6f61322d48bc91f4421afbb6251b_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1707076fdcc0477ba064e4a58a5b1a8b_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ccb5e0e99e4d75b46da24538873814_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfd01d94766464ca526949208f6d2ea_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93c2e92f70844efaef925cc4f310e71_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7006ee9335c4157a84de254bb359388_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774e651a02ec4b0f95dde0602aac4434_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440119c59b3e443b88631f1edc85ff74_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic958491514274e76939f916d7f421a97_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfe2d433ef840c286c01d47b0c5f9d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8040c0e6c157482a8f36f8fda1edeeaa_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85628854072425b81249accd9779120_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22a905697334834a0579dcebb9555a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862a0be5967d420ab21a5f29eea2436e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4fb5cc34a84085bf75a4ee4c6f7bff_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cd0871541b4364b1013eecb84d5e9f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d469dfa3d97434e966b108b21df0121_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94d1826584045bf83baf28f35342624_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie41d9301146842468fa4c70d9ab030de_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY5_0a46b30d-5722-408f-aeca-a4ab591aefc6">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZDcwNWE2OTc2ZjhkNDlhNDg2ZjUwMzYwMjUxNDI2YmMvdGFibGVyYW5nZTpkNzA1YTY5NzZmOGQ0OWE0ODZmNTAzNjAyNTE0MjZiY18wLTAtMS0xLTA_ebb06180-ccf2-43e7-857c-7a3d2ab0e465">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yNjg_ac23819d-87e9-424b-afb8-5999415ff799">March&#160;31, 2021</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ODYxYTQ2NWFiNzU2NGUxOGIzMzRiYzliZGZlYzNiZTIvdGFibGVyYW5nZTo4NjFhNDY1YWI3NTY0ZTE4YjMzNGJjOWJkZmVjM2JlMl8wLTAtMS0xLTA_0110e575-151e-4f73-b1e2-54c06ae4a6e0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjc0_7a1eee06-432d-4e91-87ad-0e6538e01928">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY2_52722974-af57-4dd0-857c-65f3e5366882">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6MTk2MGUzZWQyYmUxNDYwM2JhZTgyMjU1ZGYwODgxZDUvdGFibGVyYW5nZToxOTYwZTNlZDJiZTE0NjAzYmFlODIyNTVkZjA4ODFkNV8wLTAtMS0xLTA_89b37fa8-16f2-4cf6-b076-99a697e64fac">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6MTk2MGUzZWQyYmUxNDYwM2JhZTgyMjU1ZGYwODgxZDUvdGFibGVyYW5nZToxOTYwZTNlZDJiZTE0NjAzYmFlODIyNTVkZjA4ODFkNV8wLTItMS0xLTA_62e3bc24-4724-4dca-a80d-aa66b480bbf1">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcz_9f350a19-3e81-4be6-918e-756ecf9b3ae6">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjc1_ab1d3a71-8726-45c8-b3c5-82b36fb0d736">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjYy_857dc499-22ae-458d-a71b-e398da0b05d3">California</ix:nonNumeric> <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY3_8aded7a9-8e28-4508-8086-b4880c2ee029">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjYz_b54f54f4-3543-4e2e-9f5b-1126ee8ee72f">415</ix:nonNumeric>-<ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcw_a580aee2-d85c-4a0a-8c3a-5e790cd42eed">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTAtMS0xLTA_382b3d2c-cdd8-4593-b44b-9d5aaefd4fec">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTEtMS0xLTA_dfc0f7af-eacb-476d-bf60-059fc39eb847">NKTR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTItMS0xLTA_4986cecb-f629-4cc8-b637-220610655e00">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcx_b9811cfe-fbb7-4d79-968a-879b11816bfa">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY0_a7c89b69-b989-45d0-8936-e59b3a452a2f">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N18wLTAtMS0xLTA_a3f4febd-56c4-468f-8a71-2e6648e29549">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N18yLTYtMS0xLTA_b13d696c-752c-4920-b2e7-d58bb3a84269">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N180LTItMS0xLTA_19756bea-ec2f-4d6d-a02e-9e1a298eb31a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY1_71f99334-4d2d-4f9c-a6ac-27248a6c4081">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaec343fe356a4d8d849cff41317060d0_I20210430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjU0_d9dbc238-1aea-4d1e-b9ae-fcb0e0f7f365">182,308,999</ix:nonFraction> o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n April&#160;30, 2021.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_1173">Summary of Risks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_1173">4</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_13">PART I: FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_16">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_19">Condensed Consolidated Balance Sheets &#8212; March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_19"> and December 31, 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_19">02</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_19">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_25">Condensed Consolidated Statements of Operations for the three months ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_25"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_25">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_25">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_28">Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_28"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_28">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_28">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_31">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_34">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_34">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_34"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_34">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_34">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_79">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_94">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_97">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_97">38</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_100">PART II: OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_103">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_103">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_88">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_88">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_88">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_106">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_106">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_109">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_112">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_115">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_115">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_118">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_118">63</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_121">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie41d9301146842468fa4c70d9ab030de_121">64</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this quarterly report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation, any statements concerning estimates and predictions of the COVID-19 pandemic's impact on our business and clinical trials and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this quarterly report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this quarterly report on Form 10-Q, the terms &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="ie41d9301146842468fa4c70d9ab030de_1173"></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-Q, which risks include, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of bempegaldesleukin, our lead immuno-oncology (I-O) candidate, and our business will be significantly harmed if we are not successful in developing this drug candidate;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies could have a material and adverse impact on the value of our I-O pipeline;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the operations of our collaboration partners may be more affected by the COVID-19 pandemic than we are, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if the market size for a new drug that received approval is significantly smaller than we anticipate, it could negatively impact our revenue, results of operations and financial condition;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if third-party payers (including government programs) do not provide payment or reimbursement for our products, those products will not be widely accepted, which would negatively impact our business, results of operations and financial condition; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be negatively harmed; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Business Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our drug candidates successfully.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to drug candidates granted Breakthrough Therapy designation by the United States Food and Drug Administration (FDA); </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available on commercially reasonable terms.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="ie41d9301146842468fa4c70d9ab030de_16"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="ie41d9301146842468fa4c70d9ab030de_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:70.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMy0xLTEtMS0w_2a3256e6-cdd4-4dcd-a681-a6f84af3d1d2">150,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMy0zLTEtMS0w_d7e9901e-2475-4e72-ae40-5c5592355ea9">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNC0xLTEtMS0w_e8d863ec-5617-4a67-a4c6-721880bcf39a">887,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNC0zLTEtMS0w_21adbaaf-313a-42b5-851f-406f62c1aee6">862,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNS0xLTEtMS0w_ff78aef9-b384-495d-842e-2957fd669027">29,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNS0zLTEtMS0w_7fa198dc-3506-49ba-a151-018e66d7174d">38,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNi0xLTEtMS0w_7bd269c5-963c-435c-999b-bed54c2d9c3a">16,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNi0zLTEtMS0w_2f2bef59-7ec1-4fcd-9a9b-5e6ace3b2ca2">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOC0xLTEtMS0w_a6976649-22fc-4ab5-a943-841bcbeb1de3">15,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOC0zLTEtMS0w_d835bd58-129e-403c-815f-d8b5a48162b4">21,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOS0xLTEtMS0w_a423ee54-209c-4d28-b418-84e91dba4154">1,099,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOS0zLTEtMS0w_a951e1c4-2a3f-4624-8df4-03a56d85dd25">1,138,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTAtMS0xLTEtMA_79789ba1-54e4-4f40-a855-3a555910ab4d">96,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTAtMy0xLTEtMA_2cbcc690-b65d-4841-82ed-02b6eef93e71">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTEtMS0xLTEtMA_c6e01daa-1796-4b4f-b975-2b98aced0c21">58,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTEtMy0xLTEtMA_b707da1c-c9a9-43f0-915f-416eac33fde6">59,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTItMS0xLTEtMA_a5bbead9-c69d-4227-9560-dc9f262ed2df">124,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTItMy0xLTEtMA_8fd1e738-b16a-4984-8cd8-78086983bc5b">126,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTMtMS0xLTEtMA_bce0bee2-8094-4ca0-8b5e-73b8b54e13df">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTMtMy0xLTEtMA_6c7320e7-7015-439f-b2fd-6185e61f1b3a">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMS0xLTEtNzA_510899bc-f9f5-4e88-ab22-5fd77eb45d26">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMy0xLTEtNTA_be2affc8-2c26-450e-9781-f14af4392529">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMS0xLTEtMA_21d52f4a-2c51-457c-a9e0-9f438488ec87">1,456,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMy0xLTEtMA_48cdd78d-fa8a-4609-96fd-2912a975680d">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTgtMS0xLTEtMA_17ec8bee-59e9-43a6-a88a-7fa10a750940">22,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTgtMy0xLTEtMA_a0707b87-b620-4058-a1ec-be16bdecea31">22,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTktMS0xLTEtMA_0c51278b-123a-4155-9866-be90a4d91d29">23,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTktMy0xLTEtMA_82db75cf-6c20-4732-862e-5356cda43a08">14,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjAtMS0xLTEtMA_6276a77f-0402-4152-a264-86e06a9ed0d1">41,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjAtMy0xLTEtMA_53b94560-c0e2-4fc7-a74c-9c3769fee394">44,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjEtMS0xLTEtMA_da3922ea-13dc-47da-ac1b-a6533ce282d0">6,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjEtMy0xLTEtMA_eb6fb064-e9d5-4739-b328-feba9f6d4fdc">11,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjItMS0xLTEtMA_03c410d0-941e-4961-ba5c-f79f96954485">14,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjItMy0xLTEtMA_89079d39-5505-49f8-8322-88733842b379">9,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjMtMS0xLTEtMA_81392f91-4ff3-4881-9c5c-34c86eff2777">15,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjMtMy0xLTEtMA_31e767b7-e3be-4656-8631-045db5f82c6f">13,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMS0xLTEtMA_f716b1cf-41de-43b5-83b2-900102a31183">123,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMy0xLTEtMA_4474306f-e351-4c93-b1f0-3783ee6688cf">115,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjctMS0xLTEtMA_969022a8-8d5f-416f-a385-55354ef71626">134,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjctMy0xLTEtMA_c5a5389f-e861-4d1c-9b68-31fa15989844">136,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMS0xLTEtMTM1Mg_7c3cb580-e58f-44ec-9368-1cde6014720e">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMy0xLTEtMTM1Mg_22d75486-0463-410a-9aa0-e2f1711602a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjgtMS0xLTEtMA_99d76201-314a-4694-93eb-5c2e59589647">195,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjgtMy0xLTEtMA_193c6abb-de1a-455f-86ec-844bc8b61f78">200,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjktMS0xLTEtNjY_373855dd-4d55-49d8-986d-82eaf4b67a6f">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjktMy0xLTEtNjY_1cd061b2-4f62-40da-babb-fd6aedc5d76e">8,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzAtMS0xLTEtMA_266ac898-40bc-4053-8daf-eb2cdb47ec24">462,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzAtMy0xLTEtMA_375a4d54-badf-4cc5-8839-7c6082cc2e20">461,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzEtMS0xLTEtMA_9cd48bfb-d045-4669-9604-fe3f739e2af2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzEtMy0xLTEtMA_d79e63a9-3d08-42e2-9c33-676cac8eb166"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzIx_3a738016-4b01-433a-8944-5f14da46f06c"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzIx_7b91a096-7c83-4420-9df0-ac6f4d1bb634">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzM1_4a242f7c-0698-4f19-a930-dde5ebb58024"><ix:nonFraction unitRef="shares" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzM1_bb563bd9-3cac-498b-bd67-093bf8170b21">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_2fe14b41-3818-4744-a1a4-25e6d92ea0d9"><ix:nonFraction unitRef="shares" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_9da39e84-78da-492e-a5a5-0eb4498e1c40"><ix:nonFraction unitRef="shares" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_b51551bc-4d9b-4933-a572-5ce33d0727b9"><ix:nonFraction unitRef="shares" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_f34dd4f0-8323-43d7-bfac-f20edea4e770">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at March 31, 2021 or December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMS0xLTEtMA_8f92dda0-b70e-45f6-a400-8fc3a07bb240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMy0xLTEtMA_cd6c2168-5196-4075-a5a4-c481db0a2a56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzE4_75d2903b-88b7-47d4-9596-5d24a895a8a1"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzE4_76bfce3b-c2e1-40b6-b1c0-7cb5ce278257">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzMy_13c29224-e165-4ee9-bcc9-6af70381afa0"><ix:nonFraction unitRef="shares" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzMy_8f5a5546-ec4a-4eb3-905b-dee5fc039873">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzU0_d5e0f93e-334a-468a-8e55-ff8a31e21e8d">182,290</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzEwOTk1MTE2Mjc5NDk_a336358a-cab5-40c5-93b4-ca5679208ae0">180,091</ix:nonFraction> shares outstanding at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMS0xLTEtMA_7cbec1da-9ceb-4890-a2f2-75c712ff0e05">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMy0xLTEtMA_91700f6e-2809-4285-9266-704198ba2925">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital in excess of par value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzUtMS0xLTEtMA_c3b839e8-243a-4b9f-885c-6f107e180b2e">3,429,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzUtMy0xLTEtMA_f741b95a-6324-498d-b97e-e49954c04869">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzYtMS0xLTEtMA_9286d95e-d21e-4701-a75d-c67b55141d26">3,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzYtMy0xLTEtMA_17867719-2799-4dc6-b58d-a0d704e3d879">2,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzctMS0xLTEtMA_e6bb709a-7c85-4ce9-a035-e72a086265fa">2,432,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzctMy0xLTEtMA_9810906b-e479-4855-9d3c-a344fdfdb65d">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzgtMS0xLTEtMA_47203b2f-ffbc-4aec-934e-278a46a7758b">994,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzgtMy0xLTEtMA_5693d6fa-9253-4818-956e-dcbbe54ecd0d">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzktMS0xLTEtMA_3a8062d7-31b3-48bc-bd0f-aa3b822e86e8">1,456,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzktMy0xLTEtMA_3e27b5f0-c60e-4a40-8cc0-8435652cbca1">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1621c8221f654c90b898084da8dedde1_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMy0xLTEtMS0w_ce5b763c-871c-4e56-89cb-10eed8c08760">4,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a7998dc7414125be04c9d54bc72e2e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMy0zLTEtMS0w_75e1974f-b84a-4981-b1ac-cb5ce1187628">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2807087b245b41b19a7c3e71ee219075_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNC0xLTEtMS0w_9aebefb6-c3ee-4ddc-88f1-8876b49aebc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943b5cc32c904e4ea5c4a393252a5f1d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNC0zLTEtMS0w_4d7bd146-ae36-40a9-ae63-89cbed8b2f42">9,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7d876eb9e5443aa74b9b76ae690dff_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNS0xLTEtMS0w_f39ac13a-024e-437a-8779-f93cb3899284">18,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00bd189bf7d744bd9cc35850e01748a8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNS0zLTEtMS0w_e1db441a-aada-4e69-bb1e-d2bc21285349">9,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i540e6fef44d64cffba3a62b8928bfe6e_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNi0xLTEtMS0w_1d74d300-0075-4b80-a188-93295d9e62b6">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7955d98f7e9b4443a246cf12be211aec_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNi0zLTEtMS0w_1a2ca95c-38b4-4e35-a64f-3e24911d4a43">27,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNy0xLTEtMS0w_f4227676-3bdc-4f43-8c72-b93b087d1019">23,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNy0zLTEtMS0w_cf1a24c2-86be-4717-bce3-3f38a8930d64">50,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfOS0xLTEtMS0w_8388ca28-4d89-4b3f-a211-223abfba5af6">5,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfOS0zLTEtMS0w_2853fb7d-ae56-4e82-9ec2-7a57dbc2d1b0">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTAtMS0xLTEtMA_310805d3-b3c3-447e-b300-bbc146acce63">95,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTAtMy0xLTEtMA_f5854659-ba70-4df9-8c7e-c99624bffb03">108,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTEtMS0xLTEtMA_c94f33a0-edf0-42a0-a1d9-b592e1c66f13">31,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTEtMy0xLTEtMA_8cef0ef6-9543-4590-bc6f-3930eec96581">26,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTItMS0xLTEtMA_4c52dd6c-68e1-4fb6-8be0-6d7c34061812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTItMy0xLTEtMA_0fbee397-9bfa-4ff9-b1e7-1f1803268377">45,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTMtMS0xLTEtMA_2ce45eda-3d26-41cb-9bc3-65ed1e16de34">133,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTMtMy0xLTEtMA_c342da41-262c-4c5e-a2f8-a4a0707ca5af">184,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTQtMS0xLTEtMA_105a8d7e-6831-4f22-b63e-81e228d402fc">109,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTQtMy0xLTEtMA_1a1df8b5-22b7-4f5c-9a66-ba8754996c3d">133,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTctMS0xLTEtMA_ccdc0334-0b5d-47d0-85dc-6c81c92b0c74">13,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTctMy0xLTEtMA_3987fe4a-6b4e-4879-bf18-5d37a33e5d89">6,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMS0xLTEtMTM2Mg_30108d72-a52c-4f54-9f39-6d4ef8a19d04">1,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMy0xLTEtMTM2Mg_b0255de8-73f6-4844-95cf-fd635dfba8fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMS0xLTEtMA_290a4b77-777e-4742-acdc-9a1b3ed599d3">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMy0xLTEtMA_1f7a322b-0e84-4e5a-a24f-6326bc92bbfe">8,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMS0xLTEtNDE2NQ_411510b4-33fc-4141-91f1-ef7f5596a17c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMy0xLTEtNDE2NQ_42316467-04fc-4d86-8a53-956f46fa0c51">6,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTktMS0xLTEtMA_f5c31ce2-c3f2-46d1-b1f8-117168af17e7">13,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTktMy0xLTEtMA_21ad54aa-406e-4232-a49f-db5586da6192">4,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMS0xLTEtMA_a7aee67b-b126-4896-a808-817f1e57bdf1">122,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMy0xLTEtMA_a4d0e764-eedd-4905-88f0-a1663ff668f6">138,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjEtMS0xLTEtMA_8abdac2c-c082-41ff-b2de-b12a1bb4ddcc">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjEtMy0xLTEtMA_0507bc4d-3160-4b49-8342-f96259b1f144">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjItMS0xLTEtMA_3595af96-8eda-4a7b-9d1c-187b12e945f0">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjItMy0xLTEtMA_e53a0ab3-86d6-4844-adc3-ee894a99a40f">138,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjQtMS0xLTEtMA_23b2f169-dcc3-48d9-b6f4-a77582c5995b">0.68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjQtMy0xLTEtMA_184ab13a-260e-4cf3-a346-9d3773b108b8">0.78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjUtMS0xLTEtMA_9016703d-ff66-4ca4-b292-16988126227f">181,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjUtMy0xLTEtMA_efd97101-44b0-492b-a461-0d9acc1fa8dc">177,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:69.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfMi0xLTEtMS0w_186c6638-aa7c-4ba7-9e3d-0708af8b68d1">122,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfMi0zLTEtMS0w_9ecf8130-b3f8-4fd5-a621-675773fa4e4a">138,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNC0xLTEtMS0w_c5dbea53-e047-44ba-9699-074d5fd8d0a8">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNC0zLTEtMS0w_c93b9f91-175e-4179-b4ee-1c3461adf86c">5,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNS0xLTEtMS0w_c718f48b-f905-406b-b08b-9e7e9b2bd924">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNS0zLTEtMS0w_50b3905e-ddff-4cfd-bd31-7e4202debf0d">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNi0xLTEtMS0w_93310a93-1d4f-4fda-8bec-a43a454416f1">826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNi0zLTEtMS0w_8d2299bb-0894-40a2-8af6-6ad3a7d3f56a">5,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNy0xLTEtMS0w_d88d1bba-59ab-484a-98d2-953fe8cecb34">123,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNy0zLTEtMS0w_9041be10-f2cc-421b-9a3c-c6d5fc391914">144,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0xLTEtMS0w_e012b704-e6f1-47be-9b0a-a70e5a9d24a2">176,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0zLTEtMS0w_02d631b2-51de-49b5-b980-544c350cff2d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b555333a734eb09051cd798b9429f2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS01LTEtMS0w_acfb9f15-212b-4b54-a0b1-64aaaf3838e8">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6c19b8ac3e44e16ad9461cdc3a1ec50_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS03LTEtMS0w_47ac75df-5172-4af8-971b-364531f9092c">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9409701ed42346d398ef2df0711ebbbc_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS05LTEtMS0w_4b0b7e6d-66fd-4358-a03e-842216d655a6">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df351278d2e475f8037520497f16d08_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0xMS0xLTEtMA_66a5b600-90ce-48ae-9a3a-a7d910524b19">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i609c4b091c6f4c3c8fdb643e92816c9f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi0xLTEtMS0w_19e4bf50-795d-44e5-a5e6-cbef1e74f4a9">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi01LTEtMS0w_049bed72-153c-4cbf-bf28-ad7eaf0053a0">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi0xMS0xLTEtMA_c7665fe3-c20a-40bd-85ed-b91e4acdaaff">11,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMy01LTEtMS0w_76ae1de8-132c-4acf-9c5a-d37f163aad2b">24,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMy0xMS0xLTEtMA_33bf30d5-1f6b-4d61-a005-a236704e7569">24,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81484fe9ab834f2a96467bf9454ee663_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC03LTEtMS0w_17359e39-5eef-4000-8ebd-debac5fb03ba">5,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc5e2729e13461d9320df87f011a0d0_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC05LTEtMS0w_95dafe03-c61b-471b-a89e-e9f90b26ba52">138,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC0xMS0xLTEtMA_60d62d16-fd3c-4b30-ae40-107679804fc5">144,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ad24cb47b7a42209662cb8b069c2477_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0xLTEtMS0w_a12fe932-8f4f-4f89-965f-6ea79727d855">177,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad24cb47b7a42209662cb8b069c2477_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0zLTEtMS0w_0aebd6ef-59f4-4c36-a008-c8de6f94b943">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28232c784abe46e9b8bd80d5160c1dcd_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS01LTEtMS0w_164cfdd5-b1ee-4301-88e8-e0cf911be70c">3,306,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i774a1d8af37c4a42940da8a89d3cda47_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS03LTEtMS0w_03d3bb79-970f-490e-9d05-a244a8ecb0eb">6,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3434f78d8eda453ea4592a46d4c5cdfc_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS05LTEtMS0w_bd104128-e70e-44e6-bbba-a02f4945ab64">2,003,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4af4055073419a9a0ef11ae74dd946_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0xMS0xLTEtMA_92130a8c-7823-4d2a-864b-dec36cc94f79">1,296,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0xLTEtMS0w_5723e597-ab70-4fd8-8dbe-e863674a8918">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0zLTEtMS0w_17afe7a2-3de8-46a9-8992-af0732a4cf90">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9070274e17474fff80758eac97feb538_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC01LTEtMS0w_20a2c618-cf68-4207-a18d-7f4cc1e0bf8e">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id76a2892513a4bfc8774fe6483aaf6e9_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC03LTEtMS0w_5fdabbfb-82ce-4e28-bab8-fe4f07f51185">2,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie76d2b5ae1354fc4867eb4b9f92c75ab_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC05LTEtMS0w_5bfa724f-1df7-4be1-8a48-a9cf331251f2">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0xMS0xLTEtMA_861fa027-7d4c-4de1-bd8e-c7e3c2b9cc21">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b2f529f96f4242931a38d1274c3ec5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS0xLTEtMS0w_0cdd7b7f-96e0-4a85-833d-456b16288901">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS01LTEtMS0w_bb364c54-c249-4b72-8174-1d4ab4b7abec">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS0xMS0xLTEtMA_373b445c-1d8c-40c1-9159-4fea83e95b67">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTAtNS0xLTEtMA_926e6b12-f622-4b04-b929-b7f8411a0650">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTAtMTEtMS0xLTA_9812e96c-69c8-4940-9f33-8786a44effab">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d08917815cd4606b7605b1bbcaaf74c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtNy0xLTEtMA_77cbed7b-d5b1-4d0a-9edc-fa3addc6ed02">826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i807cf75457a848a09a842cc4c40488d1_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtOS0xLTEtMA_669c5977-215b-4fad-9166-0dc040404b5a">122,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtMTEtMS0xLTA_e21bdca7-4d2e-466d-92ce-a163061e612f">123,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdca91f683064dc98eaa5aa341fa9983_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMS0xLTEtMA_81ecd314-9e84-4152-96ad-9a99331c28f4">182,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdca91f683064dc98eaa5aa341fa9983_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMy0xLTEtMA_ff4e5740-512b-419c-8163-8e25e8b1e06f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9ab8b582354653b3fe82befd406ad2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItNS0xLTEtMA_5dd1bb34-f470-4dee-b19a-ff092f98b781">3,429,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b300b6a614240b0b082b5312aba0e34_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItNy0xLTEtMA_ba9a35f5-5a3c-4fc5-873b-d09d505db4bc">3,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibeb29d6015684948aeb9b7feb861a58b_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItOS0xLTEtMA_d1f15fbd-cf1d-4234-9bb6-cea7560b799a">2,432,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMTEtMS0xLTA_933e2e57-b2c9-411b-b58d-20691cbc7627">994,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMy0xLTEtMS0w_47c04677-9b2a-4495-8804-0d9b9cf82a95">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMy0zLTEtMS0w_036b16d6-e8ec-4b74-888a-a43dcff27db3">138,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNS0xLTEtMS0w_3eca77f9-261e-4fd0-990b-513cac89314f">18,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNS0zLTEtMS0w_840e7571-29d6-4a11-b8ff-0b69866f4816">9,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0xLTEtMS0yMzQy_e7cad4ab-83ef-4c58-90a2-9401b1c6ba57">13,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0zLTEtMS0yMzQy_532df3d7-4b50-472f-9f28-dbaefa47909e">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0xLTEtMS0w_6a4d550d-f910-47ad-b28c-9ed38634bb70">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0zLTEtMS0w_9574ac6e-16a7-45cb-9f74-ab1149fcbe73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0xLTEtMS0yMjE5_dd436716-6235-48e1-bfcc-a316b1789d58">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0zLTEtMS0yMjE5_d770bc4d-98a4-4bf7-b45d-1f0defbfb936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0xLTEtMS0w_298850c6-4a62-4e36-ae88-8482375a1fa2">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0zLTEtMS0w_736bd70a-c5f0-4154-912e-85505210c42f">25,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOC0xLTEtMS0w_c64d166c-a77c-4e7a-9e10-584e01f51391">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOC0zLTEtMS0w_78bdfc8d-559b-4952-9b8d-a25f131da08f">4,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOS0xLTEtMS0w_5ff7fa78-1e5b-4251-b7e7-6ca2b58f3e17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOS0zLTEtMS0w_274c857a-0619-4712-aca0-1e6eb8c807c5">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTAtMS0xLTEtMA_64df5e66-9734-4875-8430-7c26a252a41f">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTAtMy0xLTEtMA_f9685a9a-65cc-408e-ab2a-037bba6e9f9f">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTItMS0xLTEtMA_bb6f5952-5fd1-4f19-b0f2-57d41767ec3e">9,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTItMy0xLTEtMA_8e217bfa-374a-4198-b142-ac5b783b68c1">5,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTMtMS0xLTEtMA_7d9168af-ff10-4d78-855e-f87abfaeb44e">1,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTMtMy0xLTEtMA_7c2fbde7-534f-4c29-b046-ff73930de529">1,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTQtMS0xLTEtMA_49e9b2bb-c1f0-4e2d-bf20-482375f818dd">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTQtMy0xLTEtMA_456795dd-63a1-477c-a8ac-972ecb00a96c">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTUtMS0xLTEtMA_b99b6e17-7f02-4b7f-bcba-c3872b80031f">6,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTUtMy0xLTEtMA_feed9210-f5cb-4d5b-a9c5-7594ec75d4d7">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTYtMS0xLTEtMA_d17d9273-0c98-4955-bb32-3fe3af8e86f4">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTYtMy0xLTEtMA_587b030a-3f91-419f-998a-0518d7038bdf">2,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTctMS0xLTEtMA_935c7f48-5357-4da1-a94e-125a09a17d8c">8,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTctMy0xLTEtMA_9e78f583-5a12-4949-a7ad-dd1a1b643b70">9,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTgtMS0xLTEtMA_8357f9b2-59ab-42cd-9890-382949950d2b">7,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTgtMy0xLTEtMA_1e2eb4bb-bbd0-43a3-b2e9-18a7786520e1">7,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTktMS0xLTEtMA_b8227621-2aee-4838-b0ac-1e222ebc685e">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTktMy0xLTEtMA_6c01c1b3-2bf3-476e-be2e-435f533b11b3">2,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjEtMS0xLTEtMA_4f7daff6-390c-4cfb-baef-ecb79650a52b">77,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjEtMy0xLTEtMA_ff1206ac-8b6d-41d1-b597-e11a87e186bf">78,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjMtMS0xLTEtMA_e6cffcb7-35e8-44dc-a714-d57a6ec22120">295,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjMtMy0xLTEtMA_2b41fec0-f058-4977-a6ed-52f1c9d44424">241,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjQtMS0xLTEtMA_da41ee9f-b2ba-46e4-8540-bc9da691424c">303,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjQtMy0xLTEtMA_08df50dd-e47e-457a-8e71-6237adfce7dd">439,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjUtMS0xLTEtMA_a9538cc6-b5da-4a37-bc20-6eec877f22f8">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjUtMy0xLTEtMA_977ac785-02d6-4e7f-a3e6-7b5481e2e70e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjYtMS0xLTEtMA_a81b7785-3983-46f6-86fe-fef574ff2eb6">2,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjYtMy0xLTEtMA_4db0cc05-b3ab-4975-b1ad-9cbbf6fd85bc">900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjgtMS0xLTEtMA_30495dc2-d248-4f96-b703-4025b8d88eaa">10,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjgtMy0xLTEtMA_4d1dd018-d857-4598-97ec-e061b85b7134">197,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzAtMS0xLTEtMjkyMA_3f493210-0e75-4949-a7cc-ac2899e6de1b">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzAtMy0xLTEtMjkyMA_58224c1c-586d-4794-a0af-8c2501a0f302">11,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzEtMS0xLTEtMTc4Mg_c0383027-d1b2-4d33-a207-1088b163a16d">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzEtMy0xLTEtMTc4Mg_1154060b-68e0-4928-a77f-17fcca744f40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzItMS0xLTEtMA_e091a723-0cdb-4f08-bfc2-8455779c910d">17,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzItMy0xLTEtMA_c7fed08d-d648-4df8-8f7f-5bfbd82489a5">11,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzMtMS0xLTEtMA_d81c8825-2d5f-4e31-8660-0b9ec82238f8">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzMtMy0xLTEtMA_f9e84f1a-1c50-41f4-83a5-9b6a82c98d85">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzQtMS0xLTEtMA_0588c814-ba02-4680-93ba-e2838209d664">48,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzQtMy0xLTEtMA_33cf8b9b-ec2f-4455-9c5d-3d76045e5539">130,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzUtMS0xLTEtMA_aae5548f-9df9-4e03-8f20-21516f6808a1">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df351278d2e475f8037520497f16d08_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzUtMy0xLTEtMA_03b9294d-5fa7-4ba0-906b-4c3b07c2d6c9">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzYtMS0xLTEtMA_fb5f9f8e-0d2d-430a-932e-f00b3f4e8e69">150,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4af4055073419a9a0ef11ae74dd946_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzYtMy0xLTEtMA_b4650556-76f6-4879-be3c-16845e89b9af">227,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzgtMS0xLTEtMA_a35a06d6-10fb-4fa7-9064-2fc650187520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzgtMy0xLTEtMA_45954895-d424-47ce-b3eb-b16b6988a0a5">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset recognized in exchange for lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzktMS0xLTEtMA_dc1aeee7-6869-4fe0-bf67-f23678d71c23">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzktMy0xLTEtMA_1709e9ef-a7ee-4859-aee1-bffd48f1a685">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div id="ie41d9301146842468fa4c70d9ab030de_37"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ie41d9301146842468fa4c70d9ab030de_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzU_8f309e80-d8a1-4329-9999-506f1a0fed28" continuedAt="i111c5a0b13d14f27a1b30c7412f5c5de" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i111c5a0b13d14f27a1b30c7412f5c5de" continuedAt="i1faa0ef81f9a4d1a97c8335362361c04"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="nktr:OrganizationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjM_c35084d8-480d-4bae-b6c2-633f2f9a6236" continuedAt="i150b331ede564aa09f03da89e5f69af3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that leverage our proprietary and proven advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i150b331ede564aa09f03da89e5f69af3">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At March&#160;31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-8" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTAyOA_b2de44ea-95e0-4dbc-a745-50985ae34d3c">1.1</ix:nonFraction> billion in cash and investments in marketable securities. </span></div><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjQ_209a22f0-2c02-42e8-91f4-2b734e04aae2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India), Nektar Therapeutics UK Limited, and Nektar Therapeutics NL B.V. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2020 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on February 26, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i1faa0ef81f9a4d1a97c8335362361c04" continuedAt="i56a9116439bd404d87427b3f49a5c96e"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzODE_680c034f-6c4a-48cf-b0ba-0e3367787c8f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzA_9793bf37-02c2-4afe-9c23-fea12cc7802e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjY_75c2181e-d132-4c6b-9ba6-147583c34902" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNjk5Ng_10674298-27b0-4cfb-854a-f116ea24294c">one</ix:nonFraction> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNzMzOA_605072ae-c2ac-44e0-af15-b34fb831961c">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzI_5889c09e-8ace-4b49-b422-72a8753d93d0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2021, our accounts receivable includes $<ix:nonFraction unitRef="usd" contextRef="i4185a9a6a21b42b9a45f1c865f2c9d10_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDEwOA_b41dc2ca-ee91-4b3c-896a-6f048e5dc9d9">26.2</ix:nonFraction>&#160;million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $<ix:nonFraction unitRef="usd" contextRef="iffb9564a50a84a4eb505aab0b22a3065_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNzg2OA_ee314d23-09b3-44b3-a0da-cd5243a44901">2.9</ix:nonFraction>&#160;million under customer contracts from our collaboration partners. As of December&#160;31, 2020, our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="if9cad33a4cec459b8fbd34cf53491766_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDEyMw_72cf0da5-86e3-48ff-b95b-2e991f2269fc">38.7</ix:nonFraction>&#160;million for unbilled net expense reimbursements from BMS and $<ix:nonFraction unitRef="usd" contextRef="iedbac025559f44dc9a9f56732a029868_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfODEwMA_dfb7fbf8-1395-441b-9f66-42e87d338a91">0.2</ix:nonFraction>&#160;million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2021 and 2020. We have <ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE1Nw_51f11571-26aa-4243-ba84-3e5c11a56bd8"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE1Nw_ce53a355-1227-4e03-9b0a-1bd4e8409cc3">no</ix:nonFraction></ix:nonFraction>t recorded a reserve for credit losses at March&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzM_d0c0d401-2c33-4772-b22a-7793a5e13fcd" continuedAt="i9a5b1eece6af4e58a07a21a3602d2b33" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i56a9116439bd404d87427b3f49a5c96e" continuedAt="i454b3442fd6a4411bbb37b1b987edefc"><ix:continuation id="i9a5b1eece6af4e58a07a21a3602d2b33"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:continuation><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjg_96e3e780-9540-49fe-a812-ffbddcbf9346" continuedAt="i7f461b8ca12849ca9f557363c695a082" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i454b3442fd6a4411bbb37b1b987edefc" continuedAt="ic07cf815949742b492c81d770e49f702"><ix:continuation id="i7f461b8ca12849ca9f557363c695a082"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzQ_65496489-f6a6-4771-bbcd-5819818382a8" continuedAt="i5249e785eea34f3b82ae492e5174fe06" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="ic07cf815949742b492c81d770e49f702"><ix:continuation id="i5249e785eea34f3b82ae492e5174fe06" continuedAt="i1edd25a42cfc452d82f74a24037b1a18"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1edd25a42cfc452d82f74a24037b1a18">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i76828c455aa74a82808b4262afd668aa_I20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:WriteOffOfPrepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjIzMDA_9569eb15-ed08-4468-8367-d6a01b1aefe7">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $<ix:nonFraction unitRef="usd" contextRef="i76828c455aa74a82808b4262afd668aa_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjI0MDI_4eca6023-66e8-4f72-a33c-57ad66abb7f2">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzODQ_c0ebd1af-5abd-400e-8a37-12a1d97cc3ed" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="nktr:SaleOfStockValueAuthorizedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE0Mg_c6f1f6a7-2711-47db-a527-4a36fcf19904">300.0</ix:nonFraction>&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUxMQ_b2c2c289-b46b-49b1-a060-e071680c8132" continuedAt="i9e77ef38c9b545dc8757b6bde5d5ce44" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i9e77ef38c9b545dc8757b6bde5d5ce44" continuedAt="iaec0d237c21c47ad86b36fe2bccaaf3f"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUwNw_54700a7b-9d82-4dfe-91e6-6d1d3388e59c" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMi0xLTEtMS0w_0665fb14-a833-4b6b-9dfd-08cb0f97b3bc">150,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMi0zLTEtMS0w_f9360b30-9f78-4c3c-8457-1cd80bd2eccb">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMy0xLTEtMS0w_5419189f-aab4-4637-a552-a7d1366d2fe8">887,152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMy0zLTEtMS0w_2f3199c8-449d-4704-b8d7-9182e95e30c8">862,941</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNC0xLTEtMS0w_63103b4c-a38b-45dd-b18b-148f519068be">96,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNC0zLTEtMS0w_49353a5a-addf-4361-8cbd-d3e24a988b1f">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNS0xLTEtMS0w_6657d468-4e0f-472a-9b51-0f1f89cb3872">1,133,409</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNS0zLTEtMS0w_5fe1b95a-b641-480e-80ab-d0c2bc216aa7">1,198,558</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaximumMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNDAw_528205c9-f93a-4494-89e4-9b5b0e433ce4">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaturityTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNDU1_4c925a3e-4a1c-4776-8c87-afb041c402a0">one year</ix:nonNumeric> or less. As of March&#160;31, 2021 and December&#160;31, 2020, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQw_d76ba943-ec14-406d-8350-bfab428ccc84">one</span> and <ix:nonNumeric contextRef="i29a7d653175c4b1296680cadb5e5068a_D20210101-20210331" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQ3_2e29d4a9-0742-40f4-adb1-dd77e64008f0">two years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="iaec0d237c21c47ad86b36fe2bccaaf3f"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUwOQ_bd871056-1652-43b3-943b-d45c29bb4d79" escape="true"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481435efdba94e8490ffd332962979dc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi0zLTEtMS0w_e1b08466-b9c1-440a-b748-5deb5bb982f0">510,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481435efdba94e8490ffd332962979dc_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi01LTEtMS0w_447f9e3a-eaeb-438d-b6e4-3f9fa2b76adc">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i481435efdba94e8490ffd332962979dc_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi03LTEtMS0w_81a3f8e1-aa20-41be-9528-d53b7cb5e262">171</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481435efdba94e8490ffd332962979dc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi05LTEtMS0w_7c03e30a-4a95-4ee2-aeed-5b2e8dfaae0f">510,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3267ba79b04df19ce633889ce7df6a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi0xMS0xLTEtMA_f4c117a2-a7c2-4b84-a448-1fb7136fc751">687,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy0zLTEtMS0w_70823a30-e4f3-4f25-9c28-4f70a09510fd">478,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy01LTEtMS0w_f99e83cf-3bdd-4e9c-98d5-28a0b042a2ee">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy03LTEtMS0w_27ac36ce-8aa2-4448-ba8d-72a187b3e5c1">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy05LTEtMS0w_db39e169-20e5-4757-b0e5-92484870347f">478,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7af717d26bc4360be31f309f87c91ba_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy0xMS0xLTEtMA_24acc92c-5f5d-40b6-9331-b49c90376012">313,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95376ec14224b34a592fb4d683609b8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0yLTEtMS0xNjY2_019d3dd6-a7e0-49d8-aebe-70da10dc2146">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95376ec14224b34a592fb4d683609b8_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC00LTEtMS0xNjY2_4ca5043c-72af-4b73-91bd-57505eaafd85">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95376ec14224b34a592fb4d683609b8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC02LTEtMS0xNjY2_85681aee-c5fb-4446-84d5-d5dd0bb9a76a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95376ec14224b34a592fb4d683609b8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC04LTEtMS0xNjY2_ba884c7a-2985-4cb8-8b1e-acfd7974f728">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8561d224210461c901b5f3c17a17ac6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0xMC0xLTEtMTY2Ng_48075fbf-84ea-432b-b322-a3ff30dc61c6">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0zLTEtMS0w_0e8af12d-6533-4d0c-bd23-7befc88e7db4">993,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC01LTEtMS0w_9e5e8c28-4f10-49c5-b5ab-925cd26f1443">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC03LTEtMS0w_20b88cc4-fd73-49b0-b3b5-55766e6d1a74">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC05LTEtMS0w_06e83a69-6811-4398-91af-64d8f0581643">993,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd4b3ae29e24484a045a0ea43dd64d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0xMS0xLTEtMA_3f2b158f-832b-423b-a55f-72388443b2f3">1,003,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3229216ca2cd4c8f801d00e8cb3409b6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNS05LTEtMS0w_aa6c280e-534d-472d-9dbd-39a870ee2742">123,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83eb3c2ca3a74138bb628878b3e1af2a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNS0xMS0xLTEtMA_9670d135-9946-489c-8106-3ed615ca41bb">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b987794ba23407893b7dc6257382c77_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNi05LTEtMS0w_0aa2c2e1-fb33-4b63-8e1e-7443fba16d6c">8,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2241989dd1a448d7adaf7823411b1840_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNi0xMS0xLTEtMA_a0db745d-2644-4be6-b194-0361c16bb30a">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNy05LTEtMS0w_c5e3d0f3-baf4-4ac9-8c11-734ef0847217">7,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNy0xMS0xLTEtMA_0340a338-25f4-4da2-818b-a019b9bb84fc">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfOC05LTEtMS0w_569615b4-4413-4003-a292-4b4f885cef91">1,133,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfOC0xMS0xLTEtMA_b08af8a5-840f-4f82-9d55-d138ba515050">1,198,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our gross unrealized gains and losses totaled $<ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjEyMA_77243d91-ca40-4988-abbb-f41ffd88bdbb">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjEyNw_41275081-1d80-497b-b99d-d8eaaa22adb2">0.2</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA4OA_e1911fd5-2055-4d50-8d3a-d156f2c81e28" continuedAt="i81b444b1612b4a86987fd41d70670fa1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i81b444b1612b4a86987fd41d70670fa1"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA5MA_c92bca3e-a3ad-4ff4-ab81-1bcb04d09b97" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMS0xLTEtMS0w_76173965-0e56-476b-9ef8-03f4a19fae66">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMS0zLTEtMS0w_9b393696-d95b-477b-81c9-4c6b671b3e8c">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMi0xLTEtMS0w_b74f6b81-2d29-4138-849a-043861d5a980">13,082</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMi0zLTEtMS0w_a8dcdfc4-503d-4a75-8bee-5392504db548">10,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMy0xLTEtMS0w_1caa5d23-8560-4994-91c4-42ddb4d7d25e">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMy0zLTEtMS0w_5f3f37a8-8d51-4ce2-9f91-a555112d3a73">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfNC0xLTEtMS0w_bf322d46-9fe2-4733-96c9-f13f84e03b48">16,808</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfNC0zLTEtMS0w_bbdd2ff7-a308-4d1e-a00c-e26223f5c130">15,292</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA5Mg_f1c09046-d16f-427a-b528-1fa2e2901043" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric> Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_1140"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="nktr:DevelopmentDerivativeLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0Nzkz_cd2fc45c-faf9-416f-98c7-554ec44f5218" continuedAt="ia2f16a1e5c6842d19dc3fe6fe57f81f6" escape="true">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="ia2f16a1e5c6842d19dc3fe6fe57f81f6" continuedAt="i3297756d29a1467e87b587bb08486b37"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementCommittedFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0Nzk1_9f3fc210-092c-4395-85d6-6d3490a4e059">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp; Dohme, pursuant to which MSD will provide Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria is met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i3297756d29a1467e87b587bb08486b37"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODEx_a1f6cd09-9ca4-4c0a-9254-345e563d2c33">450.0</ix:nonFraction>&#160;million, paid in annual contractual payments over <ix:nonNumeric contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" format="ixt-sec:durwordsen" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODM0_d2fc1a13-8e12-4713-8239-e1d65d458baa">five years</ix:nonNumeric>, with the first payment being $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTkz_5cf2c30b-008b-4677-84df-2c086ef82ce8">30.0</ix:nonFraction>&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODQ2_81e8d51e-4440-46fa-b6d9-605ee51d50c7">150.0</ix:nonFraction>&#160;million, paid in annual contractual payments over <ix:nonNumeric contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" format="ixt-sec:durwordsen" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODcw_2fe43626-8047-484a-bb8c-94d1c0ae33ea">seven years</ix:nonNumeric>. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementAdditionalIndicationPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODgy_e8af3408-204f-45c8-b5b4-72b37c327e97">37.5</ix:nonFraction>&#160;million to SFJ. If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $<ix:nonFraction unitRef="usd" contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212" decimals="-5" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementCommittedFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTYy_c4d304c8-fd58-44de-86ae-729a746a8e92">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the SFJ Agreement as development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Condensed Consolidated Statement of Operations. <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTkx_3a7ef76c-e2b9-4661-aa63-d8dfcd5213cc" continuedAt="i3c06fb28bdeb457b8fae1e5963134031" escape="true">The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:10pt"><ix:continuation id="i3c06fb28bdeb457b8fae1e5963134031"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:83.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.581%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="9" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0589fec22d0240d48c2ee8a46b1e6051_I20210212" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18xLTItMS0xLTE5NjM_bb20e888-9a01-4106-8e5a-e0061778f6c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331" decimals="-3" format="ixt:numdotdecimal" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18yLTItMS0xLTIzNzE_ba289112-6333-4d87-ad5e-87c2dd709832">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18zLTItMS0xLTIzNzk_324bb369-119e-4439-bc77-3a9fa240ad60">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18yLTItMS0xLTE5NjM_eeb5f23c-bca7-47f2-a6d6-933affbcfbe7">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef844280b874a7086af284de909cd28_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN181LTItMS0xLTE5NjM_fa8028b2-e2f6-46af-a762-dd95c1c8a5df">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (ii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iii) the probability of termination of the study due to meeting the interim futility criteria, (iv) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (v) SFJ&#8217;s cost of borrowing (<ix:nonFraction unitRef="number" contextRef="ifb734f7523814332bc13530cdead90d7_I20210212" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTc5_ee4b29a5-b8cc-45d1-885b-79165e69b8f8">1.0</ix:nonFraction>%), and (vi) the Company&#8217;s imputed cost of borrowing for debt with similar terms (<ix:nonFraction unitRef="number" contextRef="ia56b311eba0f474c8c9f8effb8942bdf_I20210212" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTg1_f1c9f762-a36b-4b4e-84d9-e8de6e061bee">12.2</ix:nonFraction>%).</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMzU1NQ_cc1528b7-0144-4b8a-bef6-b8a4f8bf74ec" continuedAt="idba7cfaef59242c6b73e457ffcd84345" escape="true">Liability Related to Sale of Future Royalties</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><ix:continuation id="idba7cfaef59242c6b73e457ffcd84345" continuedAt="ifd42d74fbf9246f38f767b2c668c4114"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="ifd42d74fbf9246f38f767b2c668c4114" continuedAt="i64e0622ace9748be8c3450daad24bb0d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYwMg_a8a17b85-23f0-4df8-98c6-0a3d9e203a6b">124.0</ix:nonFraction>&#160;million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYxOA_6a22e467-b6af-4e67-bcfd-3e75d9e5be63">4.4</ix:nonFraction>&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYzMg_83f310b0-9684-4536-b1cf-ddbccbd1b7ef">124.0</ix:nonFraction>&#160;million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB (AstraZeneca), as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH (collectively, Baxalta), as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G (collectively, Novo Nordisk) and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $<ix:nonFraction unitRef="usd" contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY0OA_1341c69c-69c8-4010-b8a1-b6ced31ad7ba">210.0</ix:nonFraction>&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $<ix:nonFraction unitRef="usd" contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY2NA_0f9c01c9-7918-40cf-ae12-23f01dacf87a">240.0</ix:nonFraction>&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $<ix:nonFraction unitRef="usd" contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216" decimals="-5" format="ixt:numdotdecimal" name="nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY4MA_3ccf9188-2d30-4990-b545-9e740686e353">208.0</ix:nonFraction>&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY5Ng_a34aa00f-e2b5-44ee-8d6b-11f901661fea">150.0</ix:nonFraction>&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzcxMg_b5fa3d1a-d5f8-46be-8dfd-8a8999e7ec99">3.8</ix:nonFraction>&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, which HCR received in the three months ended March 31, 2021. We recorded the $<ix:nonFraction unitRef="usd" contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzcyNg_e05fd987-901f-4a42-b5b3-63911ef9b0a4">150.0</ix:nonFraction>&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0Mzc2OQ_0c005a2d-8d42-4b75-9eb9-21b842376e5d" continuedAt="iaba6caeaa1b7416084652fdeca429aae" escape="true">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the three months ended March 31, 2021 and 2020. </ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><ix:continuation id="iaba6caeaa1b7416084652fdeca429aae"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC0xLTEtMS00OTQ_8029a35d-ef7d-4e0c-8338-f65536a82861">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC0zLTEtMS00OTQ_f8872dab-101d-4053-b3df-83a587240974">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC03LTEtMS00OTQ_48908baf-3e18-45f0-aa40-e3be54cbed75">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS0xLTEtMS00OTQ_3c8fdbf7-eed0-4b07-883e-a5d585b64c3f">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS0zLTEtMS00OTQ_ee9240f5-83b9-49ce-ae64-f3442b23fce5">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331" decimals="3" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS03LTEtMS00OTQ_bf9eec52-e852-4e94-a349-de5dee6a0e37">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i64e0622ace9748be8c3450daad24bb0d">&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contain other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.</ix:continuation></span></div><div id="ie41d9301146842468fa4c70d9ab030de_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDgzOA_78fe0ef5-22b6-4de9-b441-287fec56b97a" continuedAt="ib7cca5dc2c164ad59c35843d5657ccfa" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ib7cca5dc2c164ad59c35843d5657ccfa" continuedAt="i2369234a14b64919a6d73d6b4dbcfb57"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv&#8212;66-7-HSG, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made about clinical trials of bempegaldesleukin between January 2017 and June 2018.  The Mulquin complaint was amended in May 2019.  The defendants moved to dismiss and the court granted the motion without prejudice in July 2020.  The Mulquin plaintiffs again amended and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit is expected to be completed by September 2021.    </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb.  After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021.  The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the two securities actions (Mulquin and Damiba), three sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf.  These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officer and directors breached fiduciary duties by exposing the Company to one or both of the securities actions.  The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH).   After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020, in U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW).  The derivative actions in California have been consolidated and the Company has moved to dismiss on the basis that the plaintiffs have neither made a demand on the Company&#8217;s board of directors nor shown that demand would be futile.  The Company&#8217;s motion to dismiss has been under submission since December 2020.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF).  No response to the complaint is due until May 2021.  </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded <ix:nonFraction unitRef="usd" contextRef="i19a2169491224aa7bdef145df847c899_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfMTA5OTUxMTY1MDk2Mw_0287fee8-367d-4c28-b020-e64297b1983c"><ix:nonFraction unitRef="usd" contextRef="ia58a7dcb93434d91861bf0ba9f446985_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfMTA5OTUxMTY1MDk2Mw_ed8ad4df-c24a-497d-bdef-05fad95071cf">no</ix:nonFraction></ix:nonFraction> liability for these matters in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i2369234a14b64919a6d73d6b4dbcfb57"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="i12cf522fabf34f9f9889d9af3e35f07e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDczOA_46bcaf4b-4470-4f45-a79e-bec0e3fa0f6e"><ix:nonFraction unitRef="usd" contextRef="i0ba18dba9b8242f69de0a47836b3bfaa_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDczOA_ddc5e328-c512-4d6d-b015-f1b59dae0d2f">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_1146"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGV4dHJlZ2lvbjphNDg3NTRhNzI0OTA0MmRmYjc5ZWUxNGIyMTZiMjcxZl8xMDk5NTExNjMyOTM1_3dd4fcbc-a2f1-4720-90ac-070c204dd659" continuedAt="i937e065133914923ba2eb6db5891d09f" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="i937e065133914923ba2eb6db5891d09f" continuedAt="i60d222a0cf5e4db7b256fa36e407dc60"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGV4dHJlZ2lvbjphNDg3NTRhNzI0OTA0MmRmYjc5ZWUxNGIyMTZiMjcxZl8xMDk5NTExNjMyOTM2_91487092-a642-49c6-a0c3-dfdf9f8b6e5d" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy and the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36426a8b19bd4b7787bbf20a576265cd_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTQtMS0xLTE1NzY_f241b752-7077-4150-af6a-1dd1ca7bb722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia868932072e14135b8de20b8fbb05d07_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTYtMS0xLTE1NzY_896c465f-1469-41be-842c-d34f4f8e20ba">510,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1e022e0df84f8ab75a646beabe28c7_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTgtMS0xLTE1NzY_cf18e740-c360-4c7d-9dfb-3d288e83d93f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890cec45aa2c403990c5450c11ff80aa_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTEwLTEtMS0xOTMw_78207a94-a882-47d4-8a6a-46dc323c035d">510,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22f93ce0e6e443c8e9e4d9bde3f79d4_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTQtMS0xLTE1NzY_84c9f73f-6c20-4419-bda6-dc455e249526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e3ac045dec48a8896e485f547a26dc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTYtMS0xLTE1NzY_56c060c9-161c-4227-8821-b0d9f5c760f7">478,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c04572e64e47e09013051eea02caee_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTgtMS0xLTE1NzY_8caf6c5f-40b0-4a85-8156-26c4ac9436fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f08688820e4c0d944e8590248a9ee2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTEwLTEtMS0xOTMw_8085d9c9-6898-49f4-bbec-56b26148be65">478,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1355795842ee48cfbb1d6f4c02802112_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTQtMS0xLTE1NzY_71b7b10e-d57b-421f-b6a3-8f6cd81a6856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acb647abce34e528ca4a74280583891_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTYtMS0xLTE1NzY_4934f389-3055-40e8-ac3f-487e7710fff1">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b49c69835b040c4950674cd1f3a94cf_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTgtMS0xLTE1NzY_f88b8d45-a927-4769-8b5e-80a70a6e3bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9fb20bbc2d40529eb5a2ad309535ed_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTEwLTEtMS0xOTMw_3bafa1f5-a007-4b36-950b-4dd2c339612c">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie451f88b893143fd96763ffbce41fe96_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTQtMS0xLTE1NzY_887b181e-d7cc-42cb-825e-dfc61f4703b3">123,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea24fab4f124cfda87387948817a846_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTYtMS0xLTE1NzY_21dab592-1c4f-4ded-89c6-b59499d47f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8141e5c62f534eaf98c103e667821511_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTgtMS0xLTE1NzY_eab0d659-d9d5-424b-8eab-7fe14f82aa15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccde389fb0334895aa528d399ab3bf5e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTEwLTEtMS0xOTMw_20400dc2-755e-4ceb-ad51-4e4019e44da8">123,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2b40706c664b82b13759271c2bd0a2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTItMS0xLTM2OTU_50d8776f-6ef4-403e-96b7-826e025b537d">123,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e2f8958bdd4de09995408abc27ba55_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTQtMS0xLTM2OTU_26b88a1b-f833-48cd-a056-8dbd78f31566">993,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1803a5ad5a74f649f0ac70f1767a019_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTYtMS0xLTM2OTU_d40511d2-b543-49fa-b3a8-df3861b67bf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6af6053ea94cd9a9631c23a09ca612_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTgtMS0xLTM2OTU_f6a62e68-cc53-442a-af5f-1d8420450d63">1,117,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2b40706c664b82b13759271c2bd0a2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTQtMS0xLTE1NzY_46c5ff5f-0389-4472-abeb-35c30ddf7271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e2f8958bdd4de09995408abc27ba55_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTYtMS0xLTE1NzY_5f6e034d-7818-41e6-bbec-7df9e8784045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1803a5ad5a74f649f0ac70f1767a019_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTgtMS0xLTE1NzY_6478c1ec-bef4-414b-9628-7624bf13b4bb">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6af6053ea94cd9a9631c23a09ca612_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTEwLTEtMS0xOTMw_1a8ce42b-cd9e-41ce-818e-3d4a70e7bdd0">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="27" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="27" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92fdace84fb408085fe38e47c50a2c2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTQtMS0xLTE1NzY_641bca0d-2e19-4bef-a435-6f6f3a6ecd91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b94fb646ce44bdaf0638dc9f141c2d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTYtMS0xLTE1NzY_3142f6c0-176b-4fc8-aeb9-a994100bd6f1">687,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c61987eb3734024b9a5c864d6cb7045_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTgtMS0xLTE1NzY_f42447d1-9469-411c-9438-6ad03cf9d46e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecb6e5d960b4fe48ef63d770bac85ff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTEwLTEtMS0xOTQ3_7d856f4f-f1e0-465d-907e-ac91745ca98b">687,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520e0275aed84e53994d2120ede4c694_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC00LTEtMS0xNTc2_0909ce4b-b53a-45cc-852f-3d750f0629be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e07bf5444748f28089939d419f2bf9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC02LTEtMS0xNTc2_d98955cc-9ac6-4d40-bc2c-a575919784f2">313,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1b5f37d97c417a87bb5004508a6596_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC04LTEtMS0xNTc2_6ea53b1b-3354-473a-b89d-3632e9b29488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11baeb47973548c88d4519c8e83b21d7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC0xMC0xLTEtMTk0Nw_adcac5c1-4502-4577-884d-5c0f9e4ce2ac">313,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af4d5a03bc141219abdd52011fe5464_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS00LTEtMS0xNTc2_af6f25ce-a197-434c-8699-2bcc1344bf23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563f7505fa2546d69c640c2577604c52_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS02LTEtMS0xNTc2_f47d1c84-98e3-49c0-a92c-d3e805ec1980">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70ed10561534c5cbf9793749b869293_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS04LTEtMS0xNTc2_0cd2dd4f-fbc0-4ca4-95ed-29f3327b5f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cb50cd1caa4f38a48308a6383f0996_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS0xMC0xLTEtMTk0Nw_29cda31f-efdf-4de1-8f41-882be8c19811">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f50476b334c4003acc68e480643a590_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi00LTEtMS0xNTc2_c2e742b8-7268-40ab-8d83-ad3409acea34">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0e28f4f5464df5bbec94c881c5abc2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi02LTEtMS0xNTc2_aa82e9ea-1776-4d41-ac64-20b4f0a2a307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00c9d902daf42809ecedb590fac715c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi04LTEtMS0xNTc2_3b69c80d-e719-4692-b99a-99e6ae964a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ddc60c546d44ef2963908af8e5d76f3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi0xMC0xLTEtMTk0Nw_3cc4924a-1297-4258-9d0e-f8efe73e1c56">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8230f0003b5842ae9c7225aa05e51fc4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS0yLTEtMS0zNjk3_6cc0925a-61cb-46ec-974a-361261fea759">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ba56e21f0a4eee853230f5c88beb8b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS00LTEtMS0zNjk3_8d3f5fc9-d6fc-458f-98a7-f7a350821833">1,003,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8524ef60ac4f2cb9edab302f616345_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS02LTEtMS0zNjk3_d6ac7331-9a3e-4cff-bbe7-17c764e85dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee84611bbab94bc893e75949080dfc54_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS04LTEtMS0zNjk3_9d94bdbb-2739-4d2c-8b3f-d888efcd24cb">1,182,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8230f0003b5842ae9c7225aa05e51fc4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy00LTEtMS0xNTc2_f5a566f1-ae4e-4d7a-9f12-9a0595891aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76ba56e21f0a4eee853230f5c88beb8b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy02LTEtMS0xNTc2_80b4b472-1fd8-4c0b-8af6-ba677d9bc65d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8524ef60ac4f2cb9edab302f616345_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy04LTEtMS0xNTc2_9b0f0782-186f-437f-a770-e41f70d7149e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee84611bbab94bc893e75949080dfc54_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy0xMC0xLTEtMTk0Nw_3eba9c55-5384-4984-a25c-b91beb89086e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i60d222a0cf5e4db7b256fa36e407dc60"><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for similar assets in active markets or has been derived from observable market data. For the three months ended March&#160;31, 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. For the reconciliation of the changes in the development derivative liability and the description of the significant inputs used in estimating its fair value, see Note 4.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTg3NjY_59cd4bc5-8351-4e8c-b889-47827c91089d" continuedAt="i31069ec4da6e4e628775c70ff886e6d0" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i31069ec4da6e4e628775c70ff886e6d0" continuedAt="i3b18ecb9a36240c39e2c43a9342042c6"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.  </span></div><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTg3Njg_80816eae-f3d2-4175-9eda-293539d496b2" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:42.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug Candidate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f24288c76d4f32bd98bf26e7db5c55_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMi00LTEtMS0w_919f2ecd-e621-4cdb-804d-dd91e2db69b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67d1e2600b64ef78e842652cb1a0ae9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMi02LTEtMS0w_4de6d943-67ae-4397-9a2d-509b9b24372a">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1ae924c35842629018e614147300a6_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMy00LTEtMS0w_ae09e1f5-07bb-4f1d-b851-49d1e112ab00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff36581ebdf74fdaac3b5805cc4f475d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMy02LTEtMS0w_ffa54837-2f60-4ff3-876a-262f6a628562">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9249ec543db649c3b5dce617f420aa36_D20210101-20210331" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNS00LTEtMS0w_7f62a809-9550-498e-b875-459e8b2648ad">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib876abacb04c4b25be485ce424922ff7_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNS02LTEtMS0w_60b71375-2dbf-4a30-b0cd-c8cde9ca4680">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNi00LTEtMS0w_9c5bc060-ed32-47f6-bcc7-f2f7b19cc88f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNi02LTEtMS0w_1045bb9c-c349-4b1f-975a-8b441fb00d57">27,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ1OQ_cf3860e8-ac02-45d6-82bc-7a84c0a3e315">18.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTE2OQ_4621420d-beb3-4bd4-b6c9-111748a6f2f7">44.6</ix:nonFraction>&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $<ix:nonFraction unitRef="usd" contextRef="ibd31d1636dd74a5db8d7c83c962c2942_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nktr:SalesMilestoneRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTM2Ng_af1154d0-6c3b-4d86-b744-d8907d81674e">25.0</ix:nonFraction>&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March 31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ3NA_f64df430-11fd-4001-9dbe-40eeb18c79b9">1.7</ix:nonFraction>&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing <ix:nonFraction unitRef="number" contextRef="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3NzkzNg_c3441081-f4e8-400b-b282-0759c2c1ba89">65</ix:nonFraction>% and BMS sharing <ix:nonFraction unitRef="number" contextRef="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3NzkzOA_2b435f89-4ef8-4b45-b7c4-6ed311b864f9">35</ix:nonFraction>% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i4cc414d1438a4b329c44637d6305aa56_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk0Mw_7ae72914-ce2b-4db1-9360-ce501327b4ac">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="ib16676af93154d568c1375d2c0a4d1b8_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk1MA_0bf41d8c-823f-4c18-824b-e9676f2c81bc">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk1Nw_c04acaba-2441-4144-a87b-d7932ea86cc7">35</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk2Mg_d6f0843f-8893-42ac-aa5e-c095080b5a8f">65</ix:nonFraction>% to Nektar.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i2cb05b3574f34baea4609a9e773edd67_D20180401-20180430" decimals="-8" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk2Nw_2f781b70-1077-4984-bb94-2e74fbb2dd83">1.0</ix:nonFraction>&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $<ix:nonFraction unitRef="usd" contextRef="if7c479692b49492685f185a1840f7899_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk4MQ_2b4064d4-ad31-47d8-9826-20ceabb76982">1.455</ix:nonFraction>&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="i3b18ecb9a36240c39e2c43a9342042c6" continuedAt="if8ba0d27988a467bbc3471e8a0a9c6de"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i847c7a3b7a4a4032b79d9bcd3421535c_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk5Nw_0e61a01a-1374-4083-b62b-6facb89e90dd">350.0</ix:nonFraction>&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased <ix:nonFraction unitRef="shares" contextRef="i1740f80f6e884279b119d237d3326445_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODAxMw_5cd9c5df-8ddb-4cd6-b2e6-dc65cf7f3400">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ie2664e0c6c2543468ac3615b87452a66_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:SaleOfStockConsiderationReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODAyNA_338e3b51-0ba7-4f39-b6e3-bfd36517c425">850.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we aggregated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="nktr:AggregateConsiderationReceivedFromAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTI3OQ_dab725a8-22aa-4316-934c-00226a7657c4">1.85</ix:nonFraction>&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $<ix:nonFraction unitRef="usd" contextRef="i5369bf90ade043dd854e6754069729a5_I20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:EstimatedFairValueOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTYzMQ_48d64ede-f2fd-4c5c-8953-eec9be309939">790.2</ix:nonFraction>&#160;million in stockholders&#8217; equity. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTY4Nw_f6f13b52-0ff6-4c88-9c24-f23262c3c047">1,059.8</ix:nonFraction>&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones to be variable consideration. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODA0MA_2c23cb65-241e-4521-90f1-736ec7d6729d">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial on January 30, 2020, which we recognized in the three months ended March 31, 2020. We have also received a non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODA1NQ_d3a84e86-f70e-44a7-b7b4-d151ab530f39">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than these two milestones which we recognized during 2020, we continue to exclude the other milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i76f602e51e0c49249c41968d3420137b_I20210331" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestonesExcludedFromTransactionPrice" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ4OA_5284d206-663a-4bc4-90f9-bcaf84d5c15a">1.8</ix:nonFraction>&#160;billion from the transaction price as of March&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three months ended March&#160;31, 2021 and 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="ibad1c0adc7fd4601afed8c117d9bebe3_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUwMg_69211016-8701-45b3-a019-6598558e52d3">26.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i638f2b550bf04881a583181b88610a64_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODE3OA_b6ca60c1-b313-4b2e-a3d7-2e2d0a3e7117">30.7</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of March&#160;31, 2021, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="iadd3cabc118142ccb19c6e19c224fdcf_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUxNw_1a33e4a6-1039-4b0e-a84a-2bd5c606e172">26.2</ix:nonFraction>&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODIwOA_7981cfb7-31e6-42b3-93bc-534b4b0a58b5">150.0</ix:nonFraction>&#160;million in September 2017 and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="id5cc6f61322d48bc91f4421afbb6251b_I20170823" decimals="INF" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODIyNA_af37e60f-f8f2-4c2e-95ca-d18f24e5370a">250.0</ix:nonFraction>&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii)  share with Lilly Phase 1B and 2 development costs with <ix:nonFraction unitRef="number" contextRef="i1707076fdcc0477ba064e4a58a5b1a8b_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI0MA_d27b5125-84c0-42b9-bbd8-74d1c700f22e">75</ix:nonFraction>% of those costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="i99ccb5e0e99e4d75b46da24538873814_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI0NQ_3ced435a-2423-4c9b-96cc-a5db95a0b5e0">25</ix:nonFraction>% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from <ix:nonFraction unitRef="number" contextRef="i8cfd01d94766464ca526949208f6d2ea_D20170822-20170823" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODQzMA_1866359c-180a-430a-8f51-cf3202b11f2b">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="ia93c2e92f70844efaef925cc4f310e71_D20170822-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI1MA_cd1548ab-9aa5-471a-ba40-7b5f278babc6">25</ix:nonFraction>% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI1NQ_e2eefb3b-cd88-4fc4-9b97-e763b96c4483">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI2MA_8bbfaf04-a360-4481-a7ec-fac324be37c7">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $<ix:nonFraction unitRef="usd" contextRef="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTE3Nw_d9aeca36-f178-4e61-ab80-6f12dde5d11d">150.0</ix:nonFraction>&#160;million upfront payment as $<ix:nonFraction unitRef="usd" contextRef="ie7006ee9335c4157a84de254bb359388_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTIwMA_4cfe8408-ced4-4b02-8ba8-83bee8d63031">125.9</ix:nonFraction>&#160;million to the license, $<ix:nonFraction unitRef="usd" contextRef="i774e651a02ec4b0f95dde0602aac4434_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTIyMA_bcd85d6e-e817-4d03-9489-dc154aab6a31">17.6</ix:nonFraction>&#160;million to our portion of the Phase 1 clinical development and $<ix:nonFraction unitRef="usd" contextRef="i440119c59b3e443b88631f1edc85ff74_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTI3OQ_e470c032-e9d1-4f1f-a159-10f4a0d971eb">6.5</ix:nonFraction>&#160;million to the drug product development. We recognized the revenue </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="if8ba0d27988a467bbc3471e8a0a9c6de"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated to the license upon the effective date of the license agreement in August 2017. We recognized revenue for our performance obligations for Phase 1 clinical development and drug product development through March 31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2021, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, in 2012, we sold all of our rights to receive royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with UCB and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration agreement with Roche. Additionally, in 2020, we sold our rights to receive royalties for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with Baxalta (a subsidiary of Takeda Pharmaceutical Company Ltd.), MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with AstraZeneca and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under license agreement with Novo Nordisk. The 2020 transaction provides for a cap, such that, if the cap is achieved, future royalties on these products will return to us. See Note 5 for additional information regarding these agreements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have collaborations agreements for products under development, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="ic958491514274e76939f916d7f421a97_I20210331" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUzMg_1bf7e950-e352-4358-9db9-7fb559dad995">40.0</ix:nonFraction>&#160;million of development milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the respective transaction prices for these agreements.</span></div></ix:continuation><div id="ie41d9301146842468fa4c70d9ab030de_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY0_9032e8a4-9631-400e-bf26-f7a18539af00" continuedAt="ib6582d9c8cef4a50bd8b4a8b5ed0e98a" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ib6582d9c8cef4a50bd8b4a8b5ed0e98a"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY2_6bb9ed23-2a5d-41ac-a6fc-46d76122a4c1" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:74.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfe2d433ef840c286c01d47b0c5f9d1_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMi0xLTEtMS0w_60f91eeb-2ffe-4215-8e65-3dc92070acce">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8040c0e6c157482a8f36f8fda1edeeaa_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMi0zLTEtMS0w_bc711dec-7c1a-42d6-a8dd-28dc35a8017d">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85628854072425b81249accd9779120_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMy0xLTEtMS0w_d3a57402-742f-4a7b-98e5-fed045d5a568">14,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22a905697334834a0579dcebb9555a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMy0zLTEtMS0w_63eb2a73-4fd6-4d2c-a461-8098556c091c">15,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862a0be5967d420ab21a5f29eea2436e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNC0xLTEtMS0w_9fd6e20a-68a2-4434-a5fd-b4301cea00e2">9,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4fb5cc34a84085bf75a4ee4c6f7bff_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNC0zLTEtMS0w_1d148bba-0fc5-4bc1-877d-196ffd9d69af">7,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cd0871541b4364b1013eecb84d5e9f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNS0xLTEtMS0w_d0abf43e-b502-4384-90b1-73ce7a5ec96f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d469dfa3d97434e966b108b21df0121_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNS0zLTEtMS0w_cfeb57d6-4196-4fec-b64f-5d45bb3a7080">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNi0xLTEtMS0w_12a6c59e-aca7-4daa-8cdc-66e00e987367">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNi0zLTEtMS0w_14596ada-4d9b-4fc3-86b7-d659e9bc819e">25,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense reported in impairment of assets and other costs for terminated program resulted from executive severance. We accounted for this as a liability award as of March 31, 2020, which we reclassified into equity in three months ended June 30, 2020.</span></div><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY4_f5b6f7f6-d23b-44f9-b602-994a46cb7bd3" escape="true"><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:74.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMi0xLTEtMS0w_900808cc-29e9-41f6-ba8e-8c6b04c2dbff">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMi0zLTEtMS0w_bfda6e36-90ad-425c-a1ff-d529cc5132fb">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMy0xLTEtMS0w_38bbdcf2-84be-4132-a7c3-3957ebffb4e9">10.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMy0zLTEtMS0w_f0172975-2c56-4df3-907e-dd42a72949c8">11.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib94d1826584045bf83baf28f35342624_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNC0xLTEtMS0w_d2e136e6-5d66-40e1-a049-3a87d2ddcbca">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNC0zLTEtMS0w_d18a3b9f-6749-462b-a635-abc5437d495f">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib94d1826584045bf83baf28f35342624_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNS0xLTEtMS0w_082878e9-3db2-4e29-9f88-c70872860b15">20.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNS0zLTEtMS0w_09241213-1708-44f8-9203-c1d6b227d08d">18.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNi0xLTEtMS0w_7e72a42e-1380-4cb1-922b-6704689f7f77">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNi0zLTEtMS0w_d152effe-08a5-461a-ac04-3090505b5305">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie41d9301146842468fa4c70d9ab030de_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8212; <ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RleHRyZWdpb246ZmMyOTg4M2RiOWIyNDEyZWJhZDkzMTJkZTUxNWQ0ZTlfOTU1_2156c680-c729-4528-806f-7cca5ad26f90" continuedAt="i342234b07e27497d85d9574500af5aca" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i342234b07e27497d85d9574500af5aca" continuedAt="ic433dfda01b348c787529384c757c977">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><ix:continuation id="ic433dfda01b348c787529384c757c977"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2021 and March 31, 2020, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RleHRyZWdpb246ZmMyOTg4M2RiOWIyNDEyZWJhZDkzMTJkZTUxNWQ0ZTlfMTA5OTUxMTYyODg3MQ_e6c5ba77-ddc1-4dbf-a569-53dbabf8a3dd" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:74.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three-months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RhYmxlOjg2ZTdlOTRmMzU2YzQ0YWU4ZDk2NjkxYWQ4MGJmMzY3L3RhYmxlcmFuZ2U6ODZlN2U5NGYzNTZjNDRhZThkOTY2OTFhZDgwYmYzNjdfMi0xLTEtMS0xMzE5_f8349e7f-ad5a-45a2-9646-01fe4b216be1">19,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RhYmxlOjg2ZTdlOTRmMzU2YzQ0YWU4ZDk2NjkxYWQ4MGJmMzY3L3RhYmxlcmFuZ2U6ODZlN2U5NGYzNTZjNDRhZThkOTY2OTFhZDgwYmYzNjdfMi0zLTEtMS0xMzE5_363138da-6b61-4567-a6f3-4301cb4e3552">18,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="ie41d9301146842468fa4c70d9ab030de_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:8.8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines in the area of immuno-oncology (I-O), which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer.  In the I-O area, we are executing a clinical development program evaluating bempegaldesleukin (previously referred to as NKTR-214) in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating bempegaldesleukin in combination with other checkpoint inhibitors and agents with potential complementary mechanisms of action. We announced in August of 2019 that the FDA granted a Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect our research and development expense to continue to grow over the next few years as we expand and execute our broad clinical development program for bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No.&#160;1 (the Amendment) to the February 13, 2018, Strategic Collaboration Agreement (the BMS Collaboration Agreement). Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. Specifically, pursuant to the updated Collaboration Development Plan, bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently being evaluated in ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), muscle-invasive bladder cancer, and adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently underway. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BMS Collaboration Agreement, we and BMS share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge. We also share commercialization related costs, 35% BMS and 65% Nektar, which we present in general and administrative expense. Our share of development costs is limited to an annual cap of $125.0 million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, but we recognize our full share of the research and development expense and recognize the reimbursement as a liability. We repay the liability to the extent that our share of development costs is less than the annual cap in a future year, or by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin, if approved. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BMS Collaboration Agreement entitles Nektar to receive up to $1.455 billion of clinical, regulatory and commercial launch milestones. Of these milestones, we received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. Of the remaining milestones, $625.0 million are associated with the approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial). As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the Collaboration Development Plan with BMS, we are conducting and pursuing additional I-O research and development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. For example, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a non-small cell lung cancer (NSCLC) Phase 1/2 trial. In addition, on February 12, 2021, we entered into a financing and co-development collaboration with SFJ Pharmaceuticals to support a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with head and neck cancer whose tumors express PD-L1. Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to enhance the standard of care in multiple oncology settings. As a result, we expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging clinical development outcomes, scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our non-BMS clinical collaborations for bempegaldesleukin, generally each party supports the collaboration based on its expertise and resources. For example, our co-development collaboration agreement with SFJ includes both financial support from SFJ in the form of up to $150.0 million to fund the Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in head and neck cancer, as well as operational support from SFJ in managing the clinical trial. In addition, we announced on February 17, 2021, that we had entered into a clinical trial collaboration and supply agreement with Merck wherein we will receive supplies of Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost to us.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also combining bempegaldesleukin with NKTR-262. NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial in patients with solid tumors is currently ongoing.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next most advanced I-O program is NKTR-255. NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of NK cells and induces survival of both effector and CD8 memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular toxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. At the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, we reported early findings from the Phase 1 dose escalation study that demonstrated expansion of NK and CD8+ T cells in patients with multiple myeloma and non-Hodgkin lymphoma.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, we are developing NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358. We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We were responsible for completing Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs and receive a royalty rate on global NKTR-358 sales up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. Results from this study demonstrated a multiple-fold increase in regulatory T cells with no change in CD8 positive or natural killer cell levels and no dose-limiting toxicities were observed. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, has initiated a Phase 2 study in SLE in October 2020, and has initiated a Phase 2 study in ulcerative colitis. In addition, Lilly is planning to initiate two new Phase 2 studies in undisclosed auto-immune indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In virology, we received on October 22, 2020, FDA clearance for an Investigational New Drug application for bempegaldesleukin to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection. The study design allows us to evaluate whether bempegaldesleukin&#8217;s adaptive immune-stimulating mechanism to promote priming and proliferation of T cells and NK cells could be useful in the emerging treatment options for COVID-19. Enrollment in the Phase 1b randomized, double-blind, placebo-controlled trial began in November 2020.  We have also entered into a preclinical research collaboration with Gilead to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future research and development investment will depend on a number of trends and uncertainties including clinical study outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements including the BMS Collaboration Agreement, pursuant to which we have recognized $1.11 billion in revenue and recorded $790.2 million in additional paid in capital for shares of our common stock issued in the transaction. While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential remaining $1.405 billion in development and regulatory milestones under the BMS collaboration, in the medium- to long-term, our plan is to generate significant commercial revenue from proprietary products, the first of which being bempegaldesleukin, if approved. Since we do not have experience commercializing products or an established commercialization organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until September 30, 2020, we received royalties and milestones from two approved drugs: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which we have a collaboration with AstraZeneca; and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which we have a collaboration agreement with Baxalta Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.). MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral, peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with non-cancer pain which was approved by the FDA and subsequently launched in March 2015 (wherein in the EU, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is sold as MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is indicated for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives, which was approved by health authorities in the European Union and many other countries beginning in 2014). ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a half-life extension product of Factor VIII was approved by the FDA in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A (wherein in the EU, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is sold as ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was approved by health authorities in Europe in January 2018, and has also been approved in many other countries).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on October 1, 2020, our rights to receive royalties arising from the worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and specified licensed products under a Right to Sublicense Agreement, dated October 27, 2017, were sold for $150.0 million pursuant to a capped return sale arrangement to entities managed by Healthcare Royalty Management, LLC (collectively, HCR) under a purchase and sale agreement (the 2020 Purchase and Sale Agreement) entered into on December 16, 2020. With regard to the capped return sale arrangement, the 2020 Purchase and Sale Agreement will automatically expire, and HCR&#8217;s right to receive the sold royalties, will cease when HCR has received payments equaling $210.0 million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). After the 2020 Purchase and Sale Agreement expires, all rights to receive these royalties return to Nektar.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A. Risk Factors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinic in future years. We are also advancing several other drug candidates in preclinical development in the areas of I-O, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In March 2020, COVID-19, the disease resulting from a novel strain of coronavirus infection, was declared a global pandemic. Many countries, including the United States and India, initially took steps such as restricting travel, closing schools, and issuing shelter-in-place orders to slow or moderate the spread of the virus. More recently, states and countries have adopted individualized approaches to respond to the COVID-19 pandemic. In particular, local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas. Although vaccines intended to reduce the incidence and severity of infection are available pursuant to an Emergency Use Authorization granted by the FDA in the U.S. (and under similar authorizations by other health authorities in our countries), it remains unclear how long the negative impacts caused by the coronavirus will continue into the future.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, with respect to the operation of our facilities, we are closely adhering to applicable guidelines and orders.  Operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with the permissions granted under local government ordinances. Recently, in view of the surge of COVID-19 cases occurring in India, we have further decreased the number of employees working at our facilities in Hyderabad. Across all our locations, we have instituted a temporary work from home policy for all office personnel who do not need to work on site to maintain productivity. At this time, we have not identified a material change to our productivity as a result of these measures, but this could change, particularly if restricted travel, closed schools, and shelter-in-place orders are not removed or significantly eased in the areas in which we operate.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials.   </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our proprietary drug candidates and the COVID-19 pandemic introduces significant challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. The rapid development and fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on our clinical trials, our operations and our business. As a result, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our specific clinical programs as discussed below, is difficult to predict and subject to change.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, for the ongoing registrational clinical trials studying the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cancer indications being led by Nektar (such as adjuvant melanoma, RCC and first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer), although we have not seen evidence to date that the COVID-19 pandemic has had a significant impact on enrollment for these trials, the future impact of the COVID-19 pandemic on these trials is very difficult to predict and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Nektar&#8217;s Phase 1/2 trial studying bempegaldesleukin and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in NSCLC, although the COVID-19 pandemic delayed the initiation of certain investigator sites in Europe earlier in the trial, we currently expect to have initial safety as well as preliminary overall response rate data for the dose-escalation and 0.006 mg/kg NSCLC expansion cohorts of this study in the second half of 2021. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Nektar&#8217;s ongoing clinical study of NKTR-262 (the Phase 1/2 REVEAL study), this study has largely remained on track although we have experienced some challenges with new investigator site initiations. Nektar&#8217;s Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to challenges caused by the COVID-19 pandemic, and the dose-escalation monotherapy portion of the study is expected to be completed in the first half of 2021. For both of these Nektar-run clinical programs, the ongoing COVID-19 pandemic could still impact investigator site initiations and trial enrollment despite our mitigation efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For clinical studies of our proprietary drug candidates being run by our partners, BMS is enrolling patients in each of the BMS-led registration studies and re-started initiation of new investigator sites in the third quarter of 2020 following a pause in the initiation of new investigator sites it instituted for all of its studies as a result of the COVID-19 pandemic. In the summer of 2020, BMS extended their timeline estimates by approximately six months for the first data read-outs for the first-line melanoma trial. We will continue to monitor the progress of enrollment of the BMS-led studies and projections for topline clinical outcome data. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Lilly, which is running clinical trials of NKTR-358, has indicated it will likely have delays of at least three to six months following its temporary suspension of recruitment for the ongoing Phase 1b studies in atopic dermatitis and psoriasis as a result of the COVID-19 pandemic. Lilly recently started a Phase 2 study in moderate to severe lupus patients in October and has initiated an additional Phase 2 study in ulcerative colitis. The rapid development and fluidity of the COVID-19 pandemic preclude any firm estimates as to the ultimate effect this disease will have on our collaborators&#8217; clinical trials. As a result, there remains substantial uncertainty as to potential impacts on our collaboration partner studies.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our IND-enabling research, although the COVID-19 pandemic has caused us to reduce the number of employees working at our sites, a subset of our research-based employees continues to conduct laboratory work in our research facilities (which is permitted under the applicable government ordinances). As a result, we continue to make progress in the identification of new drug candidates.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic.  In addition, to the extent that the integrity of individual patient data is negatively affected by the COVID-19 pandemic, we will consider measures to maintain the integrity of the clinical study overall (such as over-enrolling patients into the study and removing all patients originating from an affected study site when performing statistical analyses of study endpoints). Although these measures may have the benefit of preserving the overall integrity of a clinical study, implementing these measures could result in a delay in completing the study.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this respect, we are also incorporating recent direction and flexibility provided by regulatory authorities, including the FDA in its March 18, 2020 Guidance (most recently updated January 27, 2021) entitled &#8220;FDA Guidance on Conduct of Clinical Trials of Medicinal Products during COVID-19 Public Health Emergency.&#8221; This Guidance is continually being updated by FDA and updates can be found on the FDA&#8217;s website at www.fda.gov. In addition, we may refer to guidance documents from other regulatory agencies, such as, for example, the European Medicines Agency&#8217;s &#8220;Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials&#8221; found on www.ema.europa.eu, which are also continually being updated.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans through at least the next twelve months. As of March&#160;31, 2021, we had approximately $1.1 billion in cash and investments in marketable securities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March 31, 2021 and 2020</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,926)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales increased for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020 primarily due to an increase in product demand from our collaboration partners. We expect product sales for the full year of 2021 to increase compared to 2020 due to increased demand from our collaboration partners.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to our Condensed Consolidated Financial Statements, on December 16, 2020, we entered into the 2020 Purchase and Sale Agreement with entities managed by Healthcare Royalty Management, LLC (collectively, HCR), under which we agreed to sell to HCR certain of our rights to receive royalty payments arising on worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning October 1, 2020. As a result, we recognized royalty revenue for these products for the three months ended March 31, 2020, and recognized these royalties as non-cash royalty revenue for the three months ended March&#160;31, 2021. Please see Note 5 to our Consolidated Financial Statements for additional information on the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to recognize any royalty revenue during 2021, because we will recognize all such royalties as non-cash royalty revenue as a result of the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sale of Future Royalties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, we recognized $25.0 million in license, collaboration and other revenue for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial under the BMS Collaboration Agreement. Accordingly, license, collaboration and other revenue decreased during the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020 due to the recognition of this milestone. We expect that our license, collaboration and other revenue will decrease significantly for the full year of 2021 compared to 2020 as a result of the recognition of this $25.0 million milestone and the $25.0 million milestone for the first patient, first visit in the registrational adjuvant melanoma trial, which we recognized in the three months ended June 30, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:49.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents a worsening, since the negative gross margin has increased.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin was negative for the three months ended March&#160;31, 2021 and March&#160;31, 2020. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales from reagent materials supplied to the partner where our sales are less than our fully burdened manufacturing cost, we also receive royalty revenue from this collaboration. In the three months ended March&#160;31, 2021 and 2020, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We currently expect product gross margin to be negative in 2021 as a result of the manufacturing arrangement described above.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased for the three months ended March&#160;31, 2021&#160;compared to the three months ended March&#160;31, 2020&#160;primarily due to manufacturing activities for bempegaldesleukin which were completed during 2020. Additionally, development costs for NKTR-358 decreased for the three months ended March&#160;31, 2021&#160;compared to the three months ended March&#160;31, 2020, reflecting our completion of our Phase 1 clinical development and drug product development deliverables, for which we were responsible for 100% of costs, to the Phase 1B and Phase 2 development, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs. The costs of our clinical development program, including bempegaldesleukin, NKTR-262 and NKTR-255, were consistent between the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020. During the three months ended March&#160;31, 2021 and 2020, we recorded net reductions to research and development expense for BMS&#8217;s reimbursements of our costs of&#160;$26.7 million and $30.7 million, respectively.&#160;Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin. Please see Note 8 to our Condensed Consolidated Financial Statements for additional information regarding our BMS Collaboration Agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expense to increase for 2021 compared to 2020 primarily as a result of our continued development of bempegaldesleukin, including studies outside of the BMS Collaboration Agreement. In addition, we are collaborating with Lilly to develop NKTR-358, and Lilly will be conducting the recently started Phase 2 studies and other ongoing studies in 2021, for which we are responsible for 25% of costs. We are continuing to enroll patients in the expansion cohorts of the Phase 1/2 study for NKTR-262 in combination with bempegaldesleukin. We will continue our Phase 1/2 dose-escalation and expansion studies for NKTR-255 in multiple myeloma, non-Hodgkin lymphoma, relapsed or refractory head and neck squamous cell carcinoma, and colorectal cancer. The timing and amount of our future clinical investments will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we are evaluating in clinical development during 2021, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates by applying our polymer conjugate technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for bempegaldesleukin and NKTR-358, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the evolving situation around the COVID-19 pandemic has had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the pandemic. We have experienced delays of approximately three months for some Nektar-run, earlier-stage clinical studies (such as the Phase 1/2 trial studying bempegaldesleukin and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in NSCLC and the Phase 1 dose escalation trial studying NKTR-255 in patients with relapsed/refractory hematologic malignancies) and given the evolving situation around the COVID-19 pandemic it is possible there could be additional delays in the future. In addition, for certain clinical studies involving our proprietary drug candidates that are run by our partners, study timelines have been delayed at least three to six months, and, given the evolving situation around the COVID-19 pandemic, it is possible there could be additional delays in the future. As a result of these delays and potential delays, we may incur additional costs associated with these clinical trials. At this time, we cannot estimate if such increases would have a material effect on our results of operations or financial position.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks and uncertainties associated with our research and development projects are discussed more fully in Item 1A. Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,679&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,217&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense includes the cost of administrative staffing, business development, commercial, finance and legal activities. General and administrative expense increased during the three months ended March&#160;31, 2021 compared with the three months ended March&#160;31, 2020 primarily due to increased personnel costs as we continue a stage-appropriate build of our commercial capability to co-commercialize bempegaldesleukin with BMS. We expect general and administrative expenses in the full year of 2021 to increase compared to 2020, as we continue to build our commercial capabilities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program (in thousands, except percentages)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:49.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,189&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.7 million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5 million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and severance costs. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:49.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,204)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the three months ended March 31, 2020 primarily consisted of interest from our senior secured notes. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. As a result, we incurred no interest expense after the repayment date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:48.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-cash royalty revenue related to sale of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-cash interest expense on liability related to sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to our Condensed Consolidated Financial Statements, we continue to recognize non-cash royalty revenue for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement (as defined in Note 5). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue for the 2012 Purchase and Sale Agreement decreased marginally for the three months ended March&#160;31, 2021 as compared to the three months ended March&#160;31, 2020. Non-cash interest expense for the 2012 Purchase and Sales Agreement increased for the&#160;three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020&#160;due to an increase in the estimated implicit interest rate over the life of the transaction, as disclosed above. When forecasted future revenues rise, this results in an increase to the estimated implicit interest rate over the life of the transaction, which, in turn, increases the prospective effective interest rate in the current and future periods. The estimated implicit rate increased from the three months ended March&#160;31, 2020 to the three months ended March&#160;31, 2021 due to an increase in estimated future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the non-cash interest expense. To date, we have amortized $49.8 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $64.2 million of the net proceeds, since RPI (as defined in Note 5) receives all of the benefits of the increases in future royalties. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to our Condensed Consolidated Finance Statements and above under Royalty Revenue, we sold our rights to receive royalties for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for sales beginning on October 1, 2020, and therefore we recognized non-cash royalty revenue and non-cash interest expense for the three months ended March 31, 2021, but did not recognize non-cash royalty revenue and non-cash interest expense for the three months ended March 31, 2020. Similarly, non-cash royalty revenue and non-cash interest expense will increase for 2021 compared to 2020. Our estimate of the imputed interest rate reflects our estimates for sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which result in meeting the 2025 Threshold (as defined in Note 5). Because the 2025 Threshold of $210.0 million and the increase in the threshold to $240.0 million (if the 2025 Threshold is not achieved) limit the amount of royalties payable to HCR, the potential for the implicit interest rate to vary is more limited. Instead, we will receive the benefit of net sales if they exceed the threshold, but do not bear risk of loss or payments to HCR if royalties are less than expected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of development derivative liability</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of development derivative liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4 to our Condensed Consolidated Financial Statements, we remeasure the development derivative liability under our co-development agreement with SFJ to fair value at each reporting date. The change in fair value recorded for the three months ended March 31, 2021 primarily reflects the accretion of the scenario-based probability-adjusted discounted cash flows of our obligation to potentially pay Success Payments to SFJ using our imputed borrowing rate of 12.2%, net of the accretion of SFJ&#8217;s obligation to fund the SCCHN Clinical Trial, using SFJ&#8217;s estimated borrowing rate of 1.0%. We review our estimates at each reporting period, and, in particular, in future periods, as information becomes available, such as the applicable clinical trial results and FDA approval decisions, we will re-evaluate our probability of success estimates related to achieving FDA approval for bempegaldesleukin in the Melanoma Indication, the SCCHN Indication and one additional indication, and will record a corresponding increase or decrease in the fair value of the development derivative liability. Additionally, in future periods, we may adjust our estimate of the probability of a successful interim futility analysis and we will record a corresponding decrease or increase to the fair value of the development derivative liability, reflecting the increase or decrease (as applicable) in the likelihood of SFJ&#8217;s resulting obligation to complete the full SCCHN Clinical Trial. Such changes in the probabilities of success may result in a material expense or benefit in the period when the information is received. However, based on current clinical timelines, we do not expect material changes to our probability of success assumptions during 2021, and, therefore, we expect to recognize primarily the accretion expense on the discounted cash flows discussed above. See Note 4 for additional information about the development derivative liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense) decreased for the three months ended March&#160;31, 2021 compared to the three months ended March&#160;31, 2020 due to lower investment balances which have been utilized to fund our operations as well as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in market interest rates. The effective interest rate earned on investments which we purchased after the COVID-19 pandemic began has been significantly lower than historical interest rates, and we expect this trend to continue. We expect that our interest income and other income (expense), net will decrease for 2021 compared to 2020 for these same reasons.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, our income tax expense primarily resulted from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_85"></div><div style="margin-top:18pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through revenue from product sales, royalties and strategic collaboration agreements, as well as public offering and private placements of debt and equity securities. At March&#160;31, 2021, we had approximately $1.1 billion in cash and investments in marketable securities. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing this Form 10-Q. We expect the clinical development of our proprietary drug candidates including bempegaldesleukin, NKTR-358, NKTR-262 and NKTR-255 will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In April 2018, we received a total of $1.85 billion from BMS including a $1.0 billion upfront payment and an $850.0 million premium investment in our common stock. In July 2017, we entered into a collaboration agreement for NKTR-358 with Lilly, under which we received a $150.0 million upfront payment. Pursuant to the 2020 Purchase and Sale Agreement, in December 2020 we received $150.0 million from HCR in exchange for certain of our rights to receive royalty payments arising in respect of worldwide net sales of specified products including ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the future, we expect to receive substantial payments from our collaboration agreements with BMS and Lilly. In particular, under the BMS Collaboration Agreement, we are entitled to approximately $1.455 billion of clinical, regulatory and commercial launch milestones (of which, we have received $50.0 million). Of the remaining milestones, $625.0 million are associated with approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (which reflects the reduction for the $25.0 million nonrefundable, creditable milestone for the first patient, first visit in the muscle-invasive bladder cancer trial that BMS paid to us in March 2020).&#160;As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement with SFJ Pharmaceuticals (SFJ), pursuant to which SFJ will pay up to $150.0 million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with pembrolizumab (Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). In exchange for funding the SCCHN Clinical Trial, SFJ is entitled to a series of contingent success-based payments with the first payment due after the substantial completion of the SCCHN Clinical Trial which we currently expect to occur in late 2024 or early 2025 as follows: (i) if bempegaldesleukin receives FDA approval for first line metastatic melanoma or the SCCHN Indication, we would pay SFJ $450.0 million over a series of five annual payments with the first annual payment being $30.0 million, with the earliest possible payment expected to occur in 2024, subject to the substantial completion of the SCCHN Clinical Trial.; (ii) if bempegaldesleukin receives FDA approval in both first line metastatic melanoma and the SCCHN indication, we would pay SFJ an additional $150.0 million paid over a series of seven annual payments; and (iii) if bempegaldesleukin receives FDA approval in an indication other than first line metastatic melanoma or the SCCHN indication, a one-time payment of $37.5 million. See Note 4 to our Condensed Consolidated Financial Statements for additional information.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if delays caused by the COVID-19 pandemic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in commencing and enrolling patients in our clinical trials or those run by our partners result in a delay in completing these trials, our ability to file for regulatory approval and commercialize these products (if approved) and receive associated milestone payments may also be delayed.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for bempegaldesleukin, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the three months ended March&#160;31, 2021 totaled $77.1&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the three months ended March&#160;31, 2020 totaled $78.1 million, which includes $98.1 million of net operating cash uses as well as $5.0 million for interest payments on our senior secured notes, partially offset by the receipt of the $25.0 million milestone payment from BMS for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, will increase in the full year of 2021 compared to 2020 primarily as a result of increased research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $2.9&#160;million and $0.9&#160;million for the purchase or construction of property, plant and equipment in the three months ended March&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $17.1 million and $11.1&#160;million in the three months ended March&#160;31, 2021 and 2020, respectively. Additionally, during the three months ended March 31, 2021, we received $0.8 million from SFJ pursuant to our co-development agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. Other than the development derivative liability under our co-development agreement with SFJ as described in Note 4 to our Condensed Consolidated Financial Statements, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks at March&#160;31, 2021 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020 on file with the SEC.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_97"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended March&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="ie41d9301146842468fa4c70d9ab030de_103"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 5 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_88"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, results of operations, financial condition, cash flows and future prospects and the trading price of our common stock and our ability to repay our senior secured notes could be harmed as a result of any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2020, including our consolidated financial statements and related notes, and our other filings made from time to time with the SEC.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of bempegaldesleukin, our lead I-O candidate.&#160;We are executing a clinical development program for bempegaldesleukin and clinical and regulatory outcomes for bempegaldesleukin, if not successful, will significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize bempegaldesleukin. In general, most investigational drugs, including I-O drug candidates such as bempegaldesleukin, do not become approved drugs. Accordingly, there is a very meaningful risk that bempegaldesleukin will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from bempegaldesleukin have had a significant impact on our market valuation, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of bempegaldesleukin are delayed (as a result of, for example, our collaboration partner causing a delay of the initiation or completion of one or more clinical trials for reasons outside of our control) or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to approximately $1.455 billion in development milestone payments (of which we have received $50.0 million) that are based upon clinical and regulatory successes from the bempegaldesleukin development program. One or more failures in bempegaldesleukin studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestone payments that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating bempegaldesleukin, including trials evaluating bempegaldesleukin as a potential combination treatment with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as other ongoing and planned combination trials. Our partner Lilly is conducting two Phase 2 studies of NKTR-358 in patients with SLE and ulcerative colitis as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis. We also continue to enroll patients in a Phase 1/2 study evaluating bempegaldesleukin in combination with NKTR-262 in patients with solid tumors.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as bempegaldesleukin and NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial to the detriment of enrollment rates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay our ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.&#160; Our clinical trial plans for bempegaldesleukin, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of component therapies, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our proprietary drug candidates currently in development. For bempegaldesleukin, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Novartis AG; potential competitors in the cytokine-based therapies space include Alkermes plc, ImmunityBio, Inc., Neoleukin Therapeutics, Inc., Philogen S.p.A., Roche, Sanofi SA (through its acquisition of Synthorx, Inc.), and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences); and potential competitors in the checkpoint inhibitor space include GlaxoSmithKline plc (through its acquisition of Tesaro, Inc.), Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, ILTOO Pharma, Pandion Therapeutics, and Roche). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:18pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the three months ended March&#160;31, 2021, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $16.56 to $25.46 per share. In response to volatility in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the price of our common stock in the past, Plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into potential securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, Plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by Plaintiffs&#8217; securities litigation firms following share price fluctuations. </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations in our results of operations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our financing needs and activities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general market conditions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on BMS (through the BMS Collaboration Agreement) and Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for bempegaldesleukin and NKTR-358, respectively.  Furthermore, we will rely on BMS and Lilly to perform specified commercialization activities for bempegaldesleukin and NKTR-358, respectively, pursuant to the applicable agreement. In the event BMS or Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.  Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by BMS&#8217;s or Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for reasons outside of our control, the operations of our collaboration partners may be more affected by the COVID-19 pandemic than we are, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than Nektar-run trials under the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our proprietary drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had cash and investments in marketable securities valued at approximately $1.1 billion. On April 13, 2020, we redeemed our senior notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates &#8212; important examples include bempegaldesleukin and NKTR-358;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our proprietary drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our biologic candidates even if there is adequate coverage and reimbursement from third-party payers. It is unclear what effect, if any, the American Rescue Plan will have on the number of covered individuals.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;  &#160;&#160;&#160;&#160;Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;  &#160;&#160;&#160;&#160;Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; &#160;&#160;&#160;&#160;In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the U.S. Secretary of Health and Human Services (HHS) certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the U.S. Secretary of the HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, we reported a net loss of $123.0 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for bempegaldesleukin, NKTR-358, NKTR-262, and NKTR-255;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:18pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. With respect to the ongoing COVID-19 pandemic, national, state and local governments in regions affected by the COVID-19 pandemic have implemented, and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures and other measures.  These measures may disrupt normal business operations both in and outside areas affected by COVID-19, and may have significant negative impacts on our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic.  For example, we have implemented work from home policies for most employees and limited business travel. Although we believe these and the other safety measures we have taken in response to the COVID-19 pandemic have not substantially impacted our productivity, it is not certain that this will continue to be the case. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Prolonged remote working arrangements could impact employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks. If we, our partners, our suppliers, or our contractors experience a cyberattack, experience data accessibility issues, or encounter communication disruptions, our business may suffer as a result of the loss or theft of our important data, and we may be liable for compromising the protection of personal data.     </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties with whom we seek important goods and services. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties fully due to the COVID-19 pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. Furthermore, delays and disruptions experienced by our collaborators or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect clinical development or regulatory approvals of our biologic candidates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our biologic candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The COVID-19 pandemic could affect our ability, and the ability third parties on whom we rely, to successfully manufacture sufficient supplies to complete our clinical trials in a timely manner.  For example, it may be more difficult to obtain materials or manufacturing slots for the products required to conduct our clinical trials due to the demand for recently authorized vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our proprietary biologic candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our biologic candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us. Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change. We do not yet know the full extent of potential impacts </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material negative impact on our operations and our business.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologics or biologic substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded by the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing biologics for use in clinical trials may be negatively impacted such that there is an insufficient supply of study biologic drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the CARES Act in response to the COVID-19 pandemic. Throughout the COVID-19 outbreak, there has been public concern over the availability and accessibility of critical medical products, and the CARES Act enhances FDA&#8217;s existing authority with respect to drug shortage measures. Under the CARES Act, we must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or API is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Business Operations</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our biologic candidates successfully.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the very early stages of building a commercialization and distribution capabilities for bempegaldesleukin in the United States and Europe. To commercialize any of our biologic candidates that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which is both  expensive and time consuming, or enter into arrangements with third parties to perform these services. For example, we have committed to co-commercializing bempegaldesleukin with BMS and establish global distribution and infrastructure for us to be able to book global revenue for bempegaldesleukin if it achieves regulatory approval. Establishing this commercialization capability requires a significant commitment of financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain management talent to lead key marketing and distribution roles;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of sales personnel and medical science liaisons to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control. In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our proprietary biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning and execution. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered biologic candidates. Our strategy also calls for us to undertake increased research and development activities and establish a commercial organization in collaboration with our partners, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to biologic candidates granted Breakthrough Therapy designation by the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our biologic candidates, although we cannot be certain that our biologic candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of biologic candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a biologic candidate as a Breakthrough Therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the biologic candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received Breakthrough Therapy designation for the treatment of patients with previously untreated unresectable or metastatic melanoma, we may elect not to pursue Breakthrough Therapy designation for our other biologic candidates, and the FDA has broad discretion whether or not to grant these designations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accordingly, even if we believe a particular biologic candidate is eligible for Breakthrough Therapy, we cannot be assured that the FDA would decide to grant it. Breakthrough Therapy designation does not change the standards for biologic approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the Breakthrough Therapy designation. Thus, even though we have received Breakthrough Therapy designation, we may not experience a faster development process or review, and, upon any filing seeking regulatory approval, we may not obtain an approval from the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to bempegaldesleukin in combination with Opdivo&#174; for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of bempegaldesleukin on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of biologic candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:19pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, it could subject us to substantial liabilities and harm our financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our bioloigc candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 300 U.S. and 1,050 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic's commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. On December 2, 2020, the Office of Inspector General, or OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, and also includes the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there  may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additionally, state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. These state-equivalent laws may also apply to our business practices, including, but not limited to, research, distribution, and sales or marketing arrangements. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, suing risk management methods, to meet user fee commitments and goal dates. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be appropriate, FDA has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptability of a facility, FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. For example, we are currently involved in German litigation proceedings whereby we and Bayer Healthcare LLC are seeking at least co-ownership rights in certain of each other&#8217;s patent filings related to PEGylated Factor VIII products. We believe that Bayer&#8217;s claims to an ownership interest in these is without merit and we are vigorously defending our exclusive ownership rights to this intellectual property. These German litigation proceedings are currently stayed pending the outcome of ongoing mediation efforts. In the U.S., Bayer filed a complaint against Baxalta and Nektar alleging the ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes a Bayer patent. Although the U.S. court dismissed all of Bayer&#8217;s claims against Nektar and Nektar was removed as a defendant, a jury found the Bayer patent was valid and infringed, and awarded Bayer damages, the responsibility of which are borne fully by Baxalta. This damages award does not impact our royalties from sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with Baxalta and Baxalta is currently appealing the decision. In other U.S. proceedings, Nektar and Baxalta filed complaints against Bayer Healthcare alleging Bayer&#8217;s JIVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product infringes several Nektar patents. In addition, in response to notices AstraZeneca and we received from the generic companies, Apotex (Apotex Inc. and Apotex Corp.), MSN Laboratories Pvt. Ltd., (MSN) and Aurobindo Pharma USA INC. alerting us that they had filed abbreviated new drug applications (ANDAs) with the FDA to market a generic version of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Paragraph IV Certifications), AstraZeneca and we together filed patent infringement suits against each of these generic companies. In these Paragraph IV Certifications, all three generic companies only alleged one patent, U.S. Patent No. 9,012,469, is invalid, unenforceable and/or not infringed by the manufacture, use or sale of their respective generic products. At this time, none of the other five Orange Book listed patents associated with MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are being challenged by these generics companies.  On March 25, 2021, RedHill BioPharma (sublicensee of AstraZeneca&#8217;s global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe and Canada) announced that Redhill BioPharma, AstraZeneca and Nektar entered into a settlement and license agreement with MSN pursuant to which the parties agreed to file a stipulation and order to dismiss the lawsuit to conclude the litigation with respect to MSN, and MSN agreed not to sell a generic version of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. until October 1, 2030. In addition, on March 18, 2020, Aether Therapeutics Inc. filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. Also, on June 5, 2020, UCB Pharma S.A. and Celltech R&amp;D </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limited (collectively UCB) served notice of a Declaratory Judgment of Patent Invalidity proceeding filed in the United States District Court for the District of Delaware seeking a declaration of invalidity of specified U.S. patents owned by Nektar and licensed to UCB. UCB is also pursuing similar actions in other jurisdictions. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings other than those related to intellectual property.  In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv&#8212;66-7-HSG, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made about clinical trials of bempegaldesleukin between January 2017 and June 2018.  The Mulquin complaint was amended in May 2019.  The defendants moved to dismiss and the court granted the motion without prejudice in July 2020.  The Mulquin plaintiffs again amended and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit is expected to be completed by September 2021.    </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb.  After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021.  The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the two securities actions (Mulquin and Damiba), three sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf.  These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officer and directors breached fiduciary duties by exposing the Company to one or both of the securities actions.  The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH).   After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020, in U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW).  The derivative actions in California have been consolidated and the Company has moved to dismiss on the basis that the plaintiffs have neither made a demand on the Company&#8217;s board of directors nor shown that demand would be futile.  The Company&#8217;s motion to dismiss has been under submission since December 2020.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF).  No response to the complaint is due until May 2021. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the putative securities class action lawsuits and shareholder derivative lawsuits) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at March&#160;31, 2021.</span></div><div style="margin-top:18pt;padding-left:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business to subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks to our Business</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was signed into law and included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the E.U., a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we and others could face new regulatory costs and challenges.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions, our business may be adversely affected following new or increased tariffs that result in the increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_106"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended March&#160;31, 2021.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_109"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_112"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie41d9301146842468fa4c70d9ab030de_115"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:10.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Documents</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312519029550/d692256dex31.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000906709/000090670920000009/nktr2020-03x31ex101.htm">Amended and Restated Compensation Plan for Non-Employee Directors ++</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr2021-03x31xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr2021-03x31xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr2021-03x31xexx321.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 1998.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 2000.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on January 23, 2003.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended December 31, 2009.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on February 6, 2019.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ie41d9301146842468fa4c70d9ab030de_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie41d9301146842468fa4c70d9ab030de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ GIL M. LABRUCHERIE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br/>Senior&#160;Vice&#160;President, Chief Operating Officer, and&#160;Chief&#160;Financial&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 6, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JILLIAN B. THOMSEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen<br/>Senior&#160;Vice&#160;President,&#160;Finance&#160;and&#160;Chief&#160;Accounting&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 6, 2021</span></td></tr></table></div><div style="margin-top:6pt;text-align:right"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nktr2021-03x31xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib685147620df4cfaa88f749cde353d6a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2021 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nktr2021-03x31xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2b5489402dc744649029174a123b91c8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2021 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br>Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nktr2021-03x31xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if0c67e57b0d54268a340e204592a8dd0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 6, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gil M. Labrucherie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nktr-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.nektar.com/role/InventoryDetails">
        <link:definition>2411405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability">
        <link:definition>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables">
        <link:definition>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails">
        <link:definition>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
        <link:definition>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties">
        <link:definition>2116105 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables">
        <link:definition>2317304 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail">
        <link:definition>2418408 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails">
        <link:definition>2419409 - Disclosure - Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.nektar.com/role/FairValueMeasurement">
        <link:definition>2122107 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.nektar.com/role/FairValueMeasurementTables">
        <link:definition>2323305 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementDetails" roleURI="http://www.nektar.com/role/FairValueMeasurementDetails">
        <link:definition>2424411 - Disclosure - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2125108 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>2326306 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
        <link:definition>2427412 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2428413 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2129109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2330307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2431414 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2432415 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.nektar.com/role/NetLossPerShare">
        <link:definition>2133110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.nektar.com/role/NetLossPerShareTables">
        <link:definition>2334308 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetail" roleURI="http://www.nektar.com/role/NetLossPerShareDetail">
        <link:definition>2435416 - Disclosure - Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_AccruedContractManufacturingExpenseCurrent" abstract="false" name="AccruedContractManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SaleOfStockValueAuthorizedInTransaction" abstract="false" name="SaleOfStockValueAuthorizedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NektarTwoOneFourMember" abstract="true" name="NektarTwoOneFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_BMSCollaborationAgreementMember" abstract="true" name="BMSCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" abstract="false" name="PotentialDevelopmentMilestonesExcludedFromTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborationPartnerMember" abstract="true" name="CollaborationPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CostOfBorrowingMember" abstract="true" name="CostOfBorrowingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ImpairmentAndOtherMember" abstract="true" name="ImpairmentAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_OrganizationPolicyPolicyTextBlock" abstract="false" name="OrganizationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_NektarThreeFiveEightMember" abstract="true" name="NektarThreeFiveEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CollaborativeArrangementAdditionalIndicationPayment" abstract="false" name="CollaborativeArrangementAdditionalIndicationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DrugProductDevelopmentMember" abstract="true" name="DrugProductDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LegalMattersMember" abstract="true" name="LegalMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_Nektar358LicenseMember" abstract="true" name="Nektar358LicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" abstract="false" name="MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_DevelopmentDerivativeLiabilityTextBlock" abstract="false" name="DevelopmentDerivativeLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" abstract="false" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DebtInvestmentMaturityTerm" abstract="false" name="DebtInvestmentMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_AggregateConsiderationReceivedFromAgreements" abstract="false" name="AggregateConsiderationReceivedFromAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProfitsAndLossesSharingPercentage" abstract="false" name="ProfitsAndLossesSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" abstract="false" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PhaseOneClinicalDevelopmentMember" abstract="true" name="PhaseOneClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EstimatedFairValueOfShares" abstract="false" name="EstimatedFairValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DebtInvestmentMaximumMaturityPeriod" abstract="false" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RemainingAmountAllocatedToTransactionPrice" abstract="false" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_WriteOffOfPrepayment" abstract="false" name="WriteOffOfPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_ProspectiveInterestRatePercentage" abstract="false" name="ProspectiveInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" abstract="false" name="EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nktr-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46ed47b8-777d-4c8b-b56d-a5495770c295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46ed47b8-777d-4c8b-b56d-a5495770c295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_32659eea-e5d1-47f0-a7d0-18e0b139597d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_32659eea-e5d1-47f0-a7d0-18e0b139597d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1e1dfe52-2936-4ced-a7a8-6671022df447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1e1dfe52-2936-4ced-a7a8-6671022df447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_803ea0f4-724a-45cf-8ef1-0adffcd5f563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:to="loc_us-gaap_InventoryNet_803ea0f4-724a-45cf-8ef1-0adffcd5f563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_79578206-1226-4007-82b8-2e4e46b8e600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b00b77b-4747-402a-91a5-7139bedc7a37" xlink:to="loc_us-gaap_OtherAssetsCurrent_79578206-1226-4007-82b8-2e4e46b8e600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e66ee83-a965-4d3f-9863-ebd09afc52b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7d8c407-3b26-458c-bbb8-2832811d74cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e66ee83-a965-4d3f-9863-ebd09afc52b3" xlink:to="loc_us-gaap_Liabilities_b7d8c407-3b26-458c-bbb8-2832811d74cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9da1b018-c5aa-4340-bde3-a5bcd9978f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e66ee83-a965-4d3f-9863-ebd09afc52b3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9da1b018-c5aa-4340-bde3-a5bcd9978f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_92fe0b64-27c3-489e-b399-49a26739cb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e66ee83-a965-4d3f-9863-ebd09afc52b3" xlink:to="loc_us-gaap_StockholdersEquity_92fe0b64-27c3-489e-b399-49a26739cb21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5e75af8b-0a88-4594-ac09-03f25cac438d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:to="loc_us-gaap_LiabilitiesCurrent_5e75af8b-0a88-4594-ac09-03f25cac438d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8bf9176-5964-4820-a534-4c1bf2ab5af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8bf9176-5964-4820-a534-4c1bf2ab5af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_a4e2c391-6708-42f4-9890-7ab0dfbdc88f" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_a4e2c391-6708-42f4-9890-7ab0dfbdc88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_89c68e77-cd8f-45e0-95db-c5793ea6effb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_89c68e77-cd8f-45e0-95db-c5793ea6effb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c7adb661-605b-469b-8b93-6dd1f760317e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a95f63-4e00-467f-9287-2788d9237f95" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c7adb661-605b-469b-8b93-6dd1f760317e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cd1ff72-2ed2-41db-9f20-067632c4e995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_AssetsCurrent_6cd1ff72-2ed2-41db-9f20-067632c4e995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3a8e3847-cac8-42c6-b0e9-7cfa4e1bac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3a8e3847-cac8-42c6-b0e9-7cfa4e1bac43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_39f60774-2b84-46fd-8f9b-0577450f8f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_39f60774-2b84-46fd-8f9b-0577450f8f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07f26cb9-4e41-41b2-94f1-323e18a55e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_07f26cb9-4e41-41b2-94f1-323e18a55e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c8c500ba-9e5f-4d98-b376-25dc2b82d493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_Goodwill_c8c500ba-9e5f-4d98-b376-25dc2b82d493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_152492e3-7c6f-40b0-96e5-96e70aa0f615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_425f0dbd-fcff-484f-9900-454868440369" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_152492e3-7c6f-40b0-96e5-96e70aa0f615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_42d40bab-414f-4592-9869-5c87eb76c240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:to="loc_us-gaap_PreferredStockValue_42d40bab-414f-4592-9869-5c87eb76c240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_911aa3e8-b012-4c29-ac62-f4e4e57bee41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:to="loc_us-gaap_CommonStockValue_911aa3e8-b012-4c29-ac62-f4e4e57bee41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5b612687-07a5-4606-9d47-0a3102e40fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5b612687-07a5-4606-9d47-0a3102e40fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16c7b317-6476-4f5c-9fe6-644733e896c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16c7b317-6476-4f5c-9fe6-644733e896c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63741879-6e00-46ff-93fb-e0aeadda5ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_59405156-14dc-4c9b-8fe6-d758519aed22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63741879-6e00-46ff-93fb-e0aeadda5ce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5993d565-5723-4b76-9695-4e8a1baa4be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_us-gaap_AccountsPayableCurrent_5993d565-5723-4b76-9695-4e8a1baa4be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_059ff27c-803f-4ca0-980b-a7d8ad2a3810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_059ff27c-803f-4ca0-980b-a7d8ad2a3810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_36de960c-ab57-49e3-82b2-2cc71bea4bed" xlink:href="nktr-20210331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_36de960c-ab57-49e3-82b2-2cc71bea4bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_ddd535fe-8329-4be2-99b4-f54deaa259be" xlink:href="nktr-20210331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_ddd535fe-8329-4be2-99b4-f54deaa259be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4f6501fc-0b01-4157-89da-4a0f5a0fd543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4f6501fc-0b01-4157-89da-4a0f5a0fd543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_365cd1db-6b63-4371-bac8-9d5a7f33d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6956a9e0-8a00-4600-a73a-9c789bfd711c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_365cd1db-6b63-4371-bac8-9d5a7f33d8c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7cffc8a5-69a1-4c6c-836b-70cbcc0b806e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_546d3739-10f7-4fb4-8f24-bd33c8ff240e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7cffc8a5-69a1-4c6c-836b-70cbcc0b806e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_546d3739-10f7-4fb4-8f24-bd33c8ff240e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b9d5b611-3f5f-4659-8166-6fa9b5321a08" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7cffc8a5-69a1-4c6c-836b-70cbcc0b806e" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b9d5b611-3f5f-4659-8166-6fa9b5321a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_52e7bd98-a7e5-4607-99a3-a9508ce79417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7cffc8a5-69a1-4c6c-836b-70cbcc0b806e" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_52e7bd98-a7e5-4607-99a3-a9508ce79417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a33b9c9b-4c61-4ccc-92f0-3636cd60f037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7cffc8a5-69a1-4c6c-836b-70cbcc0b806e" xlink:to="loc_us-gaap_InterestExpense_a33b9c9b-4c61-4ccc-92f0-3636cd60f037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_99e51397-6808-4010-9aab-e6e892baceed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a639a8af-fc13-4454-8f35-5bc638fd5d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_99e51397-6808-4010-9aab-e6e892baceed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a639a8af-fc13-4454-8f35-5bc638fd5d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f0a31c92-f2d6-4adc-a093-9d937584e14b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_99e51397-6808-4010-9aab-e6e892baceed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f0a31c92-f2d6-4adc-a093-9d937584e14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0d81229-bd78-4a06-82ad-5c0e0feb7b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_99e51397-6808-4010-9aab-e6e892baceed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0d81229-bd78-4a06-82ad-5c0e0feb7b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_6c78601c-e42c-4579-97d1-76608631dc5f" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_99e51397-6808-4010-9aab-e6e892baceed" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_6c78601c-e42c-4579-97d1-76608631dc5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6d370120-74d0-492e-ae73-6d31d6e47b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff2b005-53fc-42e5-9d79-6bc6215aeda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6d370120-74d0-492e-ae73-6d31d6e47b5f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dff2b005-53fc-42e5-9d79-6bc6215aeda1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed041e12-5249-42f3-acbc-2080d9b7b8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6d370120-74d0-492e-ae73-6d31d6e47b5f" xlink:to="loc_us-gaap_CostsAndExpenses_ed041e12-5249-42f3-acbc-2080d9b7b8e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d9665eb-c733-4286-a40e-206bcffccc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd22d9f4-d1f3-434c-8323-89438571b754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d9665eb-c733-4286-a40e-206bcffccc34" xlink:to="loc_us-gaap_OperatingIncomeLoss_fd22d9f4-d1f3-434c-8323-89438571b754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_581d9722-6cf5-4c64-a0f5-ca2b9a281f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1d9665eb-c733-4286-a40e-206bcffccc34" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_581d9722-6cf5-4c64-a0f5-ca2b9a281f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ea80ca5-d60c-4f30-8581-ee6db724b149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c980cd22-25e8-4d29-a45a-f5ff8d58dc69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ea80ca5-d60c-4f30-8581-ee6db724b149" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c980cd22-25e8-4d29-a45a-f5ff8d58dc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3f329bd2-61f4-49e5-a011-00ca2f1af145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ea80ca5-d60c-4f30-8581-ee6db724b149" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3f329bd2-61f4-49e5-a011-00ca2f1af145" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b6574ef-c200-483d-9cdb-83ac7097ccec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3a3e6e33-180f-47b9-88b3-21b6443445a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b6574ef-c200-483d-9cdb-83ac7097ccec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3a3e6e33-180f-47b9-88b3-21b6443445a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_29bf3be0-6b9a-4c57-80f9-aa3ac78e644f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b6574ef-c200-483d-9cdb-83ac7097ccec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_29bf3be0-6b9a-4c57-80f9-aa3ac78e644f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_549aee99-de21-42b8-9d56-d46627eb0694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_78543555-b02d-4181-b619-3a6b7882f8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_549aee99-de21-42b8-9d56-d46627eb0694" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_78543555-b02d-4181-b619-3a6b7882f8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_35ed4b4f-fff6-4b9a-8f35-b6d5226634e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_549aee99-de21-42b8-9d56-d46627eb0694" xlink:to="loc_us-gaap_NetIncomeLoss_35ed4b4f-fff6-4b9a-8f35-b6d5226634e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a098643-7ab2-4125-a7ca-e40a880b2bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b30209c1-23e5-49c0-a365-a7d62f2fa886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a098643-7ab2-4125-a7ca-e40a880b2bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b30209c1-23e5-49c0-a365-a7d62f2fa886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6f12de4-0054-4305-9853-694c8c2998d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a098643-7ab2-4125-a7ca-e40a880b2bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6f12de4-0054-4305-9853-694c8c2998d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f902c222-0083-435c-aa27-fac6b4bda86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a098643-7ab2-4125-a7ca-e40a880b2bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f902c222-0083-435c-aa27-fac6b4bda86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6fbf2a75-7728-4f87-bf2f-80f77008a711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a098643-7ab2-4125-a7ca-e40a880b2bff" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6fbf2a75-7728-4f87-bf2f-80f77008a711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a624cffa-9b71-447d-8bd0-9f341c2fb88f" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_a624cffa-9b71-447d-8bd0-9f341c2fb88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fc51ca8f-5310-45ee-b01b-816f9d1af7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fc51ca8f-5310-45ee-b01b-816f9d1af7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a3daac6c-9bdf-4389-bc03-02c89386c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a3daac6c-9bdf-4389-bc03-02c89386c106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_8971ee01-b94b-45d8-8eeb-66f261071feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_8971ee01-b94b-45d8-8eeb-66f261071feb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_6e896a0e-5937-4258-9ad4-c17e0c8140c1" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_6e896a0e-5937-4258-9ad4-c17e0c8140c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3e473061-6823-4e7e-a45b-bc10b393e4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3e473061-6823-4e7e-a45b-bc10b393e4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ea9dbe1-31f5-4cc5-8213-a08ef054008f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ea9dbe1-31f5-4cc5-8213-a08ef054008f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3035b346-0df3-415a-a84c-3b010a39347a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3035b346-0df3-415a-a84c-3b010a39347a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_551b1594-e7cf-433b-8f04-f2f9a502c7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_DepreciationAndAmortization_551b1594-e7cf-433b-8f04-f2f9a502c7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_fedfd847-e649-486a-90fc-f4f526073240" xlink:href="nktr-20210331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_fedfd847-e649-486a-90fc-f4f526073240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_96ef0211-a3f8-4cce-951c-93bc747d84f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_96ef0211-a3f8-4cce-951c-93bc747d84f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0d2d8bbb-f46e-4d65-a1a3-16bb7fa8b448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0d2d8bbb-f46e-4d65-a1a3-16bb7fa8b448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0ab90234-8dc2-40dc-a811-98304c8565a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0ab90234-8dc2-40dc-a811-98304c8565a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_a02f61b6-5b3d-45ea-8c2d-3a24c2016a8b" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_a02f61b6-5b3d-45ea-8c2d-3a24c2016a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1118175a-4441-454c-a160-e839b5d01105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_ProfitLoss_1118175a-4441-454c-a160-e839b5d01105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dd1bc626-06ed-4cb8-97d8-ba4cae8e0a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dd1bc626-06ed-4cb8-97d8-ba4cae8e0a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_70965aa7-1d03-4393-b9d4-437b27ae0be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c89a00cb-1c9b-4d33-b119-f047bcfbdbc1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_70965aa7-1d03-4393-b9d4-437b27ae0be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4fe97431-7278-426c-9e6f-c72e7c678b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_68a69284-268a-43e6-8fa5-bf240355cfab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4fe97431-7278-426c-9e6f-c72e7c678b1f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_68a69284-268a-43e6-8fa5-bf240355cfab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ac1e63a5-9072-4afb-988f-b6054a841bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4fe97431-7278-426c-9e6f-c72e7c678b1f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ac1e63a5-9072-4afb-988f-b6054a841bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a0f25498-d546-4fe9-bde1-d175721d8417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4fe97431-7278-426c-9e6f-c72e7c678b1f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a0f25498-d546-4fe9-bde1-d175721d8417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_27abb2c2-7ed8-4282-b9e6-8249c6d3ba71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4fe97431-7278-426c-9e6f-c72e7c678b1f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_27abb2c2-7ed8-4282-b9e6-8249c6d3ba71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef252452-2f2d-42e4-bd5a-44887df0302c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_08f7d530-1562-47d5-a4af-582fd362d0ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef252452-2f2d-42e4-bd5a-44887df0302c" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_08f7d530-1562-47d5-a4af-582fd362d0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_45092df3-6de6-4f6a-bbb3-5b85fcb6a0e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef252452-2f2d-42e4-bd5a-44887df0302c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_45092df3-6de6-4f6a-bbb3-5b85fcb6a0e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ca5cf304-4692-4158-9708-6c1c671d598b" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef6b792a-d928-493a-b24e-2676664bc00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ca5cf304-4692-4158-9708-6c1c671d598b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef6b792a-d928-493a-b24e-2676664bc00d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2369a605-83f4-4d7a-8601-386b4b748927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ca5cf304-4692-4158-9708-6c1c671d598b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2369a605-83f4-4d7a-8601-386b4b748927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4d55ccc6-e0e9-4f9a-a60e-f838a8b5c0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ca5cf304-4692-4158-9708-6c1c671d598b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4d55ccc6-e0e9-4f9a-a60e-f838a8b5c0c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e5f852-be98-4359-a683-fe6695ca15cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f33ed8cb-35c9-46e0-be42-8fbe751c3bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e5f852-be98-4359-a683-fe6695ca15cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f33ed8cb-35c9-46e0-be42-8fbe751c3bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48510143-53d8-476b-b212-da15052fb35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e5f852-be98-4359-a683-fe6695ca15cf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48510143-53d8-476b-b212-da15052fb35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_93df2a27-9e45-4397-9952-9dbe0ea5bdc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00e5f852-be98-4359-a683-fe6695ca15cf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_93df2a27-9e45-4397-9952-9dbe0ea5bdc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_045a43ca-99e1-48f0-b364-b84b17a59856" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cfc78ec2-54df-4f31-a63a-dbbd9a3ec065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_045a43ca-99e1-48f0-b364-b84b17a59856" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cfc78ec2-54df-4f31-a63a-dbbd9a3ec065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8d93d554-60bd-4153-a1ee-8bbfe0a8b3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_045a43ca-99e1-48f0-b364-b84b17a59856" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8d93d554-60bd-4153-a1ee-8bbfe0a8b3ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_7847efe7-3ebe-439a-aacf-232cce2be1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_045a43ca-99e1-48f0-b364-b84b17a59856" xlink:to="loc_us-gaap_Cash_7847efe7-3ebe-439a-aacf-232cce2be1eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20210331.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_10c7133e-5cb6-47af-8428-c31ad058ff38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8c7598a4-c71e-4c08-9a91-1e16788c4402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10c7133e-5cb6-47af-8428-c31ad058ff38" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8c7598a4-c71e-4c08-9a91-1e16788c4402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_eab6ef5a-ca99-4f0d-a4a6-e20436bc7d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10c7133e-5cb6-47af-8428-c31ad058ff38" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_eab6ef5a-ca99-4f0d-a4a6-e20436bc7d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d65a73fc-536f-4712-aa79-73e5efda8074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10c7133e-5cb6-47af-8428-c31ad058ff38" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d65a73fc-536f-4712-aa79-73e5efda8074" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingenciesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2b07f280-34de-44dd-a0be-e8f99ededfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc52bde9-8011-42f3-9ea1-3942f4755d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2b07f280-34de-44dd-a0be-e8f99ededfc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc52bde9-8011-42f3-9ea1-3942f4755d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f5e6383a-64f3-4c97-a27c-e1edd86abc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2b07f280-34de-44dd-a0be-e8f99ededfc9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f5e6383a-64f3-4c97-a27c-e1edd86abc0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationActivityDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nktr-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended" id="i3738caa1ee9f41e492b5cef37d77cbd7_CoverPage"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i28dd97611eac4cd0baaf523ac8f7bee7_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="i55acf4a1f9fa4155ba98a879800c640b_CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i08c980d1536c4aaca8768e254af48ef7_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6688c7b1-66da-462b-adc4-1b689d131032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6688c7b1-66da-462b-adc4-1b689d131032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88853fa5-2fc5-479f-b1aa-2f18fa6d8370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88853fa5-2fc5-479f-b1aa-2f18fa6d8370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_88436d63-9b43-49e8-bac3-48ff17add6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_88436d63-9b43-49e8-bac3-48ff17add6d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca71aa2a-bb38-4c8f-929b-d364496376e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca71aa2a-bb38-4c8f-929b-d364496376e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_13e05a82-1edc-4a78-989e-188ee574e7d0" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_13e05a82-1edc-4a78-989e-188ee574e7d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_70e422b5-4a96-44c9-9092-78fe57b3ad64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_CostsAndExpenses_70e422b5-4a96-44c9-9092-78fe57b3ad64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f373c54-8af1-40a8-979e-79e1f136449c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f373c54-8af1-40a8-979e-79e1f136449c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_49b1b319-3183-4b16-8753-39497ae83924" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_49b1b319-3183-4b16-8753-39497ae83924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_23350ebc-0a44-4b6e-9455-65a785e11dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_23350ebc-0a44-4b6e-9455-65a785e11dd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_88f11860-d1a6-4697-8b15-b8deebfff159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_88f11860-d1a6-4697-8b15-b8deebfff159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e11cd88d-5106-458e-bb97-acc93594eb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_InterestExpense_e11cd88d-5106-458e-bb97-acc93594eb05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_76291070-2768-47bb-8e8a-79da0464995b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_76291070-2768-47bb-8e8a-79da0464995b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec2f3af8-462e-437d-8777-3a38ab1d1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec2f3af8-462e-437d-8777-3a38ab1d1f03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54f0aa09-5b02-4d18-ab9a-b29cf26d88d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_54f0aa09-5b02-4d18-ab9a-b29cf26d88d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54832f6b-b1d9-406f-82e8-d03b27e8292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_NetIncomeLoss_54832f6b-b1d9-406f-82e8-d03b27e8292c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_e1f621c0-3441-4268-8c00-a99f2e21cc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_e1f621c0-3441-4268-8c00-a99f2e21cc63" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_cbf66aa1-1b14-45a1-bbfd-15e0d333e71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_cbf66aa1-1b14-45a1-bbfd-15e0d333e71c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:to="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e3908ff-d351-43fe-9677-7305b9979f1f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:to="loc_srt_ProductsAndServicesDomain_7e3908ff-d351-43fe-9677-7305b9979f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:to="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4911a414-8d5a-4539-aca2-5140df85a157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_us-gaap_ProductMember_4911a414-8d5a-4539-aca2-5140df85a157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a843a550-b354-4e9b-a15e-81a785465d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_us-gaap_RoyaltyMember_a843a550-b354-4e9b-a15e-81a785465d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8a760b49-fe9c-4658-af3a-33dae00855b5" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8a760b49-fe9c-4658-af3a-33dae00855b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_c3c7b001-bcf7-43b7-a3e7-92be3812432f" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_c3c7b001-bcf7-43b7-a3e7-92be3812432f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i607cc956b6934af5a7172a64662090fb_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i938da091d9dd4f4283539dcf9ed1a049_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f09a703-d93b-40ae-af59-694242299d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_SharesOutstanding_3f09a703-d93b-40ae-af59-694242299d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a593bfc8-d62c-4750-86f0-a2db449ad909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockholdersEquity_a593bfc8-d62c-4750-86f0-a2db449ad909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06b3d1a4-a1e1-40a6-971c-9318dfec216b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06b3d1a4-a1e1-40a6-971c-9318dfec216b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1c8201ca-0c2c-466d-8071-72f7da9342f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1c8201ca-0c2c-466d-8071-72f7da9342f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_677544b5-5ab4-4610-86c1-d3b0f2b438d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_677544b5-5ab4-4610-86c1-d3b0f2b438d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_768114dd-2add-4f15-9afd-4a354dbfb238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_768114dd-2add-4f15-9afd-4a354dbfb238" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be024daa-3b9f-4b93-86ab-f8aa10851b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_807e2db5-b8c6-4e47-b5e5-fe11e753106e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:to="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb2f473c-7511-431b-958a-a675f8b2727e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:to="loc_us-gaap_EquityComponentDomain_eb2f473c-7511-431b-958a-a675f8b2727e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:to="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f06430ef-c35b-4ac2-a6ba-e246aa06fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_CommonStockMember_f06430ef-c35b-4ac2-a6ba-e246aa06fa25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f06b357-85fe-4d6a-8dfa-59bdea8a3fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f06b357-85fe-4d6a-8dfa-59bdea8a3fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db99357e-131f-4afd-bce3-8c20388e20cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db99357e-131f-4afd-bce3-8c20388e20cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4ec33b7a-0d19-47a9-a90b-43e1e92a9ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_RetainedEarningsMember_4ec33b7a-0d19-47a9-a90b-43e1e92a9ea9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i25d7a3c5b86f4e4787428a36fbc24b45_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ib8aa56db8ec24e40927ba2be370189cf_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="iccea3244a7f84893a7b5bcfb2d848801_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended" id="iaa98bcbe904d438a80de8d00314b6505_OrganizationandSummaryofSignificantAccountingPoliciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7eb0e6ee-106d-419c-8943-3fd334a886dd" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7eb0e6ee-106d-419c-8943-3fd334a886dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b1fc716d-f649-448a-b1aa-931d0ae94846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b1fc716d-f649-448a-b1aa-931d0ae94846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4529ba09-d044-43a8-bb1c-bd0228f6b9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4529ba09-d044-43a8-bb1c-bd0228f6b9cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8ee4500b-447b-4e76-8644-cca10ca5648e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8ee4500b-447b-4e76-8644-cca10ca5648e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_09511d62-1252-4c65-8205-44b55dcb2b16" xlink:href="nktr-20210331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_WriteOffOfPrepayment_09511d62-1252-4c65-8205-44b55dcb2b16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_d45a5374-1016-4345-8f8c-3b90dd38c540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_d45a5374-1016-4345-8f8c-3b90dd38c540" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_3baa2fe2-a673-4df6-80c0-5e5176d0d176" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_3baa2fe2-a673-4df6-80c0-5e5176d0d176" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:to="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_01ea9e0b-c9f4-47a2-a61a-def0ae5a8f58" xlink:href="nktr-20210331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:to="loc_nktr_BMSCollaborationAgreementMember_01ea9e0b-c9f4-47a2-a61a-def0ae5a8f58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_c49d09a1-0e60-473d-9c6a-d336b62d81c5" xlink:href="nktr-20210331.xsd#nktr_CollaborationPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:to="loc_nktr_CollaborationPartnerMember_c49d09a1-0e60-473d-9c6a-d336b62d81c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:to="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73cee30e-2938-42aa-b769-a4457f3f79ca_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:to="loc_srt_ProductsAndServicesDomain_73cee30e-2938-42aa-b769-a4457f3f79ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:to="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_042226af-48ef-441d-b1c7-2ac0a1627209" xlink:href="nktr-20210331.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:to="loc_nktr_NKTR181Member_042226af-48ef-441d-b1c7-2ac0a1627209" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended" id="i806fa91a963e4140a63901e1bc87094b_CashandInvestmentsinMarketableSecurities"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended" id="ib8d4872a637e4b12911a85bd347ef48c_CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended" id="i87b6396390034c08aac8a0581034350b_CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="ib9c6375c6d214c1fa68d4a2734d4b39c_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_f87d7a0e-3a87-489c-9c32-a83e9eaf28a7" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_f87d7a0e-3a87-489c-9c32-a83e9eaf28a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_7da18f08-06ca-444b-a4f0-4667c6e41d00" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_7da18f08-06ca-444b-a4f0-4667c6e41d00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_732fa4f1-fbda-458e-b73b-24a0962b4fe2" xlink:href="nktr-20210331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_732fa4f1-fbda-458e-b73b-24a0962b4fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_840ab243-9aaa-4014-a84b-3701dee29dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_840ab243-9aaa-4014-a84b-3701dee29dcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06fac748-4fc6-40a5-91ef-5149b8e41d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06fac748-4fc6-40a5-91ef-5149b8e41d25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:to="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de2073be-f0a8-4623-b5ad-62c6390617b0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:to="loc_srt_RangeMember_de2073be-f0a8-4623-b5ad-62c6390617b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:to="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_924af620-81de-4fa8-ad23-836f6ce39e93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:to="loc_srt_MinimumMember_924af620-81de-4fa8-ad23-836f6ce39e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0f33134d-7343-48af-93f9-d104e744c3d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:to="loc_srt_MaximumMember_0f33134d-7343-48af-93f9-d104e744c3d2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i83aaabe2cdcd4171b63c273e0ec716b9_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_80031cb6-733e-4da0-a342-d56dc905f210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_80031cb6-733e-4da0-a342-d56dc905f210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f9ae564-935f-4c43-a271-12690a172b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f9ae564-935f-4c43-a271-12690a172b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c46e497-6f2c-4650-8c38-a5c32cc78cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c46e497-6f2c-4650-8c38-a5c32cc78cab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef97c2ad-402f-4bda-8f14-1c7d2012d1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef97c2ad-402f-4bda-8f14-1c7d2012d1fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_241364e2-027f-4c5f-9009-3609b5c008c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_241364e2-027f-4c5f-9009-3609b5c008c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_7f65f100-5e67-4d4a-845b-2c433e758cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_Cash_7f65f100-5e67-4d4a-845b-2c433e758cab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_604122bb-f5c2-4cfa-a322-cf0025231807" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_604122bb-f5c2-4cfa-a322-cf0025231807" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:to="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_92051be1-ba4f-46f2-ada5-95e6edb7b7e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_92051be1-ba4f-46f2-ada5-95e6edb7b7e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ba9f827f-4716-4f8a-a9cf-923e9a3bfbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ba9f827f-4716-4f8a-a9cf-923e9a3bfbf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6e12de67-b75c-4fdd-a443-4633fae86b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CommercialPaperMember_6e12de67-b75c-4fdd-a443-4633fae86b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26691052-e9d6-4d15-97a6-77d5f2492473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26691052-e9d6-4d15-97a6-77d5f2492473" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c078e45c-c537-43a9-911d-150e2ac6f28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c078e45c-c537-43a9-911d-150e2ac6f28d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_99f1d601-f8c6-4fb5-851c-63deaa339989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_99f1d601-f8c6-4fb5-851c-63deaa339989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06a9f613-c215-465e-bea4-44693e394d14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06a9f613-c215-465e-bea4-44693e394d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1abf2bd-9b7f-47ce-88e9-b0835e822c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1abf2bd-9b7f-47ce-88e9-b0835e822c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_634c3845-0e4f-44c1-b14c-cac1fad04ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_634c3845-0e4f-44c1-b14c-cac1fad04ce6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20210331.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" id="ifb1ea9f498fc4a419a25b3e032a5cae4_Inventory"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" id="idb8b7ee610cc4b4da80dcbfc9fef3b3c_InventoryTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended" id="ia0dc3a7bd60444b786e22496913377b0_InventoryDetails"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended" id="i4826a96db39b4a10951f3e0d5400f2f2_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended" id="i1d3549ea7812465798ed8b5a9389f16c_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="extended" id="i45b34e073c084ae18cc33726d64ce047_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_883cf608-60d2-4a92-87b2-8c86713b91cf" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_883cf608-60d2-4a92-87b2-8c86713b91cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_b6fce210-fe49-4296-85d7-c873e4658abf" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_b6fce210-fe49-4296-85d7-c873e4658abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_f765e9c8-456d-4119-942c-d792a2a0d5ff" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_f765e9c8-456d-4119-942c-d792a2a0d5ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_50c499ab-86f9-4dbb-bba5-0201d487b68a" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_50c499ab-86f9-4dbb-bba5-0201d487b68a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_267abe07-a1eb-482d-af03-8a9bf7a9129e" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_267abe07-a1eb-482d-af03-8a9bf7a9129e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_01933d44-7fd6-4843-96de-b5092d57ec58" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_01933d44-7fd6-4843-96de-b5092d57ec58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_8e149e06-d29d-4a67-987d-feb04b7286ce" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_8e149e06-d29d-4a67-987d-feb04b7286ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_668bf914-b34e-4254-bde3-344e787949cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_668bf914-b34e-4254-bde3-344e787949cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:to="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_71bf7762-59b7-4349-8a36-e3516db71e89" xlink:href="nktr-20210331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:to="loc_nktr_SFJPharmaceuticalsMember_71bf7762-59b7-4349-8a36-e3516db71e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_91433eda-57f3-40bb-b8ab-042331f7ee87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_91433eda-57f3-40bb-b8ab-042331f7ee87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember_62c6a8ff-db2d-4066-a23f-3f9dc1a5f659" xlink:href="nktr-20210331.xsd#nktr_CostOfBorrowingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:to="loc_nktr_CostOfBorrowingMember_62c6a8ff-db2d-4066-a23f-3f9dc1a5f659" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="ie29ea4bfd05e4a49bd8aff9904d63034_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e94186f9-1eb8-4baa-bda1-5c8d21bca416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e94186f9-1eb8-4baa-bda1-5c8d21bca416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_43f3b217-d8e6-4279-8f76-fe22ac425efe" xlink:href="nktr-20210331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_43f3b217-d8e6-4279-8f76-fe22ac425efe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c430f97b-103f-480e-b97c-b71ce21f4b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c430f97b-103f-480e-b97c-b71ce21f4b94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_be1ee258-9a16-4368-8ae4-cd34bad95f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_be1ee258-9a16-4368-8ae4-cd34bad95f45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d00b262d-1265-43fc-8bb7-a2a860e0c187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c28d0688-b0ba-4066-9ca2-b6deadf2848e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c28d0688-b0ba-4066-9ca2-b6deadf2848e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_969ec9ba-3210-4e4b-85fa-45c40d4a1b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_969ec9ba-3210-4e4b-85fa-45c40d4a1b5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended" id="i055efbe7ca2f49e8b4e998b5b6385538_LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended" id="i0d04d87aaca649cf98122f6df44b1248_LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended" id="i32b156b1db6b49caa8c40fca615934cb_LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_3d2ca4d0-3e1a-4e28-b195-4406a6021258" xlink:href="nktr-20210331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_3d2ca4d0-3e1a-4e28-b195-4406a6021258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_93979373-33f2-44a6-be2d-60fc70594ded" xlink:href="nktr-20210331.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_93979373-33f2-44a6-be2d-60fc70594ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_dee1c9a0-c8ad-41f1-8a7d-20880958eb9a" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_dee1c9a0-c8ad-41f1-8a7d-20880958eb9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_cc761087-0d37-411c-9e57-b9fc59290f43" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_cc761087-0d37-411c-9e57-b9fc59290f43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_0100843e-6f97-4536-b29b-e9be653a04b2" xlink:href="nktr-20210331.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_0100843e-6f97-4536-b29b-e9be653a04b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc154fe8-9c34-479d-bbf8-cafde0090e67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc154fe8-9c34-479d-bbf8-cafde0090e67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_8c72af55-5123-4deb-b42a-7d635d7c50b1" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_8c72af55-5123-4deb-b42a-7d635d7c50b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a240c6f4-ef0f-487b-96d9-b0b3521e3e52" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a240c6f4-ef0f-487b-96d9-b0b3521e3e52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="extended" id="id751000196b744be884a792fd680fd76_LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a6e2685e-6973-4d22-bd3f-aa96817e16e4" xlink:href="nktr-20210331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a6e2685e-6973-4d22-bd3f-aa96817e16e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_44d0372f-2cc5-4b52-ba75-e95743ac7b61" xlink:href="nktr-20210331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_44d0372f-2cc5-4b52-ba75-e95743ac7b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88563821-3a9c-4182-962e-c6056a11c2d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88563821-3a9c-4182-962e-c6056a11c2d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_509caec6-3aa1-4baf-a41c-a553d733e3ec" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_509caec6-3aa1-4baf-a41c-a553d733e3ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a886463d-ca13-4f89-be3d-79d2bd5b0c83" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a886463d-ca13-4f89-be3d-79d2bd5b0c83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended" id="i5cc74fc8a79a44c290dacd285df7053b_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingenciesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended" id="ib540c44419c64151bc08f3638ec491cc_CommitmentsandContingenciesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_03e72b7b-8d3c-499d-ab7e-ccaf2035f8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_03e72b7b-8d3c-499d-ab7e-ccaf2035f8b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:to="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_30a6b12b-8436-440f-aacf-2808791b2981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_30a6b12b-8436-440f-aacf-2808791b2981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_9a935950-f879-4a52-b3fd-43ea3c198442" xlink:href="nktr-20210331.xsd#nktr_LegalMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:to="loc_nktr_LegalMattersMember_9a935950-f879-4a52-b3fd-43ea3c198442" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/FairValueMeasurement" xlink:type="extended" id="i1888dbb4d6a8467ab86d8323a0208c3a_FairValueMeasurement"/>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="extended" id="ib2d779cb901a42c4902a1b85b20e786c_FairValueMeasurementTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="extended" id="i6d24e5d7b4f94abf8a78be5f23c8fbf0_FairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5217716e-0d8b-4ad7-9428-83a59bcb91b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5217716e-0d8b-4ad7-9428-83a59bcb91b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c651e57a-4161-4ebc-ae69-8b133f4bc95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c651e57a-4161-4ebc-ae69-8b133f4bc95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d2632ce8-a6b4-451f-b250-22761b089723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d2632ce8-a6b4-451f-b250-22761b089723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3db5c0ec-5579-4891-8826-28e96e6317b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_DerivativeLiabilities_3db5c0ec-5579-4891-8826-28e96e6317b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dcc95fa-87a7-4c80-b904-947704afb87f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6dcc95fa-87a7-4c80-b904-947704afb87f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4d500585-6012-42e3-90e7-5f8f65fa08c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4d500585-6012-42e3-90e7-5f8f65fa08c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_621c3417-e1b2-4bdd-bc18-df053892a3f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_621c3417-e1b2-4bdd-bc18-df053892a3f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6e387fbc-195e-411b-8000-7b838b56e94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6e387fbc-195e-411b-8000-7b838b56e94a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e2ec6335-ffac-462f-b77b-bcb3cec9747d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e2ec6335-ffac-462f-b77b-bcb3cec9747d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_071b872b-79c0-4242-b349-43fdbf53b9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_071b872b-79c0-4242-b349-43fdbf53b9a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c1beba5-6eb8-4bd2-a827-7075587a75d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c1beba5-6eb8-4bd2-a827-7075587a75d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_05f7b3f2-98b0-4842-b4f4-674c3a0a4514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_05f7b3f2-98b0-4842-b4f4-674c3a0a4514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d3cbb3fa-9569-496e-8458-778796bd93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_CommercialPaperMember_d3cbb3fa-9569-496e-8458-778796bd93bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_098e9157-9935-40de-ba03-254890d42606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_098e9157-9935-40de-ba03-254890d42606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5dd5e571-3dde-4207-988a-0e3872434fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5dd5e571-3dde-4207-988a-0e3872434fa8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i32d53227768a49ad966095f84e7fe8f3_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended" id="if3e08a84a32d4276b73de0e5a6d230c7_LicenseandCollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended" id="i9ccb57dcfb984468aeed723d6becd568_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_fccd07f7-0e15-48a3-9733-7b59851ae593" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_fccd07f7-0e15-48a3-9733-7b59851ae593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:to="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76b99f83-37c8-4209-9f88-a53520f88dc3_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:to="loc_dei_EntityDomain_76b99f83-37c8-4209-9f88-a53520f88dc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:to="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_4e81a878-59a9-40a1-a5ba-431f61da72bb" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_4e81a878-59a9-40a1-a5ba-431f61da72bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0b737de1-480a-4923-86cd-c87f1fbfdec5" xlink:href="nktr-20210331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_EliLillyAndCompanyMember_0b737de1-480a-4923-86cd-c87f1fbfdec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_8e57175a-ebac-4695-8b52-6621cd9d6ebe" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_OtherPartnerMember_8e57175a-ebac-4695-8b52-6621cd9d6ebe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e00abc93-eeca-4cb8-9eac-96d37b10ad67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e00abc93-eeca-4cb8-9eac-96d37b10ad67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_233799fe-bae5-439c-b486-6a6c3a49cd80" xlink:href="nktr-20210331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:to="loc_nktr_NektarTwoOneFourMember_233799fe-bae5-439c-b486-6a6c3a49cd80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_f9b628c5-dabb-428c-82b9-f2f91c6a793b" xlink:href="nktr-20210331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:to="loc_nktr_NektarThreeFiveEightMember_f9b628c5-dabb-428c-82b9-f2f91c6a793b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="iba4561d156574f7dae4edd3a76f73ae9_LicenseandCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c680c05e-a0c7-4f06-adc7-c4d15b4996a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c680c05e-a0c7-4f06-adc7-c4d15b4996a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_21ae3e23-bb4b-46b3-a918-c47fda202461" xlink:href="nktr-20210331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_SalesMilestoneRevenue_21ae3e23-bb4b-46b3-a918-c47fda202461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_08397822-bef0-4514-9a71-560835168696" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_08397822-bef0-4514-9a71-560835168696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_0650a85d-b7cb-43e1-bd05-c64216af0c00" xlink:href="nktr-20210331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_0650a85d-b7cb-43e1-bd05-c64216af0c00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_1248393a-1f74-4067-b5b1-0080928a9dbc" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_1248393a-1f74-4067-b5b1-0080928a9dbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_f9582809-d32a-4f2d-a77a-cc4b70d976c8" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_f9582809-d32a-4f2d-a77a-cc4b70d976c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_894b9a87-9dc6-441c-b8be-c4bc8728d980" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_894b9a87-9dc6-441c-b8be-c4bc8728d980" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7aae5f3f-8711-431f-8414-5a1b92604ee8" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7aae5f3f-8711-431f-8414-5a1b92604ee8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_0b6a4374-224d-4157-b891-c6a403f94ffa" xlink:href="nktr-20210331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_0b6a4374-224d-4157-b891-c6a403f94ffa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0406559c-b457-4599-9cc6-ba4cf102026d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_SharesIssued_0406559c-b457-4599-9cc6-ba4cf102026d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_13f8db7f-5f53-4991-b4f5-f9fc32373435" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_13f8db7f-5f53-4991-b4f5-f9fc32373435" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_01a9acab-1342-48ae-b0d3-5d8aff8c6734" xlink:href="nktr-20210331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_01a9acab-1342-48ae-b0d3-5d8aff8c6734" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_5b302def-edb9-41c9-8fb8-9ff78ffa04da" xlink:href="nktr-20210331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_EstimatedFairValueOfShares_5b302def-edb9-41c9-8fb8-9ff78ffa04da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_876cd897-9c7f-402b-acb2-743c712bb84b" xlink:href="nktr-20210331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_876cd897-9c7f-402b-acb2-743c712bb84b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_afb7e8f5-469d-43ba-9acf-e6193af6e49c" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_afb7e8f5-469d-43ba-9acf-e6193af6e49c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_aba50247-34c0-4f60-af58-10329d1fcd07" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentMilestones_aba50247-34c0-4f60-af58-10329d1fcd07" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_aa9268bd-7bb1-43fa-84b7-67408110b201" xlink:href="nktr-20210331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_ReimbursementOfExpenses_aa9268bd-7bb1-43fa-84b7-67408110b201" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_780f9d8d-8f53-494e-a584-fe1d9af5c322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_780f9d8d-8f53-494e-a584-fe1d9af5c322" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_642384cd-b000-41f8-a752-29606aa0cd51" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_642384cd-b000-41f8-a752-29606aa0cd51" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_78d85e7a-f782-4e7b-ae8c-316bb8b92e42" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_78d85e7a-f782-4e7b-ae8c-316bb8b92e42" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_4cb8a9d5-17bb-4c07-ba48-ded4aee52ca3" xlink:href="nktr-20210331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_4cb8a9d5-17bb-4c07-ba48-ded4aee52ca3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3708fd92-a571-4dc3-a9b7-f201876cb55c" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3708fd92-a571-4dc3-a9b7-f201876cb55c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de28a285-301a-41b3-90e0-eec1717e2554" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de28a285-301a-41b3-90e0-eec1717e2554" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_e63198b2-eda9-4a8a-b6ec-b185b01627c2" xlink:href="nktr-20210331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_e63198b2-eda9-4a8a-b6ec-b185b01627c2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_607b1ad5-5fbf-4bb8-84f0-495d05b0536a_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:to="loc_dei_EntityDomain_607b1ad5-5fbf-4bb8-84f0-495d05b0536a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:to="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_55d15137-5370-4ece-b1b2-3a38470aa1c3" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_55d15137-5370-4ece-b1b2-3a38470aa1c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_355b688c-2561-4e05-a038-626623210339" xlink:href="nktr-20210331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_EliLillyAndCompanyMember_355b688c-2561-4e05-a038-626623210339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_b26b55f1-4faf-4443-92ad-038bbd0df8dc" xlink:href="nktr-20210331.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_EliLillyMember_b26b55f1-4faf-4443-92ad-038bbd0df8dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_92ac42ba-cf4c-425b-88c2-acc64f0a60ee" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_OtherPartnerMember_92ac42ba-cf4c-425b-88c2-acc64f0a60ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7d1904f8-9eb1-497a-b0a2-7badc9e84091_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:to="loc_srt_ProductsAndServicesDomain_7d1904f8-9eb1-497a-b0a2-7badc9e84091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:to="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_f818d7c3-be32-4863-b3e3-8480539f767b" xlink:href="nktr-20210331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_NektarTwoOneFourMember_f818d7c3-be32-4863-b3e3-8480539f767b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_b8d653d2-d111-4d01-b2b5-d32d8a63bd17" xlink:href="nktr-20210331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_NektarThreeFiveEightMember_b8d653d2-d111-4d01-b2b5-d32d8a63bd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_3238d018-b2eb-420e-a66c-392cbde44aaf" xlink:href="nktr-20210331.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar214Member_3238d018-b2eb-420e-a66c-392cbde44aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember_2b427db9-15d5-4105-b763-d8f43cceea48" xlink:href="nktr-20210331.xsd#nktr_Nektar358LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar358LicenseMember_2b427db9-15d5-4105-b763-d8f43cceea48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_ce8e384b-7ec2-4d11-b1f3-1b54b44b724f" xlink:href="nktr-20210331.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar358Member_ce8e384b-7ec2-4d11-b1f3-1b54b44b724f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1c191e22-e0cb-4a79-b97e-e2a417e7bc49_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1c191e22-e0cb-4a79-b97e-e2a417e7bc49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_90dab070-54cf-48c9-a6a1-33fb8862022e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:to="loc_srt_ParentCompanyMember_90dab070-54cf-48c9-a6a1-33fb8862022e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d0cb155-806e-4e8e-b763-83520bf7973b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5d0cb155-806e-4e8e-b763-83520bf7973b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_3023890d-b811-42ba-b08b-c9bf1ee4530d" xlink:href="nktr-20210331.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:to="loc_nktr_OpdivoMember_3023890d-b811-42ba-b08b-c9bf1ee4530d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48619461-72e2-4ca2-a1e2-2937258ffa42_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:to="loc_srt_RangeMember_48619461-72e2-4ca2-a1e2-2937258ffa42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:to="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bea20672-2ce6-4ae7-ad44-2c8e17397ae1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:to="loc_srt_MaximumMember_bea20672-2ce6-4ae7-ad44-2c8e17397ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aca8ba44-9a2d-4969-bcb7-d576306e4114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:to="loc_srt_MinimumMember_aca8ba44-9a2d-4969-bcb7-d576306e4114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5604e758-4b86-4b24-9afd-e86203242fff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5604e758-4b86-4b24-9afd-e86203242fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_ec3cafb9-7260-4f5f-b227-c0c45faea1aa" xlink:href="nktr-20210331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:to="loc_nktr_SharePurchaseAgreementMember_ec3cafb9-7260-4f5f-b227-c0c45faea1aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c21528dc-794c-4c23-a0f3-913a26075d34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c21528dc-794c-4c23-a0f3-913a26075d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7daed767-b0df-42f4-ab64-7caa18672450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7daed767-b0df-42f4-ab64-7caa18672450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:href="nktr-20210331.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_175845ab-07f8-4f89-b8e3-3543a8475ebe_default" xlink:href="nktr-20210331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:to="loc_nktr_MilestoneDomain_175845ab-07f8-4f89-b8e3-3543a8475ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:href="nktr-20210331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:to="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_044325b7-4180-4d07-910f-50f7e88f59f3" xlink:href="nktr-20210331.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:to="loc_nktr_MilestoneOneMember_044325b7-4180-4d07-910f-50f7e88f59f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ecc0e7-b745-4bb4-935a-68940f00c854_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40ecc0e7-b745-4bb4-935a-68940f00c854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_79aafd67-2773-4c25-81a0-43d0dce20c29" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_79aafd67-2773-4c25-81a0-43d0dce20c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_bb05a51e-a140-49d9-a5d0-b6e503be8b67" xlink:href="nktr-20210331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_BMSCollaborationAgreementMember_bb05a51e-a140-49d9-a5d0-b6e503be8b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_d6646416-38c8-476e-9dfc-ee33d60d4cf6" xlink:href="nktr-20210331.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_Nektar358Member_d6646416-38c8-476e-9dfc-ee33d60d4cf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_c37df54d-dda2-48e9-ab5c-49ed7d3ec973" xlink:href="nktr-20210331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_c37df54d-dda2-48e9-ab5c-49ed7d3ec973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_63fbf204-c28d-48e7-9abd-d0ca220e150f" xlink:href="nktr-20210331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_DrugProductDevelopmentMember_63fbf204-c28d-48e7-9abd-d0ca220e150f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_5134ee84-5563-45dd-9af1-637d2eec7fb2" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_OtherPartnerMember_5134ee84-5563-45dd-9af1-637d2eec7fb2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" id="ibfbd5809f2194ebbbd2abedb8dac5573_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" id="ib45321c72a1d4f39ae970b5b58c81097_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="ida9cbaebfd544f49b0c451322f9f7244_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3287dc70-276b-46f5-af69-06cd43a3acef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3287dc70-276b-46f5-af69-06cd43a3acef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b8407193-cb90-4b87-8230-81e0ad8e6052_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b8407193-cb90-4b87-8230-81e0ad8e6052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_48e98e83-5f0b-4d7b-9e40-6cf65dd60bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_CostOfSalesMember_48e98e83-5f0b-4d7b-9e40-6cf65dd60bec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ec30d92a-60dc-4b79-97aa-25de5b596828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ec30d92a-60dc-4b79-97aa-25de5b596828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7849d69-4aa9-463e-9c6b-f48d82d0ad6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7849d69-4aa9-463e-9c6b-f48d82d0ad6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_64e14568-d42e-490f-add2-dc3b7d5bbf71" xlink:href="nktr-20210331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_nktr_ImpairmentAndOtherMember_64e14568-d42e-490f-add2-dc3b7d5bbf71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" id="if5826173917e4391a2e58767a2a66074_StockBasedCompensationActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_260dab92-7c2d-4eb5-bbe6-ccdf8b56efe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_260dab92-7c2d-4eb5-bbe6-ccdf8b56efe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108756b4-68d4-486d-b2a8-40de19a026bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108756b4-68d4-486d-b2a8-40de19a026bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b042ed4a-ce16-40f3-8e52-68de7067aa6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b042ed4a-ce16-40f3-8e52-68de7067aa6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd7765bf-ce60-41b3-9dcb-60b31bd3bbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd7765bf-ce60-41b3-9dcb-60b31bd3bbf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_34662f90-3064-4187-9919-2edb72492139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_34662f90-3064-4187-9919-2edb72492139" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:to="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e905d5ed-cce2-4f05-841d-52965df0e609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e905d5ed-cce2-4f05-841d-52965df0e609" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended" id="i38dc71557e0548a986b8301cd0e55f01_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="extended" id="i6c20afcd54274b59806da5377d1aed72_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended" id="i5b9d069c72dd42f5abf145b674e12b37_NetLossPerShareDetail"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nktr-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8ff26891-a5c9-48b7-948e-3337d35f17b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91715a3c-405e-4f30-923b-9e8faff22142_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_72d10884-4398-4175-ac63-1dbe1cb03be4_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6e6a891a-df3b-4d67-8365-7675a0cf7a34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3bd4e52c-d8a7-4683-a82d-080b540ec649_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0c3d92af-348e-4c98-986f-750880a5a3b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1bbea767-5b6e-4dff-8fda-c8aac453c8b5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d1993811-2d2b-4975-888d-b4cef1068ea1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddf0a2dd-ce44-48ce-aa5d-6fbfafe49217_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_616aa396-ea72-4c1c-b28b-219190b20a02_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_ab44ebd2-8357-449e-98f6-417fe29fed09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_5740f1b4-b058-4f8a-a5be-85c87300be24_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e2666d8f-2f4b-459e-ba1e-0807b82d7440_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_c39e3e71-c9c7-460f-9dff-1b6406c7c066_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d9abc9e-3027-49c1-9be8-f95191579434_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2b0aaf26-7586-4ef2-80c8-ba5610789f86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e9ae53dc-5531-4ac4-9bcf-2afe0286742a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_37748960-c382-4ad3-9270-d6411d684155_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_label_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing Expense Current</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:href="nktr-20210331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:to="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_2582a046-472f-4987-81a5-75e90cfcf169_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_10e75e0e-0230-4a2d-b930-30d4dade8711_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:href="nktr-20210331.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:to="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_357d07bc-4978-4454-a185-a8973d4377d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_9da22a69-3b8a-4670-b787-3d0ea03b193f_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_165d50fd-edc2-445e-aaeb-62222e133d17_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:href="nktr-20210331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_4a9f0af1-d83c-4cf8-96b1-56b8508283a2_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:href="nktr-20210331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cf0932b7-be1a-4d8b-844f-f8b37a73e648_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6babc196-b711-4e63-bfd5-bbf208de87f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e661d8b5-c1e0-40b5-9a77-263e9cb61e60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_723379a8-447d-4f4e-ade1-148ee55e5725_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20210331.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fad17f09-c0d5-45b4-ab8a-c3fc8d8fc5cb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c2c94f7d-d4b5-468e-af7a-d0436ade337e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e028436b-4aa2-451f-9f06-f55b050f0b9f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7fa66ce8-4720-4295-93f4-028a378d0fda_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ac3671c-869d-41b1-ba01-9bbb5388dbfb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_6fc1de73-bbd5-4c5c-9a91-b417fb85b1ce_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20210331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dff1ef33-d872-4299-9363-651929520d04_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6eac21a2-3122-40e4-b6dd-bb2619c72623_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_de171cfd-789d-43d1-bfeb-42f786979857_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7dc51e92-8296-441e-a687-af31ca63e900_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f8716e3f-50cc-4962-9359-9c832538cf86_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5a192406-5efa-4e51-a3b2-19f2448ebe5e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_4ccd8af8-a674-432d-ab2e-f70b14dbec62_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:to="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_5411af02-7b48-43a9-83d3-76bc244fa2ca_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20210331.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_0884d034-f5d3-419b-949a-d32a35ff177e_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_label_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability [Text Block]</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_documentation_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:href="nktr-20210331.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:to="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e426d8fd-47ae-4d87-888d-dfc8182c1845_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_70da3cb3-4783-4cf4-87ab-7f18b4b9c470_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0f04186b-d925-40e0-9c9a-f5250c629628_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_0d55c6ad-21f6-4f1a-80ec-a9842035806a_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_d1e2bd4d-035b-486d-8050-978fdd8a4598_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_6b0836f3-f1bf-4918-bbea-9cdf1c7ceb7e_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2dac9724-c498-4fa5-9321-c924134959cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5547ff14-7e73-467f-ae80-b30d343ebbe6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5ada79fe-34af-4e8a-ad67-ff27c37e2393_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e2e7746b-3819-48ac-a45e-b60948051d17_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20210331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8b315b98-d2e9-4a40-91d1-d7e7d4186186_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_25025d58-8273-486b-90ed-405776d44ad4_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_573e3980-f128-4949-a9b2-231ebcd0337b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f64dfc2c-ef44-48c7-919e-80caf99dfce5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_283cea03-1ad8-433e-8fde-19b36a3ea7f9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_36d0c857-7d22-420d-8ee1-cabef2c4cd3c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_67f39b62-c9e0-45b8-a9da-ec0084ec1d1b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_f07d6a9d-ef1d-40bc-9bf9-24f03f9f81b7_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based annual payments, first indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_95396c86-48e3-4c2f-8d65-401d34446370_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f891e85a-323e-4dde-8c9f-942760c4f6e6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_42baa0fc-82ba-4356-93b5-3b765df8b17b_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:href="nktr-20210331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_f06044b8-7325-48cc-b1bb-afb2f4038e19_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_fa2d7184-2888-49ab-8ee0-7ec33fdb95ad_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_a87819f0-cba5-456e-967a-3f7e19fb4539_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30fa5335-c8b1-4303-afb3-e9ddb9e57bef_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ddd833b-ddb7-4616-90db-235c565b2c30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5ca7bd22-1941-4c6e-8380-633609a17c82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_f2779a1b-57a2-41e6-b3f8-0403a5abe738_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_76b30337-ded0-43d3-84e6-c5d4b62e4c85_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4abb3a51-e430-4fe2-9128-4caf75b4f31c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895386eb-96e3-43e9-9427-c22393fd13e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3b5c6baa-3ea2-48ec-abae-6d77d8614d53_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8a56ecc6-edc8-4527-aa75-adefb8646018_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_26c4e10b-b2d9-4581-b7fc-d07996b9db77_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_9d64a3b1-afb6-46b4-8f01-dd421351ce87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8af8599a-933e-4bc2-b4f5-0aefd2902eff_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2021 or December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_c5515b42-b9ee-4929-96d6-1ecaf2a103af_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7172daf5-5720-4405-9a1b-e7d1042d814a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_83372934-4bfd-47ab-b72f-144108465742_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4f847a87-461f-485d-b865-190dc194e444_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b97cd2b2-5d32-49d4-b4a4-d5c90fb35099_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_ee5bef70-6574-4544-86b5-4553d430bc4c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty cost of borrowing</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_952c284a-43ed-44ac-a099-251e67546ab8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e33c9574-4d07-41fc-bded-357b527cc5d2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_66625922-4849-41a0-b39c-391823467876_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5ce93d95-df6c-4d18-9c79-ce4430624fee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_a7dd75f2-a84e-4fea-b032-17dcb3ea7392_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_fcd8a98c-9baa-4c1e-b9c4-6520e53ae426_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_5295f448-6783-4ff1-941b-6d1b240bb818_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember" xlink:href="nktr-20210331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember" xlink:to="lab_nktr_BMSCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_b8911684-4c6f-460a-a0e5-c091ebdc6634_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4127c870-8b4b-4537-b49e-6bd2c2f282fa_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c6e3a856-0178-4627-88dd-2d837074933f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_3ee9f425-28dd-4e23-ac1a-6109e585a1b9_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e153bb27-a976-45c1-9052-1b8b05b57322_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_94ec8a1b-b1b9-4703-a073-d05ab903e6c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a43c777c-912c-4bbd-a7bb-76546210e9e1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6ac85135-ccaf-4fe2-9339-7a42a250f121_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_28e7d17c-eecb-4acc-8437-b7b4c7cd6303_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0ed9bf39-50bb-48dd-b52c-60bb05b11fee_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_532d937a-f369-47db-a924-a5714dd50772_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_27abb6dc-a226-4838-90a0-2065d838a6dc_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed8b786d-547f-4a42-a88e-e9aa5506ee74_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b21b9d77-a8ab-485f-a963-064d19ce558c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a5720c3c-6ae4-404e-b427-7af99c9f091a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d9ec2c4a-26e7-4cfa-a449-1c3246e5192f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_cf4bad0d-653c-4ea7-9a36-f981a87db58a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyPolicyTextBlock_369360ea-bf71-4545-ae9b-6c598e866845_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Policy Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyPolicyTextBlock" xlink:href="nktr-20210331.xsd#nktr_OrganizationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_04838168-a123-442a-aa49-baad3e064b7a_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20210331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1c0da0ec-5721-47ca-8fab-457e4d01b8d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_2c65441c-f251-43f0-bbdb-11ffe8478d3a_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_label_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value Authorized in Transaction</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_documentation_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value Authorized in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:to="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea670cf6-1f74-4a7f-8f65-a2a37130658f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_28ffde3e-8d57-4f42-8dc2-af522a313c35_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_df9d703f-975d-42c0-87c8-6a799dc110be_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_520c4f88-3346-47e1-9a62-4a1e6e363f53_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7203d21d-3e7f-4ec0-a346-8f547369e15c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b06164-a8cf-42f3-8724-6f71a35fb54c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d6fe15e8-b530-49b0-a2ef-6cdb24d07fe5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_002b2a29-aa46-4df6-91bf-88b43984e509_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_49285db9-c711-473b-967d-6830d3c4f06e_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f2431f46-d7d7-4c8d-ba1f-a39db9fa74f7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_162ddcb6-8f81-4888-b244-d99a45f0800d_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_47f8e3c3-7647-40bb-a1a0-8887b957811f_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_5c0f9bb9-a32d-479d-ae6d-b202e70f3899_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_c23c22c4-c161-430a-bc42-1061ba91bd5a_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_6838c6d0-81fe-4f6c-9dab-9bc171998585_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4545388a-791c-44ed-818b-2800458905ef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2ccd72f-54b3-4590-b38f-5a92dc0a3416_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_beb8f7b0-c391-4fca-9dfe-82eda4d46a23_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e3ce4f76-ffc0-41ca-9dea-a367cd765139_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_ebaf9ad4-4fa4-4967-9e43-eda2cdf50f2f_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:href="nktr-20210331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0dde85ba-c3ac-4335-8c2c-ecd42b4192c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_154d4aa6-539e-49b0-a084-8bca58948ef0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_82185710-6057-452d-bfde-1ff4ee83d913_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8bd8a329-6f21-4750-8b87-e5408a27de47_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c221ad21-887f-4352-883f-da2ad4e95eb7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b52d9214-c815-4c21-8b5b-36189fd95a32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 182,290 shares and 180,091 shares outstanding at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_2d1e74e2-237c-4c68-aebf-6e32346b4786_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_753c1e92-f465-4098-b60b-0943700cd627_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_8352c252-78d4-4378-9c8b-baff91d92794_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a956cd40-c569-4446-b9cf-d4eccc2826e7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_704da726-32ff-4360-a491-f736de9c53e1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f04758be-06bc-4d91-9ad3-1da849d0bf97_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_77d37803-0938-45b6-a33e-10be04c93217_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborationPartnerMember_0bfa1e46-9464-4d6b-a1dd-42c8929577ac_terseLabel_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_label_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner [Member]</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_documentation_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember" xlink:href="nktr-20210331.xsd#nktr_CollaborationPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborationPartnerMember" xlink:to="lab_nktr_CollaborationPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_852807ee-9653-48cd-9fa4-ccf586d9a16c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dc5b4301-5fbb-4dec-ba6a-1b79f1de2ebb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_ddee0bd4-591d-42ee-9e2b-27f0ed3c6862_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20210331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_d1b082f0-8525-454a-a696-ab3a0925548e_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6abfc315-7790-4a5b-9ebf-a7694aa75536_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea63a652-819f-4fc9-8be4-aa0d9f223b6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_49b0e073-633c-4973-a462-e659c36e34da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_65d262a8-d2d5-4edd-b62e-28b8d0723020_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5b1dd928-96e8-4590-8088-7b7071285fe4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ddd4224b-426c-44ae-b74a-62a7c48e45ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_439203ed-7d51-49a0-bbee-acb892db9be7_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20210331.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_0e4bae22-1522-4627-aef6-77803187cbc7_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fafb86f3-fc6a-47f8-a1f6-4f637c0417ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_81cb50a9-b888-4550-b3e3-ea1ec40dd969_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_WriteOffOfPrepayment_8b5a951f-53c9-4d6a-9924-69d9da7f121f_terseLabel_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_label_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_documentation_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment" xlink:href="nktr-20210331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_WriteOffOfPrepayment" xlink:to="lab_nktr_WriteOffOfPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b98bc7be-bceb-4fdb-bfcb-a5ce748d4b39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, RSUs (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_0ecffa13-48bf-4814-8e46-eacaed5e8690_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2ecab18d-c779-411e-b5e7-a720c5083ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d3f714bc-dc7d-4197-8f33-b850c99f9f7d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a5193282-38d0-453e-8f25-97faee031fe1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_432191a8-745d-4160-884b-03f89e5ba45c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9695159-7619-405e-9204-95b252f4537c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b731984f-4b81-401f-844b-1813b4058840_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_492452c0-fd3b-4a46-912c-becc061d7eb3_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, remaining minimum amount committed</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_01bc6b8e-ebc4-4d19-8a9d-d8516b475616_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CostOfBorrowingMember_e084900f-12e6-40c1-a1c5-941222daaaab_terseLabel_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing</link:label>
    <link:label id="lab_nktr_CostOfBorrowingMember_label_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing [Member]</link:label>
    <link:label id="lab_nktr_CostOfBorrowingMember_documentation_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember" xlink:href="nktr-20210331.xsd#nktr_CostOfBorrowingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CostOfBorrowingMember" xlink:to="lab_nktr_CostOfBorrowingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_c26eee1e-4561-40d0-be28-9f9883a35cb9_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_735b9e44-387f-4c13-9082-489a270b0f2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_104d7716-e15a-437d-813b-f565a1f59bcc_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_08c68dd0-4485-401b-850b-d921bf3a5eea_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6a8a85b6-9886-4168-a6f3-2b33cc3ad156_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_52195b60-b4b3-45c3-8072-16d3741310d1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2ae8b30-4e81-4ed6-9e83-a0f44008bd2e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c7d2c14-3c10-4044-a482-652e51502cea_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ad080b2-3dc2-4d05-8e42-9deef0c91143_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_02ffd9e9-ffef-4e23-bc5a-46ead6e8f57c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e37f713b-37a5-4f8a-9f1f-cf44bc8b9f8e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_47681abd-dbf4-40bd-8d35-eae98e31220a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_ec541c3e-c135-44fa-9408-0c8164f73a8c_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d3ff1ad2-7ac9-4f0d-9971-ec00bef99dd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_1cce211f-6cff-449b-b8e5-5b1195ad7a55_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_a127da33-4270-45d2-a39b-05536b21038c_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20210331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46e2ba37-ece8-4d3a-b149-80e8f4e6706d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_566590d4-9bac-4b72-b413-bbff5e67fc93_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_a3b9d1eb-67df-4d45-a1c8-647187a61a6e_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20210331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ae2a201-5285-4ab4-9707-20d30184ef8b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5c08d1b3-dedb-4d7e-8840-f875791a03e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d767a4d5-9b89-4799-a6b6-1e798b0ae122_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ad6f1b0c-36e8-4653-9512-3ebcd6b65041_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e1c7278a-93f5-41eb-8f2e-bc0a9bda85e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5ba323ca-0965-41bc-af5d-dfcd808700b5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_05656c87-acf8-4f3d-8e96-1dcdd65abfe4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_1fcd61f4-8c54-4202-8fc7-c85908e75ea0_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:href="nktr-20210331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_79657858-24f6-485c-a051-0a5b1f766d65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2294711f-5b18-4ff9-ae2e-e45834714e34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_b6b122f9-7e63-4e32-b0ca-936c9314b6db_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_1a86cf56-32d8-481b-a2dd-b3f512515362_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm" xlink:to="lab_nktr_DebtInvestmentMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_f9e6e520-42cd-474c-b6c3-d9691d89491c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_98dd783e-a621-4f2e-bb43-b030fe27f543_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_558ea134-4bc2-4e53-af6b-ebc00163029e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_bf975e1a-7c28-48c2-89fe-2bef8aaaaafa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f2798959-21e9-44b1-899b-7bb9238d3d8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53073357-30d7-498c-acb2-ad97d9ca830a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_75cb62a9-d734-4d99-a515-2653d6686b29_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bd24836c-72c4-4779-bbdd-fb72af9ee4ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_363e539d-2092-4737-9a4f-4de00c64764d_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20210331.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_30ecc781-96c6-45b3-8ed3-85de1d5fff51_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3a4225e9-1360-4bf2-968a-e57eceb8b19d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_182add8f-a8de-4712-90ba-ae161d615183_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a66f2463-2b25-4e03-9e7e-e98450a4a61e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bfb5ff21-7a82-45ed-8f00-63f9bd5a6a63_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1c590d5b-4a77-41a8-9aeb-5dd44f91216e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a385875f-93ba-4bf9-bcc5-cd5dfa0e1753_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_d67f96f8-4897-4854-9070-16c7fb32adcf_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20210331.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_726e9ef7-8645-4c8f-89b9-227920fc54d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_636206f7-d23e-4b75-bf1c-0d7edc6c52d6_terseLabel_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_label_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_documentation_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:href="nktr-20210331.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:to="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e7127b69-9e2c-45c9-aace-7f934e4e83c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bccc883f-aee6-4591-bac8-da411e89458e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a0283c7e-7496-4bda-99d8-cfdd08932ff6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_8ba8ac17-6638-468c-9506-acedbf080969_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones excluded from transaction price</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones Excluded from Transaction Price</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones Excluded from Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:to="lab_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_579950e0-4ba4-4761-8062-92a2cfbf77ab_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_75bb1963-aef3-44e6-b80f-ec94ad447cf1_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember" xlink:href="nktr-20210331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember" xlink:to="lab_nktr_DrugProductDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_84562cf0-d9f4-408b-aa5e-132af9595d79_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358LicenseMember_a123dbc4-c689-43e4-9703-21940067510f_terseLabel_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 358 License</link:label>
    <link:label id="lab_nktr_Nektar358LicenseMember_label_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 358 License [Member]</link:label>
    <link:label id="lab_nktr_Nektar358LicenseMember_documentation_en-US" xlink:label="lab_nktr_Nektar358LicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 358 license.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember" xlink:href="nktr-20210331.xsd#nktr_Nektar358LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358LicenseMember" xlink:to="lab_nktr_Nektar358LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2ae8dc6b-19bd-421c-9e1d-db3cfb4405a7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_26af80e2-2898-4258-87d0-4e9a04bd2462_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_5b5ba9ba-6657-43f7-b17c-a1166ed4d267_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_d22efc6a-6b30-48d1-bfe8-84091042b5ce_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20210331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_18cf2344-cafd-4a7a-b349-1f59cfabfcb1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_b92b921c-aaad-4b02-a248-f7f8e8ccc2de_terseLabel_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implicit interest rate over the life of the agreement</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_label_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Annual Interest Rate Over Life Of Royalty Liability</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_documentation_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual interest rate over life of royalty liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:href="nktr-20210331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:to="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_946eafb2-8b9e-4491-989a-b9515b463530_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_97deaeda-c9cc-498b-b482-3eac0467f295_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LegalMattersMember_88e437bd-6c84-4eeb-aab8-fc03315bbc3c_terseLabel_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_nktr_LegalMattersMember_label_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Member]</link:label>
    <link:label id="lab_nktr_LegalMattersMember_documentation_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember" xlink:href="nktr-20210331.xsd#nktr_LegalMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LegalMattersMember" xlink:to="lab_nktr_LegalMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b9b7252-b943-4208-880d-6959a08e735c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a0b2ad36-ef5e-40f4-a3ba-8bf86f636108_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_9e6e6e32-6840-4195-ac44-383420148849_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2e73418e-1ab0-432c-8be1-7d2ae035ceab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_02bdc91b-be49-40d2-83da-b7a3428f4519_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20210331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_66e988b6-f918-4e89-9ecf-7b7354901381_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a66e686b-52df-4985-81f2-5ea3f86e2f47_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_3f72588c-7032-4e4f-be93-fa0f7cd3255a_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_630d6380-0553-44dc-ab27-dcd34ccd29d2_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_eaf83870-fff1-4e01-a3b6-a7c01b87cee7_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:href="nktr-20210331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_6b1ec1aa-651a-48fc-b6bc-7f301433d84d_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_69da3276-a728-4473-bde5-60da2991de97_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_56d88c46-3ea1-4272-93ac-c83b94b3445f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_61b58cb9-2997-480f-918b-57e553d56fc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5795df24-814b-4cac-9dd7-487c51a1c156_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0450905c-672c-4173-8dd4-82fbc683db2e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_767f544c-f70a-479e-b68b-0d0a1a2c7047_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_10b86629-d9fc-464d-b0f6-9407f01d1b86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_646452bc-8f1e-40f8-8f86-80200d14a3b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e8d8f7bf-9924-43cc-9aae-6d0e83c779eb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_b5462470-f261-4362-ab8f-7c22ca76180c_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20210331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_efb23c32-22f8-4566-aa71-a0220c62e620_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarTwoOneFourMember_68dc7a5f-d502-4792-a5c7-11259f079a72_terseLabel_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_label_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Two One Four [Member]</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_documentation_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar two one four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember" xlink:href="nktr-20210331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarTwoOneFourMember" xlink:to="lab_nktr_NektarTwoOneFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_297d30ef-5375-47af-82f2-fc8e0d436a83_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_621bd59a-827a-4775-b28e-d8afd576746f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_2b2cf1e9-7edc-43f7-8166-80a132818add_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0c476445-f0e2-48d1-ba75-3699750f6694_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3c651354-59a7-4bc9-8c30-235d2e1b3dd4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_5f20bbe9-4e9c-48f4-8d1d-d40d9265f434_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_833e4038-73e6-40b2-82bf-cfacf1792480_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_fa785285-a91b-405f-bf57-a3f09abbd6f6_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement if threshold is not achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_198c15c4-af49-4981-af42-9a3b1197d5cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e9daacb7-b269-4868-929d-e91b224f5d44_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_de5c39cd-1ea6-4b15-ba30-8351d249f89c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_a59a666c-2cd9-4524-9485-3ca192da8dfa_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20210331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_e7b8855c-fa33-4132-85ac-51baf38e9a83_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0694cd11-3ff6-4e7f-b9df-eed5249e94fa_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3a1f51cd-3432-41ce-98b6-58c82f375554_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_2a56955d-aff5-49e8-b3f4-8657650d840e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b5b94c5-860a-4f19-a9f6-1a577017073c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_21eeb9e4-74fc-44b0-a68d-9b6aebeec2ec_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_029a0208-e37f-40b0-8ec1-4ba942dfb9f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a7a5740a-b4a8-4297-a8d3-0d940abfa167_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2144de6c-c1e8-48f6-bca4-3f967430b6b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_15d85087-87c2-4487-b2b8-4f3c1a525372_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares" xlink:href="nktr-20210331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares" xlink:to="lab_nktr_EstimatedFairValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_518ed4f9-fb68-42a9-a6ce-6d0e145755fe_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_ab54d392-a8cb-4306-8a4a-167b4370ec66_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_45dc300b-0be2-4932-a9ec-2b5d93ba2cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in period related to performance in prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4659604b-d044-4f99-9a48-af4f4fda9a8b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_85de07e9-4f5a-44c0-9434-c0effded780e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_a9ac19dc-a7b8-4209-81e5-f5f71c8f08d2_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20210331.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8f925fe9-fb06-4557-a3ee-1bec73cca3b4_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e0eaf005-0d08-4f3e-8b46-986cf815039b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_4fbf8c48-30e1-40c0-974c-c462b79ae5f6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e5f3713c-448d-4066-ba3d-17dd7f35c809_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c2fbfd4-647f-4396-b1ad-c934d9d0ca6b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8a758e0c-8cfe-45e7-b44e-7cddda0d52b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_93e0a3c3-4ffe-486e-ae00-182e4c9d03b9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f2bae13c-ca0f-477d-b212-535b9e3bbcf6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_2df11792-ce09-43cd-bb5c-37f476cfd8e6_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Three Five Eight [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar three five eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember" xlink:href="nktr-20210331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightMember" xlink:to="lab_nktr_NektarThreeFiveEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8e557936-ff77-4287-b433-7aaabd5790b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_868968ae-98d1-4e1c-af4d-205044dfb82e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_09830318-920a-47db-b05c-46aca2ae1f0f_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_b6a87d86-89b6-4112-b65d-7ac575f2154d_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_b893ca39-1990-491a-8723-d45486c69db6_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_52013890-736f-45aa-bdb9-c911869f6bce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7c8d0480-14a7-4828-a164-69b8cca0f70e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_693504bd-4ce2-460a-af3c-9761dfe7fd25_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_95672ca4-82fd-41bd-8a8f-7b7c6f9fca6c_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20210331.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7aba71ca-58f2-470a-9432-43657b0bbc96_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2cebb98-b9b6-418d-9ffa-412cf2ce1cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_48df46eb-bf21-4e03-bf2d-da299634184c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1b3c033a-1d30-43e2-b2cf-95bea450a417_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f351bcec-46c4-4be2-a756-1ab7d4a5173f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_37519898-8415-4418-bc93-3b89837b7833_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3602ca4-4628-4626-9811-e3ba6d7d399c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9b4884f8-d095-4b2f-985e-4a9977a17502_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ae5f0ca3-9dad-4007-bcb8-4865dfc15b12_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_b3cc4ae1-5f29-4555-91f9-183d6871e570_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_1312a560-2e39-4043-a0f7-e17ad0d37afa_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_label_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other [Member]</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember" xlink:href="nktr-20210331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentAndOtherMember" xlink:to="lab_nktr_ImpairmentAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9dfec3dd-f2c1-40fe-a5f5-ad9aaea88e91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_19b78ea4-f5b2-4e90-bf30-f4bab8450d5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3f546b30-cc08-4249-afe0-4356c9ea82ed_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b8557456-46bb-4318-9592-81204cc76bc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_868379eb-173f-43a9-92ee-3b02aba2d480_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20210331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c607b768-53a8-475d-af87-6276b8a36736_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a83a4b19-5ce7-4a55-beb7-a65a30512000_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8d59f627-cd02-42fa-ae29-a12f390c433c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e9637b5e-d957-486f-b338-c36e24740972_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_32ce9067-d41c-4119-aa68-700e413afde5_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_e85657d0-009f-4e77-a9b5-d96456841f8b_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20210331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3e59a51c-10b9-43f1-9a1e-0b87451bc6fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_4a460fef-8afb-4d4e-9972-45997a54b065_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_1687d36d-7419-4c96-8ce0-8bf21b2b1dec_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_5a24da0f-48d2-40a0-abf7-c876350039d9_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based annual payments, second indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Second Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Second Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_33e2229b-7a2a-4281-a092-dd041e1b0796_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_741eae38-93ea-4d1a-b7c9-b2c596704c35_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_830775a8-2a49-4e95-9d18-960d7ef200c2_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fad82c1d-3b68-4508-8b27-b66727c462eb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f88bb2c6-1be8-4ae8-8ae1-8ff912dca0c2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_88feb0cd-66e7-4789-a586-6da99e317b04_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_61bc64eb-6563-42a9-befb-c41b13011150_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_679adda1-af19-4900-964b-f5eac5a6f5d8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_84f8d799-30a0-4bdd-971d-e516dc01e02d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_bba088cc-bcac-439a-a75a-b3e1b75c43e6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_345fad2a-a5ce-4a53-a547-8522ea6d5621_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2bacae68-aa8c-40e3-ad91-fb4f0da75869_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6995ccf4-74b9-46fa-a27b-89784a7ae46c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_86dd95d5-d0fc-42fd-a56a-d297c98ed4cc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1256ec31-0e0f-4e77-8819-b4f61a20c52f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5fbc02b3-f36b-4e15-8fbb-dceda3271e39_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_ea5224bc-8eda-457c-8463-964c69871f95_terseLabel_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective effective interest rate</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_label_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Interest Rate Percentage</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_documentation_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage" xlink:href="nktr-20210331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProspectiveInterestRatePercentage" xlink:to="lab_nktr_ProspectiveInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f77da0d4-e3d0-40bd-bc18-47f13ca9b566_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_88f77f08-ad92-4fc4-82ed-5f0341dca528_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_b22611e7-dcb4-43dd-9b0b-535f52a56549_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e13ff48f-b597-4a3b-a256-b6b59277bd82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe90b9b2-621d-492e-8efc-a7c8eb5bcf04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b2527a8-9920-4a1e-a2c3-5da2f50850be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_9cb00e04-8b65-4485-9465-bffa2812d053_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20210331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_d2545973-881a-4a12-880d-6ed972bbc65e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a06b5ecc-3be6-49a0-84fe-753bc2308403_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5ce849d-5992-453a-8446-9d2cf7f88ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3ee011da-6220-4063-8008-bed889c2ccba_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_5adcc677-e8b2-4a8d-afbb-db27d981b094_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment period, first indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_edc4f66d-3f84-4eeb-8ca4-a223da801289_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d16be2e4-1d5d-479d-a8c4-d6c4de3179cf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_957f854b-4979-4036-8738-a7da8f123481_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_b6e7fd82-5859-4372-b226-1fe82317f335_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_01252ca4-db8f-49bd-94ee-92580c891673_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment period, second indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Second Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Second Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_40d2b1da-9680-4d4c-8faf-40e089ac2b7e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_64eb03bd-f137-47ff-a062-e5bb877ce9d1_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20210331.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bfe06f99-4ae9-4e79-bdc0-6ba2f3fdaa0e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a7be01f-7e1b-4b60-8dce-2790f5c82d62_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b0104727-193c-4cd0-b643-94189f8f9aca_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5aa11642-7673-4c2b-8d3f-02b558ffa444_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f46a2027-903f-4321-8bff-233bb4eb22fb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4c6ad1b4-5db4-4d06-a7ec-cd956562d458_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_26b732fd-596a-40c3-bf05-9f02612034cf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b9258606-b4e1-414e-9825-20196508fdd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nktr-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:90d49088-49d7-46e8-bf4e-aad54fe409fd,g:547c872a-3ea8-4af1-9003-f2e28b43aa2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2b46bbf5-90e3-482a-a760-8c675cde45ec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentType_2b46bbf5-90e3-482a-a760-8c675cde45ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a56bf6a8-cffe-4d5e-b303-45241c13529b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentQuarterlyReport_a56bf6a8-cffe-4d5e-b303-45241c13529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0f78e818-1903-4768-ae79-f54d56d3f586" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentPeriodEndDate_0f78e818-1903-4768-ae79-f54d56d3f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4f70f1f1-4ba5-42c0-aaa0-42a7fb956898" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentTransitionReport_4f70f1f1-4ba5-42c0-aaa0-42a7fb956898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e958d2dc-6f63-4c7a-bfab-2b7b8181cf45" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityFileNumber_e958d2dc-6f63-4c7a-bfab-2b7b8181cf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_64f78b65-2ab0-41de-995a-2839c664aa5c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityRegistrantName_64f78b65-2ab0-41de-995a-2839c664aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bcbb923e-4c6b-48d2-944c-14151034e80c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bcbb923e-4c6b-48d2-944c-14151034e80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f394b69f-e1a8-4c9c-a75d-f5ae79ac0804" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityTaxIdentificationNumber_f394b69f-e1a8-4c9c-a75d-f5ae79ac0804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7bcacf45-835b-4f33-aa37-a36ff6b4a22a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityAddressAddressLine1_7bcacf45-835b-4f33-aa37-a36ff6b4a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4666a92c-3661-41e7-b7b3-1ee9c9dd2457" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityAddressCityOrTown_4666a92c-3661-41e7-b7b3-1ee9c9dd2457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_44549d4c-6d68-4f89-b29e-f7dd63bbe773" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityAddressStateOrProvince_44549d4c-6d68-4f89-b29e-f7dd63bbe773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fae878c8-332b-49db-ab2a-22525e606f45" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityAddressPostalZipCode_fae878c8-332b-49db-ab2a-22525e606f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f9b8cc5f-8883-431b-9260-e5c24beb0c88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_CityAreaCode_f9b8cc5f-8883-431b-9260-e5c24beb0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b7981de1-2ffa-456c-99c7-0610d0a700a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_LocalPhoneNumber_b7981de1-2ffa-456c-99c7-0610d0a700a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a857adb-dfdf-42ca-ac5d-760bd5b0b01c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_Security12bTitle_5a857adb-dfdf-42ca-ac5d-760bd5b0b01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c56fe05b-a8b1-4d9d-b027-0ae4960908cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_TradingSymbol_c56fe05b-a8b1-4d9d-b027-0ae4960908cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ab4f62d4-4258-41f6-a9ae-8169dab51d6f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_SecurityExchangeName_ab4f62d4-4258-41f6-a9ae-8169dab51d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c0730a53-3a31-4f85-b853-85dff1ebbec3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityCurrentReportingStatus_c0730a53-3a31-4f85-b853-85dff1ebbec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_203b4662-8e9b-45f5-b4f8-5b9601cdccdb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityInteractiveDataCurrent_203b4662-8e9b-45f5-b4f8-5b9601cdccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_037fb139-6d64-41b7-889a-304bda318aaf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityFilerCategory_037fb139-6d64-41b7-889a-304bda318aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_03e7b63d-42ef-47cc-b0eb-b18d5aac7e85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntitySmallBusiness_03e7b63d-42ef-47cc-b0eb-b18d5aac7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e420c992-fd46-4293-bdae-94a7457e1078" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityEmergingGrowthCompany_e420c992-fd46-4293-bdae-94a7457e1078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3cf4e211-1cf7-4ecd-b2ec-dcad4b2b9e40" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityShellCompany_3cf4e211-1cf7-4ecd-b2ec-dcad4b2b9e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3578b802-d158-4ed0-b081-2f91c94f3e77" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3578b802-d158-4ed0-b081-2f91c94f3e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d335ac03-308c-4b8f-ba2f-a455d572dcab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_AmendmentFlag_d335ac03-308c-4b8f-ba2f-a455d572dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ecfe0128-fec2-4330-9e41-389cc1fa0dbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentFiscalYearFocus_ecfe0128-fec2-4330-9e41-389cc1fa0dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_48fd3b79-bfd8-4f29-9280-a2d575c988e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_DocumentFiscalPeriodFocus_48fd3b79-bfd8-4f29-9280-a2d575c988e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d64faf5a-03a0-40ba-b78e-5e9888bb72df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_EntityCentralIndexKey_d64faf5a-03a0-40ba-b78e-5e9888bb72df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4aa24334-b6ca-4384-b10d-2eeb5d52d994" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afe07305-512b-475b-ba43-e6ef88c487ac" xlink:to="loc_dei_CurrentFiscalYearEndDate_4aa24334-b6ca-4384-b10d-2eeb5d52d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c18bf154-1dbd-42e8-b519-0903929a3c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c18bf154-1dbd-42e8-b519-0903929a3c97" xlink:to="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccc920d8-d97e-40d3-b3d9-4f09d9e35d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccc920d8-d97e-40d3-b3d9-4f09d9e35d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c79b98a8-a84f-4c41-9b50-a326d7a351e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c79b98a8-a84f-4c41-9b50-a326d7a351e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4bf64d82-c42f-4bc7-8104-d14d9b8f9154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4bf64d82-c42f-4bc7-8104-d14d9b8f9154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_366f78f6-6549-4df0-9c8b-875c9b295d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_InventoryNet_366f78f6-6549-4df0-9c8b-875c9b295d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2824c7a4-b9b0-4513-8ff4-dd2877a0535f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_OtherAssetsCurrent_2824c7a4-b9b0-4513-8ff4-dd2877a0535f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11e061f3-f598-4c6c-95b2-82ff50d7ce5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93f41cdf-3185-402f-bb9a-9cc9d2587c0c" xlink:to="loc_us-gaap_AssetsCurrent_11e061f3-f598-4c6c-95b2-82ff50d7ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_78ee7e89-2759-4f6d-8010-575207e9cb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_78ee7e89-2759-4f6d-8010-575207e9cb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_79b6dde0-c04f-4633-8554-b27cf151b645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_79b6dde0-c04f-4633-8554-b27cf151b645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5a88b7-0510-4b02-933d-f4709a19f305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5a88b7-0510-4b02-933d-f4709a19f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f8d0757-919d-40e7-9aa7-fb636a916d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_Goodwill_3f8d0757-919d-40e7-9aa7-fb636a916d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_64c913a7-e802-4678-b343-580e61a36001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_64c913a7-e802-4678-b343-580e61a36001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_95587e31-f23a-416d-8134-54e34fdd0a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dadd7243-1bbb-49fd-a241-9761d417f99c" xlink:to="loc_us-gaap_Assets_95587e31-f23a-416d-8134-54e34fdd0a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c18bf154-1dbd-42e8-b519-0903929a3c97" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8ef37923-a038-46de-879d-2a8429f712f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_us-gaap_AccountsPayableCurrent_8ef37923-a038-46de-879d-2a8429f712f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_79538c70-5c02-4337-9fcc-adacf1c8eedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_79538c70-5c02-4337-9fcc-adacf1c8eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_bd90e1d5-166a-44b7-8ab2-1d3de6cc5c89" xlink:href="nktr-20210331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_bd90e1d5-166a-44b7-8ab2-1d3de6cc5c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_54597846-ab70-4c33-9a4a-df9051834283" xlink:href="nktr-20210331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_54597846-ab70-4c33-9a4a-df9051834283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4bf952bc-e533-470d-9a73-08142f212bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4bf952bc-e533-470d-9a73-08142f212bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4e5c6ee2-763b-41d0-90a9-9c23e68c9b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4e5c6ee2-763b-41d0-90a9-9c23e68c9b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_82f3c45d-10d9-4a83-9b3d-a70e1f8c2c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a805afa-2147-4451-a0b8-3c889b04b603" xlink:to="loc_us-gaap_LiabilitiesCurrent_82f3c45d-10d9-4a83-9b3d-a70e1f8c2c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7af572c6-e0b6-4696-8757-affdddd3aebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7af572c6-e0b6-4696-8757-affdddd3aebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5d9a927f-6950-4089-83d8-a7076cd33ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5d9a927f-6950-4089-83d8-a7076cd33ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0759b0fd-b195-4bf2-880c-646a964c75d0" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0759b0fd-b195-4bf2-880c-646a964c75d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b4124457-34b4-41a0-b10c-b5a5604d203e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b4124457-34b4-41a0-b10c-b5a5604d203e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dc022ff8-8ebb-4188-bf40-6852f09425dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_Liabilities_dc022ff8-8ebb-4188-bf40-6852f09425dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_56f5a275-cc15-46cf-ac11-02a39d6f0370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_CommitmentsAndContingencies_56f5a275-cc15-46cf-ac11-02a39d6f0370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_079fd552-ab70-44de-acaa-2448290fc9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_PreferredStockValue_079fd552-ab70-44de-acaa-2448290fc9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bd4006b3-a1dd-48e2-9ba7-2d65c77bee4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_CommonStockValue_bd4006b3-a1dd-48e2-9ba7-2d65c77bee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41df6f70-b4a2-456e-8451-c7c18dd61744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41df6f70-b4a2-456e-8451-c7c18dd61744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_069623e8-4c24-4b18-a910-48204a8552b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_069623e8-4c24-4b18-a910-48204a8552b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11eebd5f-ef8c-4e24-81b4-d9c48e742ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11eebd5f-ef8c-4e24-81b4-d9c48e742ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3624031f-f76f-4a7d-b211-4153eb971ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_63f062cd-4bff-4d47-a756-87bee507f896" xlink:to="loc_us-gaap_StockholdersEquity_3624031f-f76f-4a7d-b211-4153eb971ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea0c9bd-fca9-45d0-a5aa-1f6dac18453c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1353b8e5-64e0-4564-8b5b-c1f0bcb85dee" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ea0c9bd-fca9-45d0-a5aa-1f6dac18453c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ea96562e-24cc-4add-ae6d-ed4630c0c184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ea96562e-24cc-4add-ae6d-ed4630c0c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f46f8219-123e-4a85-af83-2e1fdfd25a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f46f8219-123e-4a85-af83-2e1fdfd25a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_fb5e3069-8457-4ebb-b7a1-b298435a7c93" xlink:href="nktr-20210331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_nktr_PreferredStockShareDesignated_fb5e3069-8457-4ebb-b7a1-b298435a7c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_dfa5156e-e6e5-4b8a-b12a-75749b4e29c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_dfa5156e-e6e5-4b8a-b12a-75749b4e29c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e6b1258-87ad-40ad-9c0e-df456d40d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e6b1258-87ad-40ad-9c0e-df456d40d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_05843e52-495d-4f0e-89c5-7740c30bfcd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_05843e52-495d-4f0e-89c5-7740c30bfcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_81204ee7-5bb2-4ee6-8314-141ff1675c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0484e93-f9de-48b0-aa97-28204014ce93" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_81204ee7-5bb2-4ee6-8314-141ff1675c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_12f7d254-bd46-462b-a2db-3a4e158e539f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_12f7d254-bd46-462b-a2db-3a4e158e539f" xlink:to="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:to="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7e3908ff-d351-43fe-9677-7305b9979f1f" xlink:to="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4911a414-8d5a-4539-aca2-5140df85a157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_us-gaap_ProductMember_4911a414-8d5a-4539-aca2-5140df85a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a843a550-b354-4e9b-a15e-81a785465d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_us-gaap_RoyaltyMember_a843a550-b354-4e9b-a15e-81a785465d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8a760b49-fe9c-4658-af3a-33dae00855b5" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8a760b49-fe9c-4658-af3a-33dae00855b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_c3c7b001-bcf7-43b7-a3e7-92be3812432f" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fe6e14ac-3ae4-4b34-bfc9-0293594111af" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_c3c7b001-bcf7-43b7-a3e7-92be3812432f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73773eae-a8c3-4356-9535-eadb9cc096cc" xlink:to="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6688c7b1-66da-462b-adc4-1b689d131032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_24f26e7e-ca9c-499d-b146-f063a43e0a95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6688c7b1-66da-462b-adc4-1b689d131032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88853fa5-2fc5-479f-b1aa-2f18fa6d8370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88853fa5-2fc5-479f-b1aa-2f18fa6d8370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_88436d63-9b43-49e8-bac3-48ff17add6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_88436d63-9b43-49e8-bac3-48ff17add6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca71aa2a-bb38-4c8f-929b-d364496376e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca71aa2a-bb38-4c8f-929b-d364496376e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_13e05a82-1edc-4a78-989e-188ee574e7d0" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_13e05a82-1edc-4a78-989e-188ee574e7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_70e422b5-4a96-44c9-9092-78fe57b3ad64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_35a5c57a-fa8a-4b02-9866-c4c435113ada" xlink:to="loc_us-gaap_CostsAndExpenses_70e422b5-4a96-44c9-9092-78fe57b3ad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f373c54-8af1-40a8-979e-79e1f136449c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f373c54-8af1-40a8-979e-79e1f136449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_49b1b319-3183-4b16-8753-39497ae83924" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_49b1b319-3183-4b16-8753-39497ae83924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_23350ebc-0a44-4b6e-9455-65a785e11dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_23350ebc-0a44-4b6e-9455-65a785e11dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_88f11860-d1a6-4697-8b15-b8deebfff159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_88f11860-d1a6-4697-8b15-b8deebfff159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e11cd88d-5106-458e-bb97-acc93594eb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_InterestExpense_e11cd88d-5106-458e-bb97-acc93594eb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_76291070-2768-47bb-8e8a-79da0464995b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d78b42d9-7afb-4111-b99a-a8cbaff742a2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_76291070-2768-47bb-8e8a-79da0464995b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec2f3af8-462e-437d-8777-3a38ab1d1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec2f3af8-462e-437d-8777-3a38ab1d1f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54f0aa09-5b02-4d18-ab9a-b29cf26d88d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_54f0aa09-5b02-4d18-ab9a-b29cf26d88d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54832f6b-b1d9-406f-82e8-d03b27e8292c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_NetIncomeLoss_54832f6b-b1d9-406f-82e8-d03b27e8292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_e1f621c0-3441-4268-8c00-a99f2e21cc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_e1f621c0-3441-4268-8c00-a99f2e21cc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_cbf66aa1-1b14-45a1-bbfd-15e0d333e71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cec3acf-1e92-4b57-a6c0-77144548f7ed" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_cbf66aa1-1b14-45a1-bbfd-15e0d333e71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_892a7e41-64c4-45d3-a760-b6f86d85580b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b85eb5df-634a-4b56-a7bd-60d465e28e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_892a7e41-64c4-45d3-a760-b6f86d85580b" xlink:to="loc_us-gaap_NetIncomeLoss_b85eb5df-634a-4b56-a7bd-60d465e28e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5655584d-0e61-4caf-b3a2-63d99063549c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_892a7e41-64c4-45d3-a760-b6f86d85580b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5655584d-0e61-4caf-b3a2-63d99063549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ea683018-dcbc-4809-b514-55c08542aae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5655584d-0e61-4caf-b3a2-63d99063549c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ea683018-dcbc-4809-b514-55c08542aae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b17e07c9-9992-4c37-9b00-13934c1c3834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5655584d-0e61-4caf-b3a2-63d99063549c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b17e07c9-9992-4c37-9b00-13934c1c3834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3497f6cf-1afd-4033-a2f9-f83f0a3cf861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5655584d-0e61-4caf-b3a2-63d99063549c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3497f6cf-1afd-4033-a2f9-f83f0a3cf861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f97f84a-e4e7-48c6-af0c-05538d67d68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_892a7e41-64c4-45d3-a760-b6f86d85580b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f97f84a-e4e7-48c6-af0c-05538d67d68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_115b79cf-0e80-4adf-9d1d-ac63db2a6cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_115b79cf-0e80-4adf-9d1d-ac63db2a6cf7" xlink:to="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb2f473c-7511-431b-958a-a675f8b2727e" xlink:to="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f06430ef-c35b-4ac2-a6ba-e246aa06fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_CommonStockMember_f06430ef-c35b-4ac2-a6ba-e246aa06fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f06b357-85fe-4d6a-8dfa-59bdea8a3fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f06b357-85fe-4d6a-8dfa-59bdea8a3fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db99357e-131f-4afd-bce3-8c20388e20cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db99357e-131f-4afd-bce3-8c20388e20cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4ec33b7a-0d19-47a9-a90b-43e1e92a9ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75217cea-efc5-400e-bce6-fef2f4171469" xlink:to="loc_us-gaap_RetainedEarningsMember_4ec33b7a-0d19-47a9-a90b-43e1e92a9ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53ca5604-98d2-46ed-b282-7abf3d0a6ca4" xlink:to="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20559d22-7fb6-4058-af88-0308899821e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f09a703-d93b-40ae-af59-694242299d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_SharesOutstanding_3f09a703-d93b-40ae-af59-694242299d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a593bfc8-d62c-4750-86f0-a2db449ad909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockholdersEquity_a593bfc8-d62c-4750-86f0-a2db449ad909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06b3d1a4-a1e1-40a6-971c-9318dfec216b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06b3d1a4-a1e1-40a6-971c-9318dfec216b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1c8201ca-0c2c-466d-8071-72f7da9342f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1c8201ca-0c2c-466d-8071-72f7da9342f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_677544b5-5ab4-4610-86c1-d3b0f2b438d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_677544b5-5ab4-4610-86c1-d3b0f2b438d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_768114dd-2add-4f15-9afd-4a354dbfb238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_768114dd-2add-4f15-9afd-4a354dbfb238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be024daa-3b9f-4b93-86ab-f8aa10851b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_SharesOutstanding_be024daa-3b9f-4b93-86ab-f8aa10851b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_807e2db5-b8c6-4e47-b5e5-fe11e753106e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b024b83e-09b7-4d78-8c90-af361731ae35" xlink:to="loc_us-gaap_StockholdersEquity_807e2db5-b8c6-4e47-b5e5-fe11e753106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20210331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00e50e28-0c61-426e-a5ff-b069ecd60e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00e50e28-0c61-426e-a5ff-b069ecd60e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a4b79872-c125-4f2c-927e-56d08e266aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00e50e28-0c61-426e-a5ff-b069ecd60e05" xlink:to="loc_us-gaap_ProfitLoss_a4b79872-c125-4f2c-927e-56d08e266aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00e50e28-0c61-426e-a5ff-b069ecd60e05" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_11b30411-42f4-4b63-9faf-b3e1b6169650" xlink:href="nktr-20210331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_11b30411-42f4-4b63-9faf-b3e1b6169650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b160fa86-7eda-4d65-a22a-03c3a6cab63f" xlink:href="nktr-20210331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_b160fa86-7eda-4d65-a22a-03c3a6cab63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_277ed064-984f-4128-8dcb-dd26f2be57ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_277ed064-984f-4128-8dcb-dd26f2be57ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_53188a09-f021-42e6-8fd9-f3c7cb9f0f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_53188a09-f021-42e6-8fd9-f3c7cb9f0f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_69cdbddf-a701-435b-bae2-d718b1447a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_69cdbddf-a701-435b-bae2-d718b1447a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_22b01034-73ca-4b10-82e6-bce2dc7ddd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_DepreciationAndAmortization_22b01034-73ca-4b10-82e6-bce2dc7ddd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_49d1658f-331e-4390-8050-ba60ef043f02" xlink:href="nktr-20210331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_49d1658f-331e-4390-8050-ba60ef043f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6aa0d7a3-ab0d-497d-86b8-c266846e95a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6aa0d7a3-ab0d-497d-86b8-c266846e95a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_262ba266-5e84-480f-9e3a-9111834de91f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4694408c-bb59-4568-b4f5-b97da8b60cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4694408c-bb59-4568-b4f5-b97da8b60cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b3c3c41c-075f-42e0-93d7-a6f1be42056d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b3c3c41c-075f-42e0-93d7-a6f1be42056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_a85611a3-7662-4b6a-a129-078d1ea27d75" xlink:href="nktr-20210331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_a85611a3-7662-4b6a-a129-078d1ea27d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5d04183b-8bcc-4c4d-872f-a5308b7de84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5d04183b-8bcc-4c4d-872f-a5308b7de84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_304e5fb3-d791-48fd-ae44-5000715ddafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_304e5fb3-d791-48fd-ae44-5000715ddafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_85c72bde-b931-4428-b6e3-1b3a2988635c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_85c72bde-b931-4428-b6e3-1b3a2988635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c97d2d94-093a-446f-9444-a4f8cf3f8bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c97d2d94-093a-446f-9444-a4f8cf3f8bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_55f2fc0d-302d-400b-963c-c201a76e7a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bab9fd9-de5a-4215-8001-11feaab88e5e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_55f2fc0d-302d-400b-963c-c201a76e7a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e28144d6-24ab-4ca3-a92d-a163a0cd6ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00e50e28-0c61-426e-a5ff-b069ecd60e05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e28144d6-24ab-4ca3-a92d-a163a0cd6ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5fc0939b-0bf2-4356-8621-398d14a5d614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5fc0939b-0bf2-4356-8621-398d14a5d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dbddee09-7138-4c42-b9cb-ec88b4fe5535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dbddee09-7138-4c42-b9cb-ec88b4fe5535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2884a1e9-874f-4270-ad80-78f8850ff67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2884a1e9-874f-4270-ad80-78f8850ff67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75805190-1989-4721-9190-30b887171f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75805190-1989-4721-9190-30b887171f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2259d165-8ec9-411e-b0b7-b4ff97ad25a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f425dcee-2ca7-43c7-8b6c-f76dde3f6bd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2259d165-8ec9-411e-b0b7-b4ff97ad25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f00d79b2-ed04-4dfe-b71e-563e0b5f76f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f00d79b2-ed04-4dfe-b71e-563e0b5f76f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_89a4b003-468f-4873-a234-1dee82867595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f00d79b2-ed04-4dfe-b71e-563e0b5f76f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_89a4b003-468f-4873-a234-1dee82867595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_b1ea891d-b103-4002-8cbd-16da2e8ec1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f00d79b2-ed04-4dfe-b71e-563e0b5f76f6" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_b1ea891d-b103-4002-8cbd-16da2e8ec1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b731060d-675e-4888-80c1-16380afe13e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f00d79b2-ed04-4dfe-b71e-563e0b5f76f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b731060d-675e-4888-80c1-16380afe13e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed0d8781-9c74-41f5-b17c-fcb510177c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed0d8781-9c74-41f5-b17c-fcb510177c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8634274d-9e7f-4b7b-9f72-db970fc2397d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8634274d-9e7f-4b7b-9f72-db970fc2397d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63b8cc08-a8ee-4193-9343-c4d2fe4d1cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63b8cc08-a8ee-4193-9343-c4d2fe4d1cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f01309d8-c105-4775-84fe-c74ceb310487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f01309d8-c105-4775-84fe-c74ceb310487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfb3cfa-96da-4e26-b13b-1a6b30c60ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1904b9b9-2ced-4558-a028-42cb2667d921" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfb3cfa-96da-4e26-b13b-1a6b30c60ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f918f222-3ff1-4659-9d70-635d3d68b551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfb3cfa-96da-4e26-b13b-1a6b30c60ea6" xlink:to="loc_us-gaap_InterestPaidNet_f918f222-3ff1-4659-9d70-635d3d68b551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b03b0072-cb9a-4720-9694-7c241da42c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfb3cfa-96da-4e26-b13b-1a6b30c60ea6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b03b0072-cb9a-4720-9694-7c241da42c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_236fd603-b3b3-4449-8e1c-c7e2c2cc0d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_34b6bc5f-a9bc-4762-afbe-33c20dbf6ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_236fd603-b3b3-4449-8e1c-c7e2c2cc0d76" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_34b6bc5f-a9bc-4762-afbe-33c20dbf6ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyPolicyTextBlock_199a55fd-781b-4b09-a934-7e883b75d816" xlink:href="nktr-20210331.xsd#nktr_OrganizationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_nktr_OrganizationPolicyPolicyTextBlock_199a55fd-781b-4b09-a934-7e883b75d816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c2281ebc-ec18-4e71-a7e6-bb271583238c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c2281ebc-ec18-4e71-a7e6-bb271583238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_53b51313-48bb-4d54-9047-c537cc6d57bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_UseOfEstimates_53b51313-48bb-4d54-9047-c537cc6d57bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e83e23b5-f526-477d-b34f-5469e09f3f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e83e23b5-f526-477d-b34f-5469e09f3f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47bde975-babc-4f8a-b8d0-468e44edc7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47bde975-babc-4f8a-b8d0-468e44edc7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_af386279-f1d5-4b20-b217-b041a89ebb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_af386279-f1d5-4b20-b217-b041a89ebb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_5c30d630-8b34-4fab-9d22-d99bf031d27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_5c30d630-8b34-4fab-9d22-d99bf031d27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0550ce03-e68c-47b5-8717-b92a0ea38d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0550ce03-e68c-47b5-8717-b92a0ea38d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d13aa32a-e755-43b6-8e45-e7ecfbce857d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d13aa32a-e755-43b6-8e45-e7ecfbce857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_03147b20-e771-4c91-b0a0-21adca538860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_03147b20-e771-4c91-b0a0-21adca538860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b702ae53-e51b-4153-9b8c-a5f8071f9886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad0b134d-b7ef-47b1-a916-62d4132bccc4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b702ae53-e51b-4153-9b8c-a5f8071f9886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c2dbf05-bb32-4dfa-81f7-3ec3082bb816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7c2dbf05-bb32-4dfa-81f7-3ec3082bb816" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:to="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b0e3e2bd-4218-455b-a52f-88f1a4ea3d93" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_01ea9e0b-c9f4-47a2-a61a-def0ae5a8f58" xlink:href="nktr-20210331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:to="loc_nktr_BMSCollaborationAgreementMember_01ea9e0b-c9f4-47a2-a61a-def0ae5a8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_c49d09a1-0e60-473d-9c6a-d336b62d81c5" xlink:href="nktr-20210331.xsd#nktr_CollaborationPartnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c7f3e15-d54b-4637-a0b1-41a92d91534b" xlink:to="loc_nktr_CollaborationPartnerMember_c49d09a1-0e60-473d-9c6a-d336b62d81c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:to="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73cee30e-2938-42aa-b769-a4457f3f79ca" xlink:to="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_042226af-48ef-441d-b1c7-2ac0a1627209" xlink:href="nktr-20210331.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a42d19e2-330e-47d7-ae35-85ae7b69d925" xlink:to="loc_nktr_NKTR181Member_042226af-48ef-441d-b1c7-2ac0a1627209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:href="nktr-20210331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9102f660-af23-437d-90d0-c3ce0bf0c9c3" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7eb0e6ee-106d-419c-8943-3fd334a886dd" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7eb0e6ee-106d-419c-8943-3fd334a886dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b1fc716d-f649-448a-b1aa-931d0ae94846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b1fc716d-f649-448a-b1aa-931d0ae94846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4529ba09-d044-43a8-bb1c-bd0228f6b9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4529ba09-d044-43a8-bb1c-bd0228f6b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8ee4500b-447b-4e76-8644-cca10ca5648e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8ee4500b-447b-4e76-8644-cca10ca5648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_09511d62-1252-4c65-8205-44b55dcb2b16" xlink:href="nktr-20210331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_WriteOffOfPrepayment_09511d62-1252-4c65-8205-44b55dcb2b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_d45a5374-1016-4345-8f8c-3b90dd38c540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_d45a5374-1016-4345-8f8c-3b90dd38c540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_3baa2fe2-a673-4df6-80c0-5e5176d0d176" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c7ef8847-e50c-44aa-a2c4-f4ae3b92ec73" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_3baa2fe2-a673-4df6-80c0-5e5176d0d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f0f76b9c-ded6-4104-b297-4a10bc53c818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0dc41130-9e30-4fec-a868-607adcf079e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f0f76b9c-ded6-4104-b297-4a10bc53c818" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0dc41130-9e30-4fec-a868-607adcf079e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ca7fb97-0bfe-47af-8b06-4c097eadbd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_d5b96f8e-ef4f-49c7-8e8b-878476f32bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ca7fb97-0bfe-47af-8b06-4c097eadbd74" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_d5b96f8e-ef4f-49c7-8e8b-878476f32bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4397bd53-354d-477b-970f-7b737383c81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ca7fb97-0bfe-47af-8b06-4c097eadbd74" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4397bd53-354d-477b-970f-7b737383c81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b8736027-eb8a-4f84-9173-1ebac41b9c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8736027-eb8a-4f84-9173-1ebac41b9c80" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6291965c-9e12-44e8-9c8a-1ba02983f703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6291965c-9e12-44e8-9c8a-1ba02983f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7c2af411-b833-40a5-9db0-ab3e4a050389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7c2af411-b833-40a5-9db0-ab3e4a050389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8dbd165f-aeb4-46b9-a698-e9a40f8b723c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8dbd165f-aeb4-46b9-a698-e9a40f8b723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_344c81dc-bdfc-420f-8454-fc8692e681af" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_862f8eb6-6e83-444c-bec5-a5cc57d971d6" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_344c81dc-bdfc-420f-8454-fc8692e681af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f9aaa7a4-be5b-4340-ac5b-abffa878ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f9aaa7a4-be5b-4340-ac5b-abffa878ff1a" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:to="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de2073be-f0a8-4623-b5ad-62c6390617b0" xlink:to="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_924af620-81de-4fa8-ad23-836f6ce39e93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:to="loc_srt_MinimumMember_924af620-81de-4fa8-ad23-836f6ce39e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0f33134d-7343-48af-93f9-d104e744c3d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_108ab79f-7e15-4777-a0bd-12d0beaf8128" xlink:to="loc_srt_MaximumMember_0f33134d-7343-48af-93f9-d104e744c3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:href="nktr-20210331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_d7a93a14-f3b0-41ff-8388-d5d265214ac6" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_f87d7a0e-3a87-489c-9c32-a83e9eaf28a7" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_f87d7a0e-3a87-489c-9c32-a83e9eaf28a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_7da18f08-06ca-444b-a4f0-4667c6e41d00" xlink:href="nktr-20210331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_7da18f08-06ca-444b-a4f0-4667c6e41d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_732fa4f1-fbda-458e-b73b-24a0962b4fe2" xlink:href="nktr-20210331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_732fa4f1-fbda-458e-b73b-24a0962b4fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_840ab243-9aaa-4014-a84b-3701dee29dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_840ab243-9aaa-4014-a84b-3701dee29dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06fac748-4fc6-40a5-91ef-5149b8e41d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_804e90f4-862e-48ca-9da5-cb4278e40a05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06fac748-4fc6-40a5-91ef-5149b8e41d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1328f500-3cb0-43b7-a3c7-80e06b24c1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1328f500-3cb0-43b7-a3c7-80e06b24c1d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:to="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_92051be1-ba4f-46f2-ada5-95e6edb7b7e7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ba9f827f-4716-4f8a-a9cf-923e9a3bfbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ba9f827f-4716-4f8a-a9cf-923e9a3bfbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6e12de67-b75c-4fdd-a443-4633fae86b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CommercialPaperMember_6e12de67-b75c-4fdd-a443-4633fae86b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26691052-e9d6-4d15-97a6-77d5f2492473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26691052-e9d6-4d15-97a6-77d5f2492473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c078e45c-c537-43a9-911d-150e2ac6f28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c078e45c-c537-43a9-911d-150e2ac6f28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_99f1d601-f8c6-4fb5-851c-63deaa339989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_505ff6cc-c7a8-4ec7-9280-a0ce5585e9d0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_99f1d601-f8c6-4fb5-851c-63deaa339989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_06a9f613-c215-465e-bea4-44693e394d14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1abf2bd-9b7f-47ce-88e9-b0835e822c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1abf2bd-9b7f-47ce-88e9-b0835e822c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_634c3845-0e4f-44c1-b14c-cac1fad04ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c70efe3-d3a7-428a-b521-68ad6b29fe20" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_634c3845-0e4f-44c1-b14c-cac1fad04ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ca8af3-131c-4ea4-81f4-632c02738c30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_80031cb6-733e-4da0-a342-d56dc905f210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_80031cb6-733e-4da0-a342-d56dc905f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f9ae564-935f-4c43-a271-12690a172b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f9ae564-935f-4c43-a271-12690a172b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c46e497-6f2c-4650-8c38-a5c32cc78cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c46e497-6f2c-4650-8c38-a5c32cc78cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef97c2ad-402f-4bda-8f14-1c7d2012d1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef97c2ad-402f-4bda-8f14-1c7d2012d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_241364e2-027f-4c5f-9009-3609b5c008c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_241364e2-027f-4c5f-9009-3609b5c008c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_7f65f100-5e67-4d4a-845b-2c433e758cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_us-gaap_Cash_7f65f100-5e67-4d4a-845b-2c433e758cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_604122bb-f5c2-4cfa-a322-cf0025231807" xlink:href="nktr-20210331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9345aa7-4d1a-4172-ba18-5d2f62a300d5" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_604122bb-f5c2-4cfa-a322-cf0025231807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20210331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_87c613fa-bdf7-43c8-b9fb-fdea2704736c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9ad547b3-13c4-4c0a-8264-e1180321ef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_87c613fa-bdf7-43c8-b9fb-fdea2704736c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9ad547b3-13c4-4c0a-8264-e1180321ef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ecf2c06b-5e64-4126-8343-9700753cbd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2174b4a8-14f3-41db-b45a-046f0b57038f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ecf2c06b-5e64-4126-8343-9700753cbd7f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2174b4a8-14f3-41db-b45a-046f0b57038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e730158d-a647-4d9e-bf78-60a4a9a7d02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_311bd9ea-fa33-4cbb-be1e-b249537a7b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e730158d-a647-4d9e-bf78-60a4a9a7d02f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_311bd9ea-fa33-4cbb-be1e-b249537a7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b93eae47-2bfe-47f3-9ec2-60135b840fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e730158d-a647-4d9e-bf78-60a4a9a7d02f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b93eae47-2bfe-47f3-9ec2-60135b840fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d0ce3cf8-6c65-4305-b8c3-b886999e867d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e730158d-a647-4d9e-bf78-60a4a9a7d02f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d0ce3cf8-6c65-4305-b8c3-b886999e867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b98c0b2d-90d1-48a4-8872-25c88031ee7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e730158d-a647-4d9e-bf78-60a4a9a7d02f" xlink:to="loc_us-gaap_InventoryNet_b98c0b2d-90d1-48a4-8872-25c88031ee7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_845a59eb-c979-4e00-846a-a3f96a1af285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_5d09495a-f9be-4de4-9b59-dad4bb74552f" xlink:href="nktr-20210331.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_845a59eb-c979-4e00-846a-a3f96a1af285" xlink:to="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_5d09495a-f9be-4de4-9b59-dad4bb74552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b8acc324-a24d-49a6-97c8-65250e6ca077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_c0f01054-fb4c-4ba6-a71a-4ffb02fbb375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b8acc324-a24d-49a6-97c8-65250e6ca077" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_c0f01054-fb4c-4ba6-a71a-4ffb02fbb375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76e00585-02fa-4fbb-813a-1a4db281fdd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76e00585-02fa-4fbb-813a-1a4db281fdd9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:to="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d37fd1dd-14c0-4a4a-bcd6-f173c1e5b8bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_71bf7762-59b7-4349-8a36-e3516db71e89" xlink:href="nktr-20210331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_189089ce-a9f0-4651-8f1a-e9cc6be6139c" xlink:to="loc_nktr_SFJPharmaceuticalsMember_71bf7762-59b7-4349-8a36-e3516db71e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_91433eda-57f3-40bb-b8ab-042331f7ee87" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember_62c6a8ff-db2d-4066-a23f-3f9dc1a5f659" xlink:href="nktr-20210331.xsd#nktr_CostOfBorrowingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_913345a0-b526-428d-a3ec-227ff01e60c9" xlink:to="loc_nktr_CostOfBorrowingMember_62c6a8ff-db2d-4066-a23f-3f9dc1a5f659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_374f1e51-5f07-4eb5-a677-e66edeb209e0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_883cf608-60d2-4a92-87b2-8c86713b91cf" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_883cf608-60d2-4a92-87b2-8c86713b91cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_b6fce210-fe49-4296-85d7-c873e4658abf" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_b6fce210-fe49-4296-85d7-c873e4658abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_f765e9c8-456d-4119-942c-d792a2a0d5ff" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_f765e9c8-456d-4119-942c-d792a2a0d5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_50c499ab-86f9-4dbb-bba5-0201d487b68a" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_50c499ab-86f9-4dbb-bba5-0201d487b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_267abe07-a1eb-482d-af03-8a9bf7a9129e" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_267abe07-a1eb-482d-af03-8a9bf7a9129e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_01933d44-7fd6-4843-96de-b5092d57ec58" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_01933d44-7fd6-4843-96de-b5092d57ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_8e149e06-d29d-4a67-987d-feb04b7286ce" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_8e149e06-d29d-4a67-987d-feb04b7286ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_668bf914-b34e-4254-bde3-344e787949cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b67662e6-f835-48e8-a80a-04b8d5533e1a" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_668bf914-b34e-4254-bde3-344e787949cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d34a425-f8c6-4d57-91fc-94de319bd17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d34a425-f8c6-4d57-91fc-94de319bd17c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c28d0688-b0ba-4066-9ca2-b6deadf2848e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_969ec9ba-3210-4e4b-85fa-45c40d4a1b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_126456a1-5755-433c-9564-7a6d10874cfa" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_969ec9ba-3210-4e4b-85fa-45c40d4a1b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_cd2fa707-794e-4311-90f7-cd89d01c1040" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8d20b4b5-9ace-4741-97f9-af4d17b97128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e94186f9-1eb8-4baa-bda1-5c8d21bca416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e94186f9-1eb8-4baa-bda1-5c8d21bca416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_43f3b217-d8e6-4279-8f76-fe22ac425efe" xlink:href="nktr-20210331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_43f3b217-d8e6-4279-8f76-fe22ac425efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c430f97b-103f-480e-b97c-b71ce21f4b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c430f97b-103f-480e-b97c-b71ce21f4b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_be1ee258-9a16-4368-8ae4-cd34bad95f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_be1ee258-9a16-4368-8ae4-cd34bad95f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d00b262d-1265-43fc-8bb7-a2a860e0c187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aada5110-ba26-4432-8dc8-2f5ab2a34337" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d00b262d-1265-43fc-8bb7-a2a860e0c187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_aa4ccb0d-bfcd-455a-a216-2ff0f40b8eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_0dafdd85-fd92-4540-81b3-593bfb56d8ea" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_aa4ccb0d-bfcd-455a-a216-2ff0f40b8eb6" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_0dafdd85-fd92-4540-81b3-593bfb56d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d1575960-9441-41cc-8c21-09ff62803b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_e93b841f-4ea4-4846-adb7-b8da5f10bf7a" xlink:href="nktr-20210331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d1575960-9441-41cc-8c21-09ff62803b53" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_e93b841f-4ea4-4846-adb7-b8da5f10bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4c320161-7e04-48b0-9068-020908a3a013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4c320161-7e04-48b0-9068-020908a3a013" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc154fe8-9c34-479d-bbf8-cafde0090e67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_8c72af55-5123-4deb-b42a-7d635d7c50b1" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_8c72af55-5123-4deb-b42a-7d635d7c50b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a240c6f4-ef0f-487b-96d9-b0b3521e3e52" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9647832-ca26-4063-86b1-303ff67c7e9e" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a240c6f4-ef0f-487b-96d9-b0b3521e3e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_4b04c9af-fd56-43db-b0e3-63831a4a2777" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_3d2ca4d0-3e1a-4e28-b195-4406a6021258" xlink:href="nktr-20210331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_3d2ca4d0-3e1a-4e28-b195-4406a6021258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_93979373-33f2-44a6-be2d-60fc70594ded" xlink:href="nktr-20210331.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_93979373-33f2-44a6-be2d-60fc70594ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_dee1c9a0-c8ad-41f1-8a7d-20880958eb9a" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_dee1c9a0-c8ad-41f1-8a7d-20880958eb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_cc761087-0d37-411c-9e57-b9fc59290f43" xlink:href="nktr-20210331.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_cc761087-0d37-411c-9e57-b9fc59290f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_0100843e-6f97-4536-b29b-e9be653a04b2" xlink:href="nktr-20210331.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_38ffb151-8835-41b4-a174-1d1fb64d1a78" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_0100843e-6f97-4536-b29b-e9be653a04b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6076c515-261f-45f4-950d-e24020492af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6076c515-261f-45f4-950d-e24020492af2" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88563821-3a9c-4182-962e-c6056a11c2d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_509caec6-3aa1-4baf-a41c-a553d733e3ec" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_509caec6-3aa1-4baf-a41c-a553d733e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_a886463d-ca13-4f89-be3d-79d2bd5b0c83" xlink:href="nktr-20210331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_79226684-7043-4727-af35-402fff055e45" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_a886463d-ca13-4f89-be3d-79d2bd5b0c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:href="nktr-20210331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_bc97dfcd-faa1-4868-9122-ae9077397ab7" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a6e2685e-6973-4d22-bd3f-aa96817e16e4" xlink:href="nktr-20210331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_a6e2685e-6973-4d22-bd3f-aa96817e16e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_44d0372f-2cc5-4b52-ba75-e95743ac7b61" xlink:href="nktr-20210331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_94169e37-0959-4312-9e28-7388920e2cfb" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_44d0372f-2cc5-4b52-ba75-e95743ac7b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de248911-9a34-45ee-9e4b-5fa82b657ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e27ce2f3-f6d3-4bcf-b0e8-8307ab753277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de248911-9a34-45ee-9e4b-5fa82b657ad2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e27ce2f3-f6d3-4bcf-b0e8-8307ab753277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#CommitmentsandContingenciesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e66ea07-fc85-498d-a138-4b8a487db00a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e66ea07-fc85-498d-a138-4b8a487db00a" xlink:to="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ebc0667-a3fe-48a1-be8a-4a35ed6a28b3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_30a6b12b-8436-440f-aacf-2808791b2981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_30a6b12b-8436-440f-aacf-2808791b2981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_9a935950-f879-4a52-b3fd-43ea3c198442" xlink:href="nktr-20210331.xsd#nktr_LegalMattersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_696ea1ef-ad69-4af2-ae26-dfcbcb2fe429" xlink:to="loc_nktr_LegalMattersMember_9a935950-f879-4a52-b3fd-43ea3c198442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f2539d4a-2eb9-4d89-bbc0-bc772f3c9be1" xlink:to="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_03e72b7b-8d3c-499d-ab7e-ccaf2035f8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fc24b396-8470-457f-92cf-b9e29e94abf0" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_03e72b7b-8d3c-499d-ab7e-ccaf2035f8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e445bae0-53b2-483c-9e0c-5c4023b92ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_50087d26-1b69-42aa-aac9-65e2bf9021fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e445bae0-53b2-483c-9e0c-5c4023b92ad8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_50087d26-1b69-42aa-aac9-65e2bf9021fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7856fd54-8ba4-4650-a324-3336ce54099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f180ebbd-572e-48f2-a126-01a73a2ef0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7856fd54-8ba4-4650-a324-3336ce54099f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f180ebbd-572e-48f2-a126-01a73a2ef0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="nktr-20210331.xsd#FairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_45285c97-f696-404d-8dce-3af181a420f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_45285c97-f696-404d-8dce-3af181a420f6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6dcc95fa-87a7-4c80-b904-947704afb87f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4d500585-6012-42e3-90e7-5f8f65fa08c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d04a81a-75d2-46cf-b76f-043d6a4fb33c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4d500585-6012-42e3-90e7-5f8f65fa08c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_621c3417-e1b2-4bdd-bc18-df053892a3f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6e387fbc-195e-411b-8000-7b838b56e94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6e387fbc-195e-411b-8000-7b838b56e94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e2ec6335-ffac-462f-b77b-bcb3cec9747d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e2ec6335-ffac-462f-b77b-bcb3cec9747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_071b872b-79c0-4242-b349-43fdbf53b9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e87d2e9-66a4-4f7f-b6d8-aa6be1482c3e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_071b872b-79c0-4242-b349-43fdbf53b9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7c1beba5-6eb8-4bd2-a827-7075587a75d4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_05f7b3f2-98b0-4842-b4f4-674c3a0a4514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_05f7b3f2-98b0-4842-b4f4-674c3a0a4514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d3cbb3fa-9569-496e-8458-778796bd93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_CommercialPaperMember_d3cbb3fa-9569-496e-8458-778796bd93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_098e9157-9935-40de-ba03-254890d42606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_098e9157-9935-40de-ba03-254890d42606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5dd5e571-3dde-4207-988a-0e3872434fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f58aed98-ef12-44ae-b572-7195278367a6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5dd5e571-3dde-4207-988a-0e3872434fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f0c446b-7514-44fe-bb74-389356564b34" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5217716e-0d8b-4ad7-9428-83a59bcb91b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5217716e-0d8b-4ad7-9428-83a59bcb91b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c651e57a-4161-4ebc-ae69-8b133f4bc95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c651e57a-4161-4ebc-ae69-8b133f4bc95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d2632ce8-a6b4-451f-b250-22761b089723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d2632ce8-a6b4-451f-b250-22761b089723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3db5c0ec-5579-4891-8826-28e96e6317b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d05256b-431a-469c-b997-1971b1a9f043" xlink:to="loc_us-gaap_DerivativeLiabilities_3db5c0ec-5579-4891-8826-28e96e6317b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_bdd5880a-355c-4c75-b63e-fd67982a174f" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6f0207ff-1883-4a43-9acc-318efd5733c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_bdd5880a-355c-4c75-b63e-fd67982a174f" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6f0207ff-1883-4a43-9acc-318efd5733c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_a9a22b49-ccab-40f9-879d-bdd14be563ef" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_09d3cf40-54ae-479c-926a-8a7136f43916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_a9a22b49-ccab-40f9-879d-bdd14be563ef" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_09d3cf40-54ae-479c-926a-8a7136f43916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_8ecec661-032d-4e7e-9303-8a1a9f8afde2" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_8ecec661-032d-4e7e-9303-8a1a9f8afde2" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:to="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_76b99f83-37c8-4209-9f88-a53520f88dc3" xlink:to="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_4e81a878-59a9-40a1-a5ba-431f61da72bb" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_4e81a878-59a9-40a1-a5ba-431f61da72bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0b737de1-480a-4923-86cd-c87f1fbfdec5" xlink:href="nktr-20210331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_EliLillyAndCompanyMember_0b737de1-480a-4923-86cd-c87f1fbfdec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_8e57175a-ebac-4695-8b52-6621cd9d6ebe" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7e8eea13-515d-4ae0-bb98-7180652a7b0f" xlink:to="loc_nktr_OtherPartnerMember_8e57175a-ebac-4695-8b52-6621cd9d6ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e00abc93-eeca-4cb8-9eac-96d37b10ad67" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_233799fe-bae5-439c-b486-6a6c3a49cd80" xlink:href="nktr-20210331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:to="loc_nktr_NektarTwoOneFourMember_233799fe-bae5-439c-b486-6a6c3a49cd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_f9b628c5-dabb-428c-82b9-f2f91c6a793b" xlink:href="nktr-20210331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5a0e62e-bbcf-4517-8b96-27a3c2224b4b" xlink:to="loc_nktr_NektarThreeFiveEightMember_f9b628c5-dabb-428c-82b9-f2f91c6a793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_7db3f7f1-b036-4f35-a4f4-b4f541b87dd3" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_fccd07f7-0e15-48a3-9733-7b59851ae593" xlink:href="nktr-20210331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_6c4ac110-e4a1-43cb-873e-1bb6dd1d4043" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_fccd07f7-0e15-48a3-9733-7b59851ae593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_136c050f-8a63-4f95-a4bd-1df0235fce6f" xlink:href="nktr-20210331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_136c050f-8a63-4f95-a4bd-1df0235fce6f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_607b1ad5-5fbf-4bb8-84f0-495d05b0536a" xlink:to="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_55d15137-5370-4ece-b1b2-3a38470aa1c3" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_55d15137-5370-4ece-b1b2-3a38470aa1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_355b688c-2561-4e05-a038-626623210339" xlink:href="nktr-20210331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_EliLillyAndCompanyMember_355b688c-2561-4e05-a038-626623210339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_b26b55f1-4faf-4443-92ad-038bbd0df8dc" xlink:href="nktr-20210331.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_EliLillyMember_b26b55f1-4faf-4443-92ad-038bbd0df8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_92ac42ba-cf4c-425b-88c2-acc64f0a60ee" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0dfea00-1a78-406f-9175-285dfbc0a1ce" xlink:to="loc_nktr_OtherPartnerMember_92ac42ba-cf4c-425b-88c2-acc64f0a60ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7d1904f8-9eb1-497a-b0a2-7badc9e84091" xlink:to="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_f818d7c3-be32-4863-b3e3-8480539f767b" xlink:href="nktr-20210331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_NektarTwoOneFourMember_f818d7c3-be32-4863-b3e3-8480539f767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_b8d653d2-d111-4d01-b2b5-d32d8a63bd17" xlink:href="nktr-20210331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_NektarThreeFiveEightMember_b8d653d2-d111-4d01-b2b5-d32d8a63bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_3238d018-b2eb-420e-a66c-392cbde44aaf" xlink:href="nktr-20210331.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar214Member_3238d018-b2eb-420e-a66c-392cbde44aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358LicenseMember_2b427db9-15d5-4105-b763-d8f43cceea48" xlink:href="nktr-20210331.xsd#nktr_Nektar358LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar358LicenseMember_2b427db9-15d5-4105-b763-d8f43cceea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_ce8e384b-7ec2-4d11-b1f3-1b54b44b724f" xlink:href="nktr-20210331.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a47c3cb-f5af-438c-a5f9-79ab7d5aa021" xlink:to="loc_nktr_Nektar358Member_ce8e384b-7ec2-4d11-b1f3-1b54b44b724f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1c191e22-e0cb-4a79-b97e-e2a417e7bc49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_90dab070-54cf-48c9-a6a1-33fb8862022e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_76405cd3-a5d2-42b6-9553-b94a8069112b" xlink:to="loc_srt_ParentCompanyMember_90dab070-54cf-48c9-a6a1-33fb8862022e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5d0cb155-806e-4e8e-b763-83520bf7973b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_3023890d-b811-42ba-b08b-c9bf1ee4530d" xlink:href="nktr-20210331.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ddd31264-71b2-41a1-bbc0-e25d57140a2f" xlink:to="loc_nktr_OpdivoMember_3023890d-b811-42ba-b08b-c9bf1ee4530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_48619461-72e2-4ca2-a1e2-2937258ffa42" xlink:to="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bea20672-2ce6-4ae7-ad44-2c8e17397ae1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:to="loc_srt_MaximumMember_bea20672-2ce6-4ae7-ad44-2c8e17397ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aca8ba44-9a2d-4969-bcb7-d576306e4114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d2b5e5c-8f73-4545-b223-5f415d9e187c" xlink:to="loc_srt_MinimumMember_aca8ba44-9a2d-4969-bcb7-d576306e4114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5604e758-4b86-4b24-9afd-e86203242fff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_ec3cafb9-7260-4f5f-b227-c0c45faea1aa" xlink:href="nktr-20210331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_15f6d056-754c-4e92-8482-0ebc062c2cb9" xlink:to="loc_nktr_SharePurchaseAgreementMember_ec3cafb9-7260-4f5f-b227-c0c45faea1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c21528dc-794c-4c23-a0f3-913a26075d34" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7daed767-b0df-42f4-ab64-7caa18672450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0fa25be2-b178-4d03-90b9-b06e242c1b97" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7daed767-b0df-42f4-ab64-7caa18672450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:href="nktr-20210331.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:href="nktr-20210331.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_175845ab-07f8-4f89-b8e3-3543a8475ebe" xlink:to="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_044325b7-4180-4d07-910f-50f7e88f59f3" xlink:href="nktr-20210331.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_9525bd2d-3b3c-4e0b-8245-457a80c82844" xlink:to="loc_nktr_MilestoneOneMember_044325b7-4180-4d07-910f-50f7e88f59f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40ecc0e7-b745-4bb4-935a-68940f00c854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_79aafd67-2773-4c25-81a0-43d0dce20c29" xlink:href="nktr-20210331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_79aafd67-2773-4c25-81a0-43d0dce20c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_bb05a51e-a140-49d9-a5d0-b6e503be8b67" xlink:href="nktr-20210331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_BMSCollaborationAgreementMember_bb05a51e-a140-49d9-a5d0-b6e503be8b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_d6646416-38c8-476e-9dfc-ee33d60d4cf6" xlink:href="nktr-20210331.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_Nektar358Member_d6646416-38c8-476e-9dfc-ee33d60d4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_c37df54d-dda2-48e9-ab5c-49ed7d3ec973" xlink:href="nktr-20210331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_c37df54d-dda2-48e9-ab5c-49ed7d3ec973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_63fbf204-c28d-48e7-9abd-d0ca220e150f" xlink:href="nktr-20210331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_DrugProductDevelopmentMember_63fbf204-c28d-48e7-9abd-d0ca220e150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_5134ee84-5563-45dd-9af1-637d2eec7fb2" xlink:href="nktr-20210331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0bb37f73-ec11-4aa9-92d2-5fc5dd287170" xlink:to="loc_nktr_OtherPartnerMember_5134ee84-5563-45dd-9af1-637d2eec7fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df754f2a-a6e8-45a9-b8c9-0f420f718a5f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c680c05e-a0c7-4f06-adc7-c4d15b4996a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c680c05e-a0c7-4f06-adc7-c4d15b4996a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_21ae3e23-bb4b-46b3-a918-c47fda202461" xlink:href="nktr-20210331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_SalesMilestoneRevenue_21ae3e23-bb4b-46b3-a918-c47fda202461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_08397822-bef0-4514-9a71-560835168696" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_08397822-bef0-4514-9a71-560835168696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_0650a85d-b7cb-43e1-bd05-c64216af0c00" xlink:href="nktr-20210331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_0650a85d-b7cb-43e1-bd05-c64216af0c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_1248393a-1f74-4067-b5b1-0080928a9dbc" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_1248393a-1f74-4067-b5b1-0080928a9dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_f9582809-d32a-4f2d-a77a-cc4b70d976c8" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_f9582809-d32a-4f2d-a77a-cc4b70d976c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_894b9a87-9dc6-441c-b8be-c4bc8728d980" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_894b9a87-9dc6-441c-b8be-c4bc8728d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7aae5f3f-8711-431f-8414-5a1b92604ee8" xlink:href="nktr-20210331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7aae5f3f-8711-431f-8414-5a1b92604ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_0b6a4374-224d-4157-b891-c6a403f94ffa" xlink:href="nktr-20210331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_0b6a4374-224d-4157-b891-c6a403f94ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0406559c-b457-4599-9cc6-ba4cf102026d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_SharesIssued_0406559c-b457-4599-9cc6-ba4cf102026d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_13f8db7f-5f53-4991-b4f5-f9fc32373435" xlink:href="nktr-20210331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_13f8db7f-5f53-4991-b4f5-f9fc32373435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_01a9acab-1342-48ae-b0d3-5d8aff8c6734" xlink:href="nktr-20210331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_01a9acab-1342-48ae-b0d3-5d8aff8c6734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_5b302def-edb9-41c9-8fb8-9ff78ffa04da" xlink:href="nktr-20210331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_EstimatedFairValueOfShares_5b302def-edb9-41c9-8fb8-9ff78ffa04da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_876cd897-9c7f-402b-acb2-743c712bb84b" xlink:href="nktr-20210331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_876cd897-9c7f-402b-acb2-743c712bb84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_afb7e8f5-469d-43ba-9acf-e6193af6e49c" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice_afb7e8f5-469d-43ba-9acf-e6193af6e49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_aba50247-34c0-4f60-af58-10329d1fcd07" xlink:href="nktr-20210331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PotentialDevelopmentMilestones_aba50247-34c0-4f60-af58-10329d1fcd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_aa9268bd-7bb1-43fa-84b7-67408110b201" xlink:href="nktr-20210331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_ReimbursementOfExpenses_aa9268bd-7bb1-43fa-84b7-67408110b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_780f9d8d-8f53-494e-a584-fe1d9af5c322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_780f9d8d-8f53-494e-a584-fe1d9af5c322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_642384cd-b000-41f8-a752-29606aa0cd51" xlink:href="nktr-20210331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_642384cd-b000-41f8-a752-29606aa0cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_78d85e7a-f782-4e7b-ae8c-316bb8b92e42" xlink:href="nktr-20210331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_78d85e7a-f782-4e7b-ae8c-316bb8b92e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_4cb8a9d5-17bb-4c07-ba48-ded4aee52ca3" xlink:href="nktr-20210331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_4cb8a9d5-17bb-4c07-ba48-ded4aee52ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3708fd92-a571-4dc3-a9b7-f201876cb55c" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3708fd92-a571-4dc3-a9b7-f201876cb55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de28a285-301a-41b3-90e0-eec1717e2554" xlink:href="nktr-20210331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_de28a285-301a-41b3-90e0-eec1717e2554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_e63198b2-eda9-4a8a-b6ec-b185b01627c2" xlink:href="nktr-20210331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ebf3bb14-1f2f-4489-bd50-4f993c24d4d1" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_e63198b2-eda9-4a8a-b6ec-b185b01627c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc955706-02ca-4120-aea7-8f90f8012c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_26d50ca9-932b-475e-ad4e-1629a2f2e132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc955706-02ca-4120-aea7-8f90f8012c37" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_26d50ca9-932b-475e-ad4e-1629a2f2e132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc340167-79e4-4cb1-8ee1-7ec2801c77e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fb854789-b091-41db-8fa6-f62aafdae1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc340167-79e4-4cb1-8ee1-7ec2801c77e1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fb854789-b091-41db-8fa6-f62aafdae1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2e4018ea-ec57-4dbd-8fa5-6bc5d684c690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc340167-79e4-4cb1-8ee1-7ec2801c77e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2e4018ea-ec57-4dbd-8fa5-6bc5d684c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04d8aab-711e-4b46-affd-ac643e935b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04d8aab-711e-4b46-affd-ac643e935b26" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b8407193-cb90-4b87-8230-81e0ad8e6052" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_48e98e83-5f0b-4d7b-9e40-6cf65dd60bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_CostOfSalesMember_48e98e83-5f0b-4d7b-9e40-6cf65dd60bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ec30d92a-60dc-4b79-97aa-25de5b596828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ec30d92a-60dc-4b79-97aa-25de5b596828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7849d69-4aa9-463e-9c6b-f48d82d0ad6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7849d69-4aa9-463e-9c6b-f48d82d0ad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_64e14568-d42e-490f-add2-dc3b7d5bbf71" xlink:href="nktr-20210331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_153bf8c3-40b3-454a-b2a7-97d3afaf69da" xlink:to="loc_nktr_ImpairmentAndOtherMember_64e14568-d42e-490f-add2-dc3b7d5bbf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f8ed76b-9850-445a-869f-ef36b17cae4d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3287dc70-276b-46f5-af69-06cd43a3acef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9f7cc0f5-e429-4b3b-9005-cff2fd5d5361" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3287dc70-276b-46f5-af69-06cd43a3acef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#StockBasedCompensationActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e94251e8-dd3b-4d71-9a2f-52560fd7dc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e94251e8-dd3b-4d71-9a2f-52560fd7dc6b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:to="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5b052db-2ead-4398-8eeb-0a56ec1ec4ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e905d5ed-cce2-4f05-841d-52965df0e609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a46bd117-d545-43a2-b9f6-bd3be27ff010" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e905d5ed-cce2-4f05-841d-52965df0e609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0353c4b9-9b26-49e7-9cd2-9c0af5206231" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_260dab92-7c2d-4eb5-bbe6-ccdf8b56efe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_260dab92-7c2d-4eb5-bbe6-ccdf8b56efe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108756b4-68d4-486d-b2a8-40de19a026bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108756b4-68d4-486d-b2a8-40de19a026bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b042ed4a-ce16-40f3-8e52-68de7067aa6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b042ed4a-ce16-40f3-8e52-68de7067aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd7765bf-ce60-41b3-9dcb-60b31bd3bbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fd7765bf-ce60-41b3-9dcb-60b31bd3bbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_34662f90-3064-4187-9919-2edb72492139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f0caedf-7517-4283-90d2-b51dfde212ec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_34662f90-3064-4187-9919-2edb72492139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9bc9f8cd-d77a-4b42-b15b-03f3b689e1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_732d4638-fd34-46ee-80e0-1f920cc18058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9bc9f8cd-d77a-4b42-b15b-03f3b689e1c8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_732d4638-fd34-46ee-80e0-1f920cc18058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_304b6b38-2405-4381-9ebd-9856932b3ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c250b17f-e013-4080-bb7b-fb2876d339ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_304b6b38-2405-4381-9ebd-9856932b3ead" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c250b17f-e013-4080-bb7b-fb2876d339ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20210331.xsd#NetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e5dba8c3-1441-4f6b-b064-51feb441abec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a40d5444-c854-4645-b058-3d5635bda911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5dba8c3-1441-4f6b-b064-51feb441abec" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a40d5444-c854-4645-b058-3d5635bda911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>nktr-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20210331.xsd" xlink:type="simple"/>
    <context id="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaec343fe356a4d8d849cff41317060d0_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i2e4e93387c65485f981f8737f196c2c6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8d7a648bf34494885032023666dcc3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1621c8221f654c90b898084da8dedde1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50a7998dc7414125be04c9d54bc72e2e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2807087b245b41b19a7c3e71ee219075_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i943b5cc32c904e4ea5c4a393252a5f1d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8b7d876eb9e5443aa74b9b76ae690dff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00bd189bf7d744bd9cc35850e01748a8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i540e6fef44d64cffba3a62b8928bfe6e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7955d98f7e9b4443a246cf12be211aec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05b555333a734eb09051cd798b9429f2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6c19b8ac3e44e16ad9461cdc3a1ec50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9409701ed42346d398ef2df0711ebbbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8df351278d2e475f8037520497f16d08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i609c4b091c6f4c3c8fdb643e92816c9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i81484fe9ab834f2a96467bf9454ee663_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0bc5e2729e13461d9320df87f011a0d0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ad24cb47b7a42209662cb8b069c2477_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i28232c784abe46e9b8bd80d5160c1dcd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i774a1d8af37c4a42940da8a89d3cda47_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3434f78d8eda453ea4592a46d4c5cdfc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icf4af4055073419a9a0ef11ae74dd946_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9070274e17474fff80758eac97feb538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id76a2892513a4bfc8774fe6483aaf6e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie76d2b5ae1354fc4867eb4b9f92c75ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88b2f529f96f4242931a38d1274c3ec5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d08917815cd4606b7605b1bbcaaf74c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i807cf75457a848a09a842cc4c40488d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icdca91f683064dc98eaa5aa341fa9983_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icf9ab8b582354653b3fe82befd406ad2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b300b6a614240b0b082b5312aba0e34_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibeb29d6015684948aeb9b7feb861a58b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4185a9a6a21b42b9a45f1c865f2c9d10_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffb9564a50a84a4eb505aab0b22a3065_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if9cad33a4cec459b8fbd34cf53491766_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedbac025559f44dc9a9f56732a029868_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76828c455aa74a82808b4262afd668aa_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i98038b0951d74aab974ce098dadaefa2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29a7d653175c4b1296680cadb5e5068a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i481435efdba94e8490ffd332962979dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a3267ba79b04df19ce633889ce7df6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia7af717d26bc4360be31f309f87c91ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if95376ec14224b34a592fb4d683609b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia8561d224210461c901b5f3c17a17ac6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20cf135547944cf582acc95627b3f1ac_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffd4b3ae29e24484a045a0ea43dd64d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3229216ca2cd4c8f801d00e8cb3409b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i83eb3c2ca3a74138bb628878b3e1af2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b987794ba23407893b7dc6257382c77_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2241989dd1a448d7adaf7823411b1840_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i0589fec22d0240d48c2ee8a46b1e6051_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-13</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icef844280b874a7086af284de909cd28_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb734f7523814332bc13530cdead90d7_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="ia56b311eba0f474c8c9f8effb8942bdf_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i15fe85a66b97435c972422f93be257dd_D20120224-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-24</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="id0b7119025294bdf87c0a688175b3708_D20201230-20201230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i19a2169491224aa7bdef145df847c899_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia58a7dcb93434d91861bf0ba9f446985_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12cf522fabf34f9f9889d9af3e35f07e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ba18dba9b8242f69de0a47836b3bfaa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i36426a8b19bd4b7787bbf20a576265cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia868932072e14135b8de20b8fbb05d07_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iec1e022e0df84f8ab75a646beabe28c7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i890cec45aa2c403990c5450c11ff80aa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic22f93ce0e6e443c8e9e4d9bde3f79d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4e3ac045dec48a8896e485f547a26dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6c04572e64e47e09013051eea02caee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if3f08688820e4c0d944e8590248a9ee2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1355795842ee48cfbb1d6f4c02802112_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2acb647abce34e528ca4a74280583891_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b49c69835b040c4950674cd1f3a94cf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5e9fb20bbc2d40529eb5a2ad309535ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie451f88b893143fd96763ffbce41fe96_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ea24fab4f124cfda87387948817a846_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8141e5c62f534eaf98c103e667821511_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iccde389fb0334895aa528d399ab3bf5e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icf2b40706c664b82b13759271c2bd0a2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05e2f8958bdd4de09995408abc27ba55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1803a5ad5a74f649f0ac70f1767a019_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e6af6053ea94cd9a9631c23a09ca612_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie92fdace84fb408085fe38e47c50a2c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37b94fb646ce44bdaf0638dc9f141c2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c61987eb3734024b9a5c864d6cb7045_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ecb6e5d960b4fe48ef63d770bac85ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i520e0275aed84e53994d2120ede4c694_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6e07bf5444748f28089939d419f2bf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f1b5f37d97c417a87bb5004508a6596_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11baeb47973548c88d4519c8e83b21d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4af4d5a03bc141219abdd52011fe5464_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i563f7505fa2546d69c640c2577604c52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id70ed10561534c5cbf9793749b869293_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44cb50cd1caa4f38a48308a6383f0996_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f50476b334c4003acc68e480643a590_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a0e28f4f5464df5bbec94c881c5abc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib00c9d902daf42809ecedb590fac715c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ddc60c546d44ef2963908af8e5d76f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8230f0003b5842ae9c7225aa05e51fc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76ba56e21f0a4eee853230f5c88beb8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d8524ef60ac4f2cb9edab302f616345_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee84611bbab94bc893e75949080dfc54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4f24288c76d4f32bd98bf26e7db5c55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib67d1e2600b64ef78e842652cb1a0ae9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4f1ae924c35842629018e614147300a6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff36581ebdf74fdaac3b5805cc4f475d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9249ec543db649c3b5dce617f420aa36_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib876abacb04c4b25be485ce424922ff7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd31d1636dd74a5db8d7c83c962c2942_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i4cc414d1438a4b329c44637d6305aa56_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ib16676af93154d568c1375d2c0a4d1b8_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i2cb05b3574f34baea4609a9e773edd67_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if7c479692b49492685f185a1840f7899_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i847c7a3b7a4a4032b79d9bcd3421535c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i1740f80f6e884279b119d237d3326445_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ie2664e0c6c2543468ac3615b87452a66_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5369bf90ade043dd854e6754069729a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="i76f602e51e0c49249c41968d3420137b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibad1c0adc7fd4601afed8c117d9bebe3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i638f2b550bf04881a583181b88610a64_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iadd3cabc118142ccb19c6e19c224fdcf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="id5cc6f61322d48bc91f4421afbb6251b_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="i1707076fdcc0477ba064e4a58a5b1a8b_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i99ccb5e0e99e4d75b46da24538873814_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i8cfd01d94766464ca526949208f6d2ea_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ia93c2e92f70844efaef925cc4f310e71_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ie7006ee9335c4157a84de254bb359388_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i774e651a02ec4b0f95dde0602aac4434_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i440119c59b3e443b88631f1edc85ff74_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ic958491514274e76939f916d7f421a97_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idcfe2d433ef840c286c01d47b0c5f9d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8040c0e6c157482a8f36f8fda1edeeaa_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic85628854072425b81249accd9779120_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia22a905697334834a0579dcebb9555a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i862a0be5967d420ab21a5f29eea2436e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a4fb5cc34a84085bf75a4ee4c6f7bff_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2cd0871541b4364b1013eecb84d5e9f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8d469dfa3d97434e966b108b21df0121_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib94d1826584045bf83baf28f35342624_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml8yLTEtMS0xLTA_51d040b0-6e32-4fab-98fb-85d854a43e0c">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml80LTEtMS0xLTA_bfca4caa-063a-4c01-b41e-11c9ccac8210">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml81LTEtMS0xLTA_e9e9e9a6-c844-4add-a276-b20fe116cff8">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml84LTEtMS0xLTA_fec95a8a-8aa1-49b5-b461-a089f4bdec9a">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80L2ZyYWc6MGZkOTdiZWU5NTVkNGI1NWJiYTU5MjIyMjQyNzQ3Y2MvdGFibGU6NDViMGE5ZmY0ZGI4NDNjMDgwY2EwNTc5MmI2YTRmNjIvdGFibGVyYW5nZTo0NWIwYTlmZjRkYjg0M2MwODBjYTA1NzkyYjZhNGY2Ml85LTEtMS0xLTA_955384fd-eb49-499e-9a29-91327e3dc844">--12-31</dei:CurrentFiscalYearEndDate>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i98038b0951d74aab974ce098dadaefa2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQw_d76ba943-ec14-406d-8350-bfab428ccc84">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <dei:DocumentType
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY5_0a46b30d-5722-408f-aeca-a4ab591aefc6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZDcwNWE2OTc2ZjhkNDlhNDg2ZjUwMzYwMjUxNDI2YmMvdGFibGVyYW5nZTpkNzA1YTY5NzZmOGQ0OWE0ODZmNTAzNjAyNTE0MjZiY18wLTAtMS0xLTA_ebb06180-ccf2-43e7-857c-7a3d2ab0e465">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yNjg_ac23819d-87e9-424b-afb8-5999415ff799">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ODYxYTQ2NWFiNzU2NGUxOGIzMzRiYzliZGZlYzNiZTIvdGFibGVyYW5nZTo4NjFhNDY1YWI3NTY0ZTE4YjMzNGJjOWJkZmVjM2JlMl8wLTAtMS0xLTA_0110e575-151e-4f73-b1e2-54c06ae4a6e0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjc0_7a1eee06-432d-4e91-87ad-0e6538e01928">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY2_52722974-af57-4dd0-857c-65f3e5366882">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6MTk2MGUzZWQyYmUxNDYwM2JhZTgyMjU1ZGYwODgxZDUvdGFibGVyYW5nZToxOTYwZTNlZDJiZTE0NjAzYmFlODIyNTVkZjA4ODFkNV8wLTAtMS0xLTA_89b37fa8-16f2-4cf6-b076-99a697e64fac">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6MTk2MGUzZWQyYmUxNDYwM2JhZTgyMjU1ZGYwODgxZDUvdGFibGVyYW5nZToxOTYwZTNlZDJiZTE0NjAzYmFlODIyNTVkZjA4ODFkNV8wLTItMS0xLTA_62e3bc24-4724-4dca-a80d-aa66b480bbf1">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcz_9f350a19-3e81-4be6-918e-756ecf9b3ae6">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjc1_ab1d3a71-8726-45c8-b3c5-82b36fb0d736">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjYy_857dc499-22ae-458d-a71b-e398da0b05d3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY3_8aded7a9-8e28-4508-8086-b4880c2ee029">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjYz_b54f54f4-3543-4e2e-9f5b-1126ee8ee72f">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcw_a580aee2-d85c-4a0a-8c3a-5e790cd42eed">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTAtMS0xLTA_382b3d2c-cdd8-4593-b44b-9d5aaefd4fec">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTEtMS0xLTA_dfc0f7af-eacb-476d-bf60-059fc39eb847">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6ZWU5MDUxMDRjNWI0NDM1Y2I2M2UzNjFkZjg1YWE0NzgvdGFibGVyYW5nZTplZTkwNTEwNGM1YjQ0MzVjYjYzZTM2MWRmODVhYTQ3OF8yLTItMS0xLTA_4986cecb-f629-4cc8-b637-220610655e00">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjcx_b9811cfe-fbb7-4d79-968a-879b11816bfa">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY0_a7c89b69-b989-45d0-8936-e59b3a452a2f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N18wLTAtMS0xLTA_a3f4febd-56c4-468f-8a71-2e6648e29549">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N18yLTYtMS0xLTA_b13d696c-752c-4920-b2e7-d58bb3a84269">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGFibGU6YjEwZmRmY2M1YThmNGZiNmJhOGI2ODU4MzliYWI4ODcvdGFibGVyYW5nZTpiMTBmZGZjYzVhOGY0ZmI2YmE4YjY4NTgzOWJhYjg4N180LTItMS0xLTA_19756bea-ec2f-4d6d-a02e-9e1a298eb31a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjY1_71f99334-4d2d-4f9c-a6ac-27248a6c4081">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaec343fe356a4d8d849cff41317060d0_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xL2ZyYWc6ZThjY2RhZWE4ZWI4NDJiZDg3NmVhODVkYzU4YWQ1Y2MvdGV4dHJlZ2lvbjplOGNjZGFlYThlYjg0MmJkODc2ZWE4NWRjNThhZDVjY18yMjU0_d9dbc238-1aea-4d1e-b9ae-fcb0e0f7f365"
      unitRef="shares">182308999</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMy0xLTEtMS0w_2a3256e6-cdd4-4dcd-a681-a6f84af3d1d2"
      unitRef="usd">150164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMy0zLTEtMS0w_d7e9901e-2475-4e72-ae40-5c5592355ea9"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNC0xLTEtMS0w_e8d863ec-5617-4a67-a4c6-721880bcf39a"
      unitRef="usd">887152000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNC0zLTEtMS0w_21adbaaf-313a-42b5-851f-406f62c1aee6"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNS0xLTEtMS0w_ff78aef9-b384-495d-842e-2957fd669027"
      unitRef="usd">29156000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNS0zLTEtMS0w_7fa198dc-3506-49ba-a151-018e66d7174d"
      unitRef="usd">38889000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNi0xLTEtMS0w_7bd269c5-963c-435c-999b-bed54c2d9c3a"
      unitRef="usd">16808000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfNi0zLTEtMS0w_2f2bef59-7ec1-4fcd-9a9b-5e6ace3b2ca2"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOC0xLTEtMS0w_a6976649-22fc-4ab5-a943-841bcbeb1de3"
      unitRef="usd">15771000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOC0zLTEtMS0w_d835bd58-129e-403c-815f-d8b5a48162b4"
      unitRef="usd">21928000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOS0xLTEtMS0w_a423ee54-209c-4d28-b418-84e91dba4154"
      unitRef="usd">1099051000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfOS0zLTEtMS0w_a951e1c4-2a3f-4624-8df4-03a56d85dd25"
      unitRef="usd">1138005000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTAtMS0xLTEtMA_79789ba1-54e4-4f40-a855-3a555910ab4d"
      unitRef="usd">96093000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTAtMy0xLTEtMA_2cbcc690-b65d-4841-82ed-02b6eef93e71"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTEtMS0xLTEtMA_c6e01daa-1796-4b4f-b975-2b98aced0c21"
      unitRef="usd">58510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTEtMy0xLTEtMA_b707da1c-c9a9-43f0-915f-416eac33fde6"
      unitRef="usd">59662000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTItMS0xLTEtMA_a5bbead9-c69d-4227-9560-dc9f262ed2df"
      unitRef="usd">124971000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTItMy0xLTEtMA_8fd1e738-b16a-4984-8cd8-78086983bc5b"
      unitRef="usd">126476000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTMtMS0xLTEtMA_bce0bee2-8094-4ca0-8b5e-73b8b54e13df"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTMtMy0xLTEtMA_6c7320e7-7015-439f-b2fd-6185e61f1b3a"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMS0xLTEtNzA_510899bc-f9f5-4e88-ab22-5fd77eb45d26"
      unitRef="usd">1435000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMy0xLTEtNTA_be2affc8-2c26-450e-9781-f14af4392529"
      unitRef="usd">1461000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMS0xLTEtMA_21d52f4a-2c51-457c-a9e0-9f438488ec87"
      unitRef="usd">1456561000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTQtMy0xLTEtMA_48cdd78d-fa8a-4609-96fd-2912a975680d"
      unitRef="usd">1538767000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTgtMS0xLTEtMA_17ec8bee-59e9-43a6-a88a-7fa10a750940"
      unitRef="usd">22434000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTgtMy0xLTEtMA_a0707b87-b620-4058-a1ec-be16bdecea31"
      unitRef="usd">22139000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTktMS0xLTEtMA_0c51278b-123a-4155-9866-be90a4d91d29"
      unitRef="usd">23513000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMTktMy0xLTEtMA_82db75cf-6c20-4732-862e-5356cda43a08"
      unitRef="usd">14532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjAtMS0xLTEtMA_6276a77f-0402-4152-a264-86e06a9ed0d1"
      unitRef="usd">41028000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjAtMy0xLTEtMA_53b94560-c0e2-4fc7-a74c-9c3769fee394"
      unitRef="usd">44207000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjEtMS0xLTEtMA_da3922ea-13dc-47da-ac1b-a6533ce282d0"
      unitRef="usd">6057000</nktr:AccruedContractManufacturingExpenseCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjEtMy0xLTEtMA_eb6fb064-e9d5-4739-b328-feba9f6d4fdc"
      unitRef="usd">11310000</nktr:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjItMS0xLTEtMA_03c410d0-941e-4961-ba5c-f79f96954485"
      unitRef="usd">14833000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjItMy0xLTEtMA_89079d39-5505-49f8-8322-88733842b379"
      unitRef="usd">9676000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjMtMS0xLTEtMA_81392f91-4ff3-4881-9c5c-34c86eff2777"
      unitRef="usd">15768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjMtMy0xLTEtMA_31e767b7-e3be-4656-8631-045db5f82c6f"
      unitRef="usd">13915000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMS0xLTEtMA_f716b1cf-41de-43b5-83b2-900102a31183"
      unitRef="usd">123633000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMy0xLTEtMA_4474306f-e351-4c93-b1f0-3783ee6688cf"
      unitRef="usd">115779000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjctMS0xLTEtMA_969022a8-8d5f-416f-a385-55354ef71626"
      unitRef="usd">134556000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjctMy0xLTEtMA_c5a5389f-e861-4d1c-9b68-31fa15989844"
      unitRef="usd">136373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMS0xLTEtMTM1Mg_7c3cb580-e58f-44ec-9368-1cde6014720e"
      unitRef="usd">4597000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjYtMy0xLTEtMTM1Mg_22d75486-0463-410a-9aa0-e2f1711602a5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjgtMS0xLTEtMA_99d76201-314a-4694-93eb-5c2e59589647"
      unitRef="usd">195139000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjgtMy0xLTEtMA_193c6abb-de1a-455f-86ec-844bc8b61f78"
      unitRef="usd">200340000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjktMS0xLTEtNjY_373855dd-4d55-49d8-986d-82eaf4b67a6f"
      unitRef="usd">4130000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMjktMy0xLTEtNjY_1cd061b2-4f62-40da-babb-fd6aedc5d76e"
      unitRef="usd">8980000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzAtMS0xLTEtMA_266ac898-40bc-4053-8daf-eb2cdb47ec24"
      unitRef="usd">462055000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzAtMy0xLTEtMA_375a4d54-badf-4cc5-8839-7c6082cc2e20"
      unitRef="usd">461472000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzEtMS0xLTEtMA_9cd48bfb-d045-4669-9604-fe3f739e2af2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzEtMy0xLTEtMA_d79e63a9-3d08-42e2-9c33-676cac8eb166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzIx_3a738016-4b01-433a-8944-5f14da46f06c"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzIx_7b91a096-7c83-4420-9df0-ac6f4d1bb634"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzM1_4a242f7c-0698-4f19-a930-dde5ebb58024"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzM1_bb563bd9-3cac-498b-bd67-093bf8170b21"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_2fe14b41-3818-4744-a1a4-25e6d92ea0d9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_9da39e84-78da-492e-a5a5-0eb4498e1c40"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_b51551bc-4d9b-4933-a572-5ce33d0727b9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmExZWYxNDVlYjlkYTRhZTJiNzA0NzdmNjJlZjY3Y2MxXzU3_f34dd4f0-8323-43d7-bfac-f20edea4e770"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockValue
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMS0xLTEtMA_8f92dda0-b70e-45f6-a400-8fc3a07bb240"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzMtMy0xLTEtMA_cd6c2168-5196-4075-a5a4-c481db0a2a56"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzE4_75d2903b-88b7-47d4-9596-5d24a895a8a1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzE4_76bfce3b-c2e1-40b6-b1c0-7cb5ce278257"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzMy_13c29224-e165-4ee9-bcc9-6af70381afa0"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzMy_8f5a5546-ec4a-4eb3-905b-dee5fc039873"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzU0_d5e0f93e-334a-468a-8e55-ff8a31e21e8d"
      unitRef="shares">182290000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU2MmVkOWExYzZlNTQ3MTFiYTM4NDI0OWNkY2U0OGM5XzEwOTk1MTE2Mjc5NDk_a336358a-cab5-40c5-93b4-ca5679208ae0"
      unitRef="shares">180091000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMS0xLTEtMA_7cbec1da-9ceb-4890-a2f2-75c712ff0e05"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzQtMy0xLTEtMA_91700f6e-2809-4285-9266-704198ba2925"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzUtMS0xLTEtMA_c3b839e8-243a-4b9f-885c-6f107e180b2e"
      unitRef="usd">3429734000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzUtMy0xLTEtMA_f741b95a-6324-498d-b97e-e49954c04869"
      unitRef="usd">3388730000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzYtMS0xLTEtMA_9286d95e-d21e-4701-a75d-c67b55141d26"
      unitRef="usd">-3121000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzYtMy0xLTEtMA_17867719-2799-4dc6-b58d-a0d704e3d879"
      unitRef="usd">-2295000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzctMS0xLTEtMA_e6bb709a-7c85-4ce9-a035-e72a086265fa"
      unitRef="usd">-2432125000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzctMy0xLTEtMA_9810906b-e479-4855-9d3c-a344fdfdb65d"
      unitRef="usd">-2309158000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzgtMS0xLTEtMA_47203b2f-ffbc-4aec-934e-278a46a7758b"
      unitRef="usd">994506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzgtMy0xLTEtMA_5693d6fa-9253-4818-956e-dcbbe54ecd0d"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzktMS0xLTEtMA_3a8062d7-31b3-48bc-bd0f-aa3b822e86e8"
      unitRef="usd">1456561000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xOS9mcmFnOjNkODY1MDY3OTlhNjQ3ODY5NGFjMGM2NjVkZmRiNjY5L3RhYmxlOjUxNDk0NzhhZTk4YzQyMWNhNGFjNWFkNmMxYjA1MmM3L3RhYmxlcmFuZ2U6NTE0OTQ3OGFlOThjNDIxY2E0YWM1YWQ2YzFiMDUyYzdfMzktMy0xLTEtMA_3e27b5f0-c60e-4a40-8cc0-8435652cbca1"
      unitRef="usd">1538767000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1621c8221f654c90b898084da8dedde1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMy0xLTEtMS0w_ce5b763c-871c-4e56-89cb-10eed8c08760"
      unitRef="usd">4795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50a7998dc7414125be04c9d54bc72e2e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMy0zLTEtMS0w_75e1974f-b84a-4981-b1ac-cb5ce1187628"
      unitRef="usd">3444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2807087b245b41b19a7c3e71ee219075_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNC0xLTEtMS0w_9aebefb6-c3ee-4ddc-88f1-8876b49aebc1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i943b5cc32c904e4ea5c4a393252a5f1d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNC0zLTEtMS0w_4d7bd146-ae36-40a9-ae63-89cbed8b2f42"
      unitRef="usd">9719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b7d876eb9e5443aa74b9b76ae690dff_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNS0xLTEtMS0w_f39ac13a-024e-437a-8779-f93cb3899284"
      unitRef="usd">18798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00bd189bf7d744bd9cc35850e01748a8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNS0zLTEtMS0w_e1db441a-aada-4e69-bb1e-d2bc21285349"
      unitRef="usd">9895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i540e6fef44d64cffba3a62b8928bfe6e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNi0xLTEtMS0w_1d74d300-0075-4b80-a188-93295d9e62b6"
      unitRef="usd">54000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7955d98f7e9b4443a246cf12be211aec_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNi0zLTEtMS0w_1a2ca95c-38b4-4e35-a64f-3e24911d4a43"
      unitRef="usd">27515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNy0xLTEtMS0w_f4227676-3bdc-4f43-8c72-b93b087d1019"
      unitRef="usd">23647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfNy0zLTEtMS0w_cf1a24c2-86be-4717-bce3-3f38a8930d64"
      unitRef="usd">50573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfOS0xLTEtMS0w_8388ca28-4d89-4b3f-a211-223abfba5af6"
      unitRef="usd">5756000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfOS0zLTEtMS0w_2853fb7d-ae56-4e82-9ec2-7a57dbc2d1b0"
      unitRef="usd">3811000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTAtMS0xLTEtMA_310805d3-b3c3-447e-b300-bbc146acce63"
      unitRef="usd">95604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTAtMy0xLTEtMA_f5854659-ba70-4df9-8c7e-c99624bffb03"
      unitRef="usd">108987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTEtMS0xLTEtMA_c94f33a0-edf0-42a0-a1d9-b592e1c66f13"
      unitRef="usd">31679000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTEtMy0xLTEtMA_8cef0ef6-9543-4590-bc6f-3930eec96581"
      unitRef="usd">26217000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTItMS0xLTEtMA_4c52dd6c-68e1-4fb6-8be0-6d7c34061812"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTItMy0xLTEtMA_0fbee397-9bfa-4ff9-b1e7-1f1803268377"
      unitRef="usd">45189000</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTMtMS0xLTEtMA_2ce45eda-3d26-41cb-9bc3-65ed1e16de34"
      unitRef="usd">133039000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTMtMy0xLTEtMA_c342da41-262c-4c5e-a2f8-a4a0707ca5af"
      unitRef="usd">184204000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTQtMS0xLTEtMA_105a8d7e-6831-4f22-b63e-81e228d402fc"
      unitRef="usd">-109392000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTQtMy0xLTEtMA_1a1df8b5-22b7-4f5c-9a66-ba8754996c3d"
      unitRef="usd">-133631000</us-gaap:OperatingIncomeLoss>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTctMS0xLTEtMA_ccdc0334-0b5d-47d0-85dc-6c81c92b0c74"
      unitRef="usd">13296000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTctMy0xLTEtMA_3987fe4a-6b4e-4879-bf18-5d37a33e5d89"
      unitRef="usd">6968000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMS0xLTEtMTM2Mg_30108d72-a52c-4f54-9f39-6d4ef8a19d04"
      unitRef="usd">-1599000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMy0xLTEtMTM2Mg_b0255de8-73f6-4844-95cf-fd635dfba8fd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMS0xLTEtMA_290a4b77-777e-4742-acdc-9a1b3ed599d3"
      unitRef="usd">1412000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTgtMy0xLTEtMA_1f7a322b-0e84-4e5a-a24f-6326bc92bbfe"
      unitRef="usd">8352000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMS0xLTEtNDE2NQ_411510b4-33fc-4141-91f1-ef7f5596a17c"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMy0xLTEtNDE2NQ_42316467-04fc-4d86-8a53-956f46fa0c51"
      unitRef="usd">6204000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTktMS0xLTEtMA_f5c31ce2-c3f2-46d1-b1f8-117168af17e7"
      unitRef="usd">-13483000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMTktMy0xLTEtMA_21ad54aa-406e-4232-a49f-db5586da6192"
      unitRef="usd">-4820000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMS0xLTEtMA_a7aee67b-b126-4896-a808-817f1e57bdf1"
      unitRef="usd">-122875000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjAtMy0xLTEtMA_a4d0e764-eedd-4905-88f0-a1663ff668f6"
      unitRef="usd">-138451000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjEtMS0xLTEtMA_8abdac2c-c082-41ff-b2de-b12a1bb4ddcc"
      unitRef="usd">92000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjEtMy0xLTEtMA_0507bc4d-3160-4b49-8342-f96259b1f144"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjItMS0xLTEtMA_3595af96-8eda-4a7b-9d1c-187b12e945f0"
      unitRef="usd">-122967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjItMy0xLTEtMA_e53a0ab3-86d6-4844-adc3-ee894a99a40f"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjQtMS0xLTEtMA_23b2f169-dcc3-48d9-b6f4-a77582c5995b"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjQtMy0xLTEtMA_184ab13a-260e-4cf3-a346-9d3773b108b8"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjUtMS0xLTEtMA_9016703d-ff66-4ca4-b292-16988126227f"
      unitRef="shares">181370000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yNS9mcmFnOjAxM2VjNmZjODA4YTRiYWE5NTkxYjk5ZjAyNmMzN2I1L3RhYmxlOjEyYmRiMzA1ZWE1NzRhMzBhODA4NDdmYjFkNzM5MjdiL3RhYmxlcmFuZ2U6MTJiZGIzMDVlYTU3NGEzMGE4MDg0N2ZiMWQ3MzkyN2JfMjUtMy0xLTEtMA_efd97101-44b0-492b-a461-0d9acc1fa8dc"
      unitRef="shares">177185000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfMi0xLTEtMS0w_186c6638-aa7c-4ba7-9e3d-0708af8b68d1"
      unitRef="usd">-122967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfMi0zLTEtMS0w_9ecf8130-b3f8-4fd5-a621-675773fa4e4a"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNC0xLTEtMS0w_c5dbea53-e047-44ba-9699-074d5fd8d0a8"
      unitRef="usd">-766000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNC0zLTEtMS0w_c93b9f91-175e-4179-b4ee-1c3461adf86c"
      unitRef="usd">-5121000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNS0xLTEtMS0w_c718f48b-f905-406b-b08b-9e7e9b2bd924"
      unitRef="usd">-60000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNS0zLTEtMS0w_50b3905e-ddff-4cfd-bd31-7e4202debf0d"
      unitRef="usd">-751000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNi0xLTEtMS0w_93310a93-1d4f-4fda-8bec-a43a454416f1"
      unitRef="usd">-826000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNi0zLTEtMS0w_8d2299bb-0894-40a2-8af6-6ad3a7d3f56a"
      unitRef="usd">-5872000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNy0xLTEtMS0w_d88d1bba-59ab-484a-98d2-953fe8cecb34"
      unitRef="usd">-123793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8yOC9mcmFnOjljODE1NmVlOTQ3YTQxZWE4MjM4MTVkYTkwZjQ1YmUwL3RhYmxlOjRiMGZhMzQzYTEzYTQwNWU5NWU1NWE1ZTQ5MDJkOWE5L3RhYmxlcmFuZ2U6NGIwZmEzNDNhMTNhNDA1ZTk1ZTU1YTVlNDkwMmQ5YTlfNy0zLTEtMS0w_9041be10-f2cc-421b-9a3c-c6d5fc391914"
      unitRef="usd">-144523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0xLTEtMS0w_e012b704-e6f1-47be-9b0a-a70e5a9d24a2"
      unitRef="shares">176505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i386d9920ac3f4c3f90e0ba684ea52a35_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0zLTEtMS0w_02d631b2-51de-49b5-b980-544c350cff2d"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05b555333a734eb09051cd798b9429f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS01LTEtMS0w_acfb9f15-212b-4b54-a0b1-64aaaf3838e8"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6c19b8ac3e44e16ad9461cdc3a1ec50_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS03LTEtMS0w_47ac75df-5172-4af8-971b-364531f9092c"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9409701ed42346d398ef2df0711ebbbc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS05LTEtMS0w_4b0b7e6d-66fd-4358-a03e-842216d655a6"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8df351278d2e475f8037520497f16d08_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMS0xMS0xLTEtMA_66a5b600-90ce-48ae-9a3a-a7d910524b19"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i609c4b091c6f4c3c8fdb643e92816c9f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi0xLTEtMS0w_19e4bf50-795d-44e5-a5e6-cbef1e74f4a9"
      unitRef="shares">1358000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi01LTEtMS0w_049bed72-153c-4cbf-bf28-ad7eaf0053a0"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMi0xMS0xLTEtMA_c7665fe3-c20a-40bd-85ed-b91e4acdaaff"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1645048de7c54ffea3dfb1f26a668328_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMy01LTEtMS0w_76ae1de8-132c-4acf-9c5a-d37f163aad2b"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMy0xMS0xLTEtMA_33bf30d5-1f6b-4d61-a005-a236704e7569"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i81484fe9ab834f2a96467bf9454ee663_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC03LTEtMS0w_17359e39-5eef-4000-8ebd-debac5fb03ba"
      unitRef="usd">-5872000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0bc5e2729e13461d9320df87f011a0d0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC05LTEtMS0w_95dafe03-c61b-471b-a89e-e9f90b26ba52"
      unitRef="usd">-138651000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNC0xMS0xLTEtMA_60d62d16-fd3c-4b30-ae40-107679804fc5"
      unitRef="usd">-144523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9ad24cb47b7a42209662cb8b069c2477_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0xLTEtMS0w_a12fe932-8f4f-4f89-965f-6ea79727d855"
      unitRef="shares">177863000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ad24cb47b7a42209662cb8b069c2477_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0zLTEtMS0w_0aebd6ef-59f4-4c36-a008-c8de6f94b943"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28232c784abe46e9b8bd80d5160c1dcd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS01LTEtMS0w_164cfdd5-b1ee-4301-88e8-e0cf911be70c"
      unitRef="usd">3306655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i774a1d8af37c4a42940da8a89d3cda47_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS03LTEtMS0w_03d3bb79-970f-490e-9d05-a244a8ecb0eb"
      unitRef="usd">-6877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3434f78d8eda453ea4592a46d4c5cdfc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS05LTEtMS0w_bd104128-e70e-44e6-bbba-a02f4945ab64"
      unitRef="usd">-2003369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf4af4055073419a9a0ef11ae74dd946_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfNS0xMS0xLTEtMA_92130a8c-7823-4d2a-864b-dec36cc94f79"
      unitRef="usd">1296426000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0xLTEtMS0w_5723e597-ab70-4fd8-8dbe-e863674a8918"
      unitRef="shares">180091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6b59141da8244d2bbcdb1fb4b749a54a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0zLTEtMS0w_17afe7a2-3de8-46a9-8992-af0732a4cf90"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9070274e17474fff80758eac97feb538_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC01LTEtMS0w_20a2c618-cf68-4207-a18d-7f4cc1e0bf8e"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id76a2892513a4bfc8774fe6483aaf6e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC03LTEtMS0w_5fdabbfb-82ce-4e28-bab8-fe4f07f51185"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie76d2b5ae1354fc4867eb4b9f92c75ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC05LTEtMS0w_5bfa724f-1df7-4be1-8a48-a9cf331251f2"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOC0xMS0xLTEtMA_861fa027-7d4c-4de1-bd8e-c7e3c2b9cc21"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i88b2f529f96f4242931a38d1274c3ec5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS0xLTEtMS0w_0cdd7b7f-96e0-4a85-833d-456b16288901"
      unitRef="shares">2199000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS01LTEtMS0w_bb364c54-c249-4b72-8174-1d4ab4b7abec"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfOS0xMS0xLTEtMA_373b445c-1d8c-40c1-9159-4fea83e95b67"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38763f0e30474bc2b974fcffc5635989_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTAtNS0xLTEtMA_926e6b12-f622-4b04-b929-b7f8411a0650"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTAtMTEtMS0xLTA_9812e96c-69c8-4940-9f33-8786a44effab"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2d08917815cd4606b7605b1bbcaaf74c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtNy0xLTEtMA_77cbed7b-d5b1-4d0a-9edc-fa3addc6ed02"
      unitRef="usd">-826000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i807cf75457a848a09a842cc4c40488d1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtOS0xLTEtMA_669c5977-215b-4fad-9166-0dc040404b5a"
      unitRef="usd">-122967000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTEtMTEtMS0xLTA_e21bdca7-4d2e-466d-92ce-a163061e612f"
      unitRef="usd">-123793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="icdca91f683064dc98eaa5aa341fa9983_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMS0xLTEtMA_81ecd314-9e84-4152-96ad-9a99331c28f4"
      unitRef="shares">182290000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icdca91f683064dc98eaa5aa341fa9983_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMy0xLTEtMA_ff4e5740-512b-419c-8163-8e25e8b1e06f"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf9ab8b582354653b3fe82befd406ad2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItNS0xLTEtMA_5dd1bb34-f470-4dee-b19a-ff092f98b781"
      unitRef="usd">3429734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b300b6a614240b0b082b5312aba0e34_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItNy0xLTEtMA_ba9a35f5-5a3c-4fc5-873b-d09d505db4bc"
      unitRef="usd">-3121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibeb29d6015684948aeb9b7feb861a58b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItOS0xLTEtMA_d1f15fbd-cf1d-4234-9bb6-cea7560b799a"
      unitRef="usd">-2432125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zMS9mcmFnOjJmOWZiMmFkOTViZDQ5OTJhZTFhYmNjODZkYjZkYTgzL3RhYmxlOjBjYjk0ZjcyOWI2OTQzZWE4M2Y4NGFkNzllMzIxOGRkL3RhYmxlcmFuZ2U6MGNiOTRmNzI5YjY5NDNlYTgzZjg0YWQ3OWUzMjE4ZGRfMTItMTEtMS0xLTA_933e2e57-b2c9-411b-b58d-20691cbc7627"
      unitRef="usd">994506000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMy0xLTEtMS0w_47c04677-9b2a-4495-8804-0d9b9cf82a95"
      unitRef="usd">-122967000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMy0zLTEtMS0w_036b16d6-e8ec-4b74-888a-a43dcff27db3"
      unitRef="usd">-138651000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNS0xLTEtMS0w_3eca77f9-261e-4fd0-990b-513cac89314f"
      unitRef="usd">18798000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNS0zLTEtMS0w_840e7571-29d6-4a11-b8ff-0b69866f4816"
      unitRef="usd">9895000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0xLTEtMS0yMzQy_e7cad4ab-83ef-4c58-90a2-9401b1c6ba57"
      unitRef="usd">13296000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0zLTEtMS0yMzQy_532df3d7-4b50-472f-9f28-dbaefa47909e"
      unitRef="usd">6968000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0xLTEtMS0w_6a4d550d-f910-47ad-b28c-9ed38634bb70"
      unitRef="usd">-1599000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNi0zLTEtMS0w_9574ac6e-16a7-45cb-9f74-ab1149fcbe73"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0xLTEtMS0yMjE5_dd436716-6235-48e1-bfcc-a316b1789d58"
      unitRef="usd">2248000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0zLTEtMS0yMjE5_d770bc4d-98a4-4bf7-b45d-1f0defbfb936"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0xLTEtMS0w_298850c6-4a62-4e36-ae88-8482375a1fa2"
      unitRef="usd">23898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfNy0zLTEtMS0w_736bd70a-c5f0-4154-912e-85505210c42f"
      unitRef="usd">25236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOC0xLTEtMS0w_c64d166c-a77c-4e7a-9e10-584e01f51391"
      unitRef="usd">3543000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOC0zLTEtMS0w_78bdfc8d-559b-4952-9b8d-a25f131da08f"
      unitRef="usd">4502000</us-gaap:DepreciationAndAmortization>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOS0xLTEtMS0w_5ff7fa78-1e5b-4251-b7e7-6ca2b58f3e17"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfOS0zLTEtMS0w_274c857a-0619-4712-aca0-1e6eb8c807c5"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTAtMS0xLTEtMA_64df5e66-9734-4875-8430-7c26a252a41f"
      unitRef="usd">-2345000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTAtMy0xLTEtMA_f9685a9a-65cc-408e-ab2a-037bba6e9f9f"
      unitRef="usd">1289000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTItMS0xLTEtMA_bb6f5952-5fd1-4f19-b0f2-57d41767ec3e"
      unitRef="usd">-9733000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTItMy0xLTEtMA_8e217bfa-374a-4198-b142-ac5b783b68c1"
      unitRef="usd">5229000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTMtMS0xLTEtMA_7d9168af-ff10-4d78-855e-f87abfaeb44e"
      unitRef="usd">1516000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTMtMy0xLTEtMA_7c2fbde7-534f-4c29-b046-ff73930de529"
      unitRef="usd">1655000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTQtMS0xLTEtMA_49e9b2bb-c1f0-4e2d-bf20-482375f818dd"
      unitRef="usd">-1541000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTQtMy0xLTEtMA_456795dd-63a1-477c-a8ac-972ecb00a96c"
      unitRef="usd">-2940000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTUtMS0xLTEtMA_b99b6e17-7f02-4b7f-bcba-c3872b80031f"
      unitRef="usd">-6183000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTUtMy0xLTEtMA_feed9210-f5cb-4d5b-a9c5-7594ec75d4d7"
      unitRef="usd">-1067000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTYtMS0xLTEtMA_d17d9273-0c98-4955-bb32-3fe3af8e86f4"
      unitRef="usd">779000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTYtMy0xLTEtMA_587b030a-3f91-419f-998a-0518d7038bdf"
      unitRef="usd">2687000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTctMS0xLTEtMA_935c7f48-5357-4da1-a94e-125a09a17d8c"
      unitRef="usd">8981000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTctMy0xLTEtMA_9e78f583-5a12-4949-a7ad-dd1a1b643b70"
      unitRef="usd">9920000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTgtMS0xLTEtMA_8357f9b2-59ab-42cd-9890-382949950d2b"
      unitRef="usd">-7345000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTgtMy0xLTEtMA_1e2eb4bb-bbd0-43a3-b2e9-18a7786520e1"
      unitRef="usd">7483000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTktMS0xLTEtMA_b8227621-2aee-4838-b0ac-1e222ebc685e"
      unitRef="usd">-605000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMTktMy0xLTEtMA_6c01c1b3-2bf3-476e-be2e-435f533b11b3"
      unitRef="usd">-2510000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjEtMS0xLTEtMA_4f7daff6-390c-4cfb-baef-ecb79650a52b"
      unitRef="usd">-77085000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjEtMy0xLTEtMA_ff1206ac-8b6d-41d1-b597-e11a87e186bf"
      unitRef="usd">-78075000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjMtMS0xLTEtMA_e6cffcb7-35e8-44dc-a714-d57a6ec22120"
      unitRef="usd">295314000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjMtMy0xLTEtMA_2b41fec0-f058-4977-a6ed-52f1c9d44424"
      unitRef="usd">241068000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjQtMS0xLTEtMA_da41ee9f-b2ba-46e4-8540-bc9da691424c"
      unitRef="usd">303612000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjQtMy0xLTEtMA_08df50dd-e47e-457a-8e71-6237adfce7dd"
      unitRef="usd">439735000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjUtMS0xLTEtMA_a9538cc6-b5da-4a37-bc20-6eec877f22f8"
      unitRef="usd">5036000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjUtMy0xLTEtMA_977ac785-02d6-4e7f-a3e6-7b5481e2e70e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjYtMS0xLTEtMA_a81b7785-3983-46f6-86fe-fef574ff2eb6"
      unitRef="usd">2876000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjYtMy0xLTEtMA_4db0cc05-b3ab-4975-b1ad-9cbbf6fd85bc"
      unitRef="usd">900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjgtMS0xLTEtMA_30495dc2-d248-4f96-b703-4025b8d88eaa"
      unitRef="usd">10458000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMjgtMy0xLTEtMA_4d1dd018-d857-4598-97ec-e061b85b7134"
      unitRef="usd">197767000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzAtMS0xLTEtMjkyMA_3f493210-0e75-4949-a7cc-ac2899e6de1b"
      unitRef="usd">17106000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzAtMy0xLTEtMjkyMA_58224c1c-586d-4794-a0af-8c2501a0f302"
      unitRef="usd">11077000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzEtMS0xLTEtMTc4Mg_c0383027-d1b2-4d33-a207-1088b163a16d"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzEtMy0xLTEtMTc4Mg_1154060b-68e0-4928-a77f-17fcca744f40"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzItMS0xLTEtMA_e091a723-0cdb-4f08-bfc2-8455779c910d"
      unitRef="usd">17856000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzItMy0xLTEtMA_c7fed08d-d648-4df8-8f7f-5bfbd82489a5"
      unitRef="usd">11077000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzMtMS0xLTEtMA_d81c8825-2d5f-4e31-8660-0b9ec82238f8"
      unitRef="usd">-20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzMtMy0xLTEtMA_f9e84f1a-1c50-41f4-83a5-9b6a82c98d85"
      unitRef="usd">-97000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzQtMS0xLTEtMA_0588c814-ba02-4680-93ba-e2838209d664"
      unitRef="usd">-48791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzQtMy0xLTEtMA_33cf8b9b-ec2f-4455-9c5d-3d76045e5539"
      unitRef="usd">130672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzUtMS0xLTEtMA_aae5548f-9df9-4e03-8f20-21516f6808a1"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8df351278d2e475f8037520497f16d08_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzUtMy0xLTEtMA_03b9294d-5fa7-4ba0-906b-4c3b07c2d6c9"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzYtMS0xLTEtMA_fb5f9f8e-0d2d-430a-932e-f00b3f4e8e69"
      unitRef="usd">150164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icf4af4055073419a9a0ef11ae74dd946_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzYtMy0xLTEtMA_b4650556-76f6-4879-be3c-16845e89b9af"
      unitRef="usd">227035000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzgtMS0xLTEtMA_a35a06d6-10fb-4fa7-9064-2fc650187520"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzgtMy0xLTEtMA_45954895-d424-47ce-b3eb-b16b6988a0a5"
      unitRef="usd">4951000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzktMS0xLTEtMA_dc1aeee7-6869-4fe0-bf67-f23678d71c23"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8zNC9mcmFnOjI1ODA2YzNjNzdlMTQ2NjQ5ZGU2ZTBlODNjNzc0ZTAxL3RhYmxlOjVkMTZhYzE2OTkzMTQ2OTliZTU2NDUyYTFkZmQ4YTI1L3RhYmxlcmFuZ2U6NWQxNmFjMTY5OTMxNDY5OWJlNTY0NTJhMWRmZDhhMjVfMzktMy0xLTEtMA_1709e9ef-a7ee-4859-aee1-bffd48f1a685"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzU_8f309e80-d8a1-4329-9999-506f1a0fed28">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that leverage our proprietary and proven advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At March&#160;31, 2021, we had approximately $1.1 billion in cash and investments in marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India), Nektar Therapeutics UK Limited, and Nektar Therapeutics NL B.V. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2020 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on February 26, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2021, our accounts receivable includes $26.2&#160;million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $2.9&#160;million under customer contracts from our collaboration partners. As of December&#160;31, 2020, our accounts receivable included $38.7&#160;million for unbilled net expense reimbursements from BMS and $0.2&#160;million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2021 and 2020. We have not recorded a reserve for credit losses at March&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;after&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#x201c;at-the-market&#x201d; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjM_c35084d8-480d-4bae-b6c2-633f2f9a6236">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that leverage our proprietary and proven advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTAyOA_b2de44ea-95e0-4dbc-a745-50985ae34d3c"
      unitRef="usd">1100000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjQ_209a22f0-2c02-42e8-91f4-2b734e04aae2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India), Nektar Therapeutics UK Limited, and Nektar Therapeutics NL B.V. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2020 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on February 26, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzODE_680c034f-6c4a-48cf-b0ba-0e3367787c8f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzA_9793bf37-02c2-4afe-9c23-fea12cc7802e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjY_75c2181e-d132-4c6b-9ba6-147583c34902">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNjk5Ng_10674298-27b0-4cfb-854a-f116ea24294c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNzMzOA_605072ae-c2ac-44e0-af15-b34fb831961c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzI_5889c09e-8ace-4b49-b422-72a8753d93d0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2021, our accounts receivable includes $26.2&#160;million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $2.9&#160;million under customer contracts from our collaboration partners. As of December&#160;31, 2020, our accounts receivable included $38.7&#160;million for unbilled net expense reimbursements from BMS and $0.2&#160;million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2021 and 2020. We have not recorded a reserve for credit losses at March&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4185a9a6a21b42b9a45f1c865f2c9d10_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDEwOA_b41dc2ca-ee91-4b3c-896a-6f048e5dc9d9"
      unitRef="usd">26200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iffb9564a50a84a4eb505aab0b22a3065_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfNzg2OA_ee314d23-09b3-44b3-a0da-cd5243a44901"
      unitRef="usd">2900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if9cad33a4cec459b8fbd34cf53491766_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDEyMw_72cf0da5-86e3-48ff-b95b-2e991f2269fc"
      unitRef="usd">38700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iedbac025559f44dc9a9f56732a029868_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfODEwMA_dfb7fbf8-1395-441b-9f66-42e87d338a91"
      unitRef="usd">200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE1Nw_51f11571-26aa-4243-ba84-3e5c11a56bd8"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE1Nw_ce53a355-1227-4e03-9b0a-1bd4e8409cc3"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzM_d0c0d401-2c33-4772-b22a-7793a5e13fcd">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNjg_96e3e780-9540-49fe-a812-ffbddcbf9346">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;after&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzNzQ_65496489-f6a6-4771-bbcd-5819818382a8">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:WriteOffOfPrepayment
      contextRef="i76828c455aa74a82808b4262afd668aa_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjIzMDA_9569eb15-ed08-4468-8367-d6a01b1aefe7"
      unitRef="usd">19700000</nktr:WriteOffOfPrepayment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i76828c455aa74a82808b4262afd668aa_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjI0MDI_4eca6023-66e8-4f72-a33c-57ad66abb7f2"
      unitRef="usd">25500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMjUzODQ_c0ebd1af-5abd-400e-8a37-12a1d97cc3ed">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <nktr:SaleOfStockValueAuthorizedInTransaction
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80MC9mcmFnOjdhMDk1MGVkMGE2NzRiMmJiZmVmNTdjNzI3YzczZTlhL3RleHRyZWdpb246N2EwOTUwZWQwYTY3NGIyYmJmZWY1N2M3MjdjNzNlOWFfMTA5OTUxMTcyMDE0Mg_c6f1f6a7-2711-47db-a527-4a36fcf19904"
      unitRef="usd">300000000.0</nktr:SaleOfStockValueAuthorizedInTransaction>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUxMQ_b2c2c289-b46b-49b1-a060-e071680c8132">Cash and Investments in Marketable Securities&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2021 and December&#160;31, 2020, all of our long-term investments had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQw_d76ba943-ec14-406d-8350-bfab428ccc84"&gt;one&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, our gross unrealized gains and losses totaled $1.1&#160;million and $0.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUwNw_54700a7b-9d82-4dfe-91e6-6d1d3388e59c">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMi0xLTEtMS0w_0665fb14-a833-4b6b-9dfd-08cb0f97b3bc"
      unitRef="usd">150164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMi0zLTEtMS0w_f9360b30-9f78-4c3c-8457-1cd80bd2eccb"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMy0xLTEtMS0w_5419189f-aab4-4637-a552-a7d1366d2fe8"
      unitRef="usd">887152000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfMy0zLTEtMS0w_2f3199c8-449d-4704-b8d7-9182e95e30c8"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNC0xLTEtMS0w_63103b4c-a38b-45dd-b18b-148f519068be"
      unitRef="usd">96093000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNC0zLTEtMS0w_49353a5a-addf-4361-8cbd-d3e24a988b1f"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNS0xLTEtMS0w_6657d468-4e0f-472a-9b51-0f1f89cb3872"
      unitRef="usd">1133409000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOmRiNTI3NDMyNWQzZDQ5MjNiMTE1ODY2MTNkMjQ0NGE1L3RhYmxlcmFuZ2U6ZGI1Mjc0MzI1ZDNkNDkyM2IxMTU4NjYxM2QyNDQ0YTVfNS0zLTEtMS0w_5fe1b95a-b641-480e-80ab-d0c2bc216aa7"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNDAw_528205c9-f93a-4494-89e4-9b5b0e433ce4">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNDU1_4c925a3e-4a1c-4776-8c87-afb041c402a0">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i29a7d653175c4b1296680cadb5e5068a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQ3_2e29d4a9-0742-40f4-adb1-dd77e64008f0">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjUwOQ_bd871056-1652-43b3-943b-d45c29bb4d79">&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,133,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i481435efdba94e8490ffd332962979dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi0zLTEtMS0w_e1b08466-b9c1-440a-b748-5deb5bb982f0"
      unitRef="usd">510521000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i481435efdba94e8490ffd332962979dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi01LTEtMS0w_447f9e3a-eaeb-438d-b6e4-3f9fa2b76adc"
      unitRef="usd">313000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i481435efdba94e8490ffd332962979dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi03LTEtMS0w_81a3f8e1-aa20-41be-9528-d53b7cb5e262"
      unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i481435efdba94e8490ffd332962979dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi05LTEtMS0w_7c03e30a-4a95-4ee2-aeed-5b2e8dfaae0f"
      unitRef="usd">510663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a3267ba79b04df19ce633889ce7df6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMi0xMS0xLTEtMA_f4c117a2-a7c2-4b84-a448-1fb7136fc751"
      unitRef="usd">687469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy0zLTEtMS0w_70823a30-e4f3-4f25-9c28-4f70a09510fd"
      unitRef="usd">478448000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy01LTEtMS0w_f99e83cf-3bdd-4e9c-98d5-28a0b042a2ee"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy03LTEtMS0w_27ac36ce-8aa2-4448-ba8d-72a187b3e5c1"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a54a79f3d13478099a5563cb6b5ccf3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy05LTEtMS0w_db39e169-20e5-4757-b0e5-92484870347f"
      unitRef="usd">478442000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7af717d26bc4360be31f309f87c91ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfMy0xMS0xLTEtMA_24acc92c-5f5d-40b6-9331-b49c90376012"
      unitRef="usd">313497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if95376ec14224b34a592fb4d683609b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0yLTEtMS0xNjY2_019d3dd6-a7e0-49d8-aebe-70da10dc2146"
      unitRef="usd">4880000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if95376ec14224b34a592fb4d683609b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC00LTEtMS0xNjY2_4ca5043c-72af-4b73-91bd-57505eaafd85"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if95376ec14224b34a592fb4d683609b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC02LTEtMS0xNjY2_85681aee-c5fb-4446-84d5-d5dd0bb9a76a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if95376ec14224b34a592fb4d683609b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC04LTEtMS0xNjY2_ba884c7a-2985-4cb8-8b1e-acfd7974f728"
      unitRef="usd">4884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8561d224210461c901b5f3c17a17ac6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0xMC0xLTEtMTY2Ng_48075fbf-84ea-432b-b322-a3ff30dc61c6"
      unitRef="usd">2382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0zLTEtMS0w_0e8af12d-6533-4d0c-bd23-7befc88e7db4"
      unitRef="usd">993849000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC01LTEtMS0w_9e5e8c28-4f10-49c5-b5ab-925cd26f1443"
      unitRef="usd">352000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC03LTEtMS0w_20b88cc4-fd73-49b0-b3b5-55766e6d1a74"
      unitRef="usd">212000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20cf135547944cf582acc95627b3f1ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC05LTEtMS0w_06e83a69-6811-4398-91af-64d8f0581643"
      unitRef="usd">993989000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffd4b3ae29e24484a045a0ea43dd64d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNC0xMS0xLTEtMA_3f2b158f-832b-423b-a55f-72388443b2f3"
      unitRef="usd">1003348000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3229216ca2cd4c8f801d00e8cb3409b6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNS05LTEtMS0w_aa6c280e-534d-472d-9dbd-39a870ee2742"
      unitRef="usd">123607000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i83eb3c2ca3a74138bb628878b3e1af2a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNS0xMS0xLTEtMA_9670d135-9946-489c-8106-3ed615ca41bb"
      unitRef="usd">179302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0b987794ba23407893b7dc6257382c77_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNi05LTEtMS0w_0aa2c2e1-fb33-4b63-8e1e-7443fba16d6c"
      unitRef="usd">8254000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2241989dd1a448d7adaf7823411b1840_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNi0xMS0xLTEtMA_a0db745d-2644-4be6-b194-0361c16bb30a"
      unitRef="usd">9623000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNy05LTEtMS0w_c5e3d0f3-baf4-4ac9-8c11-734ef0847217"
      unitRef="usd">7559000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfNy0xMS0xLTEtMA_0340a338-25f4-4da2-818b-a019b9bb84fc"
      unitRef="usd">6285000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfOC05LTEtMS0w_569615b4-4413-4003-a292-4b4f885cef91"
      unitRef="usd">1133409000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RhYmxlOjQzMmMxOTk2Y2ZjMjQwMWM4ZjhlZGMxYjZmMzI5N2ZkL3RhYmxlcmFuZ2U6NDMyYzE5OTZjZmMyNDAxYzhmOGVkYzFiNmYzMjk3ZmRfOC0xMS0xLTEtMA_b08af8a5-840f-4f82-9d55-d138ba515050"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjEyMA_77243d91-ca40-4988-abbb-f41ffd88bdbb"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfMjEyNw_41275081-1d80-497b-b99d-d8eaaa22adb2"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA4OA_e1911fd5-2055-4d50-8d3a-d156f2c81e28">Inventory&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA5MA_c92bca3e-a3ad-4ff4-ab81-1bcb04d09b97">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMS0xLTEtMS0w_76173965-0e56-476b-9ef8-03f4a19fae66"
      unitRef="usd">1920000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMS0zLTEtMS0w_9b393696-d95b-477b-81c9-4c6b671b3e8c"
      unitRef="usd">2422000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMi0xLTEtMS0w_b74f6b81-2d29-4138-849a-043861d5a980"
      unitRef="usd">13082000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMi0zLTEtMS0w_a8dcdfc4-503d-4a75-8bee-5392504db548"
      unitRef="usd">10703000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMy0xLTEtMS0w_1caa5d23-8560-4994-91c4-42ddb4d7d25e"
      unitRef="usd">1806000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfMy0zLTEtMS0w_5f3f37a8-8d51-4ce2-9f91-a555112d3a73"
      unitRef="usd">2167000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfNC0xLTEtMS0w_bf322d46-9fe2-4733-96c9-f13f84e03b48"
      unitRef="usd">16808000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib8d7a648bf34494885032023666dcc3f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RhYmxlOmJiMzc3ZGI5OGY0YjQ1YjdhMzEyMTFkN2QzOWZlNjgxL3RhYmxlcmFuZ2U6YmIzNzdkYjk4ZjRiNDViN2EzMTIxMWQ3ZDM5ZmU2ODFfNC0zLTEtMS0w_bbdd2ff7-a308-4d1e-a00c-e26223f5c130"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81Mi9mcmFnOjRhNTU5ZGNkYzlkYzQ2ZDI4NDk0MGJjYWFmNTlkYTM1L3RleHRyZWdpb246NGE1NTlkY2RjOWRjNDZkMjg0OTQwYmNhYWY1OWRhMzVfMTA5Mg_f1c09046-d16f-427a-b528-1fa2e2901043">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <nktr:DevelopmentDerivativeLiabilityTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0Nzkz_cd2fc45c-faf9-416f-98c7-554ec44f5218">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp;amp; Dohme, pursuant to which MSD will provide Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria is met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including the treatment of previously untreated unresectable or metastatic melanoma (the &#x201c;Melanoma Indication&#x201d; and the &#x201c;Melanoma Clinical Trial&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual contractual payments over five years, with the first payment being $30.0&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual contractual payments over seven years. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We present the SFJ Agreement as development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Condensed Consolidated Statement of Operations. The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="9" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at inception on February 12, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (ii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iii) the probability of termination of the study due to meeting the interim futility criteria, (iv) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (v) SFJ&#x2019;s cost of borrowing (1.0%), and (vi) the Company&#x2019;s imputed cost of borrowing for debt with similar terms (12.2%).&lt;/span&gt;&lt;/div&gt;</nktr:DevelopmentDerivativeLiabilityTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0Nzk1_9f3fc210-092c-4395-85d6-6d3490a4e059"
      unitRef="usd">150000000.0</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODEx_a1f6cd09-9ca4-4c0a-9254-345e563d2c33"
      unitRef="usd">450000000.0</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODM0_d2fc1a13-8e12-4713-8239-e1d65d458baa">P5Y</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTkz_5cf2c30b-008b-4677-84df-2c086ef82ce8"
      unitRef="usd">30000000.0</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODQ2_81e8d51e-4440-46fa-b6d9-605ee51d50c7"
      unitRef="usd">150000000.0</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODcw_2fe43626-8047-484a-bb8c-94d1c0ae33ea">P7Y</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementAdditionalIndicationPayment
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM0ODgy_e8af3408-204f-45c8-b5b4-72b37c327e97"
      unitRef="usd">37500000</nktr:CollaborativeArrangementAdditionalIndicationPayment>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="i021bb2b7c2024f20aa627867cc8b57f4_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTYy_c4d304c8-fd58-44de-86ae-729a746a8e92"
      unitRef="usd">150000000.0</nktr:CollaborativeArrangementCommittedFunding>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTkx_3a7ef76c-e2b9-4661-aa63-d8dfcd5213cc">The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="9" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at inception on February 12, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0589fec22d0240d48c2ee8a46b1e6051_I20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18xLTItMS0xLTE5NjM_bb20e888-9a01-4106-8e5a-e0061778f6c1"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18yLTItMS0xLTIzNzE_ba289112-6333-4d87-ad5e-87c2dd709832"
      unitRef="usd">2248000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18zLTItMS0xLTIzNzk_324bb369-119e-4439-bc77-3a9fa240ad60"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i869631de9d114a9ca6d57bd819467bbe_D20210213-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN18yLTItMS0xLTE5NjM_eeb5f23c-bca7-47f2-a6d6-933affbcfbe7"
      unitRef="usd">-1599000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icef844280b874a7086af284de909cd28_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGFibGU6OTQ0ZTg2MzU5ZWE1NDk2NTgxOTIyZjhmZDc5ZTFkZjcvdGFibGVyYW5nZTo5NDRlODYzNTllYTU0OTY1ODE5MjJmOGZkNzllMWRmN181LTItMS0xLTE5NjM_fa8028b2-e2f6-46af-a762-dd95c1c8a5df"
      unitRef="usd">4597000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ifb734f7523814332bc13530cdead90d7_I20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTc5_ee4b29a5-b8cc-45d1-885b-79165e69b8f8"
      unitRef="number">0.010</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ia56b311eba0f474c8c9f8effb8942bdf_I20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQwL2ZyYWc6YmE5NjYzNTA4M2RiNGI4NzhjNWNhOWIyNDRhMjE5YTYvdGV4dHJlZ2lvbjpiYTk2NjM1MDgzZGI0Yjg3OGM1Y2E5YjI0NGEyMTlhNl8xMDk5NTExNjM4MTg1_f1c9f762-a36b-4b4e-84d9-e8de6e061bee"
      unitRef="number">0.122</us-gaap:DerivativeLiabilityMeasurementInput>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMzU1NQ_cc1528b7-0144-4b8a-bef6-b8a4f8bf74ec">Liability Related to Sale of Future Royalties&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0&#160;million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $4.4&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0&#160;million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products are remitted directly to RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB (AstraZeneca), as amended, (b) ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH (collectively, Baxalta), as amended, (c) REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G (collectively, Novo Nordisk) and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, which HCR received in the three months ended March 31, 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rates - end of period presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Implicit interest rate over the life of the agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prospective effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contain other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYwMg_a8a17b85-23f0-4df8-98c6-0a3d9e203a6b"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYxOA_6a22e467-b6af-4e67-bcfd-3e75d9e5be63"
      unitRef="usd">4400000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i15fe85a66b97435c972422f93be257dd_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzYzMg_83f310b0-9684-4536-b1cf-ddbccbd1b7ef"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved
      contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY0OA_1341c69c-69c8-4010-b8a1-b6ced31ad7ba"
      unitRef="usd">210000000.0</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved
      contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY2NA_0f9c01c9-7918-40cf-ae12-23f01dacf87a"
      unitRef="usd">240000000.0</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved>
    <nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds
      contextRef="if8c95c52a214420fb0bb746aacbd87db_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY4MA_3ccf9188-2d30-4990-b545-9e740686e353"
      unitRef="usd">208000000.0</nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzY5Ng_a34aa00f-e2b5-44ee-8d6b-11f901661fea"
      unitRef="usd">150000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzcxMg_b5fa3d1a-d5f8-46be-8dfd-8a8999e7ec99"
      unitRef="usd">3800000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="id0b7119025294bdf87c0a688175b3708_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0MzcyNg_e05fd987-901f-4a42-b5b3-63911ef9b0a4"
      unitRef="usd">150000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RleHRyZWdpb246ODg3ZjMxZjQ5YjhjNGFjYjkwNzVhNGJlMDAxMTk4MmJfMTA5OTUxMTY0Mzc2OQ_0c005a2d-8d42-4b75-9eb9-21b842376e5d">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the three months ended March 31, 2021 and 2020. &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rates - end of period presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Implicit interest rate over the life of the agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prospective effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC0xLTEtMS00OTQ_8029a35d-ef7d-4e0c-8338-f65536a82861"
      unitRef="number">0.202</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC0zLTEtMS00OTQ_f8872dab-101d-4053-b3df-83a587240974"
      unitRef="number">0.195</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNC03LTEtMS00OTQ_48908baf-3e18-45f0-aa40-e3be54cbed75"
      unitRef="number">0.160</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i5e59b36c2fe3424182d60321158f496d_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS0xLTEtMS00OTQ_3c8fdbf7-eed0-4b07-883e-a5d585b64c3f"
      unitRef="number">0.480</nktr:ProspectiveInterestRatePercentage>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i9fddaf42c70e4ee89090950c8b975067_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS0zLTEtMS00OTQ_ee9240f5-83b9-49ce-ae64-f3442b23fce5"
      unitRef="number">0.380</nktr:ProspectiveInterestRatePercentage>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i942fb95b7af44676870f0f5b0349c754_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81NS9mcmFnOjg4N2YzMWY0OWI4YzRhY2I5MDc1YTRiZTAwMTE5ODJiL3RhYmxlOjY0OTIzZTQ1NjIxNjQ2MTJhOGJlMWM0MTUzYzVlMmU0L3RhYmxlcmFuZ2U6NjQ5MjNlNDU2MjE2NDYxMmE4YmUxYzQxNTNjNWUyZTRfNS03LTEtMS00OTQ_bf9eec52-e852-4e94-a349-de5dee6a0e37"
      unitRef="number">0.160</nktr:ProspectiveInterestRatePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDgzOA_78fe0ef5-22b6-4de9-b441-287fec56b97a">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv&#x2014;66-7-HSG, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made about clinical trials of bempegaldesleukin between January 2017 and June 2018.  The Mulquin complaint was amended in May 2019.  The defendants moved to dismiss and the court granted the motion without prejudice in July 2020.  The Mulquin plaintiffs again amended and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit is expected to be completed by September 2021.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb.  After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021.  The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the two securities actions (Mulquin and Damiba), three sets of derivative actions have been filed against certain of the Company&#x2019;s current and former officers and directors, purportedly on the Company&#x2019;s behalf.  These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#x2019;s officer and directors breached fiduciary duties by exposing the Company to one or both of the securities actions.  The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH).   After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second set of derivative actions was filed in February 2020, in U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW).  The derivative actions in California have been consolidated and the Company has moved to dismiss on the basis that the plaintiffs have neither made a demand on the Company&#x2019;s board of directors nor shown that demand would be futile.  The Company&#x2019;s motion to dismiss has been under submission since December 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An additional derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF).  No response to the complaint is due until May 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i19a2169491224aa7bdef145df847c899_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfMTA5OTUxMTY1MDk2Mw_0287fee8-367d-4c28-b020-e64297b1983c"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia58a7dcb93434d91861bf0ba9f446985_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfMTA5OTUxMTY1MDk2Mw_ed8ad4df-c24a-497d-bdef-05fad95071cf"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i12cf522fabf34f9f9889d9af3e35f07e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDczOA_46bcaf4b-4470-4f45-a79e-bec0e3fa0f6e"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0ba18dba9b8242f69de0a47836b3bfaa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV81OC9mcmFnOjNjZmRlZmFkNTc3OTRkOWY4MGM0MzFkMzM5ZTA0NDIxL3RleHRyZWdpb246M2NmZGVmYWQ1Nzc5NGQ5ZjgwYzQzMWQzMzllMDQ0MjFfNDczOA_ddc5e328-c512-4d6d-b015-f1b59dae0d2f"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGV4dHJlZ2lvbjphNDg3NTRhNzI0OTA0MmRmYjc5ZWUxNGIyMTZiMjcxZl8xMDk5NTExNjMyOTM1_3dd4fcbc-a2f1-4720-90ac-070c204dd659">Fair Value Measurement&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy and the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="27" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="27" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for similar assets in active markets or has been derived from observable market data. For the three months ended March&#160;31, 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:63pt;text-indent:-63pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. For the reconciliation of the changes in the development derivative liability and the description of the significant inputs used in estimating its fair value, see Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGV4dHJlZ2lvbjphNDg3NTRhNzI0OTA0MmRmYjc5ZWUxNGIyMTZiMjcxZl8xMDk5NTExNjMyOTM2_91487092-a642-49c6-a0c3-dfdf9f8b6e5d">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy and the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="27" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="27" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36426a8b19bd4b7787bbf20a576265cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTQtMS0xLTE1NzY_f241b752-7077-4150-af6a-1dd1ca7bb722"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia868932072e14135b8de20b8fbb05d07_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTYtMS0xLTE1NzY_896c465f-1469-41be-842c-d34f4f8e20ba"
      unitRef="usd">510663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec1e022e0df84f8ab75a646beabe28c7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTgtMS0xLTE1NzY_cf18e740-c360-4c7d-9dfb-3d288e83d93f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i890cec45aa2c403990c5450c11ff80aa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18yLTEwLTEtMS0xOTMw_78207a94-a882-47d4-8a6a-46dc323c035d"
      unitRef="usd">510663000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic22f93ce0e6e443c8e9e4d9bde3f79d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTQtMS0xLTE1NzY_84c9f73f-6c20-4419-bda6-dc455e249526"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4e3ac045dec48a8896e485f547a26dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTYtMS0xLTE1NzY_56c060c9-161c-4227-8821-b0d9f5c760f7"
      unitRef="usd">478442000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6c04572e64e47e09013051eea02caee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTgtMS0xLTE1NzY_8caf6c5f-40b0-4a85-8156-26c4ac9436fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3f08688820e4c0d944e8590248a9ee2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18zLTEwLTEtMS0xOTMw_8085d9c9-6898-49f4-bbec-56b26148be65"
      unitRef="usd">478442000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1355795842ee48cfbb1d6f4c02802112_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTQtMS0xLTE1NzY_71b7b10e-d57b-421f-b6a3-8f6cd81a6856"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2acb647abce34e528ca4a74280583891_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTYtMS0xLTE1NzY_4934f389-3055-40e8-ac3f-487e7710fff1"
      unitRef="usd">4884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b49c69835b040c4950674cd1f3a94cf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTgtMS0xLTE1NzY_f88b8d45-a927-4769-8b5e-80a70a6e3bb2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e9fb20bbc2d40529eb5a2ad309535ed_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN180LTEwLTEtMS0xOTMw_3bafa1f5-a007-4b36-950b-4dd2c339612c"
      unitRef="usd">4884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie451f88b893143fd96763ffbce41fe96_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTQtMS0xLTE1NzY_887b181e-d7cc-42cb-825e-dfc61f4703b3"
      unitRef="usd">123607000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0ea24fab4f124cfda87387948817a846_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTYtMS0xLTE1NzY_21dab592-1c4f-4ded-89c6-b59499d47f1c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8141e5c62f534eaf98c103e667821511_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTgtMS0xLTE1NzY_eab0d659-d9d5-424b-8eab-7fe14f82aa15"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iccde389fb0334895aa528d399ab3bf5e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN181LTEwLTEtMS0xOTMw_20400dc2-755e-4ceb-ad51-4e4019e44da8"
      unitRef="usd">123607000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf2b40706c664b82b13759271c2bd0a2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTItMS0xLTM2OTU_50d8776f-6ef4-403e-96b7-826e025b537d"
      unitRef="usd">123607000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i05e2f8958bdd4de09995408abc27ba55_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTQtMS0xLTM2OTU_26b88a1b-f833-48cd-a056-8dbd78f31566"
      unitRef="usd">993989000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1803a5ad5a74f649f0ac70f1767a019_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTYtMS0xLTM2OTU_d40511d2-b543-49fa-b3a8-df3861b67bf3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e6af6053ea94cd9a9631c23a09ca612_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN183LTgtMS0xLTM2OTU_f6a62e68-cc53-442a-af5f-1d8420450d63"
      unitRef="usd">1117596000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="icf2b40706c664b82b13759271c2bd0a2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTQtMS0xLTE1NzY_46c5ff5f-0389-4472-abeb-35c30ddf7271"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i05e2f8958bdd4de09995408abc27ba55_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTYtMS0xLTE1NzY_5f6e034d-7818-41e6-bbec-7df9e8784045"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie1803a5ad5a74f649f0ac70f1767a019_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTgtMS0xLTE1NzY_6478c1ec-bef4-414b-9628-7624bf13b4bb"
      unitRef="usd">4597000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2e6af6053ea94cd9a9631c23a09ca612_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN182LTEwLTEtMS0xOTMw_1a8ce42b-cd9e-41ce-818e-3d4a70e7bdd0"
      unitRef="usd">4597000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie92fdace84fb408085fe38e47c50a2c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTQtMS0xLTE1NzY_641bca0d-2e19-4bef-a435-6f6f3a6ecd91"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37b94fb646ce44bdaf0638dc9f141c2d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTYtMS0xLTE1NzY_3142f6c0-176b-4fc8-aeb9-a994100bd6f1"
      unitRef="usd">687469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c61987eb3734024b9a5c864d6cb7045_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTgtMS0xLTE1NzY_f42447d1-9469-411c-9438-6ad03cf9d46e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ecb6e5d960b4fe48ef63d770bac85ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN185LTEwLTEtMS0xOTQ3_7d856f4f-f1e0-465d-907e-ac91745ca98b"
      unitRef="usd">687469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i520e0275aed84e53994d2120ede4c694_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC00LTEtMS0xNTc2_0909ce4b-b53a-45cc-852f-3d750f0629be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6e07bf5444748f28089939d419f2bf9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC02LTEtMS0xNTc2_d98955cc-9ac6-4d40-bc2c-a575919784f2"
      unitRef="usd">313497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f1b5f37d97c417a87bb5004508a6596_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC04LTEtMS0xNTc2_6ea53b1b-3354-473a-b89d-3632e9b29488"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11baeb47973548c88d4519c8e83b21d7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMC0xMC0xLTEtMTk0Nw_adcac5c1-4502-4577-884d-5c0f9e4ce2ac"
      unitRef="usd">313497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4af4d5a03bc141219abdd52011fe5464_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS00LTEtMS0xNTc2_af6f25ce-a197-434c-8699-2bcc1344bf23"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i563f7505fa2546d69c640c2577604c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS02LTEtMS0xNTc2_f47d1c84-98e3-49c0-a92c-d3e805ec1980"
      unitRef="usd">2382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id70ed10561534c5cbf9793749b869293_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS04LTEtMS0xNTc2_0cd2dd4f-fbc0-4ca4-95ed-29f3327b5f7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44cb50cd1caa4f38a48308a6383f0996_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMS0xMC0xLTEtMTk0Nw_29cda31f-efdf-4de1-8f41-882be8c19811"
      unitRef="usd">2382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9f50476b334c4003acc68e480643a590_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi00LTEtMS0xNTc2_c2e742b8-7268-40ab-8d83-ad3409acea34"
      unitRef="usd">179302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a0e28f4f5464df5bbec94c881c5abc2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi02LTEtMS0xNTc2_aa82e9ea-1776-4d41-ac64-20b4f0a2a307"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib00c9d902daf42809ecedb590fac715c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi04LTEtMS0xNTc2_3b69c80d-e719-4692-b99a-99e6ae964a4a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2ddc60c546d44ef2963908af8e5d76f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMi0xMC0xLTEtMTk0Nw_3cc4924a-1297-4258-9d0e-f8efe73e1c56"
      unitRef="usd">179302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8230f0003b5842ae9c7225aa05e51fc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS0yLTEtMS0zNjk3_6cc0925a-61cb-46ec-974a-361261fea759"
      unitRef="usd">179302000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76ba56e21f0a4eee853230f5c88beb8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS00LTEtMS0zNjk3_8d3f5fc9-d6fc-458f-98a7-f7a350821833"
      unitRef="usd">1003348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d8524ef60ac4f2cb9edab302f616345_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS02LTEtMS0zNjk3_d6ac7331-9a3e-4cff-bbe7-17c764e85dab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee84611bbab94bc893e75949080dfc54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xOS04LTEtMS0zNjk3_9d94bdbb-2739-4d2c-8b3f-d888efcd24cb"
      unitRef="usd">1182650000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i8230f0003b5842ae9c7225aa05e51fc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy00LTEtMS0xNTc2_f5a566f1-ae4e-4d7a-9f12-9a0595891aa4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i76ba56e21f0a4eee853230f5c88beb8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy02LTEtMS0xNTc2_80b4b472-1fd8-4c0b-8af6-ba677d9bc65d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2d8524ef60ac4f2cb9edab302f616345_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy04LTEtMS0xNTc2_9b0f0782-186f-437f-a770-e41f70d7149e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iee84611bbab94bc893e75949080dfc54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV8xMTQ2L2ZyYWc6YTQ4NzU0YTcyNDkwNDJkZmI3OWVlMTRiMjE2YjI3MWYvdGFibGU6ZThmMjBkYjVlYmE1NDM3NjllMTdlOWFmNjY1ZGFmYzcvdGFibGVyYW5nZTplOGYyMGRiNWViYTU0Mzc2OWUxN2U5YWY2NjVkYWZjN18xMy0xMC0xLTEtMTk0Nw_3eba9c55-5384-4984-a25c-b91beb89086e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTg3NjY_59cd4bc5-8351-4e8c-b889-47827c91089d">License and Collaboration Agreements&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Drug Candidate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, we recognized $18.8&#160;million and $44.6&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $25.0&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March 31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $1.455&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$350.0&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#x2019; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones to be variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial on January 30, 2020, which we recognized in the three months ended March 31, 2020. We have also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than these two milestones which we recognized during 2020, we continue to exclude the other milestones of up to $1.8&#160;billion from the transaction price as of March&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#x2019; costs as research and development expense. During the three months ended March&#160;31, 2021 and 2020, we recorded $26.7&#160;million and $30.7&#160;million, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses. As of March&#160;31, 2021, we have recorded an unbilled receivable of $26.2&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii)  share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development. We recognized the revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocated to the license upon the effective date of the license agreement in August 2017. We recognized revenue for our performance obligations for Phase 1 clinical development and drug product development through March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2021, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, in 2012, we sold all of our rights to receive royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under our collaboration with UCB and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under our collaboration agreement with Roche. Additionally, in 2020, we sold our rights to receive royalties for ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under our collaboration with Baxalta (a subsidiary of Takeda Pharmaceutical Company Ltd.), MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under our collaboration with AstraZeneca and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under license agreement with Novo Nordisk. The 2020 transaction provides for a cap, such that, if the cap is achieved, future royalties on these products will return to us. See Note 5 for additional information regarding these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have collaborations agreements for products under development, under which we are entitled to up to a total of $40.0&#160;million of development milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the respective transaction prices for these agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTg3Njg_80816eae-f3d2-4175-9eda-293539d496b2">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Drug Candidate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if4f24288c76d4f32bd98bf26e7db5c55_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMi00LTEtMS0w_919f2ecd-e621-4cdb-804d-dd91e2db69b3"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ib67d1e2600b64ef78e842652cb1a0ae9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMi02LTEtMS0w_4de6d943-67ae-4397-9a2d-509b9b24372a"
      unitRef="usd">25000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4f1ae924c35842629018e614147300a6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMy00LTEtMS0w_ae09e1f5-07bb-4f1d-b851-49d1e112ab00"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iff36581ebdf74fdaac3b5805cc4f475d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfMy02LTEtMS0w_ffa54837-2f60-4ff3-876a-262f6a628562"
      unitRef="usd">1259000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i9249ec543db649c3b5dce617f420aa36_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNS00LTEtMS0w_7f62a809-9550-498e-b875-459e8b2648ad"
      unitRef="usd">54000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ib876abacb04c4b25be485ce424922ff7_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNS02LTEtMS0w_60b71375-2dbf-4a30-b0cd-c8cde9ca4680"
      unitRef="usd">1256000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNi00LTEtMS0w_9c5bc060-ed32-47f6-bcc7-f2f7b19cc88f"
      unitRef="usd">54000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RhYmxlOmQ2OTg4MTgwNjIyMzQyNTFhZjYxNDRiYzBlNzk3ODhiL3RhYmxlcmFuZ2U6ZDY5ODgxODA2MjIzNDI1MWFmNjE0NGJjMGU3OTc4OGJfNi02LTEtMS0w_1045bb9c-c349-4b1f-975a-8b441fb00d57"
      unitRef="usd">27515000</nktr:LicenseCollaborationOtherRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ1OQ_cf3860e8-ac02-45d6-82bc-7a84c0a3e315"
      unitRef="usd">18800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTE2OQ_4621420d-beb3-4bd4-b6c9-111748a6f2f7"
      unitRef="usd">44600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <nktr:SalesMilestoneRevenue
      contextRef="ibd31d1636dd74a5db8d7c83c962c2942_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTM2Ng_af1154d0-6c3b-4d86-b744-d8907d81674e"
      unitRef="usd">25000000.0</nktr:SalesMilestoneRevenue>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i2e4e93387c65485f981f8737f196c2c6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ3NA_f64df430-11fd-4001-9dbe-40eeb18c79b9"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3NzkzNg_c3441081-f4e8-400b-b282-0759c2c1ba89"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3NzkzOA_2b435f89-4ef8-4b45-b7c4-6ed311b864f9"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i4cc414d1438a4b329c44637d6305aa56_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk0Mw_7ae72914-ce2b-4db1-9360-ce501327b4ac"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ib16676af93154d568c1375d2c0a4d1b8_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk1MA_0bf41d8c-823f-4c18-824b-e9676f2c81bc"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i6a2363a7baeb42d0b1b0034084da94cc_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk1Nw_c04acaba-2441-4144-a87b-d7932ea86cc7"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="ie4c4c92a611a4610a9a3145d23dc9d02_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk2Mg_d6f0843f-8893-42ac-aa5e-c095080b5a8f"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i2cb05b3574f34baea4609a9e773edd67_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk2Nw_2f781b70-1077-4984-bb94-2e74fbb2dd83"
      unitRef="usd">1000000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="if7c479692b49492685f185a1840f7899_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk4MQ_2b4064d4-ad31-47d8-9826-20ceabb76982"
      unitRef="usd">1455000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="i847c7a3b7a4a4032b79d9bcd3421535c_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3Nzk5Nw_0e61a01a-1374-4083-b62b-6facb89e90dd"
      unitRef="usd">350000000.0</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <us-gaap:SharesIssued
      contextRef="i1740f80f6e884279b119d237d3326445_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODAxMw_5cd9c5df-8ddb-4cd6-b2e6-dc65cf7f3400"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="ie2664e0c6c2543468ac3615b87452a66_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODAyNA_338e3b51-0ba7-4f39-b6e3-bfd36517c425"
      unitRef="usd">850000000.0</nktr:SaleOfStockConsiderationReceived>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTI3OQ_dab725a8-22aa-4316-934c-00226a7657c4"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="i5369bf90ade043dd854e6754069729a5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTYzMQ_48d64ede-f2fd-4c5c-8953-eec9be309939"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i42a6e5135bb24c8fb4b8ebed286d3f31_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAwNTY4Nw_f6f13b52-0ff6-4c88-9c24-f23262c3c047"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODA0MA_2c23cb65-241e-4521-90f1-736ec7d6729d"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ia3f44e23cbea46108a3d8d69d4875eb8_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODA1NQ_d3a84e86-f70e-44a7-b7b4-d151ab530f39"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestonesExcludedFromTransactionPrice
      contextRef="i76f602e51e0c49249c41968d3420137b_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzQ4OA_5284d206-663a-4bc4-90f9-bcaf84d5c15a"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentMilestonesExcludedFromTransactionPrice>
    <nktr:ReimbursementOfExpenses
      contextRef="ibad1c0adc7fd4601afed8c117d9bebe3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUwMg_69211016-8701-45b3-a019-6598558e52d3"
      unitRef="usd">26700000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i638f2b550bf04881a583181b88610a64_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODE3OA_b6ca60c1-b313-4b2e-a3d7-2e2d0a3e7117"
      unitRef="usd">30700000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iadd3cabc118142ccb19c6e19c224fdcf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUxNw_1a33e4a6-1039-4b0e-a84a-2bd5c606e172"
      unitRef="usd">26200000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODIwOA_7981cfb7-31e6-42b3-93bc-534b4b0a58b5"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="id5cc6f61322d48bc91f4421afbb6251b_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODIyNA_af37e60f-f8f2-4c2e-95ca-d18f24e5370a"
      unitRef="usd">250000000.0</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i1707076fdcc0477ba064e4a58a5b1a8b_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI0MA_d27b5125-84c0-42b9-bbd8-74d1c700f22e"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i99ccb5e0e99e4d75b46da24538873814_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI0NQ_3ced435a-2423-4c9b-96cc-a5db95a0b5e0"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i8cfd01d94766464ca526949208f6d2ea_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODQzMA_1866359c-180a-430a-8f51-cf3202b11f2b"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="ia93c2e92f70844efaef925cc4f310e71_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI1MA_cd1548ab-9aa5-471a-ba40-7b5f278babc6"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI1NQ_e2eefb3b-cd88-4fc4-9b97-e763b96c4483"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="i34816fc9d5fb49bbb00516f1d8cdadea_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTY3ODI2MA_8bbfaf04-a360-4481-a7ec-fac324be37c7"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="idfb332e55d374ed9a1ee86ec02557a5b_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTE3Nw_d9aeca36-f178-4e61-ab80-6f12dde5d11d"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="ie7006ee9335c4157a84de254bb359388_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTIwMA_4cfe8408-ced4-4b02-8ba8-83bee8d63031"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i774e651a02ec4b0f95dde0602aac4434_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTIyMA_bcd85d6e-e817-4d03-9489-dc154aab6a31"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i440119c59b3e443b88631f1edc85ff74_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfNjA0NzMxNDAyOTI3OQ_e470c032-e9d1-4f1f-a159-10f4a0d971eb"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ic958491514274e76939f916d7f421a97_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV82NC9mcmFnOjUzY2I5NTA3MjFmZDRhMzRiYzFjYzgxMjc0N2UwZjBjL3RleHRyZWdpb246NTNjYjk1MDcyMWZkNGEzNGJjMWNjODEyNzQ3ZTBmMGNfMTA5OTUxMTcwNzUzMg_1bf7e950-e352-4358-9db9-7fb559dad995"
      unitRef="usd">40000000.0</nktr:PotentialDevelopmentMilestones>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY0_9032e8a4-9631-400e-bf26-f7a18539af00">Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock-based compensation expense reported in impairment of assets and other costs for terminated program resulted from executive severance. We accounted for this as a liability award as of March 31, 2020, which we reclassified into equity in three months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY2_6bb9ed23-2a5d-41ac-a6fc-46d76122a4c1">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcfe2d433ef840c286c01d47b0c5f9d1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMi0xLTEtMS0w_60f91eeb-2ffe-4215-8e65-3dc92070acce"
      unitRef="usd">727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8040c0e6c157482a8f36f8fda1edeeaa_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMi0zLTEtMS0w_bc711dec-7c1a-42d6-a8dd-28dc35a8017d"
      unitRef="usd">761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic85628854072425b81249accd9779120_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMy0xLTEtMS0w_d3a57402-742f-4a7b-98e5-fed045d5a568"
      unitRef="usd">14162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia22a905697334834a0579dcebb9555a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfMy0zLTEtMS0w_63eb2a73-4fd6-4d2c-a461-8098556c091c"
      unitRef="usd">15453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i862a0be5967d420ab21a5f29eea2436e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNC0xLTEtMS0w_9fd6e20a-68a2-4434-a5fd-b4301cea00e2"
      unitRef="usd">9009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a4fb5cc34a84085bf75a4ee4c6f7bff_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNC0zLTEtMS0w_1d148bba-0fc5-4bc1-877d-196ffd9d69af"
      unitRef="usd">7997000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2cd0871541b4364b1013eecb84d5e9f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNS0xLTEtMS0w_d0abf43e-b502-4384-90b1-73ce7a5ec96f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d469dfa3d97434e966b108b21df0121_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNS0zLTEtMS0w_cfeb57d6-4196-4fec-b64f-5d45bb3a7080"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNi0xLTEtMS0w_12a6c59e-aca7-4daa-8cdc-66e00e987367"
      unitRef="usd">23898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOjNiM2UwZGFjNWUwMzRhZjM5YmI3NWYyYzRlMThlOGRlL3RhYmxlcmFuZ2U6M2IzZTBkYWM1ZTAzNGFmMzliYjc1ZjJjNGUxOGU4ZGVfNi0zLTEtMS0w_14596ada-4d9b-4fc3-86b7-d659e9bc819e"
      unitRef="usd">25236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RleHRyZWdpb246NTAxOGI5M2IzOTcyNGMxMjk4OWVkODQ1MWRhMTJlNGVfNTY4_f5b6f7f6-d23b-44f9-b602-994a46cb7bd3">&lt;div style="margin-top:8pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMi0xLTEtMS0w_900808cc-29e9-41f6-ba8e-8c6b04c2dbff"
      unitRef="shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMi0zLTEtMS0w_bfda6e36-90ad-425c-a1ff-d529cc5132fb"
      unitRef="shares">49000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMy0xLTEtMS0w_38bbdcf2-84be-4132-a7c3-3957ebffb4e9"
      unitRef="usdPerShare">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfMy0zLTEtMS0w_f0172975-2c56-4df3-907e-dd42a72949c8"
      unitRef="usdPerShare">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib94d1826584045bf83baf28f35342624_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNC0xLTEtMS0w_d2e136e6-5d66-40e1-a049-3a87d2ddcbca"
      unitRef="shares">367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNC0zLTEtMS0w_d18a3b9f-6749-462b-a635-abc5437d495f"
      unitRef="shares">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib94d1826584045bf83baf28f35342624_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNS0xLTEtMS0w_082878e9-3db2-4e29-9f88-c70872860b15"
      unitRef="usdPerShare">20.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i79e4048b21294a46977a7ca525aadfe8_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNS0zLTEtMS0w_09241213-1708-44f8-9203-c1d6b227d08d"
      unitRef="usdPerShare">18.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNi0xLTEtMS0w_7e72a42e-1380-4cb1-922b-6704689f7f77"
      unitRef="shares">2199000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83MC9mcmFnOjUwMThiOTNiMzk3MjRjMTI5ODllZDg0NTFkYTEyZTRlL3RhYmxlOmY0MDUzYjcxMzJlYTQ2MjI4ZWRjZTVhN2IwNGQ1MjRmL3RhYmxlcmFuZ2U6ZjQwNTNiNzEzMmVhNDYyMjhlZGNlNWE3YjA0ZDUyNGZfNi0zLTEtMS0w_d152effe-08a5-461a-ac04-3090505b5305"
      unitRef="shares">1358000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RleHRyZWdpb246ZmMyOTg4M2RiOWIyNDEyZWJhZDkzMTJkZTUxNWQ0ZTlfOTU1_2156c680-c729-4528-806f-7cca5ad26f90">Net Loss Per ShareWe calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2021 and March 31, 2020, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three-months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RleHRyZWdpb246ZmMyOTg4M2RiOWIyNDEyZWJhZDkzMTJkZTUxNWQ0ZTlfMTA5OTUxMTYyODg3MQ_e6c5ba77-ddc1-4dbf-a569-53dbabf8a3dd">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three-months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a4c7399429f43a495d637c3795d6023_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RhYmxlOjg2ZTdlOTRmMzU2YzQ0YWU4ZDk2NjkxYWQ4MGJmMzY3L3RhYmxlcmFuZ2U6ODZlN2U5NGYzNTZjNDRhZThkOTY2OTFhZDgwYmYzNjdfMi0xLTEtMS0xMzE5_f8349e7f-ad5a-45a2-9646-01fe4b216be1"
      unitRef="shares">19393000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if4ef76c6130f49838cd0f487f1a97236_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV83My9mcmFnOmZjMjk4ODNkYjliMjQxMmViYWQ5MzEyZGU1MTVkNGU5L3RhYmxlOjg2ZTdlOTRmMzU2YzQ0YWU4ZDk2NjkxYWQ4MGJmMzY3L3RhYmxlcmFuZ2U6ODZlN2U5NGYzNTZjNDRhZThkOTY2OTFhZDgwYmYzNjdfMi0zLTEtMS0xMzE5_363138da-6b61-4567-a6f3-4301cb4e3552"
      unitRef="shares">18816000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925237178888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,308,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925162062520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 150,164<span></span>
</td>
<td class="nump">$ 198,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">887,152<span></span>
</td>
<td class="nump">862,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">29,156<span></span>
</td>
<td class="nump">38,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">16,808<span></span>
</td>
<td class="nump">15,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">15,771<span></span>
</td>
<td class="nump">21,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,099,051<span></span>
</td>
<td class="nump">1,138,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">96,093<span></span>
</td>
<td class="nump">136,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">58,510<span></span>
</td>
<td class="nump">59,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">124,971<span></span>
</td>
<td class="nump">126,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,456,561<span></span>
</td>
<td class="nump">1,538,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">22,434<span></span>
</td>
<td class="nump">22,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">23,513<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">41,028<span></span>
</td>
<td class="nump">44,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedContractManufacturingExpenseCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">6,057<span></span>
</td>
<td class="nump">11,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">14,833<span></span>
</td>
<td class="nump">9,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">15,768<span></span>
</td>
<td class="nump">13,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">123,633<span></span>
</td>
<td class="nump">115,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">134,556<span></span>
</td>
<td class="nump">136,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Development derivative liability</a></td>
<td class="nump">4,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">195,139<span></span>
</td>
<td class="nump">200,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">8,980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">462,055<span></span>
</td>
<td class="nump">461,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2021 or December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 182,290 shares and 180,091 shares outstanding at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,429,734<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,121)<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,432,125)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">994,506<span></span>
</td>
<td class="nump">1,077,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,456,561<span></span>
</td>
<td class="nump">$ 1,538,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925237545016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">182,290,000<span></span>
</td>
<td class="nump">180,091,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161066728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 23,647<span></span>
</td>
<td class="nump">$ 50,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,756<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">95,604<span></span>
</td>
<td class="nump">108,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">31,679<span></span>
</td>
<td class="nump">26,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">133,039<span></span>
</td>
<td class="nump">184,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(109,392)<span></span>
</td>
<td class="num">(133,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(13,296)<span></span>
</td>
<td class="num">(6,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="num">(1,599)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,204)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="num">(13,483)<span></span>
</td>
<td class="num">(4,820)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(122,875)<span></span>
</td>
<td class="num">(138,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (122,967)<span></span>
</td>
<td class="num">$ (138,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</a></td>
<td class="nump">181,370<span></span>
</td>
<td class="nump">177,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,795<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18,798<span></span>
</td>
<td class="nump">9,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 27,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment And Other Costs For Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925247879880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (122,967)<span></span>
</td>
<td class="num">$ (138,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(766)<span></span>
</td>
<td class="num">(5,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(826)<span></span>
</td>
<td class="num">(5,872)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (123,793)<span></span>
</td>
<td class="num">$ (144,523)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161390808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,271,097<span></span>
</td>
<td class="num">$ (1,005)<span></span>
</td>
<td class="num">$ (1,864,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(144,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,872)<span></span>
</td>
<td class="num">(138,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">1,296,426<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,306,655<span></span>
</td>
<td class="num">(6,877)<span></span>
</td>
<td class="num">(2,003,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(123,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(826)<span></span>
</td>
<td class="num">(122,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 994,506<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 3,429,734<span></span>
</td>
<td class="num">$ (3,121)<span></span>
</td>
<td class="num">$ (2,432,125)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161473416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (122,967)<span></span>
</td>
<td class="num">$ (138,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(18,798)<span></span>
</td>
<td class="num">(9,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">13,296<span></span>
</td>
<td class="nump">6,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">23,898<span></span>
</td>
<td class="nump">25,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,543<span></span>
</td>
<td class="nump">4,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">9,733<span></span>
</td>
<td class="num">(5,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,516)<span></span>
</td>
<td class="num">(1,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">2,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">6,183<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">8,981<span></span>
</td>
<td class="nump">9,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="num">(7,345)<span></span>
</td>
<td class="nump">7,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(2,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,085)<span></span>
</td>
<td class="num">(78,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(295,314)<span></span>
</td>
<td class="num">(241,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">303,612<span></span>
</td>
<td class="nump">439,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">5,036<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(2,876)<span></span>
</td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">10,458<span></span>
</td>
<td class="nump">197,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">17,106<span></span>
</td>
<td class="nump">11,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,856<span></span>
</td>
<td class="nump">11,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(48,791)<span></span>
</td>
<td class="nump">130,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">198,955<span></span>
</td>
<td class="nump">96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">150,164<span></span>
</td>
<td class="nump">227,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment From Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160430808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that leverage our proprietary and proven advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At March&#160;31, 2021, we had approximately $1.1 billion in cash and investments in marketable securities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India), Nektar Therapeutics UK Limited, and Nektar Therapeutics NL B.V. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2020 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on February 26, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2021, our accounts receivable includes $26.2&#160;million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $2.9&#160;million under customer contracts from our collaboration partners. As of December&#160;31, 2020, our accounts receivable included $38.7&#160;million for unbilled net expense reimbursements from BMS and $0.2&#160;million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2021 and 2020. We have not recorded a reserve for credit losses at March&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160238648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,164&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,093&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133,409&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2021 and December&#160;31, 2020, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU0MWQ5MzAxMTQ2ODQyNDY4ZmE0YzcwZDlhYjAzMGRlL3NlYzplNDFkOTMwMTE0Njg0MjQ2OGZhNGM3MGQ5YWIwMzBkZV80Ni9mcmFnOjUzMTNhZmE5NWY2MTQ5NTZiZTI0Njc4NzUzM2E4NGIxL3RleHRyZWdpb246NTMxM2FmYTk1ZjYxNDk1NmJlMjQ2Nzg3NTMzYTg0YjFfNTQw_d76ba943-ec14-406d-8350-bfab428ccc84">one</span> and two years.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,521&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our gross unrealized gains and losses totaled $1.1&#160;million and $0.2&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160289000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,808&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160232824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentDerivativeLiabilityTextBlock', window );">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</a></td>
<td class="text">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., an SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp; Dohme, pursuant to which MSD will provide Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria is met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;).</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual contractual payments over five years, with the first payment being $30.0&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual contractual payments over seven years. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the SFJ Agreement as development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Condensed Consolidated Statement of Operations. The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:83.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.581%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="9" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (ii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iii) the probability of termination of the study due to meeting the interim futility criteria, (iv) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (v) SFJ&#8217;s cost of borrowing (1.0%), and (vi) the Company&#8217;s imputed cost of borrowing for debt with similar terms (12.2%).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentDerivativeLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentDerivativeLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158921448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">Liability Related to Sale of Future Royalties<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0&#160;million for the 2012 Transaction Royalties.&#160;As part of this sale, we incurred approximately $4.4&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2012 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0&#160;million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB (AstraZeneca), as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH (collectively, Baxalta), as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G (collectively, Novo Nordisk) and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxter Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which are amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, which HCR received in the three months ended March 31, 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>&#160;&#160;&#160;&#160;In addition, the 2012 and 2020 Purchase and Sale Agreements grant RPI and HCR, respectively, the right to receive certain reports and other information relating to the 2012 and 2020 Transaction Royalties, respectively, and contain other representations and warranties, covenants and indemnification obligations that are customary for transactions of this nature. To our knowledge, we are currently in compliance with these provisions of the 2012 and 2020 Purchase and Sale Agreements; however, if we were to breach our obligations, we could be required to pay damages to RPI and HCR, respectively, that are not limited to the purchase prices we received in the sale transactions. However, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160183528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv&#8212;66-7-HSG, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made about clinical trials of bempegaldesleukin between January 2017 and June 2018.  The Mulquin complaint was amended in May 2019.  The defendants moved to dismiss and the court granted the motion without prejudice in July 2020.  The Mulquin plaintiffs again amended and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit is expected to be completed by September 2021.    </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb.  After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021.  The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the two securities actions (Mulquin and Damiba), three sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf.  These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officer and directors breached fiduciary duties by exposing the Company to one or both of the securities actions.  The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH).   After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020, in U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW).  The derivative actions in California have been consolidated and the Company has moved to dismiss on the basis that the plaintiffs have neither made a demand on the Company&#8217;s board of directors nor shown that demand would be futile.  The Company&#8217;s motion to dismiss has been under submission since December 2020.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF).  No response to the complaint is due until May 2021.  </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2021 or December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160449928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy and the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="27" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="27" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices </span></div><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for similar assets in active markets or has been derived from observable market data. For the three months ended March&#160;31, 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. For the reconciliation of the changes in the development derivative liability and the description of the significant inputs used in estimating its fair value, see Note 4.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160225096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:42.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug Candidate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, we recognized $18.8&#160;million and $44.6&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $25.0&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March 31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion. We are eligible to receive additional cash payments up to a total of approximately $1.455&#160;billion (including the milestones which we have received under Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones, and up to a total of </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350.0&#160;million upon the achievement of certain sales milestones. In April 2018, BMS also purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#8217; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones to be variable consideration. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. We received a non-refundable, creditable milestone payment of $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial on January 30, 2020, which we recognized in the three months ended March 31, 2020. We have also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial on July 27, 2020. For the creditable milestone, BMS is entitled to deduct the amount paid from future development milestones due to us under the original agreement.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than these two milestones which we recognized during 2020, we continue to exclude the other milestones of up to $1.8&#160;billion from the transaction price as of March&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three months ended March&#160;31, 2021 and 2020, we recorded $26.7&#160;million and $30.7&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of March&#160;31, 2021, we have recorded an unbilled receivable of $26.2&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii)  share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development. We recognized the revenue </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated to the license upon the effective date of the license agreement in August 2017. We recognized revenue for our performance obligations for Phase 1 clinical development and drug product development through March 31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2021, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, in 2012, we sold all of our rights to receive royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with UCB and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration agreement with Roche. Additionally, in 2020, we sold our rights to receive royalties for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with Baxalta (a subsidiary of Takeda Pharmaceutical Company Ltd.), MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our collaboration with AstraZeneca and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under license agreement with Novo Nordisk. The 2020 transaction provides for a cap, such that, if the cap is achieved, future royalties on these products will return to us. See Note 5 for additional information regarding these agreements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have collaborations agreements for products under development, under which we are entitled to up to a total of $40.0&#160;million of development milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the respective transaction prices for these agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160449928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense reported in impairment of assets and other costs for terminated program resulted from executive severance. We accounted for this as a liability award as of March 31, 2020, which we reclassified into equity in three months ended June 30, 2020.</span></div><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160940760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareWe calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2021 and March 31, 2020, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three-months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161157048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that leverage our proprietary and proven advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India), Nektar Therapeutics UK Limited, and Nektar Therapeutics NL B.V. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2020 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 filed with the SEC on February 26, 2021. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2021, our accounts receivable includes $26.2&#160;million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) and $2.9&#160;million under customer contracts from our collaboration partners. As of December&#160;31, 2020, our accounts receivable included $38.7&#160;million for unbilled net expense reimbursements from BMS and $0.2&#160;million from customer contracts. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2021 and 2020. We have not recorded a reserve for credit losses at March&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, a deterioration in this industry could have a material effect on our results of operations and financial position. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if factors, including the effects of the COVID-19 pandemic, result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs. As of December 30, 2020, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and other Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div>On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160138920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,164&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,093&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133,409&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,521&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158734600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,808&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160293224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text">The following table presents the changes in the development derivative liability from inception on February 12, 2021 to March 31, 2021:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:83.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.581%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="9" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160156168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule Of Liability Related To Sale Of Potential Future Royalties</a></td>
<td class="text">The following table presents our estimates of the annual interest rates over the lives of the agreements and the resulting prospective interest rates used to recognize non-cash interest expense for the three months ended March 31, 2021 and 2020. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rates - end of period presented</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implicit interest rate over the life of the agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prospective effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158783400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy and the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,596&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="27" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="27" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158933448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:42.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug Candidate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158798632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Compensation, Activity</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925248020648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"/><td style="width:74.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three-months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161503800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="nump">$ 1,133,409,000<span></span>
</td>
<td class="nump">$ 1,198,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 29,156,000<span></span>
</td>
<td class="nump">38,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockValueAuthorizedInTransaction', window );">Aggregate offering price</a></td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_WriteOffOfPrepayment', window );">Write off of prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitment, remaining minimum amount committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">26,200,000<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember', window );">Collaboration Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockValueAuthorizedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value Authorized in Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockValueAuthorizedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_WriteOffOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_WriteOffOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925164841928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 150,164<span></span>
</td>
<td class="nump">$ 198,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">887,152<span></span>
</td>
<td class="nump">862,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">96,093<span></span>
</td>
<td class="nump">136,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 1,133,409<span></span>
</td>
<td class="nump">$ 1,198,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925166177848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161968968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 7,559<span></span>
</td>
<td class="nump">6,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">1,133,409<span></span>
</td>
<td class="nump">1,198,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">993,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">993,989<span></span>
</td>
<td class="nump">1,003,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">510,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">510,663<span></span>
</td>
<td class="nump">687,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">478,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">478,442<span></span>
</td>
<td class="nump">313,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">123,607<span></span>
</td>
<td class="nump">179,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 8,254<span></span>
</td>
<td class="nump">$ 9,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925165177656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,920<span></span>
</td>
<td class="nump">$ 2,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">13,082<span></span>
</td>
<td class="nump">10,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,808<span></span>
</td>
<td class="nump">$ 15,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161624808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember', window );">Cost of Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Counterparty cost of borrowing</a></td>
<td class="nump">0.122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication', window );">Success-based annual payments, first indication</a></td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid', window );">Installment period, first indication</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment', window );">Success-based payments, first payment</a></td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication', window );">Success-based annual payments, second indication</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid', window );">Installment period, second indication</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementAdditionalIndicationPayment', window );">One time payment</a></td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ | Cost of Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Counterparty cost of borrowing</a></td>
<td class="nump">0.010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementAdditionalIndicationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Indication Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementAdditionalIndicationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, First Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, First Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, First Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Second Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Second Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925164914920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 4,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925237484824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 16, 2020</div></th>
<th class="th"><div>Feb. 24, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved', window );">Payment of transaction related to purchase and sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved', window );">Payment of transaction related to purchase and sale agreement if threshold is not achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds', window );">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925161787320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Implicit interest rate over the life of the agreement</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective effective interest rate</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Implicit interest rate over the life of the agreement</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective effective interest rate</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annual interest rate over life of royalty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProspectiveInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProspectiveInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925158838664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember', window );">Legal Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925237171272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">$ 993,989<span></span>
</td>
<td class="nump">$ 1,003,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,117,596<span></span>
</td>
<td class="nump">1,182,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">4,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">510,663<span></span>
</td>
<td class="nump">687,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">478,442<span></span>
</td>
<td class="nump">313,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">123,607<span></span>
</td>
<td class="nump">179,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">123,607<span></span>
</td>
<td class="nump">179,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">123,607<span></span>
</td>
<td class="nump">179,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">993,989<span></span>
</td>
<td class="nump">1,003,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">510,663<span></span>
</td>
<td class="nump">687,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">478,442<span></span>
</td>
<td class="nump">313,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability</a></td>
<td class="nump">4,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Corporate commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Obligations of U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925237439640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 27,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925153180152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized in period related to performance in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="nump">$ 44,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Nektar's | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Nektar's | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Nektar's | Milestone One | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice', window );">Potential development milestones excluded from transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Nektar's | Maximum | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Nektar's | Opdivo | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Purchase Agreement | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Nektar 214 | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Nektar 214 | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="nump">$ 30,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Maximum | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar's | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar's | Maximum | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar's | Minimum | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar 358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar 358 License | Phase 1 Clinical Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar 358 License | Drug Product Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development Milestones Excluded from Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar358LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar358LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925160837272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 23,898<span></span>
</td>
<td class="nump">$ 25,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">727<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">14,162<span></span>
</td>
<td class="nump">15,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">9,009<span></span>
</td>
<td class="nump">7,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925162041336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted stock options (in shares)</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="nump">$ 10.82<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, RSUs (in dollars per share)</a></td>
<td class="nump">$ 20.63<span></span>
</td>
<td class="nump">$ 18.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139925244481352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">19,393<span></span>
</td>
<td class="nump">18,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=<,T&PZ4W!)EG@8U<Y#G)H^&MXF$&<:95G W@C@]',D-5V0"(T;:) V9XNG
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M8KZ$4/O\$KXUM=_DVY]HN<[WR192:YGDAR%G 5?F ;B_E%(?3\P/%%NMP_\
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M-/WEAC.0;PS@][40^OG&?&,9OZE=_0=02P,$%     @ XJ"F4D_HX/S/ @
M' D  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RE5EUOVC 4_2M6M(=6
MZH@)WQ4@M535]C )%75[F/9@D@NQZMB9;:#;K]^UDT:D?'<\@#_N.?><FVN<
MX4;I%Y,"6/*:"6E&06IM?AN&)DXA8Z:A<I"XLU Z8Q:G>AF:7 -+/"@3841I
M-\P8E\%XZ->F>CQ4*RNXA*DF9I5E3/^Y!Z$VHZ 9O"T\\65JW4(X'N9L"3.P
MS_E4XRRL6!*>@31<2:)A,0KNFK>3@8OW =\Y;,S6F#@G<Z5>W.1K,@JH$P0"
M8NL8&/ZL80)"."*4\;OD#*J4#K@]?F-_]-[1RYP9F"CQ@R<V'07]@"2P8"MA
MG]3F"Y1^.HXO5L+X;[(I8GN#@,0K8U56@E%!QF7QRU[+.FP!FNT#@*@$1.<"
M6B6@Y8T6RKRM!V;9>*C5AF@7C6QNX&OCT>B&2_<49U;C+D><'4^43/"90$)P
M9)3@";,XN6>"R1C(S!$;<O4LV2KAN'--KJ9,@[0I6!XS<4T^DT\D)";%53,,
M+6IRS&%<YK\O\D<'\G]CND%:S1L2T:BY!SXY#G^ N(+3.CS$2E3EB*IR1)ZO
M=8!O9M$^-JDE:D$>N<0B<";(5!GNN^[GW=Q8C;WWZTBR5I6LY9.U#R2;8L>"
MUEAN?,SQRPW)F29K)E9 KK@DB1*":4-RT$5YK_>5MTC1\RG<D5V/:8-2BK5<
M;Y?Q9%C-0;MRT+[,0=$&A*ULJC3_BQO.2;&Z5W[!W]G2U:3%YYV!,P)K%CJ5
MA<Z'+"1@^%+ZPW#"0F='V7OMQR)JHKN5Z.Z'1./?M+%,)EPN3ZGNGE1]+**F
MNE>I[AU5/5%9AF?H/YJ]=UZSGPRKR>]7\OL7R+^XT_L[Y6S1_:U^3F3-P:!R
M,+C<P04],]@]@_TH&NRQL"^2TD%SUT*X=7>Y]P:\$)9<&B)@@5C:Z"&)+N[B
M8F)5[J^SN;)X.?IABJ\OH%T [B^4LF\3=T-6+T3C?U!+ P04    " #BH*92
MW8U#4<4%  "]%@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*58VV[;
M.!#]%<+H0PLDM4CJ&C@&&G<O!=IND+3;9]JB;:&2Z"5I)_G['4J*)$L4TR(O
MUL4SHS/#X3DD%P]"_E1[SC5Z+/)27<_V6A^NYG.UV?."J??BP$OX9RMDP30\
MRMU<'21G:>54Y'/B>>&\8%DY6RZJ=[=RN1!'G6<EOY5('8N"R:<;GHN'ZQF>
M/;^XRW9[;5[,EXL#V_%[KK\?;B4\S=LH:5;P4F6B1))OKV<?\-6*^L:ALO@W
MXP^J=X],*FLA?IJ'3^GUS#.(>,XWVH1@<#GQ%<]S$PEP_-<$G;7?-([]^^?H
M?U;)0S)KIOA*Y#^R5.^O9_$,I7S+CKF^$P]_\R:AP,3;B%Q5O^BAL?5F:'-4
M6A2-,R HLK*^LL>F$#T'B&-W((T#&3KX$PZT<:!5HC6R*JV/3+/E0HH')(TU
M1#,W56TJ;\@F*\TPWFL)_V;@IY<K4:8P*#Q%<*=$GJ5,P\.]A@N,EE9(;-$_
M!RZ9J;I"E^C[_4?T]LT[I/9,<H6R$GW;BZ-B9:HNT)NSY\5< T3SH?FF@7-3
MPR$3<"CZ(DJ]5^@/@)6>^\\AM38_\IS?#7$&_,+D>T3Q!2(>P18\JU]W]QQP
M:%MN6L6C$_'N^(F71W[E".6WH?PJE#\1ZIO0+(>95 6T5;IV#RMW,YM/2T)#
M/UK,3_W\QU:!%T2TM3K#%K38 F>:3<.4.[01"GH(F@'QQX-I-.7*/6SCA\[<
M5Q#5-.9.B%0A:-O45H Z1M!/+0K"0?YC(QIC;$\_:N%%3GAW7'$F-_LJ[Q1&
M*!<',YEL(*/1]Y,@]/P!RK$5]N(DCNPXXQ9G[,3Y%R]AG/(*)DN!73*ES;B=
MK/T4CRN%PR@9(!U;D9#@":!)"S1Q OU4'%@F30G-J#.E>--40N^Y;)H,- UI
M+B&-BL(.4NPD*VR9)".,WB"+L84?X#BQ9X&]CFR]7YBSPC$[K)3IC4>?4H\.
M2V^SBWW2:Z9SV#V-P$[8GX6"\DI1/$,'); "Q2, E]A+:$*&2&V&E(9T8N)A
MTD$E3N;Y*LK+KKY9N1$%1V^;ZKYS<0_N.!Q39SG,-S9,[2$\]!L'*FKB(UB7
MY!E;9WFFGX":\ZH1M4"*Y=QT[O:HCY(C*9Y8KK.)T::VVI!D2%PVNS )XXD*
M=K*"W;JRVK-RQXV.;V'.H1/+CQ7V'H_!O<Q.%5%T^5IS\2VY!,FH<<=FWD0:
MG0+AP$T9SV/3]$#'%L.FN$ EMU)S\X6S^>3C42^/K6(:D G\G<)AM\1]&O26
M%>!8O(9$9C&Y#*<IH5,X[):XFLE*YVR;+NQ8SJ#%_9@.P5OL_)A,]48G>]BM
M>Q6?K3D(!C<R<<JJ38G1CR8%S1XG)N=8WBXQ(7$4#*';#&D,*C(!OI-"[-;"
MV]\#/%:R,1N/;6 7:,=).JTC;JW["GO0' IM0]6XAH,R)N%P=6HUI'$X54;2
M:1IQ:]H-4]FF7J!E^='P=-D 1M#0]>X&O0463$6>,]E[^\Z:4?VUN _4>]]C
MXR8?JUDT0=JDDSU"G-G\J+:KD 0[P6P$^FYV9[!Q5QJ2--/S:'9YD! TS.%8
M3=CUK]:@CF9/G%@6'9A&0R*RV441CH.)U#LU)FXUAOF0'C>ZTECEVC%V"DC\
MUV[22*=#Q*U#+V[3&O]^B_M1,N03BQ7U_0D:)YW*$+?*W%4KD2<[OO.8G320
MZ-7EZZB:N*GZY?*-B7;4>F.3),(3BWG2$3%Q$W&[#)3G1?S]A=_Y44+'L-1[
M;:%IQX?4S8<O%IJ.U^PXCI(APUG,DCB9F.6T(SCJ)KC/V<:L*2Z O8".UZ+>
MA?16=2]W,.T=TKSZE(9V;$)?>4Y#+4<PP_V_Q89$ 1Z6==X[""RXW%7GHPIJ
M=BQU?6;6OFW/8#]4)X^#]S?X:E6?I'9AZH/=+TSNLE*AG&\A)&@7C+2LSTKK
M!RT.U7'C6F@MBNIVSQGL&(P!_+\50C\_F ^T)];+_P%02P,$%     @ XJ"F
M4CKI6 W\ @  9@@  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R-5M]O
MVC 0_E>LJ ^M-)J0D 0J0"ITTRJU6U76[6':@TD,L>K8S':@W5^_LQ,\H('N
MA?C'?7???;;O&&Z$?%8%(1J]E(RKD5=HO;KR?945I,3J4JP(AYV%D"76,)5+
M7ZTDP;D%E<P/@R#Q2TRY-Q[:M0<Y'HI*,\K)@T2J*DLL7R>$B<W(ZWK;A4>Z
M++19\,?#%5Z2&=%/JP<),]]YR6E)N**"(TD6(^^Z>S4=&'MK\)V2C=H9(Y/)
M7(AG,[G-1UY@"!%&,FT\8/BLR90P9AP!C=^-3\^%-,#=\=;[)YL[Y#+'BDP%
M^T%S78R\OH=RLL 5TX]B\YDT^<3&7R:8LK]HT]@&'LHJI479@(%!27G]Q2^-
M#CL \-,."!M > CH'0%$#2"RB=;,;%HW6./Q4(H-DL8:O)F!U<:B(1O*S2G.
MM(1="C@]G@J>PYF0',%("49SK&$RT_"!P](*B05LE7!%"G-V:X+NA%*H@YYF
M-^C\[ *=(<K1MT)4"O-<#7T-K(QO/VL83&H&X1$&$;H77!<*?00F^3[>AVQ<
M2N$VI4EXTN$]EI<HZGY 81!V6_A,_Q\>G* 3.84CZR\ZXL])^5;)6YZ)DJ"?
MUW.E)5SH7R?"]5RXG@W7.Q+N"[Q\!B?4=A U,K%(\[S7XTXW# =).O37NP*U
MV47]).XZNSUJL:,6GU3BJRZ(1-F>!+26X-Q0OK@ZD7_B@B3OYE]Q*&B,_H&+
MO(1"UGA'IFJL,65XSD@'"F!'8688K(G2]JZW:59'BW>U2)/D0+ 6H[@;'I$K
M=9FD[V8"+*$0<:@$4A*>O2*X)UPQ;$O@3FYMS-.WI)+@@'B+37KLF/N.=_\D
M[W>/N8UL_RV1?G@H<XM1W$_#=KH#1W=PDN[^DSSV= 9M3R=*!]$!Q3:[7B\.
MHP.2_D[)+HE<VDZF0+6*Z[K4N577+*]MCSA8GT 3K7O>/S=U!X9"MJ1<(486
MX#*X3$$X67>U>J+%RC:&N=#09NRP@#\"1!H#V%\(H;<3$\#]M1C_!5!+ P04
M    " #BH*92&_+*'ZL$   )$P  &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;+U8VV[;.!#]%<(HL U01R*I:^$8J&_8 EUL$/?R4.P#(]&Q$$ET13I.
M_WY'LB);%&4[0-"72)3/#,]<.$?1:">*1[GF7*'G+,WES6"MU.:C9<EHS3,F
MK\6&Y_#+2A094[ L'BRY*3B+*Z,LM8AM>U;&DGPP'E7/;HOQ2&Q5FN3\MD!R
MFV6L^#WAJ=C=#/#@Y<%=\K!6Y0-K/-JP![[DZMOFMH"5U7B)DXSG,A$Y*OCJ
M9O )?US@L#2H$-\3OI-']Z@,Y5Z(QW+Q.;X9V"4CGO)(E2X87)[XE*=IZ0EX
M_*J=#IH]2\/C^Q?OBRIX".:>23X5Z8\D5NN;03! ,5^Q;:KNQ.YO7@?DEOXB
MD<KJ+]K56'N HJU4(JN-@4&6Y/LK>ZX3<62 :8\!J0V(;N#T&-#:@&H&%/<8
M.+6!HQOX/09N;>!J!J0O:*\V\*K<[Y-597K&%!N/"K%#18D&;^5-5:[*&A*<
MY&5G+54!OR9@I\93D<?0)SQ&<"=%FL1,P6*IX (-I"02*UB)Z'$MTI@7\B\T
M_[5-U&\T1-^6,_3^W162:U9PB9(<?5V+K61Y+#^@=ZWUR%) MMS2BFIBDSTQ
MTD/LJU L-9A-3YM-199!PRXK2@;SV1ESMDE@WY+[_#GBL@K_EA7H.TNWW.!O
M?MK?IRC:9MNTRNF_:LT+2',&(V!=GLTGCKX(:6*YN-SKC*^2*%%M)Q9T0=,*
MI&D%4GEU>KQ.^$.2YTG^ $<U97G$T7M(P[ZX5X@IV"JZ1A1_0,3&H:DT>_]N
MY;\<:4]C['NN[8ZL)P,OVO"BK^1U 9?)WJ=WS,6Q71KBALR>LP'GMR&S+H02
M']NAAIMW<4-L'T6_+ZT)%7B.CP-SFIPF34YE27O2]#F/0%HD5 UR4]U=E6UL
M/+L_[T2:(AC-.U;$_YWH';?9W#U9HV4] J3<0D]N8:84B._WBJ#AH=M9)20;
M** \[BM3Z=QN&U$WT.IV!M2*PFNB\-XN"A-SK]M,F#IZ/WE=ZBU4B[O?</=/
M<R_K/"Q%-FZ1-='T.P2(0[!V,F;G4"V:04,S.$FS/?Y2\_B;!)VMA]AQ7$*U
M$V? N8%/M!-G\D8#S^T))6Q""4^&,L_C$\/R'U:\#"ABFX9E:!B6?N!1,REL
M'P3=?@VM"ZA,:H\M+B3T'.)IAZX&GIR6!F>4VI[G:H-P;@ .O<#7_"U,,'AO
MIM0+>U)U].Z#WTSQS$6L-VAE+K#ML*>U\$&+\6O%^ (ZD]IIJSZV[Y/0U0MI
M  9Z(;MR3FD0^-36"]D%#DEGSX411B%7?6,;']X0,/WSVH</RHN=/Z=^]5ZM
MN8O#4"_@&50[DH.,XS?4<2-[US AL.WIO660[Q:LS?\@X/B,@K]"!7%7APD-
MPLXQ. =K4SWH-3XMV)<I(>ZJ\! 3ZH>Z%)J @3[ %V9W,.M[WC[P0=?Q:6&_
M7 VQ<9!V11H'0,SNX740:?PJE;Z RZ3V>-S#8>BX>A-/#;CN$.UBJ$-"GSIZ
M_;K (<4$ZP4TP(A#"2;Z?UG6T4>!\B,1A V2(E'*5V!J7_N0ZV+_W66_4&)3
M?2>X%TJ)K+I=<P83H 3 [RLAU,NB_/30?/T:_P]02P,$%     @ XJ"F4L>P
M8?9S!P  Q1T  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R]F4%SVS83
MAO\*1M-#,Q-%!$"*9,;V3**TTQS2>NHO[1DF(8D-2:@ :,?]]=\"I$F) !&G
MAUXL2EX [RX6^P#$U:.07]21<XV^-G6KKE='K4]O-QM5''G#U!MQXBW\9R]D
MPS1\E8>-.DG.2MNHJ3<DBK:;AE7MZN;*_G8K;ZY$I^NJY;<2J:YIF'QZSVOQ
M>+W"J^<??J\.1VU^V-Q<G=B!WW']^70KX=MF[*6L&MZJ2K1(\OWUZAU^NXLC
MT\!:_%'Q1W7VC(PK]T)\,5\^EM>KR"CB-2^TZ8+!QP/?\;HV/8&.OX=.5^.8
MIN'Y\W/O/UOGP9E[IOA.U']6I3Y>K[(5*OF>=;7^73S^P@>'$M-?(6IE_Z+'
MP39:H:)36C1#8U#05&W_R;X.@3AK /WX&Y"A 9DWB!<:T*$!M8[VRJQ;'YAF
M-U=2/")IK*$W\V!C8UN#-U5KIO%.2_AO!>WTS4ZT)4P*+Q$\*5%7)=/PY4[#
M!\R65DCLT8ZI(_H99ERA'S^WK"LKL'F%UNCSW0?TXP^OT ^H:M'_CJ)3K"W5
MU4:#,M/_IAA4O.]5D 45%'T2K3XJ]!.H*2_;;\"CT2WR[-9[$NSP$Y-O$,6O
M$8D(]NC9O;QY%)!#QRA3VQ]=BK()X-X&<"]%@V 52J:K]M"G<:4KKMX&QHG'
M<6([3KPPSJ^P[FNAO#/0M]S:EF9Q/]RL,2'Y-KW:/)Q'QF='LVV"1[L+:<DH
M+0F&X%WY%V1SGU):0 4H1%M4-4?MH-G\:IX+$ZO.9"3DU/<&:CNJV88#)=JU
M'4B*)U;K)]#SP-N.PV=M%P"(40S40?;O.]U)/EC"^+[@]J,E%T'+TCR;Q=9C
MEF=YXH]L.OJ2!GW9'5E[X"9:>U9)],#JSNHNP:5:G$S(X5E6#\Q43%17[+ZJ
M*_WD\R-U!&(*.3)SP[7:YMO,[T4V>I']9UYDKA=)GL^<<(TBOP?YZ$'^PISB
MBC-9'!$4PPO]_.O)U%J?Y-Q10T@\3Q_7:$$RCJ;R'P5%WVE1?%D;$):H$(W1
MQPQ?O34\<D72S$ERGUE"Z'9!ZAFI<%#J!PX;E:)B/?XAM*P14E?_+.O%CA":
MQ'0NU[6*DX@LJ"636A)4^[$Y01[;:8<L9N4#:PN.3NQI+(%0 +6$L@8X;[L]
M/$"5D<IZQO_NJCYE8*.&-)= ?EN63E(<)&N\WI) =@RNNB8DHDN5'4]TPS3H
MZ[NSB3#>PCPU5=? ;J&L5"$Z</C5:UO<C7-"'[E$[?-J@1A SME-G7_G0#U9
M%R=SUUPKP%N6+[@V 17'87+;LJ1F+%**ZWZFGNO0-[B$)TSB)!S+H@^8(22'
M:G=?>^O%T,NYOWE*G=QVK=8)0'\A*A,]<1B?'UN@I1;26WVQ#X8)GD/$:[9-
M%F"()QKB, Y_&Z>IYE#6E$T\KTX/[)(8SV6Z5B2/E^KN1#L<QMUO=A'TB>05
MY^)IBS-G?CVDB\YV=)?B)I#A,,G&'(1RM9B +HS2=,Y8CQ'99@OZR 0M$H86
MZ)/="X!%7!(!KN8S[+'*<[(PPV3"%0GC:ICA0>J ?N]<$Y= Z]0M<1ZS-#Y+
MB4N=$ZA(&%0?^)Y+"1*'+;!7H0N.]39R!'JL2(*7(CGAA83Q\NM+3@5>V1XH
MI&F4.<)]=EF4+M0B,M&#?(,>LW-?!753?<=QADS8(&%LW':PX33ESO"W'\9N
M-+QA\5"!Y G%\3PN/L,8*LS"7I], "%A@'QBL-NQ[K]$KTL*&M$M)G.YKEU,
M@8I+TS@AA821<@<GP1<)=5F11'0./H_5TA*9<$+".+F8?M@DP@+13Z_1J6:M
MOMQ1>G6[&%F3+'6$>\SR:$G[1!ORC7/3\_(&W0]5"4O\_LF[4KS27<+@*$[F
M9Q*?69ZF2ZBD$XIH]%TK? \;];9X^0JG$T]HF">W4A2<E\,XZLBDV98J9>C2
MM7 TMG.LGRZH:#/ &SCJT@2GL+1G@?.9X2A=BMM$'1JFSJX_*,,6]Z0'E_[-
M29^ZR$F3^;''8[20M/3LA=X+F72>M+[)]ZIV>8/3+'%B[S$+Q'ZB$@V_)?QI
MO^>%/9;"Z9)7AQ9V)T7_^@6P:FI(V_MF"H=],)GU $5PH>X-XUW6#V<6/$;Y
MDB\3]VB8>V8>JK:09JL/QTW>/[TRNX3O<\&#NCA+\_EFT6.'*6RY%]X7T(F(
M-$S$W9):Q#2ZYX>J;4UBF?(.:T.47B=< &+S?G&^W_'8Y5NZ7=A*THF3]!MO
M(D,^<'/T#ZKWG<<BO)WO2CQVA*31$N;I!%&:!6OY77<ZU?;6@]7(O+FHA>ID
MS]3BN<Y#9O679U!=@X5]XA\-\\]&[<2JTK[LJ5K-84POIVGH!> 0'-<DSI?>
M\,03YN+PB6MVJ$;2W(ZMQ7X-6_+^%&O?Z!_:ZI]^BSY6%.-3W^;L58GW?B)R
M+AYPE#BW$ZX5P72>N9NS"[&&RX.])U3(GFK[2Z3QU_$N\IV]@9O]_AZ_W?4W
MBE,W_07G)R9A32KP;0]=1F]2"+GL[PS[+UJ<[+7;O=!:-/;QR!F S1C __="
MZ.<O9H#QYO;F_U!+ P04    " #BH*927PQ;WFP=  "!7   &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;-U<^W/;1I+^5U#>U)9=1=&2[+P35\FRG=4F
MMK62D]3>U?T  D-R+!##X"&:^>NOO^Z>!T!2DO?V[H>KNKU8!##3T]./KQ\S
M/VQ<<],NC>FR3ZNJ;G]\M.RZ]7=/G[;%TJSR=NK6IJ8G<]>L\H[^;!9/VW5C
M\I(_6E5/3X^/OWJZRFW]Z,4/_-ME\^('UW>5K<UED[7]:I4WVY>F<IL?'YT\
M\C]<V<6RPP]/7_RPSA?FVG2_KB\;^NMI&*6T*U.WUM598^8_/CH[^>[E<[S/
M+_QFS:9-_IUA)3/G;O#'1?GCHV,09"I3=!@AI__<FG-351B(R/A#QWP4IL2'
MZ;_]Z&]X[;266=Z:<U?];LMN^>.C;QYEI9GG?=5=N<W?C*[G2XQ7N*KE_Y]M
M]-WC1UG1MYU;Z<=$P<K6\M_\D_+A(1^<Z@>G3+=,Q%2^RKO\Q0^-VV0-WJ;1
M\ ]>*G]-Q-D:FW+=-?34TG?=B_?-(J_MG[FPJ"ZS:]F=S,VS:[NH[=P6>=UE
M9T7A^KJS]2*[=)4MK&E_>-H1 1CF::&3O93)3@],]BQ[Z^INV6:OZ]*4P^^?
M$N&!^E-/_<O3.P=\FS?3[-G))#L]/CVY8[QG@1O/>+QG#^#&)#MW=4MK+2-S
M+AO3FKJ3'XA#;VR=UX7-J^R:?C0DK%V;_>?9K.T:$K?_NH.BYX&BYTS1\_^;
M_?E?FRP;?/N[R?*&_I>!7WE3+(^@.64VLVZ]S$F9"M-W-%:5%6ZUSNMMMB2#
M\D>?-YUIZ#U;9]=YG;UIP-VV<+07>67)!-4V9\)L7;AF[1IB.K_]RE3YAJ:<
M^JE+<TL&9PT2\VQMUP9KQ3K*IE]DM(H2^TIT=\N\RRIZNR$;E+F^R=:-6S?6
M=%@XYJ*_;PWQH[PE:FBZM:NV*],0Z?7'?D&#9)TIEK6KW&*;K:N\@ZEL)]EF
M:8NE$M,2]^C3SF6FSF<5?;(,-$)J0%E-)FSER%SU5=[0>YWMK">0B%F0A;ZI
MW:;.5C0=\;I=M?@L9_,VS=X3Z9[=3'<Z?,H!S&/K6]-V=L';1=L KK3@:M43
ML;3$#O/3 Z*SR=>@@U:5.6([ECG)[&K5ZY(QUZUM^(][R& ;+,M:YK>&7ORC
MM]CP-I$N5R\<]DUHY.^(;]@M'@\,-9_69-6%H;0-)(F]P;]UO,%P<9AI=M:*
M3)+)IOWQXXQ'(3;T\%NDQKEPH7)M2S1C^MJ :41[D;?+;$Y.C5C3N%5&?K)A
M=H*/O+_SONM5)'FU<[861#6D+'F=I(VTS%9;^JIQ_6(I8R],;43 >7S2,_C"
M>C$A8JLJG[DF*NHJK_LY<;=O6.(7C5%CA(<R+QZ06:I;$9B6N-%E;WF;O 5E
MGBQSXO&:A/X34=49HNJ+D^D)J6Y5839:&U,G6NA9RVNF1=R0VD"\6Y+BAC=Z
MFKW,6\N2.K">8DZ)U79=&7X\-+>0(_JEI#43!^(S^F.OU579%<:'%]:NM6+,
M9==YHH3UH"+92#RD>3=+8O#VB'0-HDER8$M+&V3:[[*+FA2"EO/26[()_51,
ML\?ZX,DD>V=N2%VS#ZPY;.=:/*8AGF#%MQ#D7^S*8BF/]65YO/_;7W_VKT^8
MWGWOO/LE>SG]+8H:*3N!!>967E7$'+*KWM3F8KUE\:E$\-ZFF\#C$=9;YXU*
M[>?LR)R8Z#8L=LN@ZO*(^(S?KH.4,"VO/\&ND14^=ZN5;1GW/;Y^??Z$;0^O
MP:YH(++[\#VLSK25Q!K0T!-E#0WK6IJL)YEB:5[E6ZR)B<Y@P>CMK#!-1WB5
MAG5=[> %\ 2F+A$=6POD!15L@V%X:OQ$LA$MUVR;_3J]GJJVXA'QUZR9\]%-
MKJ.D/_[I[.Q2EI37=0\AI76YDC3E0NP&W)8"#-)K<DM@V@2/VE2VVUWAQUX+
MB<S0!OP5BU!^[+VF\F*(-=AJ"Y[5IC!M"W<'HEB!<@L_. 0[V/]=S>*)5*-H
M(E6SZ6?KK_C)VGFQI>UAOI:P=0VL%7&S*6F.BMR/" I+K/%2T[ _GYEN8XPP
MDLP864TV2+0R N@DW\004Q?BM?!.,@E!;^)?/I^S3Z!GK!Q58(#)R5;Z@8)9
MV/[U+]^<GGS]?9LPQQL;DEDW6 9S>-T3=&G%Z 5I9O86*9MVAF-U#'8NH6U!
MPBPJI([*(MPI^A4A"8PDH@W];\P23N26QW$KDSW&%T^\QZ)PH[@AXT=2T>JR
M,@AZMX5%3P7AP-:^S"NXN.P: 0D1_$$<]X381;Q3BMA[^GU(UY%**9LQ4D[:
M4-K-U*$32^_@E9=+D<#AFK%6$?NV"\:^)ES%#]95WXJ0CV7E3E[CGWU- 7%E
M_R1*P#ULY\Y[6-]M;BN(XQ%-<=3F(T<)BVY(,]G.#)9,BESE9!#QIYAJBJ\%
M_-V]R[PP8IAL;E"VH1,L!36PQ"\).1 *Y2C-($H;001>$?WCF,EE$\=>!0-\
MKKKW==Z7\&LRUD-$"M)$$0"OX!69K=6,EJRT'6<;>D"B2PM7S,1&0.8X)"\)
M5R)@5R5C*P2).!-#?<7*BIU$1B [.3[Z.9C,K6'0CH]V"9O;BG[?V&XI?N_U
M.0]B9DT/LWOZE3!7^) ZGI20;DFXXQ\2(Y&;V27F'UF[='U%/@GN-B_5GW_L
M:U'=,/_]K/#6<;"_XBI9FMP]GNC?Q;DI?4G!5T\6!%B=I(/<.FD"&1<!0Y7-
M"9D*AB!5R6[!3Q5HMM<:5'K(@<F$S=Y&"PJB^3UN;TW &I\KT;!7WIL"SUN"
M=848/)W?STI<G"5Q3'"\/7D@9@C#@ZTJM2"$:?9KRP.]IM!MQ=X."Q& %KS4
M_9LK8@$A@V%GJ0 F\9BF35 'Z%SE-T1IF))CL+;M5VNQ'H*-HM,4CP;XLQ*8
M"3/%.[:S81P>4GQ/5HH")24>SI!CQ0/?R"P<#BI/'R[.^VAK1,#X'2]CJ4F,
M'MKO0I+^.,P6,2.PZ'5'DD Z** 3GW=]@A$*5MG2$@>;#&,UEF&D&C!HVL%9
M)*)=2\:"_2SA.C"N%4\6/V1=D 5,LG[-[*/5K21JGB-)JOZN&Q@@3!BA+?DA
M1U[I3\.RF8 P=N]Q-H43,A]M2=/2J"52"G,+<W^UX\_.%9*3J5XA(C:WUO4M
M3ZE;AEE(6_#-ODTF[5?.,W)@U!#=9D@58&7>(?KU*IDIWIUFUUC1KM\M'2MY
MLD^6[",Q;Q_)C;==$1_#(4\"YB!0[SJ =;5HJ:"3 3@,QX@^L^!E7R2;];O1
MF0R;WYK8T+>VAC2T^KKXN+DK>H])""-O/?[<D\CBW(ND<&CE]-]Q!DV 5IC(
M08YI/-V'EN)03F<1[PG;%R+""E4H@";6(6Q&$#M1Y^$5C^( M0HDWV5?J!X/
M4QWT".86;J';K@532]J<>#:!=>D:.^N9/2M#ZE2V&AHM )L<>0M3(WM52X9(
MTX<#%$5;*A:Q9.2QCZT4!3(J7EI#YOD3@3HV^N_G)#F&'$Z:/2574M W'GTQ
M3/44\^0Q'S1*EH+PF77)+HEW#FE"?%VYP@=0(;[AZ+HG*R%FCDW^9DGV9:/Y
M L*0G3UBQY,W#=2:#:?L;4@8D#H8>\OQU$Q1&0PV(UWDA\ @1L/Z!ZVQ-,E7
MFBG3[<P @&F/2$#(<A!;*396S32?.G8^2['VVT2GR8Y9<ZLS<=!(MCN /2;4
M-.0/N^V322IKT;&L\RTO#D""&("0#TNSJUG?M+RXPB$^X$&35!OG*P\E-D/&
MC4TR">$XL^8.,#+D7+\X_6IZ"F9PF@V (/ 1YD)=4R#4)UDX]<B13IH3! /(
M:&<OH5NN.GJ[A7!=D^V8S9!>X430XY=OKY_P4KXXG7X;II9$BA=)YAS4]+ZY
MPLIW0-R]BR<"GGTS_?I?6SPM0M9PG+*/]VYG":S?T9VI,?=98UY6AV?)4KUF
M2B[,-&P3<[4?2'7?HO2HL61XVUOKHC$4?62T"S=22Q#9RY;8%F044Z/G!9.L
M#7(Y\RX@/\#C:?8W^:@ [9.@NE@!^$.C<7)9I]2H,RQD'_LU1^0:; &%G+,<
M4CV+_/:P]'/"PM\3NL+@4@EJ;F7((8GY. T-U[<G$@B5G34HX$(!KZSMD>9A
MXUF78:\3/X%'9%A0Q[&P1_DF^&_%H%S] $Z-4 J!0P5\+$SRGED31X2*$8TF
M":8P[\B[I'E/SO#YY&.1MYJC;.!A')(<]0(I 5I4(9Z,E\;E-W@=8LO*04Z1
M,( _"*N8<GQ",S'8G'C;#_BA5E29Y/-L5;Y%QD"SJDV_]D$([ +%CBU2YE$R
M\U@W\:#[_/UO%Z^.3KXEJ:7=(,^N6JY<2E"#UM#(Y$M];80?=K[31;-K:\!$
MW1\N0$')*EOS\CM>^R33WY,A>'.";! #9Y76NCS>G@V*1 KCD-#U=3MYC24Y
M#XQ&$9"DB3@K\8Y*H(<#DP28(ND<$Z1[JP]3!,-"^EV)H:CJ:4JH&*((&MA2
M7 !1U\V?Y?4-[UT]"(I("6W!$+TD8]40DOQ]20Z8R4@J;FO4=8/TQJ2QJSFL
MQ7N8:&D7RVI[)&6J=IC.1PE"=H',B41XM#40,!5T(9C<,(D*^.L=BL]U>!(/
M[,5P#P[7=_;E!L]*V1PQI6MR*7V26MSA0R@EM( +R3IG!LE"T(1?B#.B'+*R
MD!CV7D!"@&7>"I0IW:9> ")!'"NWX;E7)-RK?C7Z)K4B7D)!C^HD\KV2ZW.:
MR"41&J7,B3280]?L &UA9'N'9L=I LWM9]$LY<(YV%A2#%>R*# S)>$RDG8L
M+?JT)(/*<2;C1IB\%)J=); 5KL+ L$D"?E0N35]D)/P E+T/[TP4*<EN*-7$
M&Y(:J=5*LNPP8,+3>=\P/DV-)5D^PA"06$3:3JKVX\Z$'2MJ+ ^45^HJ.,NS
MFJ&<,DK^[:,E !:RNH032C&KNZM):>];,XX:.9NPBY$QL253MZGO6@.[>#"1
MK+H+6,N/-TD!]V1<\:Y+;^N3'@/9G]T-2-'ZN5;!Y(DO(D(F(_ %3:'$1B^M
M"57%0&(RC 2&[C\);NX)1O9C7-(]M\TK,3;<0T-4 A*S$@3,@H"(O>1D)$'Z
M7B C3#BV@?O6[!&3T\R*AX,!6$,@"*R01=MMG;E\_=-6:R8!ITQVVF\ .0(=
M$40=#+2"_Y*=:B7U:080G\)V;NXX: '"]J?YLLW2\.9PVCNU$7-45:$^ODA6
M((XFSI]=GV??''\SN<L2/=:7GL3=.S@1N1U7T0 ?G06Z#3FC1*(Y>M?O9PZV
MB_0QM--(BZ/\5MAUXDT',Z5M-*Z5U-B@VD31BL^2;/*F#)XA&8-+>WM"]<$\
MX%Q[-^OV\S]$0KZ:VZOZ' QT#VZ2:%Q2BB>,",9R9\[%7 OAOG<DCQJ9)A7V
MS<@&$+D^21N&<KJ\Q1_G05.T $J>7XUI-C=F%+ \H&M*^"5K46U$?CB0?(C5
M7QU_-?&5%"'M/"@Z.X;SD(!ZK.\_H7C3;= 7-U''/633X:T@Y(;8+RY>8CX-
M>T;"3)OO"LOP,9I"SZOTN_V)F'N=0F()1VST^\:3!0YJI(/\E-93#FZ+-]CP
MDY)2D!65@$-MIY3J6Y.!_G.9-U" [6)S)HE8_2*4OI M1]:="4+$8*JTC08"
M,# C'JHSJ%ZAZ2^6!55V--@3&QH$)-5%KH3&K=)JWB$[*FE+<=B<%DP#+HD_
M#Y#@#7BU5?YZFD/_A30G(2E:F#V&R*/AD$?CY[P,WUC)%J5Q,Q\@<MV<LXC^
M#>G4V^^L8R_D0,,E>-MEO,<)G%%=5P?9$J6<098TJGKCX!K_&7[_' O!GP[L
M/_V?.)2V,YR9C\U.4 XT3WG#4DGN.  <3K?O( <5&ZB)-G.@3[(4X E,KPU/
MM%[)N(\"D8V):'=<1_2IN(]]N0B=GP.9.#@7I,E7N?8P/*D_>9?H^<KU8.+Z
MC=D.*$IAGZ\2(MPK\A96*N0ATIWH[(H;;;UMYS=1XV23W80B7I1'JT4+/]H(
M0)*4H, QS2XU:W[-@.XRS:&/J@:#%HC#.#EJ+[N W6RG8 I6)6W_\Q6SPX.F
M^H#?>8PDX^KWLDR2^QYF#J EX6R!G9\-,G?%K6L,S27"$49J6(AA[K$]#1%&
MEA>NHHV%924F!/)*T6,[)?.<[Z+/)]AA 3%$/P_. 56=6")WR[P8@2DV49:;
M=#W*/LAD<K!)MR$\[=Q^@@-E/9 :V98S7/WLH_8W^U9#R<,U^JXE3?Z4/;Z\
MO'B2-E]IH]FM\^/%NN^@=@-71OMC.Y]+1IJ;EBGM5'EL/8HP2(QU)-\5)%-D
M4M8([I=V+>SP<"3QR\U C$@3GQUG9;Y5F,9)[37S6.GF-71(4ZG,2 61<YPE
ME^4+3D)P\,J*YZO+ZK8TM>.)^IX=5RI5>[/ODMY*.[=H_^IV;T'ABB.[;?#S
M/_GU36*N\W#J8N!M>#OTD$4(&".5[&+,7?@Y^IZ0 R.GC+8 %1M:(LK.ETFJ
M3$+&E*C)7=D.;&&W74O]PEMFB3[6"/J5\*VN+(EWN1J<QKR23AA&OK$"VKHJ
ML?%D=U%HB;"+.;)W>23 BR6W9-P:W_]A-?V\6]TZ]M6MD)[%O)R+E&$X&8)B
MRX']X5T^OWC['Q=GV5__<O+U\^^S2?;VXNK\]57ZP_O?SMY]N/@Y_G+VZI_O
MZ,</K_U/T+VKUR\OWOWS7?BI35)+9-[L3/S>.T(SV9<"7OY-PN7C@FC2@RS9
M5L&7*;FQ%\TEG32=B"'@!IO #P849H3H4@B_!XP,A 3G>"HNG$B*<.P(HAWS
MLA9:-&)*U.M>[>HC/AN0KGFIK<4)7E>IA"&+U'!9 -8G-L5XLKPC4+%"A3WH
M2#1Q4(G(&=?L94.K54(.Q(%8U6_1- 22FM#\)OW Q H&1>SNO<N"_,,G$R6_
MR*X-\AF^P9LER1LJ?3'["6:ES;[[+&G*-:L(%/X@HS,9-*NG:0+_M0Q(PH9V
M#YJGB[%[Z)_;&YH,VRM'"8[$'!,!&XY?AC'P2-3#['8('_!,#GVAZ:\V<YL0
MZ+\/^5D"^5H #%4A/I34B=+&9*PW=W[:L83+9JGK(6%NS)RD%N--QBG,47(R
MR6/XF*#TKCS0ZS4A;"$)D=8V%KU(C;<0"O#D+$H\;9#VF1'BS9M0D4BT:[^A
M?BBN0*("+=ZY" RQR:Q]8+^SX6^#=;GT;/D.AZ3N^U+"?@68L5W0]]@1^(22
M[LMU;4)L'M/+VWU6+IY/P=E"T'!+6-\7GI/]4D'>B9PGN_G'? 144-G,J[0E
M<M#3IG)5^OR.1#"5$>P&J:WZE$&AXY&[U<"_?0L3I,I'$>@W+^R](D+A/,5(
MH;LUCX%2V_4EH)*M@M5N4B"8!%&"%+ X;;/ECL11EER&5Z2HRL3-':*5Y%MR
MSFGZ1K3"-D6_0CQ:2&TD!JH;34'KYL9^RWT;$ZMYZD,$>,K;=K$0*,*U_)C<
M+MV=HS([=MD]#/,M%T\?$L?/^ A?;!<)$L+?I\<Z\JY8'O5K^<*O+1Z'"7(D
M!<(04Z>BUM)0+<?IA\VV9NVT(5?2N'?RXPZFCNRF:CN:(,Q!=?*QG>_Y0/_F
MG:X\S1'LN.]1-FK_SE^ER9]7R7#7OB0B?MBW-@\LM[OK5.Z(M?EA5[[?Q7!(
MRYF/#(T0"]$B-H-<U4FW<>5*4TUBVCP</ &'Y]*GOW#HTN3DH*Z,&_5B]U62
M[;I5*,#>QYMFG]FX@VFO-7E[=8@IT@/H#QOS&8"\E:/!C78?)O@XEUXN]>ZI
M.XUE'!G19_U<W\%LAS5.DA:=NDQV#TO$Z7CY?M"&=G!'/82]H]@J?4RQ<CNN
M8::Y]VYIFS*4FK0_\&!%]<T#)_> KZD9@NZEA,8@<+<2PZ5M)WQZ>E-G0#.2
MN\)AJ$'9U)=?(N'<Y^+S[O>Q;Z>$G&L*=2@@"0,FR;Z.></([N7;ZZ \3:FA
M:;N7;!>MR+@<<:"\/BA'L.\9#AM,@K;+JH?UM>Y487X/).8<,S2]*7?: 7U,
MHS(9NA\'C5DI%Y7C<EQV($V2^HHM.AR*J"*W9EQB2!):M5DXQ043.?6C_;IJ
MDO5,?VC)&W;+]#5,5VC'E-/?:B?I0>F0G[D<)KS3E'&K;8AP@-I5$R2 .3JT
MZ%Z1V)1+ZA\@>-Y7%+8U)"W^1>3LM3=9BE?KRH2#/;X2=HC-H^Y6V3UOR&*=
M+40:Y.Z;#LY:''LXYH+\:(A21]UV2' 22MM&RQN%H>SC*:1[Q_]<8CF'*S9!
M\K?S'=(&J8!(U@/E,.T]46K"<:#!R')D8Z@#T6V/J(0[77,BDS<V05)>J3HY
M*!/>$+-PF,O^O60JZ1$.1/HW$M$*.$82Y!?)69H!C-U?>X5KU_R/5C0&,& D
MD(%K'@Q(%4@;A,:'S^4@'/>UZCFDY+1<9[D Q@?#VBZZW_^AG=IM$1ZU6?P_
MM%<>K.R-_/=&"@S=/\O,R8S[;!:)UR+:E+U'> 0X#,_&QU@AE-'W!M%1FI:A
M1"%8G8=&R-KV.(MCN4$:UW99N=N#<Y"Y/[D(=BM)7.7 B=)9'-Z(XR8$2S(J
MUR+EC%;Y*(E!CH.+ +,MISRMRG*4N'YX=\36FJJ,I^5VZ7:A J*"-C!$FKWC
M428^M!T2I^ARHMGO<%J*=UVG'U^7A-9=3!X.+(8NF0&/F4#1WD-,&5B) 3[Q
M^<_ ::3/9 0C:]EH[FZ#>MP,"9RTNO0O$169L8^N>U*WJ38-SA:$XB!C59E?
MNJ:&JJ ><1&/1PZ/I:1G*_F *MF;/P_HJ_JG]+C@0#*"<0_FB7-3@VR7/W$Y
MR-2F77\[,Z<N8:C0XV38GD1/Z!V\PSXPZIGL%-K$%(JQETNXAL.&,)$U>7AQ
MA$XGAQTDL,2S(&L[YXMY0%F<Z,S!C8?,(H+M*HFQ\]UE\\86^=IVTLN[E_S=
M<%><)"XCF2&D%N)Q1)TIQC?:L/*0"&98O_72K@9<*BZETJ!G0Y0S*47!(?**
M9KX4GVB('CJ0<P')^>&0PU8C"RR1M)8ES9_I9TE:<) %[T>7:R7),T3,&[S@
MCZSG@BIP1087Z3VQ&$&_'MZ\@_T,"2$MH0=;+<4\D<'D+IW[ [)V=[YH ]6$
MA[J5[IM??*L'?KPE'D#F8/O8B_F4%4M2:?P?W#G7(D,UN#-G<*#<G__N<!Z<
M<W0/6)'"5@#/]&3W!1^C\8#@+)[A?\^^^EQ.5A*)'SA5RL)W*4%^]K[._D[Z
M!6QT\MP75S&/!-]O7IUE9S613GZ?3-LKN(]+7]<_*V]MBU3ON>]IDI0/7KK.
MYT8/;EW!A[R-UQO$MTM;AB-KJQ4P3TP:"VQ\1_.#\G<_?[@Z.OGF9/<Z.00K
M96,VX75A8,&U#R^6=6SZ']V?QA*H&8_1X!Z_WW,.3XK1F\;QY0CS[(N3;Y-C
ME9"OL0%*8>?PQ-Q\6'.<(;,K%C\R $?R$"^%M-@7IU].OQQ.F#1W<^@0^Y0P
M@Q19B:2JTFH&-B30=@"NA\-^WGWP_8UR'CDDR6)W96M"_,!L' II<M&$KX!Y
M(>VBD.J^9'R+HK9#'K@>)%P*@M'?)\>]+N3.I0_Y)V+DF\\^6SG1E!D/TN6?
M@C&/+/69=BDOYI_\*5M\H42G-\XEMU@EUQ3V E+YO*:DZ?@0^=R4W.1*X-GP
M9H,$9=[HKD)_K]+PW@/CCUSCZ!#B!E0@M)K$=JZR-X9O0238C1\#,O=54^\3
M_6U+4]P*5,VS*[/0CENY!4'[U"H].$[#R1DG+G+P%TWZ1;Q$PE]0<WWT+'N,
MF7D#]DP2]O@)QT8X01>O][GW6CL?7=$&\NDZVAK9<YKNN828]TZ<+%(NP1./
M[N]?F/ A--8);AU#@8OBDIXUN%]+3QC%JPM47KOX76RT_>+9\?'T.%5F*">S
MRQ4W4&0O"/H#'QT>'0+<,#04U4O/L,9K(B23+A>*Q/-*$ZX5TYS1P<_T*P0(
M?,!.P)OO]@$./SW^/N^.B U'<A<E_W;RO?9=I,?\(!)RL=G@BH@0OVM;/,$4
M*67KF?E)]LLOYR(9K^7S5^GG9_[S)]/LG4MY$2\P8'ICA'[_/JN=N'.^Z;ZK
MAI\FUT*3&5_PY=>MM$3)#='AU\S?KWTFUTK'U^5R;I+.!6YYJ,R</CV>?OWE
M(^ER\G]T;LV73,]<U[D5_Q-%"]/@!7J.JQ;]'Y@@W#K^XK\!4$L#!!0    (
M .*@IE*B?O0+E00  *8*   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MM5;;;ALW$/V5@6H4-D!+>]>N:QN0[20-D"!&7"</11^HW9&6-7<IDUS+ZM=W
MR)5D^=H62!\L\S)SYLR-.\=+I6],C6CAOI&M.1G4UBZ.1B-3UMAP,U0+;.EF
MIG3#+6WU?&06&GGEE1HYBH(@&S5<M(/38W]VJ4^/56>E:/%2@^F:ANO5&4JU
M/!F$@\W!5S&OK3L8G1XO^!ROT%XO+C7M1EN42C38&J%:T#@[&4S"H[/$R7N!
M;P*79F<-SI.I4C=N\[$Z&02.$$HLK4/@].\.SU%*!T0T;M>8@ZU)I[B[WJ"_
M][Z3+U-N\%S)[Z*R]<D@'T"%,]Y)^U4M?\6U/ZG#*Y4T_A>6O6R2#:#LC%7-
M6ID8-*+M__/[=1QV%/+@%85HK1!YWKTAS_*"6WYZK-42M),F-+?PKGIM(B=:
MEY0KJ^E6D)X]/>>F!MY6\+&]0V,IW-: :.$SUS=H^50B7&'9:6$%FN.1)9-.
M<52NX<]Z^.@5^!@^J];6!MZU%5:/]4=$=<LWVO ]B]X$)%Y#B$,&41"%;^#%
M6_]CCQ>_@O>>"PW?N.P0+H0II3*=1@._3Z;&:BJ9/]ZPD6QM)-Y&\G_%^ ?"
MPU9:/)9N'J3-5IK132F[2K1S*)TBWG;BCDNGQ(!K!&Y@IB2UMH%]0K&UZ@RA
MFX,C>&>LH+;!"G:"S*WC5=;;',(%EMA,46].@@>*3TW"'H1IP,(L<:LB9T6:
MPE6MM#VTJ)M'+N7YF(5I!'D6L2()X9-JY\^EBHP%10QAG+$LB^ W9;GLS?[;
M$#DF+(QCE@1%OR9>:9K#=USK.U4IR(N*04V/!-QV7 J[HL=C:G>0AO"ETT]M
M/I'Q,3?=]$]ZU, JDB"7G U-@08MS,V0G' /A6C$7TCY0,#[A:]JJ"C^I,/I
M+:SN4!M"JL7,\WN$0ZE=[I+?,;\4MJ8XV,U>S< N%:R0:]IHD&B,#YW['ECZ
M TY8[F6D,N!DE![ZC?[*::L6O?9&>0@3C_JD2!SDLT*A"I32@U#<Y(OYK7FU
M2W>*=HG8>JLNV LJ'2I?H1S*?TM[WQCXO.S_L;PG#5FEY%1PKBC '[2BF%VW
M]$F5_O0#A<T\/_Y$>S*WTTL[RW.ER1=7 ZVRV*=@JH@0E60:!BPE)GM$(:;?
M_7 <'JS/L\R=9-0K25;LH)2J:5"7@KIAP1?$/AGG+$ERB%/83TB]WT<.DB7%
M&+Y,I9AS]Z'UZ;L>7@UAKBCAK8LC4-K;TH4M87D>0 (__Y1'8?2+WR<0L3B/
M8'+'A71Q/J1AX]!0SS]*Q1X41<SRQ+593)U-GA#$P?J\R/OV"X*8Q424OCNX
M6N<.9IT+11C%+ O&$(X+%@<1G"/E829*5_*.=(74*,)"SJ(T@8)E4=R_16-J
MZ (R%N7I#WTB)O:EHG;5//?9[QZR/_=%X2S*O@ZLXT$7>^$PI'Z7TL\X=+\7
M#*/- :.YR2S03SYR-7SI6S;:F1THY7,_(1DJ@*ZU_1BQ/=T.89-^]G@0[R<X
MJORY8REQ1JK!<)P.Z$GR4U&_L6KA)Y&ILC37^&5-@R1J)T#W,T7%N]XX ]O1
M]/1O4$L#!!0    ( .*@IE(&:R G!P0  /P(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;)U6WV_;-A#^5PY"'SK M60YOQHX!I)FQ?I0($BW]F'8
M TV>)*X4J9&4E?2O[QUERT[19,->$HJ\^^[[[HX\KP;GOX8&,<)#:VRXRIH8
MN\L\#[+!5H2YZ]#22>5\*R)]^CH/G4>ADE-K\K(HSO)6:)NM5VGOSJ]7KH]&
M6[SS$/JV%?[Q!HT;KK)%MM^XUW43>2-?KSI1XR>,?W1WGK[R"47I%FW0SH+'
MZBJ[7ES>G+!],OBL<0A':V E&^>^\L<'=9453 @-RL@(@OYM\1T:PT!$XY\=
M9C:%9,?C]1[]?=).6C8BX#MGOF@5FZOL(@.%E>A-O'?#;[C3<\IXTIF0_L(P
MVB[+#&0?HFMWSL2@U7;\+QYV>3ARN"B><2AW#F7B/09*+&]%%.N5=P-XMB8T
M7B2IR9O(:<M%^10]G6KRB^L/=HLV.O^XRB/!\68N=ZXWHVOYC.L2/CH;FP"_
M6H7JJ7].-"8NY9[+3?DBX$?AY[!<S* LRL4+>,M)VS+A+?]-&]SJ((T+O4?X
M\WH3HJ=F^.N%""=3A),4X>3_9.\_NL)A)1TU>X@!7 6Q0:B<H4NC;0VOM:4=
MUP=A5?CE$BA5LIER!;<HL=V@W^\4<"\&:I.(7@L3X!4L9F]I]Q64LY.RA"]T
M4]YH^Z;S3F((L%C.BHL2%L7LO%C">VTU=92"VCE%A[.+XHP<%V?G\+N+PH">
M&!/P&1U?\.)T5KXE:*2XMJ\HPYSNZBG6P;/OTJV6J+O(>BOM6^AZDD5W#)Q7
MZ,,,2"X,C/CX!%6BC_3@$!PI;%%I4IJN_[&H@WQ&F:#]D\SPC59 5*9S>NA0
M"JY"Y5T+KO=4%V/$QGF1'I).^&B)W9RU:BM-KQ"4)J]X )[M=Y+C*.2@@$OJ
MMN@;>D8AZ=BGA>T4LBKJ%PH<(I,3G)X02=ULMZ+WE;GKP'Q_T,08R2ET*'6E
M)6A%\+P:%1P<?\P9NSXM65*Y%:;'8Y8Q]2<U)_4<%6_DZ<'2%*'18/0WL3$[
MMZF(@]=4)>4&R\\FIN>8G? AA3Z@1_=3H$.M&KHDSI,:0\X=J48K$Q3)^)N
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MM_T"'TG-/JXU!*=P2[ZB+12B3@E86Z  @I^9+I;ZUPOA02*+5X<K![1KL=4
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M^\JE)J2Y95"PS'+NZIZ$JF0GP+4*OS77SLMOR)]#HQ:)M+1S*!$EBP0AM*#
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M,N>2V?EB<7KS\?3#S^^?=M$FX925,GX450&=G.= QAB0XV<$>Q&3>^$D_X/
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MV!2:5*SKM#=+$1!&-V[>5L&DZ,_]H%(N2 -:@UN2F;=',JE$*P;T3,?L"?@
MT("*$%\#CAJ"7+;<\/G$8D4)[YBO]$4G#V=V;[9(5PHGL.5KE%;+ -F^KOOI
MFP_2(V0:+*7^Y+,<+@?PYW!P)5]"#&[%^M><CI](0/U-K7%1DW+#P'B8>$.1
MZPZK:3S/:7HHI#_.0$].5*24_$;Y'OU0;,3C:#TW9?U-_?/W +>+:KL7G,U-
MWL(1D&989FFL8_DJG*(N%$.^WR7?\1FYC<B11-L9T@48-IIONVO+G:YB[-;9
MAU/G8:0)$(*_@6"XXT=*34DD$R0Z)5\J39H*DN6';?R"$58RT.A-D@;%<O!H
M$ZEQ.$.[^WPX7VH>(SF<7;9/,(0KU$'D/UK)#B\FYT,.8U;N@^[>8+&K6T_,
MQ\9[NU#)MG@'D&'(L_M8QD,/%-#WCRH_ZDX YWF]6N_,,JY3NM5<K?==K'<=
M;B3AABZ>G@9I?2[:SZX#DGT_GD@?U2'X0-?]'VJP_[<::1ETA(E2N! >>6B
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M=S)1L4=:#TCI*T@9O%72-@:^DR66Y_H1L3I22P_4UNE%P+=,CR!+0DCC-+F
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M(+9P/,37"J1(.9@0@8NK8(T:K"(+"DFL#E+CR,W,=+?6FAFI5BO ->0&8&>
MZT"^@2&Z+=F8XCO9(H#8@']J/@>@2<](.>K( *W X(>)HEG8_.TO+T]/7GSG
M,^8$8P,R:P?;( ZO>O"HGHU>E&9B;YFS:6<Z4L=HYS+:%B#,K$*U]9[9 L+7
M-^#@<"86;=1_IY<(Q&]H'MOHX@A'/,8!N&% J>47,'X@%5ZV5:"@=YO""_H6
M0=ASM.>J1M]=7"..!8(_V0(?3(!=P#NA")>/YY#O(Y=2,F.@G'"@<)H^0[#
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M,>/L!/9W)TH>>AEOWN;7DB@W;S_S]WUZ#QZ(#CQ(4)H_V.R[LLVY#_"YYR*
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M;+2C?>J.)3U@:'P"Q7.MW<[P!88G<?474$L#!!0    ( .*@IE)\B\0_Y@(
M &T&   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;(U5;4_;,!#^*Z=L
MFC8)2)NV [JV4E]6 1I311G[,.V#FUP2"\?.;*>%?[^STX8R09D4)3[[7I[G
M[GP9;)2^-SFBA8="2#,,<FO+?AB:.,>"F1-5HJ235.F"61)U%II2(TN\42'"
MJ-7Z'!:,RV T\'L+/1JHR@HN<:'!5$7!].,$A=H,@W:PV[CA66[=1C@:E"S#
M)=H?Y4*3%#9>$EZ@-%Q)T)@.@W&[/^DZ?:]PQW%C]M;@F*R4NG?"93(,6@X0
M"HRM\\#HL\8I"N$<$8P_6Y]!$](9[J]WWN>>.W%9,8-3)7[RQ.;#X"R !%-6
M"7NC-A>XY=-S_F(EC'_#9JO;"B"NC%7%UI@0%%S67_:PS</_&$1;@\CCK@-Y
ME#-FV6B@U0:TTR9O;N&I>FL"QZ4KRM)J.N5D9T=3=3S#-=6FI$Q;&&<:T:\V
MW.:PG%_!(F?$/L;*\I@) TPFL&\R0\W7S.46OG&VXH+;1_AXRU8"S:=!: FD
M"Q7&6T"3&E#T"J .7"MI<P-?98+)<_N0R#4,HQW#2730X373)]!I'T'4BMH'
M_'6:C'6\O\XK_O;X7DIC=>6R4*?E I.,RPS&KM6XY6A@QDTLE*DTPJ_QBM2I
M#7\?0-%M4'0]BNXK*)9T.Y-*(*CTI0JXT,S"G'$-=TQ4^%(A#D9PTZ!O2BK\
M,*#K;E"O,1C=Y@BI$G25'4_KB@S^U*7 TF&<,YE1<"Z]F.PU2O($4S2-DFI5
MD'*,I;^D],QQI2N:#]".ZIJ!54!%C/.FBGVXS:E/GW5*S77MN#KF;[A\#Q_>
MG47MZ M\5_(X9B8'Q\)'<97<QXT/- $-0G04=<]@6NO&R$NB[.&[6W+::\'4
M<]]13Y_P4(W>3$3[J'=^_@^)YZP)=)>43N&E]@GW1D"!.O.#SD"L*FGK:=#L
M-K-T7(^0)_5Z$%-4ZF(# E,R;9V<]@+0]7"K!:M*/U!6RM)X\LN<_@>HG0*=
MITK9G> "-'^8T5]02P,$%     @ XJ"F4GS$9OOQ @  S@8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL?55M;]HP$/XKITB3-FDE$&C758 $[:I5
M6E4$;/LP[8-)+L2J8V?VI;3[]3L[D-*U\"5^N9?G[O'=9;@Q]MX5B 2/I=)N
M%!5$U44<N[3 4KB.J5"S)#>V%,1'NXY=95%DP:A4<=+MGL6ED#H:#\/=S(Z'
MIB8E-<XLN+HLA7V:HC*;4=2+=A=SN2[(7\3C8276N$#Z7LTLG^+62R9+U$X:
M#1;S433I74P'7C\H_)"X<7M[\)FLC+GWAYML%'5]0*@P)>]!\/* EZB4=\1A
M_-GZC%I(;[B_WWF_#KES+BOA\-*HGS*C8A2=1Y!A+FI%<[/YBMM\3KV_U"@7
MOK!I=,]8.:T=F7)KS!&44C>K>-SRL&=PWCU@D&P-DA!W Q2BO!(DQD-K-F"]
M-GOSFY!JL.;@I/:/LB#+4LEV-/XFQ4HJ24\P1R4(,R #"Z$03 [7-=4686Z>
MA"*)#MXOQ4JA^S",B;&]ASC=XDP;G.0 3A]NC:;"P1>=8?;2/N:8V\"37>#3
MY*C#6V$[T.]]A*2;]([XZ[=$](.__@%_=U2@A1T=/MDKZ5)EG&?@UV3ER'(%
M_3Z"-&B1!@%I< !IP8V5U<SP70ZOZ5]NZ6?AS!!JDD*]>HBW^#\.NBP0<J.X
M!Z5> _EG!.YBQP .3&T!'4DN<LZ;'YZY *%US=!2$[(>@6V$#\R2%RMNIF?=
MM44L@R^ALW#%-MP8'JRRQE48NN]_;[5K"LYB:M9:_D701I^DPA7/FOC( \CY
MZ!M@*A@+RJ::T%<3<"VD15L,(03>=#O\[24PJUG*C1ON [>37;A![:C"\AC:
M46$()?@/NYN7F9]X?4]?A5::;/<6[.&FK)1,);WD:I_X'%_QSAB=!-Y![W/G
MU"]GG2XOLSWF,<_?>@,8G ?5?K,TAF\5>;PW8TJTZS!)':2FUM2,F_:V'=:3
M9D8]JS>3GCE:2^U 8<ZFW<ZGTPAL,SV; YDJ3*R5(9Y_85OP#P>M5V!Y;K@S
MM@</T/["QO\ 4$L#!!0    ( .*@IE+3SA7>L ,  !$)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;*U6;6_C-@S^*X)7#!M@Q*])G"P)T+0[W( K
M5K2]VX=A'V2;B87*DD^2D^M^_2C9<=(V[3;@OE@B)3Y\2(J2%WNI'G4%8,BW
MF@N]]"ICFGD0Z**"FNJ1;$#@RD:JFAH4U3;0C0):.J.:!W$83H*:,N&M%DYW
MJU8+V1K.!-PJHMNZINII#5SNEU[D'11W;%L9JPA6BX9NX1[,Y^96H10,*"6K
M06@F!5&P67J7T7R=VOUNPQ<&>WTR)S:27,I'*_Q6+KW0$@(.A;$(%(<=7 'G
M%@AI?.TQO<&E-3R='] _N-@QEIQJN)+\#U:::NEE'BEA0UMN[N3^(_3QC"U>
M(;EV7[+O]D[''BE:;63=&R.#FHENI-_Z/)P89.$;!G%O$#O>G2/'\IH:NEHH
MN2?*[D8T.W&A.FLDQX0MRKU1N,K0SJP^4*;(%\I;(#= =:L ,V[(3P\TYZ!_
M7@0&G=BM0=$#KCO ^ W A-Q(82I-?A4EE,_M R0W,(P/#-?QNX W5(U($ODD
M#N/H';QDB#AQ>,F_1WS-=,&E#5J3/R]S;10>DK_>\9$./E+G(WW#QSWV3MER
M(')#COY\<JDU&$VH*,DG1G/&F6'HN\]\2?"8WD'1*L7$EJRI9OI< =[U;;MX
MKAM:P-+#-M6@=N"M'BH@&\FQ!2VRL<4E;E4@'2:ZYG9=DF/G$MDJ0H]<^0E7
M4U%#J )2'TBCO+$Q[EQ.+09VZR&(W ;A0)@H64&-@P#"80?<IL<*)^85 T55
M43TY&[MH]1TW T4EV-<6(?9 6H.4_D;_1F(;&E#8'8"72U&=X,TQY=;+C<4<
M3A'YY+P?QK@?$_(@#>5]E>;D2JI&*J1,A+2\+:-<BE*3"_+C#UD<Q;_@;!R%
M_F22G-4=$0I9UZ *AO -;4 -F]-IYJ=I_$K^/>=LZ^)V 7P>W8_(5NY "=>@
M>&&*PM9CL/.S+'TA82?"$]X6ZA%O]TUKF4=QXD_"Z;#Q,![T70;ZVE\,Z@LR
MFR7^+)L]"S/RHVCJCV>3T],\)]<VF[)Q/$M0;$?MS3N<HJ=G&,=9BDC38>SJ
M=@T%U#FFJR]=^%U+-\FF?CJ9G=7]A](E4>*GL^DK^?^6+O:3+'XAG2O==.8G
M8?RZ=+W^6>D.2END,$S\),U>EBZ+_<DX_"ZE>ST[=XD&)\\49G3K'F.-^6V%
MZ5ZL03N\]Y?=,W?<WOTL8#]O&::7PP9-PY%]7E7W '>"D8U[]')I\ EUTPK_
M64#9#;B^D7@N>L$Z&/Z"5O\ 4$L#!!0    ( .*@IE(>4EKOS0(  ! &   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U546_:,!#^*Z>LFE:)-B%
MRQ@@0=MIU=H-T6Y[F/9@DB.QZMBI[92R7[^S QG=6K:7Q';N^^Z[\]UEN%+Z
MSN2(%AX+(<THR*TM!V%HDAP+9HY5B9*^+)4NF*6MSD)3:F2I!Q4BC*/H)"P8
ME\%XZ,]F>CQ4E15<XDR#J8J"Z?44A5J-@G:P/9CS++?N(!P/2Y;A#=HOY4S3
M+FQ84EZ@-%Q)T+@<!9/V8-IU]M[@*\>5V5F#BV2AU)W;7*:C('*"4&!B'0.C
MUP.>H1".B&3<;SB#QJ4#[JZW[.]][!3+@AD\4^(;3VT^"OH!I+ADE;!SM?J
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M0*"L +Y?2VF>-_: ]J-J\AU02P,$%     @ XJ"F4I*MH^JX @  $@<  !D
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MN-E9"UD1;:9RXZM: BD<J&(^#H+$KPCE7I:ZM4>9I6*K&>7P*)':5A61[W?
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M!9!CP7;"/JC]7]@*FKAXF1+&_\*^G1L%D.V,554+)@85E\T_^]H:T0/$Z1%
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M-RYX;6S-FE&/FS@0Q[^*%?6AE=H-V,8A53;2=E?55>KVJFZW]W"Z!R=Q$E3
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M3<9C883<B4SG2CMUW,=C1;R< [OI>$S&X7@RW-7U:IOYGD<(#2N[1KY!E6\
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M((I[1[%0/+-']Y0K?1&PCXF^JX$P ?K]G'.U69@$U>VO]P]02P,$%     @
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M,.1SYOE*(UWXLNW@FT2L[!P:-8!)@1*Z7_GS< ][ .(Y#$@'0/H2,#T"R 9
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M(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$
MA:S)?Y+U7>O57_]+:->X5F5S]&?=#YOY)U!+ 0(4 Q0    ( .*@IE('04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ XJ"F4M:[N\[N    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ XJ"F4IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #BH*92,N%R@48%  !V%0  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ XJ"F4BZJM2V\!@  7QL  !@
M             ("!B0T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( .*@IE)/Z.#\SP(  !P)   8              " @7L4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #BH*92W8U#4<4%  "]
M%@  &               @(& %P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ XJ"F4CKI6 W\ @  9@@  !@              ("!>QT
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .*@IE(;\LH?
MJP0   D3   8              " @:T@  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #BH*92Q[!A]G,'  #%'0  &
M@(&.)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ XJ"F
M4E\,6]YL'0  @5P  !@              ("!-RT  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( .*@IE*B?O0+E00  *8*   8
M      " @=E*  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*@IE*U(9Y"0 4  +$-   9              "
M@:ES  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ XJ"F
M4N#G5&W@$   (#0  !D              ("!('D  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #BH*92<$)7V= #  "]"   &0
M        @($WB@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( .*@IE+*]2\)4@,  $@(   9              " @3Z.  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ XJ"F4M3O[WK<&P  SUH
M !D              ("!QY$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #BH*92^@?AZ.D#  !F"0  &0              @(':K0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .*@IE+U+W=H
M;@(  !X%   9              " @?JQ  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ XJ"F4GR+Q#_F @  ;08  !D
M ("!G[0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #B
MH*92?,1F^_$"  #.!@  &0              @(&\MP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .*@IE+3SA7>L ,  !$)   9
M          " @>2Z  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ XJ"F4AY26N_- @  $ 8  !D              ("!R[X  'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #BH*92(UZKLYP#  !)
M"   &0              @('/P0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( .*@IE+20]X*2P(  /8$   9              " @:+%
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ XJ"F4IQF
M@6/+ P  8 T  !D              ("!),@  'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " #BH*92DJVCZK@"   2!P  &0
M    @($FS   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M .*@IE)Q7H:E'0,  !P*   9              " @17/  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ XJ"F4I9PKCC?!   WA8  !D
M             ("!:=(  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #BH*92%H))]V("   L!@  &0              @(%_UP  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .*@IE(:[)5(. ,
M  D+   9              " @1C:  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ XJ"F4EKM-?C^ @  6@<  !D              ("!
MA]T  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #BH*92
M^4LEK3D#  !Y"@  &0              @(&\X   >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( .*@IE(#H?F.P0(  /P(   9
M      " @2SD  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ XJ"F4J99Q?H] @  &@8  !D              ("!).<  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #BH*920%57@.<%   S*@
M&0              @(&8Z0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( .*@IE+F'::^]P(   D*   9              " @;;O  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ XJ"F4EZMZ3BB
M"   GC4  !D              ("!Y/(  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #BH*92)T QDT\#  !8#   &0
M@(&]^P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .*@
MIE+E_GI*+P,  &$)   9              " @4/_  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ XJ"F4K;?7-A> @  7 4  !D
M         ("!J0(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    " #BH*92/<(Z5R8#  !N$@  #0              @ $^!0$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( .*@IE*7BKL<P    !,"   +
M  "  8\( 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .*@IE*P3DA@F@,  ( <
M   /              "  7@) 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #BH*92OLLS09D!  !U&0  &@              @ $_#0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #BH*92(]5N#:@!  "X&0
M$P              @ $0#P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..,@ R )4-  #I$ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>158</ContextCount>
  <ElementCount>289</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2334308 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetail</Role>
      <ShortName>Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/FairValueMeasurementTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktr-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20210331.htm">nktr-20210331.htm</File>
    <File>nktr-20210331.xsd</File>
    <File>nktr-20210331_cal.xml</File>
    <File>nktr-20210331_def.xml</File>
    <File>nktr-20210331_lab.xml</File>
    <File>nktr-20210331_pre.xml</File>
    <File>nktr2021-03x31xexx311.htm</File>
    <File>nktr2021-03x31xexx312.htm</File>
    <File>nktr2021-03x31xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 158,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 365,
   "entityCount": 1,
   "hidden": {
    "http://www.nektar.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 56,
   "keyStandard": 233,
   "memberCustom": 26,
   "memberStandard": 24,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Liability Related to Sale of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Fair Value Measurement",
     "role": "http://www.nektar.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Net Loss Per Share",
     "role": "http://www.nektar.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Liability Related to Sale of Future Royalties (Tables)",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables",
     "shortName": "Liability Related to Sale of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.nektar.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334308 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.nektar.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "ib8d7a648bf34494885032023666dcc3f_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Details)",
     "role": "http://www.nektar.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e4e93387c65485f981f8737f196c2c6_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "ia56b311eba0f474c8c9f8effb8942bdf_I20210212",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "ia56b311eba0f474c8c9f8effb8942bdf_I20210212",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i0589fec22d0240d48c2ee8a46b1e6051_I20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i0589fec22d0240d48c2ee8a46b1e6051_I20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i15fe85a66b97435c972422f93be257dd_D20120224-20120224",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
     "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i15fe85a66b97435c972422f93be257dd_D20120224-20120224",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i5e59b36c2fe3424182d60321158f496d_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails",
     "shortName": "Liability Related to Sale of Future Royalties - Estimates of Annual Interest Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i5e59b36c2fe3424182d60321158f496d_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i0ba18dba9b8242f69de0a47836b3bfaa_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetail",
     "shortName": "Commitments and Contingencies (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i0ba18dba9b8242f69de0a47836b3bfaa_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i20cf135547944cf582acc95627b3f1ac_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Fair Value Measurement (Details)",
     "role": "http://www.nektar.com/role/FairValueMeasurementDetails",
     "shortName": "Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2e6af6053ea94cd9a9631c23a09ca612_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "License and Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "idcfe2d433ef840c286c01d47b0c5f9d1_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - Net Loss Per Share (Detail)",
     "role": "http://www.nektar.com/role/NetLossPerShareDetail",
     "shortName": "Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i386d9920ac3f4c3f90e0ba684ea52a35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i386d9920ac3f4c3f90e0ba684ea52a35_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20210331.htm",
      "contextRef": "i2a4c7399429f43a495d637c3795d6023_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 56,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing expense current.",
        "label": "Accrued Contract Manufacturing Expense Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborationPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration partner.",
        "label": "Collaboration Partner [Member]",
        "terseLabel": "Collaboration Partner"
       }
      }
     },
     "localname": "CollaborationPartnerMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborativeArrangementAdditionalIndicationPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Indication Payment",
        "label": "Collaborative Arrangement, Additional Indication Payment",
        "terseLabel": "One time payment"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalIndicationPayment",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, First Indication",
        "label": "Collaborative Arrangement, Success-Based Payments, First Indication",
        "terseLabel": "Success-based annual payments, first indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndication",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, First Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-Based Payments, First Indication, Period to be Paid",
        "terseLabel": "Installment period, first indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, First Payment",
        "label": "Collaborative Arrangement, Success-Based Payments, First Payment",
        "terseLabel": "Success-based payments, first payment"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstPayment",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Second Indication",
        "label": "Collaborative Arrangement, Success-Based Payments, Second Indication",
        "terseLabel": "Success-based annual payments, second indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndication",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Second Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-Based Payments, Second Indication, Period to be Paid",
        "terseLabel": "Installment period, second indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CostOfBorrowingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Borrowing",
        "label": "Cost of Borrowing [Member]",
        "terseLabel": "Cost of Borrowing"
       }
      }
     },
     "localname": "CostOfBorrowingMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DevelopmentDerivativeLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Derivative Liability",
        "label": "Development Derivative Liability [Text Block]",
        "terseLabel": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability"
       }
      }
     },
     "localname": "DevelopmentDerivativeLiabilityTextBlock",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated annual interest rate over life of royalty liability.",
        "label": "Estimated Annual Interest Rate Over Life Of Royalty Liability",
        "terseLabel": "Implicit interest rate over the life of the agreement"
       }
      }
     },
     "localname": "EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment And Other",
        "label": "Impairment And Other [Member]",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentAndOtherMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Equipment And Other Costs For Terminated Program",
        "label": "Impairment Of Equipment And Other Costs For Terminated Program",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Equipment From Terminated Program",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LegalMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters",
        "label": "Legal Matters [Member]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20210331",
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions",
        "label": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds",
        "terseLabel": "Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties"
       }
      }
     },
     "localname": "MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358LicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 358 license.",
        "label": "Nektar 358 License [Member]",
        "terseLabel": "Nektar 358 License"
       }
      }
     },
     "localname": "Nektar358LicenseMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar three five eight.",
        "label": "Nektar Three Five Eight [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "NektarThreeFiveEightMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarTwoOneFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar two one four.",
        "label": "Nektar Two One Four [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "NektarTwoOneFourMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Policy Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement if threshold is not achieved"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Development Milestones Excluded from Transaction Price",
        "label": "Potential Development Milestones Excluded from Transaction Price",
        "terseLabel": "Potential development milestones excluded from transaction price"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestonesExcludedFromTransactionPrice",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_ProspectiveInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prospective interest rate percentage.",
        "label": "Prospective Interest Rate Percentage",
        "terseLabel": "Prospective effective interest rate"
       }
      }
     },
     "localname": "ProspectiveInterestRatePercentage",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockValueAuthorizedInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Value Authorized in Transaction",
        "label": "Sale of Stock, Value Authorized in Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueAuthorizedInTransaction",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Revenue",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales milestone revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule Of Liability Related To Sale Of Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs related to sale of potential future royalties.",
        "label": "Transaction Costs Related To Sale Of Potential Future Royalties",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "TransactionCostsRelatedToSaleOfPotentialFutureRoyalties",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_WriteOffOfPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Prepayment",
        "label": "Write Off Of Prepayment",
        "terseLabel": "Write off of prepayment"
       }
      }
     },
     "localname": "WriteOffOfPrepayment",
     "nsuri": "http://www.nektar.com/20210331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r281",
      "r282",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r275",
      "r276",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r229",
      "r230",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r344",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r229",
      "r230",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r344",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r148",
      "r217",
      "r218",
      "r345",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r148",
      "r217",
      "r218",
      "r345",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r220",
      "r229",
      "r230",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r344",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r220",
      "r229",
      "r230",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r344",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r17",
      "r151",
      "r152"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r50",
      "r51",
      "r52",
      "r364",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r97",
      "r98",
      "r99",
      "r280",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r231",
      "r233",
      "r252",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r233",
      "r244",
      "r251"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r153",
      "r167",
      "r169",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r131",
      "r140",
      "r146",
      "r165",
      "r275",
      "r281",
      "r299",
      "r348",
      "r362"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r42",
      "r93",
      "r165",
      "r275",
      "r281",
      "r299"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.nektar.com/role/FairValueMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Debt securities, available-for-sale accumulated gross unrealized loss, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r158",
      "r175"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r155",
      "r159",
      "r175",
      "r351"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/FairValueMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r157",
      "r175"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r157",
      "r175"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r30",
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r88",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r192",
      "r352",
      "r368"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 182,290 shares and 180,091 shares outstanding at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r66",
      "r356",
      "r371"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r119",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized in period related to performance in prior periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r228",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r345"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r86",
      "r186"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r43",
      "r44",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Counterparty cost of borrowing"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r106",
      "r108",
      "r116",
      "r166",
      "r205",
      "r206",
      "r247",
      "r248",
      "r249",
      "r265",
      "r266",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r287",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r290",
      "r291",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r227",
      "r228",
      "r287",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r227",
      "r228",
      "r287",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r287",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r168",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r184",
      "r185",
      "r347"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r131",
      "r139",
      "r142",
      "r145",
      "r147",
      "r346",
      "r353",
      "r358",
      "r372"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r107",
      "r108",
      "r130",
      "r260",
      "r267",
      "r268",
      "r373"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r91",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r200",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r129",
      "r308",
      "r309",
      "r357"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r79",
      "r83",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r182"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r40",
      "r91",
      "r115",
      "r180",
      "r181",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r182"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r182"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/FairValueMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r93",
      "r141",
      "r165",
      "r276",
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r93",
      "r165",
      "r299",
      "r350",
      "r366"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r93",
      "r165",
      "r276",
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r57",
      "r64",
      "r87",
      "r93",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r131",
      "r139",
      "r142",
      "r145",
      "r147",
      "r165",
      "r299",
      "r354",
      "r369"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r139",
      "r142",
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r96",
      "r125",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r47",
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r61",
      "r65",
      "r205",
      "r301",
      "r306",
      "r307",
      "r355",
      "r370"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r75",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2021 or December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r77",
      "r246"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r74",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r57",
      "r80",
      "r93",
      "r100",
      "r107",
      "r108",
      "r131",
      "r139",
      "r142",
      "r145",
      "r147",
      "r165",
      "r274",
      "r278",
      "r279",
      "r283",
      "r284",
      "r299",
      "r358"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r187",
      "r367"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r14",
      "r349",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitment, remaining minimum amount committed"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r255",
      "r404"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r206",
      "r250",
      "r365",
      "r381",
      "r383"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r106",
      "r108",
      "r166",
      "r247",
      "r248",
      "r249",
      "r265",
      "r266",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r138",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r216",
      "r217",
      "r345"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "verboseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityNarrativeDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r233",
      "r243",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r233",
      "r243",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r238",
      "r240",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r235",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, RSUs (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r232",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r97",
      "r98",
      "r99",
      "r101",
      "r106",
      "r108",
      "r116",
      "r166",
      "r205",
      "r206",
      "r247",
      "r248",
      "r249",
      "r265",
      "r266",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r116",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r206",
      "r234",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r93",
      "r154",
      "r165",
      "r299"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesEstimatesofAnnualInterestRateDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/FairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e13051-110250"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r405": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r407": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r408": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r409": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3505-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000906709-21-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-21-000008-xbrl.zip
M4$L#!!0    ( .*@IE+4DY =#4," %0.$P 1    ;FMT<BTR,#(Q,#,S,2YH
M=&WLO6M7&TFR+OS]_ J]['/VZ5Z+PGFO3'</9]$&/,Q8P@:YO>&+5UZAL*1B
M2A*W7_]&5DD@,-A@!)*@W#,V2%5961D13SP1&9GYY_\[ZW8:)[[H9WGO'TMX
M!2TU_M_JG_]?DOS/7SL?&NNY'79];]!X5W@]\*YQF@T.&U^<[W]KA"+O-K[D
MQ;?L1"=)><^[_/B\R X.!PV""+[Q9?%6(<<4DC)ARJ4)$UXF)C"?:.TX"YXA
M%=SRP5O.4BM3HA/J-5RK TX40C0)Q!-I&-6:^&7WUC/L%$48,R$9@;^"9C9%
M3FF#*'(^/O9P &\';]CKOSWK9+UO_U@Z' R.W[YY<WIZNG)*5_+BX U62KTI
MOUT:79J=#9*^M]<NAM]7#O*3-UD/KO1Q<-X,"MWKA[SHZ@$,WAN",$^03"@>
MM7/WPV*WQ@_K%X/+"X/NF_(R^!#:(RA!^*H]Z->U)L],T2FOAB?3B8Z-+Q_V
MDP.MC[]O??3%;4_HYXS@]*['('A,=<7XAN\&]?K5\6NC^WY\>?PV^U'KO?Y
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M_9#W#MJ^Z&[U3GQ_$+&[J0?# DR]0N\92[F5J:[M;O:VCSY?--NM0VB7M[[
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M[6<6OY#95D%E((9S9 **I_)J+BEP8R-E+(D3;*'+4FO=?2[=G4E5KG:.6FT
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M>F,4YUPOTI["<R_@F5BP%$0CX[D2J8M[;AI@53P0!6!,&!7^I5GP>P_<1W=
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MDKZU=^WX-5:471NB>_/PYV$:]Z.%FWG1&!SZQG_&=M:H(OP&!/[>39^#3 #
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M^WXPYO+ D^5(NJ Y("EQ8NB@<5#DIX/#\=<KP,%\V3?G0]8KUUF6,^=Q/HK
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M&!E+;!G,P.7EL&4QVB@!=GA<7O5C68$V6W\\B$T7_C_#K*@0IZ-/2[TZ/NX
M%$;S&WG@J HKD:?&FZKQB?V)E@/!0&6UIUG?CULK97LOQEC2!+#Q2SR+QV5
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M_[?X;2LNT<J'T$:<6AKM)@ADJ%K_^?O\O\"EK=S=U^M+Q,0=BE\>@7#%)0H
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MT^H*GAYT>C"R#Q50[B-;C7.^]_@@CB(HKYV$7M[0!,4-<3!J'M5S6N]SIM[
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M;3W?V(<_]O;AU_;FSOY>9_<%O+3]\M7FO^%]6_]L=O[:W6O_??VR-0"C,9S
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M5$*!S S05FX)04ZGA+"31DL) B9R;=UT]2K:T[>(K]X_GI)3>ZHX&G?BUUP
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M.NP-ZFS6HVKXH;*')49R2RSE; 2WSFN;BW8W;<XD]:(:'NZ?".IE(Z<"<LN
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MH*7;=CQ=[*M@(O=W7Z&M1*0:PMH.H]RB9BZJEU6<]1C;&(1GMM\?[:;+8:Q
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M&B0DQ]@'O:QSR+:^24-K8 U44_:"]<X(%6O%>I4=MKU1A3/ 3H!6#U7]W)F
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M]$/%Q6S/0T8CYDLPK6*JB(Q2ZB4T\&D()R("%MX7SFZMLGA39.*TZ.3E9?'
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MNJ+9:(JISO>J3'?J*Z]N6L16\_ZB1()S2D5;<C YOL2FP"G9C(?MYE?N:2Y
M@/_VZYS?P=^7QR*)&<U(Z$KN$Y=XL7#3,/)<IB@C0<HY3XD^/ZNY]7'<RGH9
M340<A7X2<<+\((NQ)8T*%LG(BU/Z/:R'R:+I%JM?6_0>_!T>!S+(!*&9ZR4D
M@ -4Q(7-]ETADD3&8"6DRKM%]-ZKD_67!;V,-J"7:["6'PAZ^>QMIM@!9< 6
M-*A*5U*THL7^\!/:P]C"_P>.GOB5FTKW_SYF(DU\+XI=/XY Z(4L=$&'@3-*
M(AYDC!&19/<%,UHK_TU/]2S*L0('M] 8$*LD+JHY"S]5#VD8;P51_%*:/;VM
M,"._^F+#Y&%WW2SV6<@@V KB^S'8XW7AWET3XG]W_?I= G^J*?7I5< *3;W3
M+O",]?(=FWJOGH"?K$OW,8GR'BW0+ZO_>=M.>A$:?/M[6L@?I7_\96W>A[(8
MC9POPPJ)T/E \^'RXM7-)MYK$__2*)&;75QI%QO@C'MLW"^)]+!DAWZ%&ON=
MHKPH=*YN6%1C*%@!CN%]F&S3-;WIFO[.FA"2^B2,I!*8:9 IR3RE1!@&61QD
M22;X$S0M3-<TUU8.&CDZ?O9SU(&<_7W3'72O]@_.@\/@Z R><]G]VB5'9Z?]
MHP_=J\.SHT'W9B_J!4?GLW4@6#MR>/,NVC\XPE_!.VU?'=Z<#O8__'-^>/,^
M[PT.;[IGY^'1X--T [7TF9>2.'99QGV7$(^Z+"&I&PG)(L:R-,!\0^1[G2A8
ML6=J@QBQD7T;V5?)OI4$'.>3P43/)=3V=&-.HTORAP0YBI,0-E)O-:GG-QT=
M)%&9#*DKJ60N"5/ALE@2-U29H@%+8BKXJ[>A_UA=6AN)MY%XZ_3BKU^0R,,
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M69</!9#>;V&LY>X/YM] PY>,G5W)Y8#)TAQ"Z'<<Y,..4TQ*YP0; H&IJXY
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MSDVXA":1FS*)L#)9$'E$,!"IP'Q>)_%6;"U\G@["EQ='>I\/\]$I%E04Q2U
M9+?VL<R_]<\G:7ZDFJ_.Y ,>R4;2/%C27+?4O,\IC7"&21K%6"*0$3?S0?"0
M0 A&1"*"2&( )?7B1W(JUBA&LF'CYS 8-FS\6&S<& R1"E684+#11>2[A,O
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M;,#^::\/S]P]CWH'[Z[@]U[OYOSFF(,%QTG$X<P5)N]!S&4I3]PH(I(3HJ+
MGVN>HH'R8^K+B",A"C\38)7+6,DH4:FOXEF)N%.XK1-QMD]**?6?+O/QJ?/Y
M_9_.QU,*ECN7$VV0&<77OJ0Y1:<^Q@=T8MV]\.D7#8,L2:)8!!D%IDMDFK (
M_F%>2M*8A<G21J#U,@+WA\Y[R<H)!5'J!Z;U0<M,W94@T>8!24;AY=TI>5Z?
MTVN4;GA.]=&]67YV_V]OK^/\M?5Q"S79PE]\*(O)!4I+V(MKYS7\Y$T'E<)H
M0N%AL)3+TYR;FU_F_3Z8>&B@XA>KM![#2S(6L(3#ZQ(5>)3&09+&"><I@_,F
M5HB ,'*K/ZS<@VS0*AI[])O<+DLZ/-%[M /J(!^#YGP_&:(_LBX]QNL@>/SC
M3(6*P[:[7A9P'#09N2E(=S<6(<D\2J079>@\>EO+ZK&KGG2PV'FUU7H:&-KS
M+=5,D0!![0?_"H'S)N(:U3*3@PMY0OM"COIR<IY7MV'YT @,3=__(Z]!A E:
MR99'Y=X81<*=[/N[GEH!*_I-VV% 8K^CA'%#??6L#POOB3=XA5N4D-^?9-WW
ME#K.ZPLY8"6X$3>3 65OM-EEW"7\L3,&@U7CM>!Q7,";:20^O>T#.0:7#S[B
M:#,B9L4(S%1M<I78V8^MJ\[H/Q,Z*,"LY+*/L'Y@> UAU563HW;F4(\,)3^W
M$FQGY]\]9P>>KFWA _3/0)"=%D <X\F@*$=H(I9H77_<=?_RVU?M 5D9?^W-
MUD*A!BX<=4[Z!8,[:WNO+4HK68<Y,F,._]&'/X)9/D2-IN I7%OE1O5M Q6>
M@#,X/MURIH2W?YOP;GO%=%K'=C_OPAO [PUQPQ(_#-B_G=?P^1LMIJE2H%31
M;X?MZX(1>]YQ/L,;7CC_APXN?G=VB].!7"2D\<Y&2(,U"X[MAF6^AV7 Y1@6
MQCU$;IEH/\Q91KL.FXS-Y@^+,4@T6CI(9 7\OM0WJ3M^Q_CSK;O:>]?/<JE-
M@%,*IM]%";I7.Z2C"VQI-G9@[<[Q:G/TVZ)W1XTBKG9AT1XV[C8^AAG74]^^
M*&^[SER&UP#S%V9]HT(+J+G%M3Q9'2(S6JP*[\!M3TSX9TXG;3D'RQYOV<U<
M2&WL+1^ _AN;!\/;]Z]'N8W:389]%&NZ^[OZ!<<  ]S,H>#_@LCM:+D&<JR4
M_YGDI?'X47+UY5BV-L+N&Q)?KI;<$NY2WQ&4KW7HIW8&14B.'CI&.)9O,SP$
MZ%AO+9*TCE'@&_W1_3PMC_ 6\*&S,R4(:XL5H4D&&*7$6_5;1-0W 0&P'='Q
MU[8#W,F8#.$,48WN;SKL7P"#%1LIN#K3=VP8MSJ*:4.AE-]RT/IP@I.A_@:C
M5VT+ <ZR93\,X-VU6:!U.08? N_W;O5AH]7U-_[OFK06_7*:+.VOW]PK>&.W
MS[XCP=V?/YH:_^"_IIU*FP+QFDLH PJ>C)=?,M=W_DS"VX]G=J?U[].R212?
M2)?!09Z[5,%B?Z/]2WH]>O6O:0T%ZJF]@;/OOO0-E7JR-S1J$CQ"*VM^ ]=#
MEH:+_INNS5J<TQ+]X?]U=_PP>?7VP+"0 BDZQ*#GZ+__1=\N.L:%\96?)5ZB
M#:CQ*35ZJ=!N)$8:M-+263+0]I\G7 ?B/])K R(.:JZ8C/%V8.&#Z7_9J#\P
MZG3.T5R?#QCHK=HT,98:R#QT;+1S@)=55LU"K6B-0HDA>A.IQK\N$5:U3%MX
M*U%HZY'RTQQNY[S?W:[#[5K7UA$87!10-:8/M!H<F?=W39J!#H$2] _-9KQ&
M?Z0" NN8Q\]LV)OIUX!;MA^^6--6N[) @G><1=Y:!_4!"-'3C@5]O_V)Z(]A
M]MAZ28M4?75G:YS-4H'=3R:!ME%%Y7UC4DX8:"2=1:AL*F2;6RQ,<W\-RGC'
M7E>;HIWKU@KK' /2%+QI!],OFK9OV49GBN[:&XD>+GJ68%&=6$_Q1<7C[%']
M@7M8'==[W++F)3<A.ANBV]]]=W5,?15SX65NQBEQ"?>HFP41<4,2R2@.1<##
M\-5;<G>(#@QUFFOFLZ2+A(&_G")C3,'?FA9Z$ 6U: ;T ?]-3,K+HA0C.7PL
MHOD(*RW$0?&'_ AO^<L33M<[QIR23WT]J!++'?%/09BYTA=Q)$B4,DI?O56H
M1:\E+4>SJ9R.<:$:F69I!*0J.@4_A]2Q?]F('$,YI'MP?G,<<052Q6.NYZ7,
M!1LR<5,BE!MP+XVE2@,NTU=OPWM(G)J"@,#Z8+( $14CX^Y7U(3U +RJ;.!@
M?J&$PEH'#+(276L!UU[CWZ(.:G LEJA"#8^IT.<T.0BJ0ELK&U5^;Z;ZK/=L
MH\L7B.2_@^/4E]CP(UU"$  Z5M1EL<C<V(NDC'P1>3RY5[KM)]/ELU2S4>93
ME,,OCP,E21@'L9MZ)'%)2H!R6,K=C @?3$(9AA*4^0A=JL7:?,MYGP^Q>*IS
MN_NU, 1NX]O7;5E83/OG*TF^*M(_H.?@Z:&_YX[S0:,37IHDW*Z=U18-;RR+
M&3(^N3Z6*54A\5(X!Z)<$O'493A-* D8EI8%B<Q  (;)UK(1?56Y >C_S^__
MW'+VE+4#3 # ICZ*)D:Q-"6#ZA=C! ,YUD$)D^4:BM'MN1 =X!@N#*68BL(A
M<-AMY@ \ZU_VZWO&.'1JJ)1BPM%**0L'Z(\VA:6FZ''EZ)56#GH5M0%B"CA>
M) =NRGR6&O2'U\><B- CP&Q*1"D8'T*Z:4PEL%U&$Q+35&;!O>R.%YB]/IBM
MFIO.VE9M$R:S\TW::I434^?(@4N&U/!VG0XK[5 DG3Y&-0<^"VWRJ9H+'?!V
MFF]1".E [,0DC2_@H5,EW?/LKS-E\Q_O?7RC@ZD4O*@3K6&!#[_):ZV=6]%M
M$QV'I10#:;PP.Q.B\IP6W=IYW5+J97%-^V/3?6$^[N?<5&Y+\%58/S^A9@O@
MCN:KHAS!ZK T_F+<". 1)H>Y=F_ 1LSA8SW:4V)9.!O7?P&9!>8)OE'+J>O;
M#TT%-[RTG#Z*96^RY?P,A JN<0['9OJ"\%5;]A%NRUS8VVC%3E5H8)QN. ;=
M.J-IC8XJ\L>$K; J8.JQ-J0^M1)L-L*RC.9&<%PRUV2!O3^FQ((Z(ZHD_ 7^
M?"J!>DZ1.H'#&G5<E9@UKC/<R.AI(2^D/@9'H'X;%*!N"MT65!5N%?K7@XEF
MHZ:X"G,40*%Z(;D<+5N_+A&Y^R6JGB$'TZ'8/8#L.RKZ( CX=159X,4$[0I]
MU0N4B5^QC$>.3-YJ=J^ 1-I5<Z*I^NY75=_H0B!#[A3X,FB'[&"M3E]W5@CG
M#]K7'/_Y5$ISU%BDIMM#!I+BL!2D5$7STC;)4*!UW.M28I(/CQQOM.5LC_3:
M;%7(Z!:CS/:>E""[BZ&KQPO?V8&BQ2+6[)6F#$5+%) M<.XC6<G)N[;"9+2H
M62B\'];)M,I?)Z-V$6RE"\JA=MEM;=A,T<NX?B--L?:UOG>=.HW8/G2</.:\
MQJEC;TQ7GZD.L@=44<+.*5I8>-ZMX\(VG>^CD,]C^$_%O/N@#HTJ>?+&NF8(
MRWQ+"LZI&K^'M_P'7W*=AK*L@1%Y?G4<TD2J),;.8I:Y)(Y]%\S\T!6I4%Q$
M@1]R/M>[P;U8L2!EH.I)E+!44>G+*(M#']S <&["S\'48!132F2)UG _U_0X
MJF(8=Y*AIFS@%;!(=$1B01,&<M#T1(K?;N]JN6TDR^\S,O_5LB*-NS;F:4:[
M9.E6&CUHLDL:;L7APX:EW/Y=F#[LRCM&L$3WO*W%-)JI#PO-<)UI4(VRN+P;
M?FR%6>WK<+\7,2;EX!1L$Z<+OSL=.>^&:+O^-RO_==L<F<7'&F1SYYK5>U5Q
M$O"]?#AT)I?R]NU=.U24]U-VV.VR\AZS>N[<D_M//C#7_9I3KU=[^9\&=L:+
MTDQ)'@3""X@G2,H#*5-*8N;+V(M\"Z8U&S^<@9VYD64AP >8-?]JZZ[;6+E?
MP0OX,BP80AJB\MP;7DS&HT^8D>*Z&P<-TT^ZX0FV^P^$B:B[7_6]U@6ZYCNL
MQ/<Y^_ EWC_XVSLZ. FZ-U^BHZ_O_-XN6(L')U?[!WO71V>G@Z-='AT=O#\_
M.N/VFG_@6='PZ*"(X'[]_5U\7K]_>/#%VS\X]/=WWT7=LS\'L-[SWDV_W_WZ
M:=#STZN_#O;&=BH,K+%[S%C@R31-W8R"Z4Y\+W93&5%7>E[L)TFJ8NYC2;QN
M6?]N.,15^.J'(2[?K9773I3U[NMG/TAGW-?L6='4^?F08-,8?08A,^'[A&:<
MQ@+<"9'Z&8D3QF2=>0E;3O&*@%TZ\_)0V;E$='ZR5+,]%"V,@7>&9#8B=361
M>MV(5$01>W?,:)!FOA^X<1B&+A%IXE(123=->"!$XF5I&""^;$!613J\I^CZ
M04#U+\_:WC$B4V-\63BMS^__? J[^GYHV?,[N)&1"V3DX]B12V3AWF@T61\T
M[9<B]&ZFA=[Y<1@0QL(X<WT_PQ*[,',93Q(WI)FBX$U0$7NOWB;1]X\67"AV
M-I;B,I%7YQ!T+?E*>82-\;CF@A'+$.!/*\"^/K+P_$#SX5_%:+1G4"?%WE!W
M#NX4@XM2GH(U"?2TI^L@-@+VP5:E<=2E9)$*0@YBE28N253@ L7$;A:&5"G&
M%9-8OMR)LFQC53YC#'?E^>I/%;-=#!V\B>A^]];\-!J(2Y42$J0>2Q-"$R^-
MJ0I2 BK)R[@(TD<8GK )^JZ!+O%G=8FBJ1>D+'!EH&*7P+&[-(D#5X@LXCY/
M:234J[<$=,GW3\!Y/,9['"#S.8"2%U4YIM6,L.47M<4^&6'%!@6VD$-:YH5M
MJA/YR-3*@=[!R(?J%Y=8<G]:"%T"6$JLP</:K^I"W12". ZCR>#"0C0QA/;6
MY8-EP:K2#@VHD \T;KAJ[MX@I%?/QNZ T]8/L."CJH0R.K-:?)F/SETJSB8C
M7'"I:]"P).5<8D$3BHBJW JOL^4<%NT<JYWD"!:$X,)5G6!=R_*;\SI_<\<K
M&/0'_,M41TZ^M,%F,=B"*4BK(<ANZRSHP*KLLIIE/*ROT@!@8!'< ':O1K)@
M!DK:%"2;39ZI6M5K6+ W^"Q;J=EZM(&.%!-=]S:0LJZ:F^OSJ%"P\/[?S.T1
MJ? VM(_\,9I)X'GP.+B=3E@EOX\LT#@6J9:E*6QZO51#@B9CLIQ1DHHE(5%)
M%(2I3\(P8-P/H]#C0E*1>2)9G!2=BUHM0&%NJ42M FNUY@8O5J\]5LD;C\#A
M(2S(:.2RE'.71,)WTS1B;I+Y<23CC*4*)P8MZ)KXKS=&#+W^9DE[Q]0PUT21
M#V"[42K.$0<2FZZ,U_6I(^#+/C4UW*-5"8=&,0M]7S+J*9(0GO),I: +69J1
M@ FU(9RG()P3'T<69 K-&1K&S"6,2.R@SUR9"AE++_:9Q#&=P=;\2);_NA^>
MV?W Z*-HS:'HHQ\"1=_*.NJ6FX/B,\4BX(_53('W$YP_\$FWO.1RM"9UOW[O
M<S5PXX3T@L.;[M=##^B6'-Y\.CT,]J+N+O</#S[E1P?;>+]H?_?/?';@QO[N
M27ATUKTZ.H-[GP'M?WA_=GAV?MF[^0>>^6>_NXMK/R?=P9\*G "_]_<QYWX$
MMGGB>CXA0+TI=4&/QR %*5$I4PF1<Y6^@M&$*RI5E 4DX#&H+$FB1"DN4A*2
M:+;2MSX2YU/3!H6GHCN2]7$X]7FL6H^+E!TO,YL7UN/>O?SIUU6"!"(ABBGX
M?:S"%+@]87!AG'("_/C\(//&20H(!H&P?&\>K+@>[X.*:H1;/P,VCQ<Z']N_
MT@<TBS__Z>.>;B['EH^#$JV_U_#1 DCC3[:ES* V+P(ROM3XK<+H3KQO/:6D
M8\:>S':X55UJ#>19O?"#$C;2JLF:DMXXX&-H:[_N>;@LRKZX1-1D'.""^P N
MA/Y6&]((A^C\28?-GOK5EL(KO:9OS(<[>]VCO>T-TNA#D$9K=K[;,?[U\#N3
M#7[G&JSE!^)WWJE:9E113,"@# +*99:0E,F4@[[R!*4"\^&>6(KW&3];%,ET
MGA:3NJ>X,S,(3FNDR<4%]O].@^A_V?G#Z@_G-?RY<K.8%</=O4\[[SYMY/"#
MY/!W',O[+>??A5+P\Z'[%S5G\:G@H%[_&IL)$$N^WAOR+5#:Q8GI!@8NDZ5%
M/:<C1__FC>Y=M!I?M/$J,*2GQ_1),5H5LL*/E$PC&L<,V":,>): X1>H+&0R
MB!(AT*> C0D"XE9_>!ADQ4>[P/=@4MSN=GPHB]%H79 K?KSS<; =[1]\@;\?
M>MV;P\ONR3%-J9^P-'*#4'DN$2K%N5BQZ]%09#+P0AHS=*/)G>-IJ@C><LMP
MRURP/=*]X";>F(^T/:B-YSI8J .S5SK."WRPEB37>L$=C'3>T^W=D)XAO:O]
M[>.8!H$D<>(R3$T1B7_B2KBA3"*@O8C)&&%7M\C=<Y'&+7+3@>>J(QYQ?>@
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M6\?YZZ^=V1DC_][Y!/[ZQYF18'<MP< =X=^TDA[A,$GX+]RL!NB[PVB=3P'
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MM! ?QTXOGV*DT9U2N\5J:(7CPUJ\.GNWR<@(9Y1[)T,@^%NDWBUV[+0=JI>
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M9W#X%>SD&Q[UX!E'9R>78.>"O0W_X#3VW;]A'>]5;_?D9G_[.$F5]"0XQ4'
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M,6S?$4_+SXLT6&L$+[6Q/N>^8*#6<EURX.9"YE)EK?:RS4R][&+@*N<!-HV
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M+8K96YR7C&CC#<D+FU/G0@G;]X,,S"OPQMTP,EN4NT\H=S.G!2W*_5B46ZF
M%82G.7>DE)DD//,BU=8H75!>EI*#G=FB7(MR+<K=[('!A2ZU%NIN!NJ6HW$%
M+Z7- -M,#/G(N"%*,$E*P;@)66ZX,9CE5Z@;#OAH@:X%NFV9^7:=';1 =S-
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M X;.,J.]X:4J@1"DE=B!+E-6>ID;EKFR%=-;S=7QO\C91Y_HP>D'[:RVA<U
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M/DKH'3I/T*@:8+:6?KQN&U<H/1D^@CK&F*8V%)X[4QI6B*!SX3DM,=7RP<6
M]I/H=(T\/:^\P34G((F-]X-T*H^PA+"R7I[M=IX/QU%B36'YX2L8Q<FDXV%7
M7&=?C^U)@L@\V^F 00H_4:+ZSJF/PK8S'<.$ @*1\=-3?&F"R2P"4PV9E5!L
MP.-)%Q +GGYV$YKDMLB1[9S*M^NR^=;KLF\&#;)>5?,FL]%H.*[4.=# IDG?
M ZJMY3RR3A<$+=+JXC802-T *NA@BM)[A7 OUN]J9@+%>#BP\'$"G>HF"\KV
M<5)<\4]W20!--2R\<&+'W5'S4<U!5O.>H4H!CP8]H]N'1PV..UVTYN9C!ST=
M./P U((.W[V*0A"Q\E(T%OS!Q<9\)F^!4\\%"T;ZB).5G8J"._^SY-18+7D#
MT\)>6TP%GFNN"B?RTN8E_D)9_N$IXA^%_Y'X2XZ>N66OVY-AKZ>C"0'[N#<>
MXV[C[B["=H_@=7_TAO;3S_7 L8,GJF_[SP>'']]\?<=>%@='>_G^Q^?]]T]?
MG>Q_?=5]]_7YQW=?C[_L?[3T@+TY??_QCX]_Y:]Z_O^^.GO_UHT,$,+!T<''
M=Q\_9?M/[=G^V_>?#EX\^WKPXL^/^V\//AX^?79V\/6?_/W1'_W]%P=A_^@X
MAZL_%,HZ;FQ!9%YDA'MIB9%2$5Y*5EJ54:DJ1RE0HG=[Z.;,,RJ4M]QID,]>
M,%F6!1!@"%(*+QQ] !1O]0@5RO',8X H:).HS@/W-'8$>&?O&$1</VD+*^ZM
M)6Y8JS-</HR589M,>FL4J!6,4YLKSRS0E<HYHYQ9\> BWU=3/.39;O'31!V8
M1B<:0"GJYQ%?HDTT[@YG$SP<::RNGJ\N7&5[,Y1X &;59BR^Q'VQ34[IH,F"
MRL#.$B2FZ^K&@]VOY]YRVIV>S,<R.M'COK9^5GFMX&;3!>ZW)P-8JN,S?!2L
M7T3I-ZAS(HQ._.H<%DP[V0$E)PH$=$B [(BV' "[3R"=YA6\APMG(U"Q8,@C
M?5;="EL!.#P<)#),;HA$'\=^Z<+Q\$SW4'@ .FNXIW'GXB)\1OU7]$"@"("]
MG04080 K\0(4=[UH-*+!"1;B"*U(#;;CW\]>G/72!$$P "'H7MR&?\.3QK[;
M-[/Q),XY/KO>C?C0I0U)XC(N(=#%PNI,VYVL9#N<3&-/AY$?XTD%$D%::933
MM<=QXSO\EQ&NZP[\8OTH#2@]$G^#2;F9G58K59G6RSLXTN/I /71TY,N//_4
MST<'K\4GX=B.AT,WP>![%V>B![IW]C6-OT%?\'SGT:D#7 &/\W$3X8&3D^&L
MYV Y['!6K5E4"98ILQ+R$SL<1:UA[_63CJ0R;N9.IQO@]8G"JI=?_ (]..OX
M7O7X:#/%!PHJ=CN=<^CU V7<:WOBW:SG#\,F:3?9&[@#T'XV?'V$%D,Z#YE$
M*^Y^R\3C#T 4F?#:DY [1GA6%@1#'@A3>8%- I4P;%7&W071\7(0*7CL],#Z
M!-;GV77!-)$94&\&Q?8K@&V%L#NK-\SA= RP =(6_<X!+AF>3CJ_1:8#<0!7
M31X^NNRDJ?)9B;A$\?1KX<V*1V[QU:.)?U3_\KOK3D8]??:H.X@3CC>MGJW!
M3E1^'Z5V92'0]5/E E2/K[Q"N]$KM'(,F+[C;)>K<N/7=#?[QN^*3'W3G1<-
M-H<;67Y'!IO179YM_GH+!WNUE;TDY>0:63 _Z5)U[M(UP2[)47P[01_R2OEH
M1QO\9IT\VUDZZ;_B!ETWPN<BI_(/FG>$][^3HK7B1[A14MGV_8_K\'0\.^X\
M 8'3=:!;7R'IZ3KY:)NR1=<$?FSM*M%TQL*RJR2$767"]VWAZ'5@Y"HIC-=:
MDEL&GRLJEW^,NV D]\C^&=IZK_\[ZQK3>1)-_+,K0])MI8S>W'K_E*7V_9$_
MUCWG)ST_^]0=_(BLZQM;S5\M1/;:\_]E(F0##XPS*6TI' \Y,TY)$YCPI3.%
M+8JUSHJKA\H./DW'CRI?\9*;^!"MRU?)N-R6D-EO=4Z<O.M_Z1WVX;E'QWS_
MZ/CTX./+L_VO,+:CYR?O/[[[<O 4[_VC=_#U4W[X]*1;WP/OFKUG;\3[I^^*
MPZ?'7PZ?[K']CR^_'CQ]F>W'$%L8,SHV7KS)#X\L/WSQ9VBTDSC]H#(5F+>.
M>,$RPJTS1%+NB',J\\P9H<S--:7\!LC]F96M6[!KP6ZU4K\H'?"%H-0([D,I
MO>1,%,R:3%/M500[6H,=O0SLUA85:A'O!R >FR,>=UXXQ7,B2NT)SU5)E&:.
M%%0991C/2Z9!GR]V@.CN"N#==AV3GV9//.MU.W]U\3 K'1M_KR%Q24K8+[V6
M!_][](KDA;R%Y6N[288,I /C-L?:)X(IFDDO,I[Q,J=4BU9)WC:1<=90DK6G
MRF>A(+0TAL!>.F(D!L8H4 :RC&E#:=L4]AZP<0BY*&3FC0LE#TYKB\6,:&$M
M#[PL7*O^;2DO+]2_$'3!95X2%@0%7@XYD:70!$ Y""V8+ 3#>I*L4%O$R;]6
MQ<CU^DBD[Y]=*O)6GG'O.V6!)J2\+7CNP(Q6"*+.@CI4!LZHUOE5U*$6+'\,
M6!Z\;B@^91!,2ZJ(*@J*:?0>%)^R(+Q07AHFN-3NP>.";U$?K)97;]KEA>(1
MYFXHM]RPPG@N"^LYL#!C(92MSK.E;+S0>00U998#WS)G N$ZI\10"V0LK?/*
M:BXD33J/V").OE<=[?ZZ8ACE#^UV]Y.?<=E]%Q=8:7LZ?._2_#(BZYOBYUOU
M\E;DTM+ALRV,I6"&>Y<SPDLLN&EM20(+I<F4M5*&FU O;Y!)[G2-NA8B6XB<
M1^WX4 HKLIP&L.MRT 3A%UF&3*N2519XJ]5O'WHNM/J,\L(898G-N2+<9(&H
MLM!$&LZS8"AU1?G@,2MWBJSX!1#TFXO?1>;9FG2KI[-QE6MYQ5(>T09 'ES-
MO/K7+6I$Q36:86&I%QS2V^[TY,EL EOHQW^G+%-,,3LTL+D1!E[#STGH>O=R
M\#>8-Y@?#-=UAVZ.">)N8L)WY!KN%8=';V N]A0^SP[_^6!#+@7UDFA+04>"
M[2*2&4M*+;FE.O=Y5H#M+G<W]2\%&N[5IN1U2.9[)41+,K=$,L\8D D7+..,
M.F*\R4$8.$Z,L(ID659RJ06JU \><[Z[R<-3D<D.YGR/?"Q6A"4#AV&>P!DS
MNQ>;TAG.=Z4JYG**10A B-1[A*G<(]B<>!OL4:S#UIUT=#_F2U<)W_!WKU>G
MPZ<T^[-%TB@0+8R56#TY6?UR!U-*3WT/:U]&/+T.=1N79RX3N7"NY+IP1KK2
MRMPJP2P#F+P)0(SZSVO,@=^OBP6L*CWWCUKWV<'Q!QVRK.".$F%S0[B38/B5
MG!,G%2V=S$3)/<;@[6Z*P*M!;5&%H:KXX*JL>R2F/_9?;ZHLTG&7B^%.)8%I
M5=C'8(4BWQN>[L _5F,IPHKB1Q44]5+YBI['8D:QNL,&=L':!F,=RTS$(51)
MU!=5GMQ:A68O3F=M#;*+\LA3IOF\#$0%!K"60ZP3U]6]3IC%FAE+!356"X^,
M_?&LIZ?#\=F"%+ B!%;1@K6-%2*_8)DE +/K*4R>>Y7GLK2BX+((2F9!ECE(
M/R4LLR+6_?X.6/B[GF:C/=O>P+V:SV<.&8MZX.K>@<62-I0?['T(@CM08"G(
MM> ($&1&E#,>?O/>9-*6RBC0AG;+#;AA:BFW*'V3I%%5U'.EM$BD4801I+6U
ML:>KV+#;P7H*8.U,XVL68+29#S97KVE4HME<=&9CT9K$()7,;!2IF9P;\]T#
MG:-8W3"6/(HE%&.QN%0R9UZ^;6W=F:7J1]>PPJZV1C^T@MK& H'K$YXO2KWL
M_ 9$_? '5P3<.-[U6_JH<RZ#$8BU-T%V"'X\3JP!U!OCED';O9*LW*I2*X>#
MSG-OQC,L]I3E2%B9C%;]4MDNW7D]Q?+6QUV[47WY#2GW OWF861^>-()8LO?
M,Z!G#?K*X@$ULH$N,\2*+Z$JQ(2:31\&%$*R ;#X\1XH\;U.-=Y=?-IDUJBZ
M>,$PJLI)+F$HC.3C$*;8.ZOE..*O.;_K<W#>B>,<SJ:@(?6!DJ85=J.:9;J#
M]+9Z*C'^MOQ]TCD< 2T,?PAU"Z2>RZOGGJ_'C+1(\GCWJI<+-B85^07$*?E/
MK=/9^6T *]>;];5YN+-4$JT_0G=@5/4BU<QB44V$DNE)=^RB(G>6ZFSCKUCW
M/:)SQ-O(N?76-VO%^?.[CP2G.Z?#<<^==IW'$MS=5,AL[*<:1IQJ;4:'824K
MA_!^M"$7-R5IB0KCN>?'1YV"&.],(F\<]X8&A<:Y"G:@.89N)45[PPEHYPMU
M8.V3$['"5GR:ZG%\.I+W1IT3=$/CQZOM9KCE5C$MLDQSD5&M=)[QPK'<6>5H
M-$LS"?*(D>J7O*E_OCQXOJQEICF 8OE7G,'K-*B_8:; G?IX88@2=F^5RW?Y
MP==/7\$JM3GG&949"=Q+5"X-,4PR0LM"@<Z?&2U!N13GG>G_9XYQW[;K0K-<
MY+HTVAO.'#69H33G5'*G%;>VW?4?M>N'>Q^8X7D1L+BI#[#KAA?$E)83X5V>
M948*'F#7\W6[7A7Y'<3. *MHL0R&"6SPZB[*^D%5^Q)((/W1-&P7A13/H^.*
M[ /[%_!_T.A4X+$A0D3CN3RLA5!G>(JV]DEWE 8!ID2M!"\ ?FZ(5]_4;TB&
MS4JAN*5ZBK'F^,J$OW%:\>$_4(P7N_+[Y'BVY8)\YYH(!"##,^XRGDO-3<Z4
MY5SDI1,Y+;0NQ'41: XUAZ%"GY>#AJ?C"9)"BT(5"M']TP^E]B53&2?6,_2(
MFHRH7%#XLZ!9SDK#M0794^YNP*'$7* /U=Z*Z^V_R80HA0XJ1[]L(:3%>%''
M+-5 %4:V^_\#]S_;W_M 3>"9DY9(E@?";2;A-VZ(5[ O@5F9&=C_G*W=?]CV
MI'6NDSD+V%VN1HQJ"A#.&C7VYRHOZTCG[U10& ;34LX2Y1R<?K 4H$$;31AH
MKP10G!,M2T-<J7+FM136EIOUE^_$C9NV5]K-O_KFL_WC#TX$8#1 #"E53CC3
MEH"X]L1255!)3:$Q@G*MR;( C;OG_GU9.Z62!PUI=Z2[#KT2.IX7CWT ;3:6
M"JZ+OL<CY,H-CI1_K=,@:VAA\J+D(>< =$#K5&GERS+WSHFR(G,>3XOQEYPN
M'0O)JQX+O4F#!=-M?O[S=^6Y?U4=<#X?#_M54-VB44)[1E3Q!  B"R5(RY*2
MC)9EZOUJC.*$>=@^8YAS,L<SHDUGR]4942HYCR<SH-UWD9(:)S/U"0]ZCAIT
M-0%JBU[J= 2)9/;M1Y !K-!2"04&JN**"5F$3!8ZDYS"#)6Z+$1!7)7HGFRJ
M$+^O8>"S_MXQT-DQ3&!O/NLG,.EEPD1>>S,:#O;L21<4/?SF,+2'FU<E7+[_
M#WHBJ. .Y+?+09*73A(EF8#=M5X;4PKX"PF7%YOB.2O2Q0+K]?%F5/H61^/S
M=@O1.[L2-+$'&^4B/AX,=SO9ZCGA0Z#N8?(*Z,4N1RT"+&'='5SM>#XYEL\Q
M2MOZ\(+6A]G*ZK2M#W_&6&ZQ]>&E;8E6VA@%:31UK%12@G)2&F-S7F9>:E#)
MK7";>U'@FOPDJKZ.,)2\M*7.3:FYYC1GIE1.&>M@/;(B+^PE&E@T-*XF#9]5
MXO[:PNY) L'E@+_)/0[U6Q)P!6AFU(M,TTR3+"\YX53FQ AFB C:&JF\HLZA
MJ4HOC?N[3!"MA,LD[_6JR1"#"T;5V?@%EF_THTQ6"#(K00V3- @O 0)*9;),
M@=E;NCQG@O," \2^E0[G37SBBU].)L#E<SJB]YB.#I_"G$X_%-8I6SBP>ITS
M6+16$,.\(,Z*PH82;#2LQR5WF.0[8DT5Q^09F]1!QWCV.T3T&]I/2 ]+T0T;
M(RBB1RTJ+ZO& -#)!+L^SYM*7@?H/!.">VJ%907/0;1HFXNL,++D!=-"7&9J
M7BLP^3"\QDD_:0ZXMC-;X$H$=W:P]R'/I<]-D1%J-)B4(5< 7![0*[A<%!D8
M:JP @KL<N.Z@K^6M7[17J]JO7A+UTPFZU[N\NUK=56UX'-.9@-^J5FF+5FVI
MLQJ:,?C1YHCJ^B36@:W^V8_/ZK_KN.K4(R[:)N?Z%:Z)0;F#NU2EE<TCRG1M
MLZ=PF014WP5,'-#'%UE>&& H*X/A1GJP#9D4+@]Y5@%35@%3QE;<$>55@6GN
M;E@+2^C^:OU>X>#C'CWXNO_EX.G>Z<'1R_SPGP].FY(56A+&M"8\SP0!<\$2
M2AD3NA0%P!2Z#^1EWH,5K\!*T\086-CK#6TDKNYTWE$\,GHM0Y.TK#LC5QD[
M)/6BC Q==TE<2J:HPV@&_G@X[<ZI=ZG9XW'JOU@_>A&IB'U]:L:_")U.8P3T
MR$>N76B2ZQ^T2?Q7$6D8#E$-LNKGC'W<S[6A7N@;U^&X(A?*!$6U\R#FG9,%
M]Z(L.!6J9$I7*N8Y1KNR!O"L'O%S&/!_<+SIU.4>&RW+;/7NZ_X_'[ATH) Y
MCU4I'"B;A252%3GQWBKC<ZI4KAX\+A7=99<8+=U*QSP9@J@93ZKXG([_[ZR+
ML9/H;I[S5>*:/M@RR"RWB=-7)I]7]?#V8@;%7CWVHV&C=^C?8Q#!+3DE<N)@
M P<1,E E&:$A"" G*8FRC -U@=W(;&XI+[$6%RW4I2F]E8DR72PWYEO:.>QL
M2'W867B!&^GD0)TIOONMGRL*\2EU'M8\,:OAY=UINGAC=^,5PQO':'QL_QS]
M84LJR%U,=SL<=/[4@QC"KW86>?FUY%J*Y%_UI\>H_?F'#Z\00'\^VGY^^W)L
M_3S,>C:*X@LO77YFXRRF\W=/#RKI/B>%%"LROP,SHQ9-G]<&ZJ=HD]BLN8Y[
M76@,B[DG&,-VR"DSQ]6R,RD9JP>V.QT+"]A-?5[/)3Q=5X;J/'#N66Z-CP$*
M4N<. %TY+LO"&QGS^#"+7=U<'E_K_%NUH>G^W@=F<1=$01C//.$%RXBB(2-E
M+KPMG0"5QETIYW=A'2ZY_B)4=<<33(";=B.#I#\_=R?=:3.<=3)-+ %0UI]-
M;,\#L'S6$U3]3$\[I&"+!B:\)B:4#1<LG],YSZ^'T"LE%$<&2.D1*;]I(RO$
MW/>6'7XQ=L@.P%K+M>1>"A)*"NS =4E,:3AQ69%I4^0TH%IYR^R@W<?99Q0V
M?0\2 H1E@P-FO;,.*VL"?EZ]=1UQ)N]Z=[*4TPI<,+/)=535?X@1.S'KMM(P
MFJ?'#0W"S6+HQ6S2D"[#<1?4 QSQ7%+>054B&K)3$(HX)[ NIZ?#M6?U#8AQ
MM9^GTCOJ4T!<(?\EANZG!8K/;CP,2"(=N5\'+DH1!&5@37AJ.1;MMCQ30N*I
M&\WRTFS(@K]RN-/%</$LS2>Z?#::%/?-\;.2%,\/]SX43'+'J"!"Y)IP8SE*
M5D6,U0&^*6Q6Z.CXN<3O$WEQO4&A-Q5YJ+DS>CFZ0*2A:Q% 9H/J*"Y&(H-\
M'?90PL7$#@NL@'D3%X6+Q+"IS[I7Z8K$HS^E5FS7C&^:$E_&?C0<1^4UE9Q)
MWJK)8C@=]$2A%VN,CYVD4:%O.>4Y5JGCF([2'=M9?S)%10 F;^WL+@9*[H$M
MAAPV1-\]:/:?*W"N'%+UHHSF<;=QG\]G[70','^T:\Q9#+),WOLJP/Q;'@*#
M.&=IHL,0/7#=2#,QVFX$HTP/:(2H-:^J I=6CA7F@-F9S.S)LHD"=!5I! 1>
M#,F;)S(M'2TD 9I"/\[P-MB ST!ID[GC+SU_D7<,'W;[!JRUN0A.9XLX<XUQ
MJ6-?A3&GHDH3'W7"AI$5[_-?1GADD9)OL2+2ZE,;;YP__+*G[79NH.Q<]'1>
MJ\:2=IFEVMDR."YHIH-WTF99Z93QQM](T;G*$]58H\/P+$VZ53>3C'ASNG_\
M02B6P4(+(DM8;EZ8G&B:*2(*)8M"^H*Y'-1-L;%RRK>6D1.Y#,P4!36!<BDS
M7<@\DYF1$M,%!+^),G(M$5QJ<SS+05$PPFI!;49,GF&1..8)V'\E89XY+"58
M F\^>)S3RXA@M4C<-\ ;6BT-)$N2I,+,ZIK)3LRLK3Z<7]&XJ[YPMW-!$:I&
MK&N"L.CZ0IW'N\KTKB/UKF5).Y=;;0#.9,:9M5BO6GCXP1@/SH;O*!!5A__L
MI>/O1LS9@9\^01$ZF+9DG;#MR\'IATSGN>=:$%AN+(0+]C38UIHP [JOH+ K
M)8O8=MD!352 H^TZJ&,/)DT2P>H40(I/AJC98<@8GE!CE=MX9/.'[D7=X?6)
M]U<W1[>F7M#Z\E:_Q8^VJU+0PT>=NG?IG:P!E%PIJ9Y.N:[^SZ*0217 LG!S
M)'7UHKUZN'-1*9_9\0QTX<7+X7UV2.K8F'I9=Z(K$C[K=/O]V6"(,3K18!O/
MCM$WZKK5(4.J^@GF'<[ [7;>S#TT&#$TJ?5HO500Z+?NPX;/$\]%N_%<Z1M]
MFBZ8/&>^*%Q><N^4SKR7PEO*BJ+4A8D'GB55Z< 3?OG6B+DK)&?%^:]F9[58
M'560EZ>@@I1*9C:8DN29%X0ST$-5;BPI<FX N4$[-%C.^ HAP #&K_UHZC$K
M-1)SLO6;"5NH9%S?Z05"PXH@LIPQQZ6Q*@N<,[!>C!&LR*+3"\A(LO.IK#^N
M]N,])QT,PM0A+[V@@02P* BWH+VJPFKB,OB;^R(O:6S<?B72:<3LKG<[[P!,
M 4[%2E%K$#+A< 3<G4AG<V?MJ4^NI1%Z-FHJK,K"H@G^=PPDRC9[P>;)5 BV
MHY3\?.ZBR6PT0OB?>T+B>&' E:*\&%[]PC^21;_&+Q.OO5[>-] __$^ HHOQ
M"J715'!0P0H)>)MI66.N9(QL9)9+\[YQW$>GP[9NQ :FP%-5QTI39*P@6 T>
M\5018YPD)7>9!44O,.8?/"XW5B\:3NH*$68X'GATS2T4B^O1A%)@!16>>J4\
M=V5AN'":\2*7LLS!2&IIXC9HXN"?#[GUCN<%5H1@8.9;98@2UA(L<ZX*37&3
M$"@W5[1:H8A91)?/%1I&:SJ>,8VF5102TL&X:V93C!8:I+S3804\^1+B1 \2
M + #Z,.[B3DCB[]2M;\.9B#'H&^TQZY'A-(&1S.G>"D$%]SJ@@G,GJ8R",>\
MO@H1-J0X:/D6)3EHY&[B!QL)]'F:=2)/]*^N$NCA8&_P<C[//\X:O^.4_\"E
M;E-\(@W_\Q5P+9-"Y(6R)),4@YGAAPQ%1FS(&64FRP(S#QY_]>/A^>P>(+WK
M$8U6.6@3B@6@!\Y]T#XH%INZYQGU9?8=R'6SA''?T0TK)5F7%5QJP#2M"\++
M3!.C.24@!P,KI='&BLWH=D[[26=&OZT!-SPE0KHY6RK\L.A"@19PLBYBJLGP
MM#,]]>F\,U7CBZ'EZ#!:!X3Q3&J.F[5G/3X)KXJE(P:#&>B'58726A.,$9:[
ME92.8S;G]4T=M58$<6PUL*'$Z?RX;#%SP.8FJA-X:1^LE3I<Y,WNZ]WJR*W6
M4F$*29-&+VRG.EE;Y..LC>CHZ[,T:)A0.@Z\'K_F7&8B6.6*8+@RQE!:P =8
M/\MI=S60W\"O:P,1:BO_:/B'7[+TJY3?)_,U:#FUYE300SSS/IC<$.ND)#Q@
M7()1)?&ER UH))QC(9;BO+7V?S;2V$XJ9IE"BE*($YIP*+'1=FZ07@H@P(82
M%=_4[#7M]JO29ZDW31UI !H.LMS9PU06JS\"<RVZS:H'5':2[DS@ 3T][O0]
MA@MT)_W(JS9Q5#(#[7#6<Q5]5R?;YTOWWTVZ?QD6U'Z(41$MR5<DST X26."
M#I03C<4;@< SHDMO2= V9]SXO,1B;&O-,:"^6(I]0>QW-NKDZ&398QV%416G
MAOF<O4IZ#88@-@?'P.DG>(0X.%MM5['<-&>\@XOD];C7]>.=N9>Y+AJ[ZFNN
M3W&:!6NQ1&_T3*?8]<6UE4BJGY>D4AIE\M^@B[OKX4%):N+U,7AW^:9EW*J"
MBIJ11,W.(_..%5BSQ9[<P8U^"YH!CJ(;VWVAJE,?6,3V1@C2E8MLH09M\'PU
MDGGKT)>-#K#FM9-SH6>;FBY5.HQ>%+C:[?Q1ETV.Y\Y5/MS\V +WS.D>@O;$
M]WHI>JAK%Q=L>%5*S5C*Y6H/-'X%Q&_D<YT='CW+#TX_P/9X"VA/0E:"DN,%
M(+Z1E(!89L[YPF69N]J!1EVHL,8^(.UK%8XH*14>FU85EF<%]H=TGA7<&+"C
M<REOC&I2NM]A6 W);20 KNW=V%)-I!H8Q]X';H.7G$J"KCH,66 $+%=)9&Z
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MUK+^#V7]A>X"4*]SHP(1)3 \%\P0+?*":&,+GI<.C//PX#'CWYW]<8<34>^
M8^UR':<U/W]Q\_,[];:;,S^OB=VM87JCX-[,V*62R5)Z4.2<881[IH@*4A);
M4EDR*:C)"@S:V!7;5-^H];>U@'<5P/M.;;4%O%\%\!;:+%6,9RS+208(AU'1
MDBA&<V(S)PQCI:/2/7B<R5WUW?$EK2?N^OKLZRH4.P5XI[YS52;"4K+%J <O
M:5UUMQ$E=^7,L=A3[&7<N:>S,2QK K.TI>NAL[7*KX-CS2BYTI>PM\R3+)>4
M<&LRP#$PS45)N9 JE*'$'-V=3+4UWWYM%K_-Y-"6Q7\XBS<=;P7SV.6#2ET0
M+C)-M*6<Y%31@A:FR&F!A5?RXJ:R\&\IU7-M9]7$:H__QXS__?A\[M45VZ[F
M#S8G;&U#V]6,WE;?U6=Z/("MG-26T=:D0IY57-A__S&F+SX]^/3N8Z\+]WP!
M[NB^B^\&[GOQ)ML_^L^G@Q=OBM54R/?]_;/#HV.^SUYU#]^^A/'!]6__/'G_
M]-/7_:,_/[T_>O/EX.T_]/U1+QP>O<D^L*P @ 0Y:4NF""^8))**0$H+QJ!V
M3 1UKJ-JSAG+N:&E9R57I9.%4T7)"TIU*+0]UU'UP$\[?PTGDPZL>"<N^<6]
M5.] S\SU_5XO7YCEA;0\SUUPFF8FY]*6LBR8RB50>%%:A5K*6VP<W;,S[ B,
MS:Z!';#3=0]7<P2K&<7>H@LV=G<^7?5[@]@R<&G5%QO3/*O<S]ET,M6#V/;>
M19&5FE)'N06/AVM\3)_&S-'%*%RW-\-/OV,<B^33I<33->BWB2ZJS>!  ;^/
MAI/8\/[1&!LG=S_[W^L\Q[A3C;NJQ%2ZN$6;R1"GL_&6<QEC/XG@6+YBTC5^
MGHP7"8?'GIBQUY^(#C#81[IWJL\F#_Z]S%3 4<T%7)W[QAF&\,-FF%@;=*NJ
M??JC:.#B53 FO35CZ9R,40S]/U<0N \>QT1[I/(G*,$&4[#*]>-UV[@63"X'
MA\U ^9.(M($H.YWN %O2(ZJ,ACC[KN[USA)ZI%H-%C!GVO63W<[SX3@VKC\/
M/=V$)5C*H0\3.L/'7;/G\$[,<)^CE?ZLN[VX,=/A$OR<#'NPRQ/TJ8#V'U\[
MKU=1W[W;N7.2ZGFL?>'7E:J(.<U)':[J7F01ZU,!C"1M8M>BS8B/_^'3)Z!A
M@1")B]I<;I_J#J3%_.^L.XX[A%?Y+T@>_C+BJ.MP#&<]USD!40+/@_^?=N?7
MHAU@IRAUSH]OM_-T(=BNL0*KQ4 N&R1P[Z0[P34"TELK_)9%;P*42,U-*9S$
M8)WG@0/!H^G+B6Y1<.'W<SAP6S5']AI[\GJ^,L_2+KOGXV$?3=_9M&HOWRKA
M20G?/]HK0!&'N;P[.WQZG.__\\$+6QA=EL0YFQ'N3""Z$(H4N3/:!*ESY\Y5
M)VG+;+1E-NYDF0URNV4V-AU%_5)E)&ZU_L:]6-&?6YCC9^B-?U^L\GQ3PX8V
M!?^VRP%_GU*VU\<">MMS3/%MNEE5T/*8O3]RO<.C5_W]KV_8NZ__T'=OWW#0
MR=C!QT]?X%Z^_^)/^.Y=OGI,<?CT?>^ O2D.7KS[>G#T_N/!TU<G[X].8-SO
MV.'1<]#KCD_?]>&[CZY9K^,+C*7X$&3.E2]!AW.%)KS0C"C!!:%9\-RP3!B?
M/7B<J9U<?7<<65NVXQ?%C%NM<MMBQNUCQM<ES,A%GN72:2*,  NP$"71(N0D
M-JTSW.=%P3 2:T=F-UP(][;JW*X>_\P/0\\=?E[7O[;IF/3>'ASPS0<'US@^
M5O/CX_:TX8Z?-FP^_Z\9G: U\JAD*WQ&\).?%"/P<NK["=G8;OKW_,]]/= I
MV#A&$I2_3SI/NQ,[FTQ0PJ([=6^@>V>3;CPA>-X=Z($% R<>*$2N3B[76"-W
MY1#AF]S^/^\@!JMQIQJ^\7!WL0@(K[H[B)6U,?J:](;#3\GU/#\]F9[H::<[
M^#SL@<4W[DX^)5?T;& !W^'F=&9S.!MW0.+,8/W&U8K9Z*1WW1#\N /*!HP]
MFH^Q2O?T9#CQ]5"\ZYQX=,\_AT<,Q]4[T_U6S^#"X3B.==PU +)X7C"9V9/J
MV1Y&,JG.E_Q.!ZZ(YQ"#X;33Z_:[Z(:'&U9?&(^28.O!ADU[/>F<^EXOECNN
M1N'\Q,(;T\5_Z_&T\_+E3F=!>ME>C%%A]/=7L"SUX'?C9]GOWQJ:(]GVAN8<
M@DS_W/6G5Z3_'S?*^,1'W2E(5'N%<;_&7M?^N&L! <;5AB-# ]'^,9O Y9,K
ML;3</5??^^<Q]8'_--7C#O#V6(\\Z.<6H\$[&OG/H]^TJO=MNL,1:.)];>-%
MP*#5X6GB,N2(X6<\Z8QG>_ZS[PU'R$Z#X>>H!74&,-Z^=UV+ZX2L -R5BN2?
MP'  "/I^FBZ 9P^\=PD-ZF$TGQM/^T;=D<?IX!/PV8 M?C+M'D=HA4>X\>QX
MSL^3Q6$;GJ3!5/& #2OX#P>XTL=G.YUNOS\;Q-_CNSYWQ_&/6/6_YZL3-SR&
M'(V'HW'7P[*E*^'OSQY0\,3WL1WZ&0;+3]$R0L"H%Z8:_P14MSA<'!Z@$L@(
M/&@&Z(,=0&19_K@#:]V#W8SOU>XSMB& %PY[9_W8SF#P<7:,X3-3;T^JL=<O
MG]3=!A#%THL3A/E!.J@^\4OK62UC?]CS&),S[N!RQ7/(N,$PVV/8H$^#X>D
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MY=Q.]VBUC_1XNC"XZ]WM#$\'8%Z==$>H_( 2-)G67@*T8_!,=^Y$FR=.("?
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M@L+<PS.!@=BZ?-!<MN+H+H18/?<:S,%V'GH*^OU)PXZH$3<&L*<+DQV%$:-
M=+5OH: -@PSCX&95S9L6J'\V4*^#YJ6#Y+D1N6&_^YA44N/2?-O6J0.GS4BQ
M)=V@K'6#&IY.8% K2L+RHU=I-D9DCD9X++],OOM^#/,ZQ6P*!$:?C.G:^35W
MX .!M93T/4>64X"\Z.:-,3R3NX?<219&;UY2$M:;&I&H4ORL8+OSWU*,<=*6
MJ[AS>-CQ$(\8FE'GJ+_T>J37_91<HJ,8@?G;T5^O)@\!-A$7HP=L@'$852@Q
M:M_S@&>,-5Y^;3,@?A&CC-<N/V9R-IGZ?AWFW\>:LGT]G34X*!J!\V-]C$,
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MC8#EZ[(PR_&YPP:JL#K0%9/WHULH.56B?PE08[E,#8[L*6J/&@]5[$5Y_%C
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M>;$S S1,4-] EPEH,-WAG?-('#6U].7 WO6Q>XLPD:1L)_=?M&@:!C50#";
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MPU(LHD>A,BG=WSGEWPEK(M]4V@^TO#5YESJ4J3:B7[X >BSPY/[Q$<-L#GS
MY3=42UQM*YB^OZAC>A-_T#K&9]A2]9C-N8E*G;E!TUI11V-Z0#LPJ2'^.I'&
MM_<&WI)^EV\-\U[2-+JQS;;M2$=A>M_Y]@'Z)',%BI,2D0Q0RKZ@$(-MZ1A(
M1QML[)7,#:\>KJOW-EX5XL:[%G2)RE]=BML.IT:ZV8OIT]95F*?!ZV!9:R]E
MF1Q$<C65D2YLY826JQ&ZWL,W@_DN'GI*=2P[^<85U< 3&\7IO"NT)\@O$:H
M084@W36L+=YXVIUW;B(\@%Q-8? 2"[K9R77",MR-TSB8(F=!-1B:1JN<Z]H9
MH>SV;/3?ID:H09%S1KL/10P36XA?(!17VAP2LR8Q)#?D558>3ETGL$U1/S=:
M]&QI4[7O$.FFQFFS.$0X>DB"EE&M):6?'6IQ,II DT3F]NIB =\=[.X>!;/I
M\R]3GK_+QYM?$.I$6PR&6H<<,B3EB*G$!3^ O1@VD'#/5U>-XZ=O^V6LP$=[
M##^SQ_3CZW^\/GO#G]L.W55#E9TBTRKQ5\Z8_9FXUZ/QE_:U8/D"!!WC^#I<
M> D+T)(S1QZ1<;53F=R)X_BY1W",G';,A#ZC@XR97XK?EW+SX*#AAB3$ O4[
MAE./!7"(8V'0B#,=/V3;Y5Z)Y]44WUEN.9&=/K^5H6Q*2CE*'.D:N<2*NNL,
MQ2-\(49%3,3H)CC%*[E3U%G;.@X]P["M+CB*!=L$9U/NVVOWC:=+ZMZYQD'1
MS_&#:*DCZR$3:&E<V,8!G*@-NRN'B65 N<YI9:L.]T&0<!;[)BW:><T$UI9H
M#!)U1A+9@ _NI(2$M3:\&0/'=Q"G5+"4N/J]\\R9C T<=M B_ZKQFX5(TZ[3
M7#J"$4GQ7OOJ6/;HR@W\VK N4>.;,;?BJ4LR8ASO1GR,'AXO&Q4GQGRE)06%
M>,D MO[O:-&@"RV3KTS17#8:X=*%@WFRG;RN&G]DL]KO,6RI>#U,60ZK(U^E
M@X8H'(RLVQ/1V$UW ^$;0A$M \CG;-!KB=,0'!SL-9?6TT.<G/2(DS48R_?F
ME_R!^&O1WX;D6]/E@XK//--+/%"'PU@SWNI2_*3R'$<RH\A6YUZ&%7;?(*[
M0BG&>#LJ3"MIU*LVNU;6Y5R9K@>%&A=U4KENM;GWN_A[6QR]K)PLC^]*>EM3
MGG/^,M W4P=+KT5AY)SW5\)$[-Z$NF*F@_?78RI;B0/X/N*M]QIN-;CXW$:2
M&R+4"+$RA98&&;B860LZ7\B +"S6B;\OQ>-K4=C 4$3#+<(IGK][M:,R9";+
MID[._P9?&25,[/NZ; !55LB72T(A8M*8RC+5\>MWF-7>?EV;$*5P,!+1@I$(
MR99+IM+@@9VD_);1/P0SJ"RX0+#X!AK1A3+8;O=P;>'DC3&CK4!)GH\]2[!A
M]FZ@!)U3:P1V3VCR[+,H'[5S4P9C21HEV"+W#)<0MJGLR$1I$U9WOJK45*.@
M&NXOFH#;%M" 6>),$',8?U'IO"NO[9KJ)G&)IK/"?(F[ZY(AYP[ #(_"X11%
M33"WB #;HNT2V]QM$'QP\ Z&_!"?C,RCW75$H!@+X^TF#:9EB9$;HIJ2LQK-
M_NF1E"V:HWBEV]/R>K%?@L_7_=F=="8%@R\)B4X?ALE7.8A<<)GDJ4:TD#1D
M";()D^X';8Z+H;UW0Z1SF<"[^/,(!)K!]88"A(.65>*/Z$O>QA&H,8"WN YD
MP<5!(;4.E6U,L9P#=B5CN9PIT&HQ.P\:#].V1JQ<28R"=GN.[7R$#M0,E!>%
M?"-#2SM"'Q#N20[R+ M_P-GWF/;E7B2737>))&_2$7$GZJX'0*_&0D4Y>IBU
MT C#Y9&7*^N:E0CS\+;: (5:[_<2P!)EDNBD2<'@+W8ZG769(7^/_?%93OEX
M?(#Y(%A14TJK&=1M9J=D997K2F%3L&4;)?4Q.</-T. K4;J0UAC\%?"#YV#0
M5:3,G;O-02C1YIF^,2.5J4E2,=Y38=\)G??34_:6)FHL3&C/D7S/?1/'CBR^
M-&)9#[@'I6[38U9KX\) %)-(2HU=M$H(2ZN23.?^V>08DQR3AM/!ZTFJOB8C
M;A HBI;$V2TAL@#39CY<T*MH\C/$&UEC*&CSJT9J;!%"R1C?]9S+S@W1C#0A
MWN9*<8Q#H-6YM_L"GVV> J-]*<8(^FE: #X;E^8M9M 2,KMU&7S,*$J+GV<H
M"5>?6XSN@-XW? &F.*RC>6-B+B%*4'+83(\>%DB3\?&ON$)HI&PS65D>$SN^
M4B,Z3%@Z=W4UF,31 $R@=J]FAD-/N%>8P;O$^;AFM)13&^KN$4Z%-DBT0^-J
MJEP>,UDK&/09K8 9HZS\^<PT$BB;T'OM.&SI9=W&R;*V-VT;(RY8HCNVF0#@
M>U:ON5DN7!/P( 8*!XG_X_:SE08T2W9CX\[L'PVPL51^">C.,E&;RFH$FI9$
MGX$F/!J$%PPBP<,GF_:[6@2OK O))M5G9I^'3[U)_B7N)/5A$_+LC[I;?:@W
MY,K&+(U%I^T83;FM6\F3_238&C-6I)!&6!:W%G5B!L+X7EVI]%*:T_6-:9S
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MGW<'PZ5_N^ZQP]W!R?'1G1Y[_=\.]^[VS<<TV(.#@TT:[,E*CWU.DLO2"Z<
M#]A__V7_+]8NC-$I_VDW&-(ITL\S'SUM?71O_A4__*)E +<PAG1<[UL/G30N
MZI;2V;U)G1HUTYSK+9:E_=&-6)9SZ0_[G @.MEY)%>4V_4BWS"58 -XM\_06
MZ8.YDH([KM>W'CK[4;G(Z)Z#VQ)\TB0.] ILU*KB:JT@5"M-^*DMW#V?QOM:
MXP=]Y0UG:!2-OTRI-'!']F$\5@I\_VOV-E63-A!>[^QUX8T']2D_N+W<&T$
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MC$;W$;PI\4+=.^2KFLA=[YGZBLTDD'2W$?.NO!S*TO5$SEXVD^E6H!YD&&?
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M99-9PAU!&V>7YMET!QXV6PYL9X2E)K28U6F5S!$L!HLVYC)G4XUDP)B7"4C
M19XBNGM,E#+$ H'/A0>#["H[N:B3)&.,B;T1U; UAHR;U2#/<%#U7FVF;'T[
M9L*K1H>&T(X>7#:9S2-:[M&"#MLL^4I?N,S3>J8\KAA,..*T5 3S9JS]QL'*
MNRS2X K+#K62N26E!:Y5!Q#:W?'&_A4%ZCU;_!]I,"H#H4W51^0QJ(A@ED&*
M\%?X9&90SHM@5!>PL"INO(K$2L]'M 47$%PYX&MX9IE44J9@*R.4QJ;"W_4
M8:T$AXO :A# \\P4P^)7&W0:R'\AKPVP6@-!S"5KL<0BR_7#65N@%//745;M
M9/'W-TZ6"@'@'6T> P/P9V88F).G F@FM]QUKCR@I5WM)01D53'7-IM^0XW;
MC<_LQIVK-J6*=\)<L4(VJ10^42-)E94H5BBEU/P(U41ERH9(B8%NPAH<;]]=
MRA^"3-<EF#B:YV5<%X4B17?#\$:.G0&_X5UNUP<L/\MP9,=%,D(6L5%^J9;O
MX-.K(QTV?/Z^CK2O(_V.I0<?W8*Z5XX5*Y7?&UEO<#S8.]Z]4[W!R>!P_P&
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M$*#&5KBX'Y,7(MVGT3W//6@/" HF.$'<9[0*"-]3Y3:]EO-'=SG!#-J Q6?
M577!L%S4@J!('8R-"&ZB2?E0K39 9N3+Z2/4E,\DTR.[20/0]4%(L#K#N+-[
M#$.)%F/R!O>BY!,V0N0PC1#U614@&+*2,X566?)5CI:<]3NO5_BM"W;6(ERC
M2@#ZJ ]4XE\2P@;SQ&!:U1XZ4TR'=J/MLI5HAM<*#2*N&SU2+EU]TP?)A&]#
MC6_45Z$A>.3B'O03Z6ID2)?&;*%>U_8+W9 3 R_5YWKC[L?/MIEYLS]Z)X?I
M4O0HR#I:(XRZD(;IR.V8%YK<$F0$FZT'P[-!X+98[Q*7QDCL\^0:%QQ7G5'D
MDG(HR >+\*=K#2LRK^O"HA4=T\\K!;AQGB$!C]AP;UF0I;#F\CM@>%=XVF''
M"1,D!J:FMH1[&"5RDN97XDA%35Y;AYXPUX9HAT_0-'4WK[O\KV)XX+*=Q;"?
M"7E=N$P/0?+V4*1NIX/#HY,[-I$_.MU_D+[LQP]"/;9WMV\^IL$>'!QLTF!7
MXXKK2=UZ4K>>U*TG=?OAJ]J3NO6D;@]+ZC:9[$[&&T7JYEK)D6\EWYK6C6?_
M=*FP;CO_]:9[ 3/EZ/CTMDQ8MUR#!R<F\D_DZDQ8O2P_)EG>.PKWAK=F=7M<
MLOP$Q'6#)/(P/#C:NYM KI',K4;LMJ+\K=\F[=VZE_R][- FD;NU\@]#Q@#]
MD S$S<:L#[BA"D2JC/<^6U;19$+U\[KNV2^_M 'S4/(VC 1),5'L-6-;;4#"
MY13?FF7',&D8F-MJC#Y!B\_*CJ+),4=U*+:^.6((P XEX^$QF KCHG+#UZ$7
M!U$?#M)KG.^XF0;519,EA&R$!!".D>F-2^BD#%,N-L6QT *Y_"--VI&P.353
M'K]L&BM#S]8I#7(.LTX*#7P\*TLE^*GW1#/RTC#F?*:D%Z6@/@C^Z0[YD0?+
M@@SWC^^8!3DXOEM;EQO"WZ=[=VN5<E.L_FX9@,<TV(/3A\F"/-!@5Y.N/@O2
M9T'Z+$B?!?GAJ]IG0?HL2)\%::ACSTB.K)',7'R65K*R1K(4"?3ID:<94B9\
M^]Z+IQU3[H7Y<0CSP6$X/'GBN;XG(*X;))%;+)*WZ*O2)T>^\P[!_WSO[>DS
M(W<EQ<R"OT59C=5#PP/=T %CYMP^Y9=79\%9IDKX#58-OD+H_P?NTU &9_%E
M4F))U<M\-DNJ2G&V@S[TR1(B4!W&6UMF;S\=)US-BGT 9O"WV%1[ZZ3!.WB_
MH78>G@R].HZ0RQRJB[B Q= ?YV**<2+$5S,DG,RP?)5*K3VZ98IB8PT26^R-
MAR?7MU (; ,,' 82Q\*H)T%/TV1HFO9[FJ8U&,N#TS0UE-L/DK9GPU.GN0<E
M;YE&=QXM^+@+'7.C-1<V;*)Z2YO8&T75^(()=ZSB^</VO4+2X#AXMG<X./1?
MZ)<4ADXZ%=^ #/1$$8]U5RG75R65&9NIYF^/C[D D307)R0$_IN7<41=!,IW
MP\JL^@3CDQELGV#L$XR//'?6)QC[!&.?8-RXA>L3C ^?8+S.C7Q0U\48QLW*
M*O:W^IS+D\JY] G$7I@?C3 ?A7N[!T];E)^ M&Z00&Z11/;IP_7=H#Y]N#GI
MPZ;ENDJM4M!1;:3;EU.U4*(?2D1E1(NLL@29/(D3FG*&6$1UG@7OQU6.G8_V
M=H?4"3U(RK+FV/SN8-<$YY&=<SK%SLO8Q!)&B)QJJ=.8]7B ;=N[7D.%4/8U
MV/7\?1:<P4/28+@?NLW,YU'"9(?.&S"G.1X7-751D&E);E/>QF^I<HRBP\K!
MR \&)WKD[7RG23]DN7VB7GU*H$E#84E[!-TD;2PN?Z4HQI(__OB$P;L\VWF)
MS'4?\T645HO@H[I45&R&5-'ZC\VTPNHY@Q?NN=I[N!S"\>#TY&Y4;2>#W;WE
M?_Z&X/'QP["?[3\(K]S!R=T>^T,&.SR]VX;]@,'N#4[V]_H<0I]#Z',(?0YA
M,U:USR'T.82'S2&,E9I,UK1(:=G6#O>"#S7<2TAG@+;QIPB,V#.DID87X*=5
M#LQ-"['*[O3/^,'/N+6T3^@_:RKMW2&'=X2B [^O$*>P$*>0H+0,^BTC!C%*
MSQK^9*+*E<-*'>ORV$*W75-<[XC9:7APZUJD;@%_T/!MXY4KIPMZF5M+F3L>
M]C+7R]QWS8#L[=\B [)^TK92@FI5R5O'[?G>F[,FZ:EO=Z-X@W<[=(O7.?6T
MHU'96IB<K81+G@5IHKGL[M, [5B_QZ:8NZ:XWF?B.#P^O359\/*#\&#X@>N]
MS%[F-DGFCL+3HY->YGJ9^XYS.]F[->7'VDG<:BBI%:5O_;9H>&N.\'O9H0VT
M1#<KQ+GKH:H*ZO.X@^@IM":Q^7&.!&.JQ/Q2?*>X_JK.6_^,]7G&O;I?^^LN
M_;-YFHRQ.[![#(+\4J!M:3)1NH5KI'-<2X_"XU3_>[N#IWH!]/;!2O;!Z>"P
M%Y"-3^BN45)X,RZ/#T5>8GL(:@-!'=;Q7]Y-<J>K8G/#U8@A_B$)K,W1!$\[
MG['?"\B/MN_7Y1E/ RVWM]NCY?IG//I04H^6>](HDM-P?[='+O4R]SWG=C?J
MDE[J>JGK-=T]62#KMSW_.:U>X+]Z0%D/*.N!%LUFWZ>;#[7H96Z39.Z.]'*]
MU/52]^0UW3W%1-=O>^['1MNL^%@/M>J?T4.M>JC534B:HUNG1WLDS4/<FM^3
M4V7%Y7KW_&Q=%FPMG]%#CYXT].@.JK-'ECQ$4/@1J<Y-L"'7R Y=$XVYA%X1
M26^E+=X#0Q3ZH- :JLSA27A\VA>W]D+W?;/%MV?TZ66NE[EOD[G=X\V7N4<>
MZ#G=?Z)AGL<5YU_)U/Q^N(L>,;:&\C_<#_=.CS8>,M8+W28)W5V8?'J9ZV7N
MVV1N?V_S9>Z1A\E/AT\T2+YZT[.]N8_HW3_Z82W/SLH@3LIQ79;4TRMXEU<J
M.$1;$9MZO<QQ@/@G^!?U)R!+\I<DB[)Q B;HIPI^@6GTDMIYC>%]"08[X?N%
M&N?3#(:R/"0ZR3DQ?Q/E/_V*/WA]M6.P%<%\U 2FZ<QF>Q#<U$7+Z9GU0+M
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M"?9RB0N"[I""^<$^PWOD$2.5P0<K(XS6,($O-F/T9&+ +R+\_R"K9]C"&=<
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MAQ8% 4F":X$D*^*WUTK(&CQ-X]5DCGJAB+TLV-/0V0D+Z'5\&R,#&LD4<L#
MM"DR9CO\$@,_N%?=C$^VAL!WC<VS8JIQ(4,!Q^+:[-IWV_R+@&,R&WX1_*$X
M1_ML;W#J*6S:N&>[S=_J,ZWISO#2!R&#DRJH,@1O%"BS&.Y#Y\86=LPU=/L6
M-XJMT)*X&T@N @@W7GH<SV>CI<?@(F'7QQQ0I,.A;?J&->XVPJ-F;[-YFB]
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M+3ON1E,A'US,3#*1,#D36<R&4LZ-#-O -UW?R46>D\<BP'DZ4*6Y4O#(\FJ
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M$G.FZRE),.#AB[DMU^Z=4FDF'T/2FEB&NXN P%S*OVZN68[;!5WL3 <I3RU
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M\&5,+IZKD*2^;?\M_6]P) A:297/T;'O(=&6%;3AT:6['CLKG39-.OE@;EL
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MX44BCK).VA7)@[)O_$)Y2KOD)FWM0FM<M0MJD:$7&PS_>^5@:C+0C.,LKO"
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M28\(_). !B,W"'W\,>]10'W8TRAY=$"><T@9F#7^S/4%U 8WS#Q+SW.^:=@
MZP(K3-(<1193D9KP $J0>C<L8;GAP^S2GW ;BK_/>0L%A@JZK@KJU5T96LSH
M$_B"<;8N!=WE#6BWV,"(K_C;G<LI73%D8",NI2X[?ZU3S7@Q[J8,]770Z67.
MK$2KS6U6:**7:HPH5NBK*ZIR+$F9JW</1SLJYI%YR:OR=YXANE^HX5O[G5C
M*5/IBJO9FAEG"N5!H/,C08)WD8U10^T!XI9:A'J0G-O1\M46/KI98F!@6C<!
ME&1W0XW2S"MWG7(-,@(!S6P5L -HCMT )N\QQJYG5 .JAS=O0/%PVM4,,T#P
M!OK6K_HF.KH9O<EE<R86-@==A<<S,<V3-[9)*&8.F]T8W].U_]_)*;_Y=^^
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MY-*TF;,F); GF6LW685["5^38(>3/ 4*R]JJ=A[/M0:&2H3FH0=<$0DFR51
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M5C2FK3M5F\[;> D4LP'FSE8,9M2Z9-LI9_74.+M1@0M5;P7_0'<CYDP\/G1
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MHQ0YK-W5!5;*9\=3)<J$2?-MH/XPT@"KLJYW_4_ZVLA/1O/R@@AS$E%4D(;
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M?/7QM&K'0U?S,70F\'(Y+V%ZQEWN-:=9R&UIE\$X4;9@3WI6/2B=FE;E_72
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ME>>1P6;A$$46T->^1/Q0L<7B_\BGGES!N8^J[T;SZ7:,,Y*>)E_AL'Q5<F6
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M/Z%RPH!&6[7$<A#)7QYX#NC'=NVU6"^NC<)0W#T^09W8F33?Z6G^DZ]6P]@
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M(YR62T^B1 9H6J47Y+LJ69)OEW!_0ZU7SWZ[$TYQZGT6,]/2J)#I!O?32K<
MMT^"F ,(>\ERQ1<$N8G*X;2.(7:7W1:W,'1_YF\,;5 5GA<Q(;_M_6//345:
M>S[>5/ LTJ.HW3)[O^TEC+/ !/N.NI^J[&/>\.R.W5I1A@0) .&B=\,NISK%
MV<<5>%-*PV2LX[EM,SO,QHSYU)N,&N183JB4:=$[H?0[*N@B)7+#!B4D:;#S
MS[T@/28W\2.F9P?1Z2J%&R"[7/PCZ>JX0&;;&4ED*@*TE&Y\D7(^HREA,.\5
MPV-H*7=$G0EZLX0GEZOX^\R%'-E%67W07:-]<U K5G;?@6FR5P"UZ3;:G ;S
M7X$<&)N*TNSXNW.*G(F*;:J9[:LF%U\I21%W:9-+D($LT5T@SNC[Q+.$K&U3
M4BPV,18%V6AW;5=8&2J]+73BY?%G93G=^$C<[D0W2[20>I7Q7T3=).'/!_]B
ME97.)[AL-BDEIMK-VAD9/"!=&\__=JW9$XY[3J>(J01DF?Q>:U5]B[&G?;[$
M9O[I@!,/]K? B1LPEF^JOW.SO;6?-SI3\,+Z*:,V\"0L4TKN>%<*77 2>/\
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M4;S4P;OS+WXX*50]R3__U\5PSEI$>H(.]60NC;?CR2>8(.[BW+V?C#]/_/F
MH26EO.6XDR8TL[RQ* X'A%D+H(P$DU:VEG6?^(#Q'SDQ^I+\.EED;8-S8"A(
MS@/N==YI(F5TQ%&TKHS-""?@]+7LP]!\Y)2H(M]U?:M#];V,X(P^OQM%=()^
M'4^G Y6%$5%)8LO!HJ0>*6B0@OA_EME\T8HM5+X!RZ-W*PZ5;P-CX??Q:'P;
MU9*,5P1/Q@;)DR/&YT D8XP$YSSQ-@:?LY'<-S$7[D7VZ.E05_:UC05$]]I/
M3]^-9C"!Z:5Q^P'.R@;U:?S1G\%)_C#^YL]F0URZI LL".90C19-W< TL48)
M(IQTQH,5CLM.1L)NX_9/@LI:&_<C\@;NYZ]#'X9GPP+E+1HW_]N?7<#+]/]?
M3&?E%1EP(12%$ GU4B(Z#<1)I8A6:,8H8"RU\3_OAO54^-) "0UVE[EYNU4
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MMUG93M;,/0/U6[FID6[&C01;\6A@<:QQ$]A[G/$()I=EI:1+U'E&*."6*8W
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MD$&0)$I4G9=&;(HSHJU/.G"7@;<]QS@>P>Z)SCPX?NVBJI:\>C?Z<C&;SB7
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M4%0\$9^I(-:[D(UWC+M[G:F#47RG6V/-52_%>P#PE06:,B=$DI*87'( ;2F
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MAT$ !L"51?.UU/\5VA+K09*8!.Z2R:DLVS9;[7O&W]^GQTB]EH4@JQJ:B=+
M-2^-Q+7"2>5(; B&>.ZMID C:W/6V(-O<M3HR.*X,2:>O:&&&%=R.@5#9YMF
M@Y2Q+E$6&95MB]=5FDCOO7B>8,1C=T8<.PMR0Z'!J_?M]9F?3N<G9)';1+6U
M)-#@%\<?+GI.@D[@4^966FC*\4VHCEYP]BA\V5YW]D"]M:S6>+BD5J>W/.;K
M,L%>2M2VFN'1R]H>RJIVBVU%2CQ*[J,U)Y4N 4.CBEDG(G&EI[GQ.C%J36EL
M^)WS7;-#'C/E=V%" ZI?'Q6_'8[\J'1Q>3>:HM4R3]^[->M%M7WM(#J4HR@%
M/23(0*S**%85)4W2LZ":6!,[XGS47GD-IFR]X%9?S7WDS-P(/Y_Y&:39N#2&
M'>>W%S,4\(?Q-W\V[P>_1Z)+UT<?G)VRUQQ64DJH4I #&%R_LG1@@P3G;%!!
M"ZN4L(,]9M- #_L7;]QM@+YTTJ'@(DU4)FN\CUY+%[.SC/.L4Y8R,"X[:^:P
M4HH=![EYB3J/)^?S96>1(M10:7>-VI<F.\]\1;V"!Z9T8"GH@.KUWN)"F%'7
M3#DA8^BJWKO&/^!,>'7T3_/13U9'OPZZ")LSSH@1.[]\RH(DGAE)6&(YZ-(<
MV70KK+'KR <=?;^?C"- FK[%[7<QS/LQJFF&V]G*>+],QE.<9>+1RT1)N4N+
MVQA'(Y YG"]:@5[C7'C'\B$[#MR?^=%>^[<.DULJH':IP1NW2TIB\'1%.-N
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MJJ"-!,:#,*ORNT:Z?'W+EX"+TG_^V_\%4$L#!!0    ( .*@IE*E]#). +
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MI5AP]86%V/=AP ,*49I$$&/,(45,2-^+L2"^5=##&%+.C9HV2NJ)MU%S,^_
MN4/S&[!35K^X4[<]\P:UPLIFT"I;[C6-\W$8!D8\]Y!/& 6QC6[8G1;?@-;5
MX8TM2!ZR%5EJG=2(WQ=K]?2E(;4/:A@3<J<1#*,(.FVXPIA8'\4FC-K9L(7G
M]I%D2]W.FZ+\0I9*(K8NLY6VA 5=[?ZUX%QZ). <,H$01)CI</*(PUA22:1
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MY00*YGD8">9SW\AC->QO;JS21BSMR=R)6VHE!UITVV"O?MS[^64$-$=F&!=
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M*>EN=[6$NF4"-DJ"(C],0#>T:(.+(3?C_V<;R)'7 7=C.%'A!X?PCU,-PH6
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MP#W VJ[I+&N+D$8LIH3 4.B]/RP8))0(&/,DX3CV$8_"Q4-=O_'+BI0KPQW
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M?V@^E$?5CUHX_E:4O]>[PTRT5PX_"YV$6%0+%HN0X"A6]E&"E;<0)!!CSF'
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M;N_NROI2!BB4TFTMNHP9'CI:P6U@7XT XMA,T=XCJ66^:4\(=F+KS)D=P4=
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MKC401H'Z6R@A)P'A2*21H,8I@TYU,+>ULRLCT$*:9Q(ZB5__TN8"E9%7J"-
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M&&T#_]$QAN.;)S5\&W%!+>^F>G=U\:;-,!@M7$K'<$[D6%[X*@%K)'?E75J
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M'LIN)*&C ]ZMZ.C3U37?/-5MC-K;>E4G*TL8"TD:0RI5#!&2*60X4%!R@JA
M*./**C3OXDQ3V[ ,K:!IG-6BUJ7_:!>P%D<U7W -K-_/(=6G2%LG9"Y-6SU!
M-U;;5@/A2PUAR\'@K4NK!1S=?5J[!ABQ4ZL%'_N]6FU>Z'<DJ>X;9Q@EJ3X1
M!% 0I0\* 6:0TD3",#;U:A.2B(RX./6K8:?FMO]AYNAUY5_#9&<ENS,_L&Z[
M[^;8V8+<9]"G75>//*JUM<_-H0UT\*]]RKS*/]<TCQ/\9<Y-CZ]Z'Z!A% O&
M$>0I)A#%$D&2!3&,0H*"(,V2,+!/93H]Q]2LD8I*H,D$-9TNE4]/PVAA@5P/
MSL#K\QB77J5A3P/D4B/V:J#&*A:[ VQ1D>K+QNB&H+MJ[.E71RP?VTG[?AW9
M[D>OL27>U_%P$958\)3!D# !411R2&0HH& Q5PRA(*&9NTGQOD<PX6B611VS
M=86%\=XIF+ W)*/8&W?@O>_8P9,,^[<_WM\B5O D;Z>MD<.'W L4UB-\FA><
M+OX?2?./2_&!KN4L2JG"@8Q@A G6JS;!$&<B@$@2&B#3UR*-;&L3GIMD:F9)
M32>H" 6&4O#1=!C5M-J7)#P+:?=:]@74P$NZ%T9.10@O@7!%_<&S0X]6>O 2
M<^VJ@Q>?[;<[?Z+S_'_1Q4;O]=1X98V99@J _;Y<L4+FKZ84QN?ERV9=F*IZ
M2SY?S.N"-F9;FR^?WM%B7GRI4W??/A?%1A:SA"6,$D9AFB:9/L6H#+(PXY"&
M89I*@424.J4.#$+EY!1.U0J:R_G+NJX;__W3_W"S%X81IYW=<7,A#:SL#'^@
M9/ .M%BL*B*VF005EV"?S3NP9124G-Z!+:]WP'!+M<+PZ(\95!X^S:MA"!W5
M3!L4ZT-S;]C)>OBR.I+4OYB_?YL__5P_J-\+62>RF##0_4>^[(H_S$042<53
MO7NP6-N86(20*:E-3A20,$ 12[B<+>63J:AFX07S2YV50B*50FK3.& ,PK;
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MC 6,<>*60=6?EJFIP]T&OBC+_N2&-;A2<&-:+!KN#CK&R::;B[&9JG<6%N6
MO,O4\IYS'$D-?2O:"$7S 4I&0,.)$<G'MDAV BW9V=9J.E\EW_TJ]7I0O5Z\
M7D'.N->TU^-V=*GK8<B^'JB%_NO*C/PJ[_/<3%:ZO^^7HJSU<?J?6[%RK7[D
M/.*2,8(AJP(^L(!$*:I_BKC2_Q8ZM^_T1]S4-/8>;Z#-7!EPK]F#_-PC[?#\
M/MWF!Q&^K?_L-B(=W.%V3E1&F.V_5]D8:[VJP?Y+5F+LX:#SC[=?CYY'^D9V
M ?I']MAG., <?9V,KWKD5?Y6!8::N- R+'2&L% HE0PR%9G4B" V/PDH:$1(
M&NM= %DY'BY--#4%OJ73U=-X!D=;E^/UZ SN>ZQ)O -U$/&@P<27$/'K9CPS
MU\C^QFZ.CQV/%YZ_IECH#_IW7?G@G5Q*-5_/0A;S((XI#$4<Z,.YC"#3]A\D
M"9,4)0%%8>98S/C4/%/3!X]>"W,>PVJK'ZX&:W#UT!2X;$J9@%]J*CUV,KR
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M7YW.I7"DV"<-%UMNIV$W@'2?OAQ P%T Y<V</HW$,?V&K\(Z7+ U$4Q&98P
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M\SOY)GKJP ;=X.M>IB,XID,)(+BRH)3F$%AT()-S/C(5#6N23WZ8I'&O6=M
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M==]N^E%B%$59F<#J.FM0\@A>NP#!6%U<%%;8)H?BHU1U J@]U/T0<@Z6?0=
MNL/#1<<OJP6W">GPWG0*8 PA)C10L!!WW')EFM0U;Z6F$^ <KNV[M]('B[X#
M_-SHNW_1RJTPHR3# DGJ2$8Y"9)&)'Z$,B$P4X)H4L-\CY)Q<3. =A\><;"'
MJ#O R@,CY2^8J8-WH]06G"X(*IL +I< VL>,P0598I-#ZU&JQLV'#8^AX530
M YZ^/R3^@K$<O2>^$'B=Q:QJUH-$)L$EP:1S*%AJ,MAA9PK'S1DTP%D3U72
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M)'Q:/%64PH@8B%70Z%1]@5O HPS@.>=.JHR>MREK:L#,R#VQCXOCT='0R52
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M:7<2NPS[6X&SD>8Z<&-_+@53?:SW1_H2YI_Q [E>[S:=2NK_:LSX+<QP\PB
MY#A-%-+5'] Y<OL;-WYS0@+.SCJ**I,E2?/Z/H!;"AA2U)QQ:Y,3+<#;@)=Q
M4PC-'.&QM=Z!,3Z(V?,&\?>K+-+LM/9?OBG6<U%/G)%*6)7!HZT=F6T$7ZR
M'+UE)0GI;9-LV7'9'#>WT6R[=(R5#HZ0P\R&D=&EQ$@;#NF\Y%Z"ETI"4ED4
M5)F35]C=QABWRK9/G#])D]T,ZSJ,Y<*X9#X[2)QI4-9J<(H<2SH!$T9R!"F$
M?I[@;5:6VREXGZ+)7B8FG'[].MN(,LPN1?EF7A;+DW-E7@K5I!)E*@&\J:T$
M41ARS&0$'DR4+!F&;?I3[$C?N 6YS>#80CL=N,V7_2OK5"6*BB?%<U>$$"!+
MX:",]N"S96"DSC(;%[5N]&S_%ATC=ZIOH>M[)=W["[X#W-QY._LNGL]+?S._
M]']?+Y;;G]*>32*3D;':2#WZ4.^K&0G0*[!)*)X#[4;5)&5[ ,TC%\P> 8_'
M4NA@V!UTFLR[Y><POVBE%N;YX^G)25B>+<K'Z>?YM$Q3+;DX?QE9AS$N9M-4
M4Z:W6-IMGLQ^"PTP468 #@>:*7.3DNOQ-N<M[=[?X.Y=N<C'AMGUY)OKYS32
ME&R8A"BC!*64!X<\D8.'(@F*6[)MTZ5K".H/;EYV"!&OIJLT6ZQ.EYO;P\?4
M_XDT_A.M^]M$JFABT@6"CW5PLQ$02D20,@F68S&E-)F??6Q&Q_4[CK\S[O56
MZQE8?Z*CX^A'R.A'R3,X4D)FY"ZI#-%B(2Q&3JCD!HS(BDL14TI-'LN,>J1L
M.N7<I&"CJ+/S/Z_W*?<^:%TR6,<CJ,@\U*'28-$Y&:W.CIOO 7>WI?X,)O@I
M2+K5LFA81700)]Z2X5U>DA".(]E]3-Q1O&))3+;V+(["<NVDD*Y) X['B!HW
MTAL/?H,KK /P43#[KOR\6D\I3L8Z52!J+CGY1"[2ULE:@6?*0M+2IF2RMK')
MG>UM,L8MM!D?8 <HI0-(O5].%\NK>?*SL%IM/)Z-!*\ZT+["55I.OV[ZLJ.3
M*(A'*%J8>A%!0I.J@%;&(_-%%M.H/O%IA(Y;&3,^+)LJM@/@?L3/E8,/^+4.
M#;CPR^]Y%R2SC-YJB*&&8\4%B"ZS6C^,2F%.-C8I]=J)NG&K4<:'Z/ J[ "7
M),I:R[[<R.[#=/7;2Z)ANJY?34*1S@CKH?"LR=<EZ$3!+42F>' >8S2QD7_X
M$$WC5HJ,C\&AU-4%\F;TW<5R4YC^8KFLEQQ54'=R%V<3G23+1C)P9.!I1X4(
M/@L!V?M8F.19M'FYO2N!XQ: ](#)!HKL * 7@T[K"XIM[;[N&GZF-4O()*!Q
M-95*KDE]_0O1B\ P2)=;C;Y["IGCEH>,#]:&2NT"LML&^UW,9[G8A9G+$*0(
M@%;3,2&C ?),-/T54XD)G6Y3.KT#;>..,.D!G,.JKP-$GH]_^13^N+>S)"?A
M$%+06@XJ>4Z.2F @>,@I:.F<:6(N'R)HM[PW^_.";Q!-=8&X\\$7]R*S:)D(
MJ,F6ZYJZY_25CV35@RZ.65YJ\^(VB-M.T&Z(^Q->M0RJJ3_1K?0K7(?I[&AW
MTA?+C74CO8W;KNZC;1*9XA(-,4I17[@&<+Q8D$AQC!,QWKMS_3/>1[^XTN>[
MQ_7Y:3.PP',FBC$,0A&2W!.;P;/,($ERHTF:R2?Y/30?2,.?X0;[*=A[\ :[
MH>I&/.=7R_7D964 EZ21]=FOX01?_#%=32)#B2+FVMS;U><%D0X,4<"YPH.B
M8"W[77I5T>??V*OTM[O[]"$"QL'=4;6^&% %(T/H WX]I5 KK/#%YR5NMM]=
MEEXM3L)T/E')%HE<0]:*O!$C+01R>L@OJ0VT/7DG:I<T^$ZXVIFJ<< VC.(7
MK;4P]H#MGW[Y>",I2BJYY.T7/(FXG#".P=/N@N2+(J<Y" B&!\A8&/F]P17M
M=CHDO[/0>"!II-=%(R&/#9A;C+PG"<UQ><%&4CXS'S@P)".MK"3[G RQ(:6)
M%&4YGG8;7_CP&N/47!T))@.)=N33ZOURD4_3^MWR(RZ_3=.YT;5T1*-D",+7
MELTB!(K"C8>@E"9I%>M3&.I@VD; .+@9R^$Y6 5]0*AV [_@8'6QMX(2F7L4
M("LGRM;)L"@U.!W01N.S%[O42#T%1_>I&.^L.ERQ]U%RH)3'/H]^_1^?/G#'
M+T]2)80PH78PK#D^M>D0ERR(D%C@1EC!_$Y'T*V/'5WAA^IH,8C QE;U7I;T
M[72.;]9XLIHDB\4Y90$U2\0J[9,@DH*B2'#1"TRV8;[GBHYQJGK'.(J.K;2Q
M\5D?7-_N,W*GUPCQ?W=HP'D_[$U&;6*18E.#")R97-OH)'!>29"%W#P5G#,Y
M[^8_'T;(<\L.[8F6Q4BJZ^#B\=?3:OQOC#"_*!BMC55+LIQX*$9YDF"M">4D
M1B]YIEC4*Z?:="I_B*+GYKD?!L9A%=0!TBZG1'_ A+27:/?4CJJGRRK\B=+"
MQ\ \9*84'2K!023O V)F0KABHD]-7G4]1M1S.YZ'P=M@:MH;<M]P&1=#@6XV
M6_Q>6Z&3I7ZU.(WK<CJ[S^'$(2I=)YXJ96-]HU;'I1&'*07.4M"&?.(F\-N)
MO'&>V8P.Q.%5-[9;^(_E=(WO2GE7K@>=39C7G&<C@ LM0*4Z_434_G,J:IU3
M%'''5]+;/GV<YR^C.G '"[F#L_+]18+YY>+D9+H^?\!38WV2U"_TY\GIR8N3
M*KGSGY.?.LE*!RVM(K>3&[+,BA@L+@&)BN4L7=*J267BDRD=YS',V,:LK4+'
MMFOG4_ ^KA?IM_\59J?XXG3]9;&<_F=M!?9I&>:KD#;/'V4,012L=UI6U@(1
M4_OB,]"HN36997ZW_](#IF['!<=YY#*J]6NABCZK%6M8'N;Y1NP]G?\2EK_A
MNOH%-\:J[E&:N/-G#U"'N!\? Q4=O@[3Y08GUWV8;D[+*+:Z]$#KD GB3$$4
MWH(BSRHF+9/CKL69\AA1#7H]T_;<)N\;M>0Y*<XE X_TARJ8(#CCP# ;<BK,
M>FSR''\/6L<M(QP,33OT=1Y4:\_;PFWR\DWMW,4*1[1VVW@ZALUS*=@2"98L
MEGJ9%@JXR BOB7F+(<=LF_3S:FGS/J8OF$^K7[!]'WTD#V']"9<G-[2RD?_U
M9LHZ>E,< I8ZPMC7^9_H(CA+3HHI4L321"R'D]ZQ17P*UN[U=3BN3CN(B:]$
MN>DUO/H%0Y5F?C?_4(W&DMSHG\)J>N, 4-+;F+4$J56NS58BU-DI8*.55KIZ
MX.Q2:;3_5MZ1T'&[AS5#:%-]/>\#>]??NQH0=&=_[__FZL@4'M%A:"'38S@<
MT5EIF*!(/[I06^\H\)Q"<HXQD -+#K-KDKAKZ7!</1*Z'MVYNOK>N3GX*<QJ
M;O_C%\3UWY:+TZ^DD1MVQP@ZF*(!@V[3CCA!Q*0AZ)2TS=[RW.3N^5#".W8V
MGH*S>Z;\F/KLP-6XF!1TUZM:OPS+Y1DQMA'RQ C/O=&) DPNB"ET0$(,P&-@
MPCM9+-OEZ=9>:8'O4C<R$H\*F"W)@F&UUP$D[Y8<71]HKS"N;QR#%S?U-HE0
M%.<0G:QCD8,&GR.#$"6JP#23KDGS_2?2.;+O.R9,6VKT&0'VU\4\77#H*)[@
MIO;UQZA F>@A&.\ ?5"LN&B%;%,$]&12Q^W'^RQ@NZ=>Q[[*/+3\4Y(P'<^U
M)*HD4(+B5Z>T@I*<\0(-Q;"EF\K=9JUY1T'HT?4WV-S=49(0+W*>;GJ?S&Z,
M!6N?67ALV2.F"W;F_B@7K3Z$8(,BC.M8:SWH5$_U-7HL)3CK2FF<J1PP!W"U
M"U_<TL*;AV]Y)MD&+P.G32;)GU&\T)Z3SD'661@MN IIM[*0)RW;<:S^%#S<
MLWYMY#YVXXO:GW7SQC&C8%9&A,*"(V="2(@Z9# B&>F9X3;NDB_;K;'%Y:HC
MOH-IJ-+%H?+M 107KQ<Y<R%:7\#6]_;*VLU3^PQ<9!8Q%,?%+K4JN\-B[/>@
M>VKLKL[W$-_(6K^HE[P@W L5BB$5D=.&M3VS@Y!) DZ:8A)*C\/U3[JU\LB:
MWT=OBR&$.+;VPQ\W"&>%SO_:R-%*5:?!A )>%@^9,X667'F9=QD]L9OV;ZX\
M8O>1(;2_MQ![",]W.0W?7E72.F+"LZ* 0DK"MDL!? X:4E3".E0LL!U;T3QU
MZ1'?*[9W&HZ@C;&Q5O-9UZQ=[IFPKDR=G4_]F11G27H,09)?3OSX!#Y) <%)
M]+0#A0MV)W3ML-@S<$+W5/2BH=1[0]$Y([4R:V)SX*XP!\R0>)12%.&I4J?N
M&)L,*IX9VPL\UVL\ QO4 #-[RGALJ+Q=S#_?+MF[@WLK12'J.928B1GM$")Y
M_D#N&_-&1%50[ 28[ZTTXM/G(\)F4'EW>.5V^T+F14JG)Z>SL,;\M^5BM?K[
M?(EA5E\&_2U,YS]A62QK(_V)(X%%09Y@34*!8N07!$?;1EI&T0$*GQL]Q1^"
M^A&?2A\'N./I^AD#_"W][9II9DI(5CD*=).YN$CG6$!SY:.K1\).G>..!O!;
MU(_XH/MY 'Q_73_OFN+WB^6Z+&;3Q:+L^D_:7_;M3]01KP('DMPQ+@JY%*YH
MQD"F&JG+:"'(^FZ#(3-DR!//S^Y%YIUW F1AWDY#G,XV@M[R:H!^X=<%;?=;
MCP@V>0QI4W"A2."2)U 85)T_H,!(D9BPTB79MI3Z4 XZOI)\"O*^\Q+D2!KN
MP%^YMB.?Z%]L+FN\8)I'Y!!#?71EBH!0CT2OT6".-EJT+3!ZGY1.P'9<3&P9
MYG2 @KJ#V$MRB#[7=@\;/5[D]S73I9B4(-EZ/XBT:[UP# )+J+73Z'.CH77?
M(VU<"!ZJ_$>Q=+ F.L#6R\7R:^U!?\?WOF F!E^<L'5^6FU04V>&!Y\*<231
M!QE++$W>Z#Q*54^(.AP"]V86#Z6/+L!U<H++6@_Z/GR]FFY@D(N,QD*TN@ZB
MS[DV+Y=U=H(L 9V)IDVKC6W4C/LXH3F8#I5_!R#Z^\>_+;[A<KZ9W/T9Y^E>
M&?H%7\(8SYD60"*AS9$YV70;#%B;=1'*"W6WX_<PN-J5P'$?%#2&6A,M=8"^
M7Q9S/#M/#[P^G>=++A*KN2W:/DE+6YND>O"<9^":H0B)G K79%;U=G+&?0C0
M&%D#:* #'+W$Y7K3$VZ-JW?E%7Y=K*:7 Z&\+SP;4G9Q-8%9ZBQW37&.D1E#
MD-+[-N_X'J%IG!3TL8[%@731 :RN0NR?SJZ^_/<I+HFH+V=OZZCV3<S###F.
MADM(HA:1&8T0:Q"ME/$2I2<SW+;CT:/D==(<9=0L10-%]@3/"SF>/Q*[Q]_U
M*#5&=$K(,I!)%[79O18<C O91.$+BK:YW5VH["2E-B!,'D+BX#KK"9!OYE]/
MUZN-Q,1E<,U#+'54J(^;"#LA.(<>(G-2HQ,B^=(4?O=IZ@1LPR/A(<P=J)9.
M$78Y?LM(E:13&AC6U*-*'")7Y,.$Q$O(3"5LT_+F89HZ.7M'0=@^:ND)80<X
M+-?U&\5+I4.59^8!%+<"8N .=!;%B" 9RTVR<8-R,7*OAKX\R*/#HH,]\9U*
MHI,%17S_B?GE8K7>,#IQ1 1/T8"5$HG)0*&C5 *R-CEY"BX%;^)K/I703CR
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M@SUR?4R^GLX#<5?C\:OS\I:4SJ<-&X_)D]QEO315J"(X79_IZ*185H%'W<2
M/Y'.3O#;!\H>#'2'5WD'B!Y0^->)!9<%BRIJ\!3"@;**SE1;/(2BR!F,WG+A
M.C?T;Y]4:]=^:E57[LY86/ES[9>789;JH"/Z\L-B-GN]6/X>EGD20@Z:D^V(
MH=;Z*BG Y>1 %!VB")+,5Y-'&LTY^].<,GN"M]UN&@!)/6VM&XGD?TS77^XQ
MO[K-_>K#G5$3%Q[ YK,FZ!7?%$UPC*[VLJC-X:LKD$AY/*:@>-N9S$-R\Z?9
M0D,@=H>Y]L>%S]Y[Z.OFDOGC.BS7AU_[[BN'!\10>VL22U]>W$K!__S'5YRO
M<*)DD5%P"]EA?9AB/;AB#104(B0E-(EAI_OB8U+]IW'I!MQ%?4/G&9].#\CF
MS6IUBJM)4I(5;R/0=BB@'$,@KR%!M+P66A<5O>KI='J4FTX&G':UK_J!SY]O
M#]6!R'4H[)MYFIUFS&_F[]9?</ER<4(,?B$CL[G.2HL3G-2N]BBT(T>=D^JD
M<> "*@I[)9WIV>NBFC2L&XWC3N:S_E?8BXU@V,_0XC:>=68L"B-RG5A>D[(E
M@8O10A#!&88L\3;-*,8+S-I/GOU3;;?AX'-@8/;S/+<J,+OA*V]&GJ\7=6SE
MHKP^79.D/BS.PFPS;7N/JK!=/WJ 4JZ]N!BH_FIC:V_@?DN!2@@JI<@RQ)(R
M**T#H83LKRB%%<6BP]@D!?1]T@X*].]*_=-&ZN_*^P4)=CT-LSOBO^[ORG(H
M.3L-)7M! E$,'(\2M)>Q1&TH(MOM+=C>)(R;R!H8,[=BZ.-HI<]RV1WMP/[M
MT9^VP/$L6\.6YCM@-7-MM3<,O%(<%$]T%";!@?E2C'!,1BV?H7V[[C/RY#UU
MNYTUT@9RBE. C$'51SL&0B97(3IR:@IG]4G:3N9N*(JZMWY/0=3M%GICZ.Q9
M&\.;+WO*8GFR6?6\8+VAA7QLU>.9S9UY/YXM54D*Q@T'BZSB+M(>8!2FDP7T
MS 49&'^.MO2AW;AM$TY49"KY4,@1T35+42?/,I1@I),\J"#LW4D83W0/MZW:
MO4U\"C)V\@@/EGT'&=W:H^Y=N?E0L=:<EL2U*NC )TFBLI[<Z%@<)')PD9&X
MT#1)[6RE9AQ@-=;\8F@U=("E^\\9P_87C!>5EL$;99T4Q$_-23$CP9E(H&"2
MO!2;+-YM%3$,RIY(Y[B&;0!D+(ZGIK&?S+^_;#$]SW6G7KU*),,O+MAQR8I0
MM ;-A:RCSNI8=A' 9B-UMDFSR'<Z'+^_UKC(::KG13NA]XLAP2Y%)11+IBC
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M2O5FF"BE,*VQS7NN/\'=[Y.0<>#=[U/4-':0LL,UI&8^!4R&1%>W:0P%@J+
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M.V^GIQ-DC1LW#*"J#A"W:2M"*U<Q?L3EMVDB$;TK6[A;U>9(J^T_NMC%1;N
MV3O PC?MK4F>V@JPY$$(ZZ2QH4TGLP&9&-GS&P)5=]N=C:7B#N#]<K'\NEAN
M&F7&]<=J BZLQ/GIH(N-M1.[K[/IE*NG@RH*C%5)!A84F846>'V4JI$[H(T&
MEGO/E8?27!<P/#G!9172^_ 5EQ=,9)DB,1' ZUIPY@V"4]J!M<YZ$[.7L<D5
MR%9JQHU'.H+=H9KJ &Y___BWQ3=<SC?'Q]7#\6W;R#OT7%OP?M,W+).D I,@
MM'*>924,:W)@[TK@N(YF-Z!LHL\.</K+8HYGOX3E;[A^?3K/EUSHG#5J2ZC)
MQ( 2C/AQ+@"K"2FAI"JA21'X=G+&F;30'08'T%4'B!LB=GQ[/1<@,RTTQ8]*
MUGE2QB>(WEO@WO+(@R_L[FB0?LK!WC[IS5HS?'<2S(\&BP[VQ(MO83JK(GR]
M6-9V:M>GRNTS9J(%MY:3[\.R(^9"IKVN1&T)%+2/*7H>FX1+NQ+8R:7-\3%T
MM^=T"X5V -0W\V^X6M].)%]7DDZ2T9R.(I)6G3FO,"8(2.ZZBUS*HF*MF&H!
MS\?)ZN2>9W10#JB\#J!X+LYMC&1AI$CH()A86[3Q E%H!D)8PR-SWHHF/L&#
M%#W_9/U 5G$0E>V/O<4ZS ;!WBM<3K^%VIGTABA)-%$GA@FTKFT=G*_3JH0!
M01&A02.YC4TJS;92\_Q]RF$P=[BJ^GQ@]7::<+["37/"&4&T)FJK<B\;R>\Y
MGNM['SK(T*TG47[@DZN+IL6;)5\\N.35$YA(P;1S+(#4.H%*5D,T$J%D8[T3
M=>9<^9X4G[;DX8GMJX__AC?F%VSK*&H*61!;"G#G)'F;2H(/*9%!<5BRME*F
M1NU@=Z9QU&[I+5!R/[W=1E_/U$SM_S1^UX\^ALEJ\&C^B9 ,/@@1E:_]6.B@
M9(4<=^LS$%2YBJ@)GIT9KNLGTP]MB8L1+.F!']^<QW+G 37S6::B&.B:8566
M/ 8O3*@#D[DT14G/F]RJ-.3I61C&IZ#PX2?TX^+AF1K2BU^X]5/Z[<V@R _X
M#>>GN'_/[0%7/X8YWE,6Q[78#A,F8S@P*3(HM A>,DF8K"&-"R7CCFT46UOL
MW58YOP.P.<IB"X?(:F_+.@PKU+*0J(I6M1(TY]U&A>VVWK.PBD_1])U93H/+
M?,3,7<;I>3?,G^?KZ?K\&:TU%,D7<FZE3:Y>7GJ@OSH(6FK!Z*N<MN3J5I<G
M]0K37S\OOOU('WU^2-,7=\_F+<OVC)H]5+H81KXC0^.<ZHM[<HL.L<Z]TUS3
MEJG=QF+T#BQWS&@1;&1;;A*>C(N;:XX#BH.5MAA @F,W&?YI.5VM%[-?SNCC
M/O['Z33&EXN3KV%^=ODR&1T/SCK0/GAR*P,G6<10\X'%\!RLB+M-"_S.0N-!
M8'_5+1K)<6Q,_#R;OIW.9F<;2WF3"1:MM!GK4$1&I'M!!ZE)&9(C>UDB':9)
M[P2&AU88Y[YP.!0,(KFQU;_QU=^'Y7I^50+J:I63U0$P;MZJ>0VNSGPS]<EO
M]ME@_&X@\\!GCW-#-YS*#Y16!]>YV^=^(V,A)B\!,1%B4W3@D=CQ)DL;.0O9
M-$E8;Z5FU*F+S;S&X130 8J>.K\YZ\"P#I*/=;J:TMS2)O$&A TR"2%45+$%
MOIY(Y\@/4@Y'QMU"@(9J&OO@^G63K/KT^^+='%\O3B_-L9#2DE-?J\%1D\-5
M[["5,V""23(HG[)C.QU>VS]_7(0TU>=B6.%V@@_2,;Z>?L.?IY^_K"_8*#X:
MX9*&'&*DN,\E<")Z**)XGDRP7NX6YCR\QKBU<,?&R:%"'ALKWSWVWU[5R)BD
M0N*< :HZ+UZF",Y*!!ZCR9EG=:\0?M^\Z]LGE:T/[C2W]H=:"KX3/-WBZ>:E
MR*2DE)DM%AAR74>I2?!62K!1>Z<Y65?_)!0]N%+/&=@]=;L%/\,(^IE>2+[(
M>;JY>)N]F9?%\F3SXX97D(^M=XQ+QYWY/>XU(Y<F,<T*N/#_MW=EO6TD2?I]
M?\5BWV,G[P-8+."K!P:ZVX9L[SP2>43:1$NDEY0\[?WU$TE1%T5*1;)*65+O
MBTV;4E4<7T9&9$1&&$DVT%<;&#/P7)B0NB0T+[XP9)*+U:J( ,&@(T<B>(@N
M>6"E-K6VW(5A+B;TS\J8#>=!F!N^#&0O[8\L/VH8Q=(A:] ED@<<*<IVJC!0
M7F>F(]/2;&G,]SSSHV-!P /IU'W4,:9T*K)<,# &/%CBGYD"GEL-PNE<8F*!
MIRWM15](.G4OI>U*I^XCP=9N_F-I0*TSUUQ:T+(."\1$ 79MEBJ#K.,# _'2
MS<M_'NG4O52W3SIU'SFVQL3.I*#4.AKG$@B]NO;':*]FTH$1Q@BYTKCO!(:1
MIU,/1D$ODAN+^M>D1V&BUH6H+H%,HJH7"T3(0.3'F$E2+J>]E#ZJ-.K1JCY
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MNZ+6^]?P'DE4-XB_\.Q**R4_2W"_+S?<?DCI8C')*%P03H-D/) '%6N'5&2
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M2-ZI!FTT$7;NR0[ \0?4-<*:(?>)8JKDE+L$6-!)?<ZN:W[D>2G5G*-UEJG
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MEDD5*MZY=%TU4[.N."L6,L:..E.[+(_<T^;?V:VQN;\^_A]02P$"% ,4
M" #BH*92U).0'0U# @!4#A, $0              @ $     ;FMT<BTR,#(Q
M,#,S,2YH=&U02P$"% ,4    " #BH*92RY] E*@0  #*M   $0
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M,2YH=&U02P$"% ,4    " #BH*92=7='"!<(  ##)   &0
M@ 'PS@, ;FMT<C(P,C$M,#-X,S%X97AX,S$R+FAT;5!+ 0(4 Q0    ( .*@
MIE*$AWF5^@4  !H7   9              "  3[7 P!N:W1R,C R,2TP,W@S
B,7AE>'@S,C$N:'1M4$L%!@     )  D 7P(  &_= P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
